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Abstract
Interventions for adults with a history of complex traumatic
events: the INCiTE mixed-methods systematic review
Hollie Meltono ,1 Nick Meadero ,1 Holly Daleo ,2 Kath Wrighto ,1
Julie Jones-Dietteo ,1 Melanie Templeo ,3 Iram Shaho ,3 Karina Lovello ,4
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Background: People with a history of complex traumatic events typically experience trauma and
stressor disorders and additional mental comorbidities. It is not known if existing evidence-based
treatments are effective and acceptable for this group of people.
Objective: To identify candidate psychological and non-pharmacological treatments for future research.
Design: Mixed-methods systematic review.
Participants: Adults aged ≥ 18 years with a history of complex traumatic events.
Interventions: Psychological interventions versus control or active control; pharmacological
interventions versus placebo.
Main outcome measures: Post-traumatic stress disorder symptoms, common mental health problems
and attrition.
Data sources: Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1937 onwards);
Cochrane Central Register of Controlled Trials (CENTRAL) (from inception); EMBASE (1974 to 2017
week 16); International Pharmaceutical Abstracts (1970 onwards); MEDLINE and MEDLINE Epub Ahead
of Print and In-Process & Other Non-Indexed Citations (1946 to present); Published International
Literature on Traumatic Stress (PILOTS) (1987 onwards); PsycINFO (1806 to April week 2 2017); and
Science Citation Index (1900 onwards). Searches were conducted between April and August 2017.
Review methods: Eligible studies were singly screened and disagreements were resolved at consensus
meetings. The risk of bias was assessed using the Cochrane risk-of-bias tool and a bespoke version of a
quality appraisal checklist used by the National Institute for Health and Care Excellence. A meta-analysis
was conducted across all populations for each intervention category and for population subgroups.
Moderators of effectiveness were assessed using metaregression and a component network meta-analysis.
A qualitative synthesis was undertaken to summarise the acceptability of interventions with the
relevance of findings assessed by the GRADE-CERQual checklist.
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Results: One hundred and four randomised controlled trials and nine non-randomised controlled trials
were included. For the qualitative acceptability review, 4324 records were identified and nine studies
were included. The population subgroups were veterans, childhood sexual abuse victims, war affected,
refugees and domestic violence victims. Psychological interventions were superior to the control post
treatment for reducing post-traumatic stress disorder symptoms (standardised mean difference –0.90,
95% confidence interval –1.14 to –0.66; number of trials = 39) and also for associated symptoms of
depression, but not anxiety. Trauma-focused therapies were the most effective interventions across all
populations for post-traumatic stress disorder and depression. Multicomponent and trauma-focused
interventions were effective for negative self-concept. Phase-based approaches were also superior
to the control for post-traumatic stress disorder and depression and showed the most benefit for
managing emotional dysregulation and interpersonal problems. Only antipsychotic medication was
effective for reducing post-traumatic stress disorder symptoms; medications were not effective for
mental comorbidities. Eight qualitative studies were included. Interventions were more acceptable if
service users could identify benefits and if they were delivered in ways that accommodated their
personal and social needs.
Limitations: Assessments about long-term effectiveness of interventions were not possible. Studies
that included outcomes related to comorbid psychiatric states, such as borderline personality disorder,
and populations from prisons and humanitarian crises were under-represented.
Conclusions: Evidence-based psychological interventions are effective and acceptable post treatment
for reducing post-traumatic stress disorder symptoms and depression and anxiety in people with
complex trauma. These interventions were less effective in veterans and had less of an impact on
symptoms associated with complex post-traumatic stress disorder.
Future work: Definitive trials of phase-based versus non-phase-based interventions with long-term
follow-up for post-traumatic stress disorder and associated mental comorbidities.
Study registration: This study is registered as PROSPERO CRD42017055523.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 43. See the NIHR Journals Library website for further project information.
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Traumatic events that happen often and that are difficult to escape from, such as childhood abuse,are sometimes known as complex traumatic events. People who have a history of complex
traumatic events can develop post-traumatic stress disorder and can also suffer from other mental
health problems. It is not known if people who experience complex traumatic events can benefit from
existing psychological treatments or medications, or if these treatments are acceptable. This review
aimed to find out which treatments are most effective and acceptable for mental health problems in
people with complex trauma histories, and to identify the frontrunners for future research. We
searched electronic databases for evidence about treatment effectiveness and acceptability in adults
with a history of complex traumatic events. We found 104 randomised controlled trials and nine
non-randomised controlled trials that tested the effectiveness of psychological and/or medications, as
well as nine studies that used interviews and focus groups to describe the acceptability of psychological
treatments. The studies were split across different populations that included veterans, refugees, people
who had experienced childhood sexual abuse and domestic violence, and civilians affected by war.We
found that psychological treatments that focused on improving symptoms associated with trauma were
effective for reducing post-traumatic stress disorder symptoms and depression across all populations
and fewer people dropped out of these treatments, suggesting that they are acceptable. However,
trauma-focused treatments were less effective among veterans than among other groups and less
effective for reducing other psychological symptoms commonly experienced by people with complex
trauma histories. Phased treatments that first start with helping people to feel safe before focusing
on trauma symptoms might be beneficial for both post-traumatic stress disorder and additional
psychological symptoms. There was little evidence that medications, other than antipsychotics, were
effective for post-traumatic stress disorder symptoms. Future work should test if phased treatments
are more effective than non-phased treatments over the long term.
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There is growing evidence that, in addition to post-traumatic stress disorder symptoms, exposure to
prolonged and repetitive trauma of an interpersonal nature, such as childhood sexual abuse, is associated
with mental health symptoms related to problems of emotional regulation, negative self-concept and
interpersonal dysfunction. To better capture the symptom profile of people exposed to prolonged and
multiple forms of trauma, a separate diagnosis of complex post-traumatic stress disorder has been
proposed as part of the new International Classification of Diseases, Eleventh Edition.
Evidence-based treatments exist for single-event post-traumatic stress disorder and these include
trauma-focused psychological interventions, which are recommended as first-line therapies, and also
pharmacological therapies. However, it is not known if these therapeutic approaches are effective for
people with a history of complex trauma or if they are safe and acceptable among this population.
People with complex mixes of comorbidities may be excluded from clinical trials and they are further
disadvantaged because their health needs are not well met by health services, such as Improving
Access to Psychological Therapy services.
Complex trauma is increasingly prominent and relevant to the NHS, but existing mental health services
are not well equipped to appropriately manage patients with complex traumatic histories. There is a
need to identify candidate psychological and pharmacological treatments for this group with a view to
informing practice and prioritising future research.
Objectives
The primary research question set by the Health Technology Assessment programme was the following:
how effective are interventions that treat mental health problems associated with a history of complex
traumatic events? The funding brief further elaborated on this research question by stating that the
global objective was to undertake a broad evidence synthesis that builds on and extends previous
reviews, reflective of the patient group seen in clinical practice, and to include pharmacological as well
as non-pharmacological interventions. A key objective was to identify leading candidate interventions
that the Health Technology Assessment programme could fund as part of a future round of
primary research.
To achieve these objectives, we specifically aimed to:
l descriptively synthesise evidence from randomised and non-randomised controlled trials of
psychological and/or pharmacological interventions for mental health in people with a history of
complex traumatic events
l quantitatively assess, with meta-analysis if feasible, the clinical effectiveness of interventions
delivered to adults, aged ≥ 18 years, with trauma and stressor disorders after exposure to complex
traumatic events
l provide evaluations of the comparative clinical effectiveness of psychological interventions and
pharmacological interventions using a network meta-analysis
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l identify, appraise and synthesise qualitative and quantitative data that address service user and
provider perspectives about the acceptability and feasibility of using psychological and/or
pharmacological interventions to treat mental health problems after complex traumatic events
l identify leading candidate interventions that could be feasibly tested and used in the NHS and
make recommendations to the Health Technology Assessment programme about future
research priorities.
Methods
A mixed-methods systematic review was conducted that included eligible studies to address questions
about the effectiveness and acceptability of psychological and/or pharmacological interventions for
mental health problems in adults, aged ≥ 18 years, with a history of complex trauma. The methods for
screening and data extraction and analysis followed guidance from the Cochrane Collaboration and the
Centre for Reviews and Dissemination.
The quantitative and qualitative findings were presented at a stakeholder research prioritisation day
attended by the research team, as well as by practitioners with an interest and experience in complex
trauma, by voluntary and third-sector providers of services to people affected by complex trauma, and by
experts through experience. Research priorities were co-produced during workshops and ranked following
an online voting exercise, which was facilitated by the Beyond The Room (http://beyondtheroom.net/).
Data sources
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost (1937 onwards;
search date: 20 April 2017).
l Cochrane Central Register of Controlled Trials (CENTRAL) via The Cochrane Library (from inception;
search date: 21 April 2017).
l EMBASE via Ovid (1974 to 2017 week 16; search date: 19 April 2017).
l International Pharmaceutical Abstracts via ProQuest (1970 onwards; search date: 30 August 2017).
l MEDLINE Epub Ahead of Print and In-Process & Other Non-Indexed Citations, Ovid MEDLINE
Daily and Ovid MEDLINE via Ovid (1946 to present; search date: 18 April 2017).
l Published International Literature On Traumatic Stress (PILOTS) via ProQuest (1987 onwards;
search date: 2 May 2017).
l PsycINFO via Ovid (1806 to April week 2 2017; search date: 18 April 2017).
l Science Citation Index via Web of Science (1900 onwards; search date: 20 April 2017).
Two separate searches were run to capture eligible studies relevant to questions of effectiveness and
acceptability of interventions.
Study selection
We identified the population of interest as adults, aged ≥ 18 years, exposed to deliberate and premeditated
events, to a series of events that were extreme and prolonged or to events of a repetitive nature
from which escape was difficult or impossible. Studies were included if they assessed treatment
effectiveness and acceptability in this population. This approach approximated the definition of
complex trauma used to describe complex post-traumatic stress disorder, although we did not use the
newly defined International Classification of Diseases, Eleventh Edition, diagnostic category of complex
post-traumatic stress disorder to search for eligible studies. Eligible studies for the effectiveness review
needed to be randomised or non-randomised controlled trials and needed to measure post-traumatic
stress disorder and/or mental health outcomes. Eligible studies for the qualitative acceptability review
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needed to have used qualitative methods, such as in-depth interviews or focus groups. Studies that
evaluated any first- or second-line psychological therapy that aimed to improve symptoms (including
comorbidities) of trauma- and stressor-related disorders, delivered to either individuals or groups, were
included. Complementary and alternative therapeutic interventions were excluded. All drug treatments
subjected to experimental testing in the context of the treatment of mental health problems in people
with a history of complex trauma were considered for inclusion.
Data extraction
Data were singly extracted by the review team using a prespecified data extraction Microsoft Excel®
(Microsoft Corporation, Redmond,WA, USA) spreadsheet that included domains for study and participant
characteristics, outcomes and attrition. The risk of bias for randomised controlled trials was assessed
using the Cochrane risk-of-bias tool. The risk of bias for non-randomised controlled intervention studies
was assessed using a bespoke version of a quality appraisal checklist used by the National Institute for
Health and Care Excellence in public health guidance, and based on the Graphical Appraisal Tool for
Epidemiological studies.
Quality assessments of the qualitative data were undertaken using the Critical Appraisal Skills
Programme checklist and the validity and relevance of the data to the questions were assessed using
the GRADE-CERQual checklist.
Data synthesis
For the quantitative review of effectiveness, we undertook a series of meta-analyses that pooled
results across all populations for each intervention category. Mean differences and 95% confidence
intervals were computed for outcomes measured using the same scale. Standardised mean differences
with 95% confidence intervals were computed for outcomes measured using different scales. We also
evaluated the effectiveness of interventions with a meta-analysis across population subgroups. In
addition to the meta-analyses, we explored if the treatment effects of interventions were moderated
by population subgroup, intervention components and delivery methods (e.g. individual or group). We
further explored whether or not certain components of composite interventions were more effective
than each other using a component network meta-analysis.
For the qualitative review of acceptability of interventions, we undertook a narrative synthesis of
qualitative data extracted from the included studies, mapping data to themes and subthemes related to
acceptability and feasibility.
Results
In the effectiveness review, 104 studies were included. Of these, 95 were randomised controlled trials
and nine were non-randomised controlled trials. The population subgroups that were included were
veterans, childhood sexual abuse, war affected, refugees and domestic violence.
Effectiveness of psychological interventions across all populations
The pooled results across all populations with complex trauma showed that existing evidence-based
psychological interventions were effective at reducing post-traumatic stress disorder symptoms when
compared with the control post treatment (standardised mean difference –0.90, 95% confidence
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interval –1.14 to –0.66; number of trials= 39), and there was some evidence that this finding held when
treatment effects were measured up to 6 months post treatment. Trauma-focused cognitive–behavioural
therapy and more broadly single-component and trauma-focused interventions were more effective
than the control post treatment and at follow-up. Multicomponent and trauma-focused interventions
for post-traumatic stress disorder symptoms post treatment were also effective, but the treatment
effects were smaller than for single-component and trauma-focused interventions.
For the symptom cluster associated with complex post-traumatic stress disorder, we found no evidence
that either trauma- or non-trauma-focused psychological interventions were superior in improving
emotional dysregulation or interpersonal problems. Multicomponent and single-component trauma-
focused interventions showed benefits for negative self-concept. Phase-based interventions that
included stabilisation work before exposure therapy had positive effects on emotional dysregulation
and interpersonal problems, although the results for these outcomes were of borderline significance.
Collectively, psychological interventions were superior to the control, but not the active control, post
treatment and at follow-up for managing associated symptoms of depression in all populations with
complex trauma (standardised mean difference –0.94, 95% confidence interval –1.20 to –0.68; number
of trials = 22). The most consistent and the largest effects for depression across all time points were
observed in trials that tested single-component and trauma-focused interventions. Similarly, pooled
results showed that psychological interventions of any type were effective for reducing anxiety in all
populations with complex trauma (standardised mean difference –0.81, 95% confidence interval –1.18
to –0.46; number of trials= 13). Trauma-focused approaches, when delivered as either a single-component
or a multicomponent intervention, were superior to the control for anxiety symptoms when effects were
pooled across all populations.
There were insufficient data to assess the effectiveness of psychological interventions for other
secondary outcomes.
Effectiveness of psychological interventions across population subgroups
Among veterans, psychological interventions were effective for reducing post-traumatic stress disorder
symptoms, but the size of the treatment effect was much smaller than in analyses that pooled results
across all populations (standardised mean difference –0.48, 95% confidence interval –0.72 to 0.24;
number of trials = 14). Trauma-focused cognitive–behavioural therapy and eye movement desensitisation
and reprocessing therapy were the most efficacious treatments in this subgroup for post-traumatic stress
disorder, but superior effects were observed when multicomponent and trauma-focused interventions
were compared with the control. These two therapies were also effective for reducing depression and
anxiety in veterans.
For people exposed to childhood sexual abuse, psychological interventions were effective for reducing
post-traumatic stress disorder symptoms (standardised mean difference –0.90, 95% confidence interval
–1.43 to –0.37; number of trials = 9). The largest effects for reducing depression in this subgroup were
observed in the meta-analysis that compared multicomponent trauma-focused interventions with the
control. There was no clear indication about which treatments were effective for reducing anxiety in
people with a history of childhood sexual abuse.
Among war-affected populations, psychological interventions as a whole were effective at reducing
symptoms of post-traumatic stress disorder (standardised mean difference –0.46, 95% confidence
interval –0.68 to –0.25; number of trials = 8). Individual trauma-focused cognitive–behavioural therapy
was the most effective intervention in this subgroup for post-traumatic stress disorder symptoms and
for depression; there was insufficient evidence to draw firm conclusions about the effectiveness of
interventions for anxiety symptoms among war-affected populations.
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Large and positive effects in favour of psychological interventions for post-traumatic stress disorder
symptoms were observed in refugee populations (standardised mean difference –1.84, 95% confidence
interval –2.18 to –1.49; number of trials = 6). Trauma-focused cognitive–behavioural therapy and eye
movement desensitisation and reprocessing therapy were the most effective interventions for both
post-traumatic stress disorder and depression in this subgroup; meta-analyses that assessed the
effectiveness of interventions for anxiety among refugees were not possible.
Only two trials were included in the meta-analyses of psychological interventions for people exposed
to domestic violence. Trauma-focused cognitive–behavioural therapy was effective for reducing
post-traumatic stress disorder and depression in this subgroup.
The meta-regression showed that psychological interventions were most effective for post-traumatic
stress disorder symptoms in populations exposed to domestic violence and were least effective
among veterans. The component network meta-analysis showed that cognitive restructuring, imaginal
exposure and relaxation were effective components of trauma-focused cognitive–behavioural therapy.
Mindfulness and phase-based interventions were also effective components of composite interventions
for post-traumatic stress disorder symptoms.
Effectiveness of pharmacological interventions
All but one of the six trials that compared pharmacological interventions with placebo were conducted
in veterans. Overall, only antipsychotic medicine was effective in reducing post-traumatic stress
disorder symptoms in veterans (standardised mean difference –0.45, 95% confidence interval –0.85 to
–0.05; number of trials = 5). No pharmacological intervention was effective for reducing symptoms of
depression or psychosis in veterans. There was evidence from just two studies that prazosin had
positive benefits for sleep quality among veterans.
Quality of evidence
The risk of bias across randomised controlled trials was difficult to ascertain for five of six domains of
the Cochrane risk-of-bias tool, owing to inadequate reporting. Only a small proportion (20–30%) of
randomised controlled trials were rated as being at low risk of bias for sequence generation, allocation
concealment and blinding of outcome assessments, which were the primary indicators of study quality.
Similarly, study quality was variable among the non-randomised controlled trials. There was a high risk
of bias for outcome assessment, with only three of nine studies taking steps to blind investigators;
domains related to allocation bias were poorly reported, leading to judgements that the internal
validity of non-randomised trials was low or difficult to assess.
Acceptability of interventions
Eight qualitative studies were included in the acceptability synthesis. The acceptability of interventions
was associated with how congruent they were with participants’ therapeutic needs and social contexts,
as well as the means by which they were able to provide participants with opportunities to engage in
personal and interpersonal improvement and confer demonstrable improvements. The feasibility of
interventions hinged on more instrumental features, such as scheduling and timing of treatment sessions.
Conclusions
Trauma-focused cognitive–behavioural therapy and other trauma-focused interventions, including eye
movement desensitisation and reprocessing therapy, delivered as single-component or multicomponent
approaches, are superior to the control for post-traumatic stress disorder symptoms and associated
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mental disorder comorbidities. Positive effects were mainly found post treatment, with few studies
showing benefit over the long term. The quality of the randomised controlled trial evidence was generally
low or sufficiently unclear to be able to make fundamental recommendations about the effectiveness of
interventions.We identified only a small subset of evidence from non-randomised controlled studies in
which study quality was variable and internal validity was low. The sizes of the positive treatment effects
were not evenly distributed across populations exposed to complex trauma, with the smallest effects
observed among veterans and war-affected populations and the largest effects observed in those affected
by domestic violence. Phase-based interventions, along with non-trauma-focused intervention components
including mindfulness and relaxation, are potentially among the most effective approaches for post-
traumatic stress disorder symptoms in people with a history of complex trauma, such as childhood sexual
abuse. In addition, there is inconclusive evidence that existing trauma-focused interventions are effective
in treating the symptom cluster associated with disturbances of self-organisation typically seen in complex
post-traumatic stress disorder. There was little evidence of effectiveness of pharmacological interventions
for post-traumatic stress disorder or for associated mental comorbidities.
Recommendations for research
Following the research prioritisation day and based on the synthesis of the effectiveness and
acceptability reviews, we have identified the following priorities for future research:
l definitive and fully powered evaluations of effectiveness of interventions in complex trauma with
long-term follow-up (i.e. at least 12 months), especially in veterans, people exposed to childhood
sexual abuse and populations affected by humanitarian crises
l qualitative and quantitative process evaluations to assess the relationship between intervention and
programme theory and anticipated outputs and trial results
l qualitative evaluations of the acceptability and feasibility of interventions among people exposed to
complex interventions to inform barriers to and facilitators of treatment uptake, especially in
refugees and asylum seekers
l evaluations of the lived experience of people with a history of complex trauma across population
subgroups
l safety and adverse event profiles of trauma- and non-trauma-focused interventions for people with
complex trauma
l a core outcome set for trials in complex trauma that includes outcomes related to disturbances of
self-organisation and mental comorbidities
l the validity of the new International Classification of Diseases, Eleventh Edition, diagnostic category
for complex post-traumatic stress disorder to identify and recruit eligible participants to
experimental studies.
Study registration
This study is registered as PROSPERO CRD42017055523.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 43.
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
Trauma- and stressor-related disorders and their relevance to complex
traumatic events
Trauma- and stressor-related disorders, also known as reactions to severe stress and adjustment
disorders, are mental health problems directly related to exposure to a traumatic event or series of
traumatic events. Post-traumatic stress disorder (PTSD) is among the most common mental health
disorders to occur after experiencing (or witnessing) a major traumatic event. Typical symptoms include
involuntary re-experiencing of the traumatic event in a vivid and distressing way (e.g. flashbacks,
nightmares), avoidance of activities reminiscent of the trauma, persistent numbness, emotional blunting
and detachment from other people and previously significant activities, along with hyperarousal in the
presence of reminders of the trauma (including hypervigilance, difficulty sleeping, irritability, poor
concentration and an exaggerated startle response). People with PTSD may also experience comorbid
psychological problems including substance use disorders, depression (with increased risk of suicide)
and other anxiety disorders (e.g. panic disorders), and functional somatic syndromes, which can further
impair social, educational and occupational functioning.
Post-traumatic stress disorder can occur at any age and it is relatively common, with a lifetime
prevalence of 7.8%;1 12-month prevalence ranges from 3% to 4%.2 Rates vary depending on the type
of stressor experienced; for example, physical assaults in women are associated with a lifetime
prevalence of 29%, combat experience in men is associated with a lifetime prevalence of 39% and
lifetime prevalence is 15.4% in people exposed to war and displacement.3
It is argued, however, that the PTSD symptom clusters described in the current and previous versions
of the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification
of Diseases, Tenth Revision (ICD-10), do not adequately capture the full range of clinical symptoms
exhibited by those who experience complex trauma (i.e. developmentally adverse interpersonal trauma
such as prolonged domestic or community violence, childhood abuse, torture or exploitation).4 People
who experience complex trauma especially, but not exclusively or necessarily in formative periods, are
more at risk of other psychiatric disorders. Complex PTSD (CPTSD) and disorders of extreme stress
not otherwise specified (DESNOS) are labels that have been used to define syndromes that involve,
in addition to core PTSD symptoms, pathological disassociation, emotional dysregulation, somatisation
and altered core schemas about the self, relationships and sustaining beliefs.5
Recent empirical work using latent class analysis in people exposed to different types of acute and
chronic stress has gone some way to endorse the distinction (to be included in ICD-11)6 between PTSD
and CPTSD, with the CPTSD class scoring highest for symptoms related to affective dysregulation,
negative self-concept and interpersonal problems.7,8 The symptom profile of CPTSD is thus characterised
by the loss of emotional, social, cognitive and psychological skills, because either the person’s development
has been interrupted during a formative phase or they have been seriously impaired owing to exposure
to complex trauma. Beyond the prototypical case of childhood sexual abuse, complex trauma experiences
have also come to embrace ‘other types of catastrophic, deleterious and entrapping traumatisation
occurring in childhood and/or adulthood, such as repeated domestic violence, trafficking and exploitation,
and being forcibly displaced’.9 Compared with single-event PTSD, complex trauma is characterised by
sustained or repeated instances of trauma of an interpersonal nature that are ‘extremely threatening
or horrific and from which escape is difficult or impossible due to physical, psychological, maturational,
family/environmental, or social constraints’.10
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Impact and burden of complex trauma
Mass conflict, persecution, generalised violence and human rights violations pose a critical threat to
global mental health. By the end of 2014, 59.5 million people across the world were forcibly displaced
(19.5 million refugees, 1.8 million asylum seekers and 38.2 million internally displaced persons) and this
figure has certainly been surpassed owing to exceptional numbers fleeing conflict in the Middle East.11
Asylum trends show that there has been a huge increase in applications in industrialised countries,
with 80% being lodged in European countries (82% of these in EU countries); the UK saw a 5%
increase in asylum applications from 2013 to 2014.12
Among forcibly displaced people, 30.6% are affected by PTSD; reported torture is consistently the
strongest population risk factor associated with PTSD in this group.3 Depression and anxiety occur as
frequently as, if not more often than, PTSD among refugees and asylum seekers, with rates as high
as 40% observed among some displaced groups.13 Similarly, human trafficking (i.e. recruitment and
movement of individuals by force, coercion or deception for exploitative purposes) is associated with
high levels of physical and mental health problems.14 Worldwide, up to 2.5 million people are known
to be in conditions of forced labour and are exposed to high levels of physical and sexual violence,
economic restrictions and controlling behaviour.15 The risk of depression, anxiety and PTSD is significantly
higher in women who have been exploited for ≥ 6 months compared with the general population,16 and
higher in women trafficked for sexual exploitation than in women trafficked for labour exploitation.17
Other critical cases of complex trauma are associated with exposure to childhood sexual and physical
abuse. Although under-reported (one in three cases are not reported), 1 in 20 children has been
sexually abused in the UK.18 Victims of child abuse are three times more likely to experience PTSD
over their lifetime. Rates of PTSD and alcohol dependence are especially high in women who have
experienced childhood abuse and related interpersonal violence. In total, the cost of physical and
mental health (depression and PTSD) and substance abuse to the UK is estimated to be £3.2B per year,
in part owing to under- and unemployment and the high spend in the criminal justice system, as well as
costs attributed to the use of mental health services.19 Stigma, discrimination and depression similarly
affect victims of childhood abuse and severely impair their quality of life.
Treating mental health problems in people affected by complex trauma
Existing international guidance makes no distinction between more complex variants of PTSD and
recommends the use of trauma-focused therapies for people with comorbidities and PTSD. However,
many of the trials included in existing systematic reviews [on which National Institute for Health and
Care Excellence (NICE) guidance is based]20 were carried out in North American or Western European
countries where the type and severity of trauma experienced by participants may not be comparable
to settings and scenarios with a higher risk of prolonged exposure to complex interpersonal trauma.
In addition, the World Health Organization (WHO) guideline excluded systematic reviews based on trials
of treatment of PTSD in refugee populations.21 As such, it is unclear if treatments that are effective for
people with single-event PTSD are equally effective for people exposed to complex traumatic events,
who have significantly greater psychological comorbidity and functional impairment than the former
group. Standard cognitive and behavioural therapies and exposure-based treatments for PTSD might
have limited utility and might be harmful if used prematurely for people with psychological problems
following complex traumatic events.22 Many people with CPTSD have high levels of disassociation and
psychological comorbidities that might limit their capacity to engage in exposure-based therapies, and
findings from effectiveness studies in single-event PTSD cannot be generalised to people with complex
trauma.23 Compared with brief trauma-focused treatments, phase-based approaches or sequential
interventions that first focus on stabilisation (ensuring individuals’ safety, resolving symptoms –
including dissociative symptoms – and increasing emotional, social and psychological competencies),
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followed by processing unresolved aspects of individuals’ trauma, with an emphasis on consolidation of
treatment gains to facilitate re-engagement with social, educational or occupational relationships, can
be effective in more complex presentations of PTSD following childhood sexual abuse.24
However, the quality of the evidence for the CPTSD expert consensus guidelines is mixed: two studies
were not randomised controlled trials (RCTs); only three included an active control and none included
head-to-head comparisons with trauma-focused therapies; three studies did not follow up with
participants; and all of the evidence was drawn from populations exposed to childhood sexual abuse
and no other types of complex trauma, which limits the validity and generalisability of the conclusions.25
Indeed, patients with a history of complex traumatic events might benefit from existing evidence-based
psychological and pharmacological treatments. Crumlish and O’Rourke identified 10 trials (n = 528)
in a review of psychotherapy for refugees and asylum seekers.26 Cognitive–behavioural therapy
(CBT) and narrative exposure therapy (NET) emerged as candidate interventions for reducing core
PTSD symptoms, but small sample sizes, inadequate allocation concealment and the use of different
comparisons limit the conclusions. Similarly, Palic and Elklit, in a review of 25 experimental and
non-experimental studies (n = 1113) of psychosocial treatments for PTSD among refugees, identified
CBT as the most effective therapy for reducing PTSD symptoms.27 Trauma-focused therapies such as
CBT and NET appear to be equally efficacious across different types of trauma too, including repeated
traumatisation. Powers et al., in a review of 13 trials (n = 675), showed that there was no significant
difference in effect sizes for prolonged exposure therapy across types of trauma (combat/terror,
childhood sexual abuse, rape, mixed; p = 0.14).28
More complex presentations of PTSD include psychiatric comorbidities and there is growing evidence
that existing non-phase-based approaches are effective in this group. A wide-ranging review with a
meta-analysis that included 148 anxiety-disordered treatment samples (47 in PTSD; combined
n = 3534) showed that effect sizes post treatment or at follow-up were generally unrelated to
psychiatric comorbidity (for comparisons with active and non-active psychological or pharmacotherapy
treatments).29 However, in cases of PTSD, there was a positive association between the presence of
comorbidities and the treatment outcome: people with comorbidities did better. More specifically,
there is emerging evidence that PTSD symptoms in patients with comorbid dissociation, depression,
substance abuse and/or mild borderline personality disorder can be successfully and safely treated
with existing evidence-based trauma-focused therapies, and their outcomes are comparable with those
for patients without these comorbidities.30 CBT is also possibly the most effective approach for PTSD
symptoms when compared with multicomponent interventions that seek to first address additional
social and psychological problems in refugees.31
In addition, consistent with NICE guidance, trauma-focused therapies that target PTSD symptoms can
have a positive impact on comorbidities. A review of 93 studies with 116 comparisons showed that
there was a strong correlation between effect sizes for PTSD and depression outcomes, suggesting that
psychological and pharmacological therapies are equally efficacious for PTSD and depressive symptoms.32
Rationale and aims of this review
In summary, there is expert consensus that phase-based approaches effectively treat symptoms
associated with CPTSD in adults, but the evidence on which this consensus is based is methodologically
weak and exclusively based on studies that recruited participants with childhood abuse; findings might
not translate to other populations with complex trauma histories. These consensus guidelines also
did not review evidence about the effectiveness of pharmacological interventions in CPTSD. There is
accumulating evidence that trauma-focused psychological therapies can reduce PTSD symptoms in
people exposed to complex traumatic events who have psychiatric comorbidities. These treatments can
also reduce comorbid illness in people with PTSD and can be used safely without a stabilisation phase.
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However, existing reviews of the use of trauma-focused therapies in people with complex trauma
histories have focused on narrowly defined population subgroups and we still do not know how effective
psychological therapies are across all populations with complex trauma. The comparative effectiveness of
psychological interventions for mental health outcomes is also unknown for people with complex trauma
histories in all settings. The acceptability of psychological interventions, either phased based or trauma
focused, has been less well studied. There are also no comprehensive overviews of the effectiveness
of pharmacological interventions in people who have been exposed to complex traumatic events.
As such, a broad synthesis of evidence is needed to build on and extend the findings from previous
reviews, but uncertainties and questions remain about which interventions warrant further evaluation.
Furthermore, both pharmacological and psychological interventions should be included across a wide
range of populations with a history of complex traumatic events.
BACKGROUND
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Chapter 2 Methods of the effectiveness
review and meta-analysis
Parts of this chapter are based on Coventry et al.
33 © 2020 Coventry et al. This is an open access
article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
Aims and objectives
The aim of this review was to provide a broad synthesis of evidence about the effectiveness of
psychological and/or pharmacological interventions to treat mental health problems (with or without
PTSD symptoms) in people exposed to complex traumatic events. In addition, where feasible, the review
aimed to identify and synthesise qualitative and quantitative evidence about the acceptability and uptake
of delivering mental health interventions for people with a history of complex traumatic events. Together,
these syntheses aimed to offer estimates of the clinical effectiveness and acceptability of existing and
novel treatments and to describe uncertainties about the strength of this evidence to inform a broader
understanding about which interventions are likely to be candidates for testing in future definitive trials.
More specifically, the objectives of this review were as follows.
l Descriptive synthesis: to provide an overview of existing RCTs and non-RCTs of psychological
and/or pharmacological interventions for mental health problems in people with a history of complex
traumatic events with specific reference to participant characteristics, intervention format and
content, and the outcomes measured.
l Clinical effectiveness: narratively and quantitatively, with a meta-analysis if feasible, to report on
the clinical effectiveness of interventions delivered to adults aged 18 years and over with trauma
and stressor disorders after exposure to complex traumatic events.
l Comparative effectiveness: to provide evaluations of comparative clinical effectiveness of
psychological interventions (e.g. phase-based vs. conventional trauma-focused therapies) and
different pharmacological interventions using a network meta-analysis.
l Acceptability and feasibility: to identify, appraise and synthesise narratively qualitative and
quantitative data that address service user and provider perspectives about the acceptability and
feasibility of using psychological and/or pharmacological interventions to treat mental health
problems after complex traumatic events.
l Research priorities: to identify candidate interventions that could feasibly be tested and used in the
NHS and to make recommendations to the Health Technology Assessment programme about future
research priorities.
Literature searches
Literature searches of the following databases were conducted:
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost (1937 onwards;
search date: 20 April 2017).
l Cochrane Central Register of Controlled Trials (CENTRAL) via The Cochrane Library (from inception;
search date: 21 April 2017).
l EMBASE via Ovid (1974 to 2017 Week 16; search date: 19 April 2017).
l International Pharmaceutical Abstracts via ProQuest (1970 onwards; search date: 30 August 2017).
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l MEDLINE Epub Ahead of Print and In-Process & Other Non-Indexed Citations, Ovid MEDLINE
Daily and Ovid MEDLINE via Ovid (1946 to present; search date: 18 April 2017).
l Published International Literature On Traumatic Stress (PILOTS) via ProQuest (1987 onwards;
search date: 2 May 2017).
l PsycINFO via Ovid (1806 to April Week 2 2017; search date: 18 April 2017).
l Science Citation Index via Web of Science (1900 onwards; search date: 20 April 2017).
The full search strategies used are available in Appendix 1.
Inclusion and exclusion criteria
Population
Neither DSM-IV nor ICD-10 distinguishes between PTSD and CPTSD. DSM-V does include a
dissociative subtype, but it is unlikely that many studies have yet been conducted using this approach.
ICD-11 criteria that will include CPTSD are not yet published and few studies will have used these
criteria, making it difficult to identify studies using this diagnostic label. Our goal was therefore to
identify studies based primarily on trauma history rather than diagnostic criteria.
We included adults > 18 years of age who had been exposed to complex interpersonal traumatic
events, which were defined as follows:
. . . deliberate and premeditated event or series of events of an extreme and prolonged or repetitive nature
that is experienced as extremely threatening or horrific and from which escape is difficult or impossible
due to physical, psychological, maturational, family/environmental, or social constraints.
Cloitre et al.10
This included (but was not limited to) adults exposed to childhood physical and/or sexual abuse, being
a victim of or witnessing domestic violence, forcibly displaced persons (refugees, asylum seekers,
internally displaced persons), torture survivors, those recruited into armed conflict as a child, those
who had experienced ongoing armed conflict and combat, and those who had been relocated through
human trafficking.
Studies were identified primarily based on trauma history rather than diagnostic criteria, and only
those with adults > 18 years of age were included. The interpersonal trauma experience may have
occurred at any age, but only studies of adults were included. Inclusion in the review was not
restricted based on psychiatric comorbidities, with the exception of substance misuse disorders.
If studies included a mix of participants with complex interpersonal trauma history and single-event
trauma history, studies were included if > 75% of participants had experienced complex interpersonal
trauma (unless the data were presented separately).
Studies examining preventative therapies or interventions in populations not yet exhibiting
psychological problems following complex traumatic events were excluded.
Interventions
Psychological interventions
Studies that evaluated any first- or second-line psychological therapy aimed at improving symptoms
(including comorbidities) of trauma- and stressor-related disorders delivered either to individuals or in
a group were included. Complementary and alternative therapeutic interventions were excluded from
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this review. As per the protocol registered with PROSPERO34 and in keeping with the classification
used by NICE,20 the following interventions were considered:
l trauma-focused CBT that included one or more of the following types of treatment techniques:
exposure, cognitive therapy, stress management
l eye movement desensitisation and reprocessing (EMDR)
l other psychological treatments used to treat trauma survivors and victims but that predominantly
use non-CBT techniques: supportive therapy and non-directive counselling, psychodynamic therapies
including interpersonal psychotherapy (IPT), hypnotherapy, mindfulness and compassion-focused
therapies, acceptance and commitment therapies, accelerated resolution, and sensorimotor therapies.
A more detailed study categorisation was undertaken to better describe the volume of evidence
(see Subgroup analyses: categorising interventions).
Where possible, analyses of group trauma-focused CBT and group non-trauma-focused CBT were
considered, as planned. The approach used is detailed in Meta-regression analyses: predictors of treatment
effectiveness. The volume of evidence permitted further superordinate categorisation (see Subgroup
analyses: categorising interventions).
Pharmacological interventions
All drug treatments subjected to experimental testing in the context of the treatment of mental health
problems in people with a history of complex trauma were considered for inclusion. The following categories
of pharmacotherapy were considered: selective serotonin reuptake inhibitors (SSRIs), antidepressants as
a whole, antipsychotics, anticonvulsants and other medications typically used in the context of managing
the symptoms of trauma and stressor disorders.
Comparators
Psychological interventions
Psychological interventions were compared with the following:
l waitlist
l treatment as usual (defined as non-experimental active treatments that conform to best and/or
clinical guideline recommended care and that are ordinarily made available to patients)
l no intervention
l symptom monitoring
l repeated assessment or other minimal attention control group akin to psychological placebo
l alternative psychological treatment
l pharmacological treatment.
Pharmacological interventions






Comparisons of two or more active interventions were included. Differences in comparators were
taken into account during data summary and analyses. Network meta-analyses were conducted to
provide comparisons of all interventions within a connected network (including comparisons of active
interventions not originally evaluated in the included trials).
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Outcomes
The outcomes measured were core symptoms related to trauma- and stressor-related disorders and
outcomes associated with psychological and psychiatric comorbidities even in the absence of PTSD.
However, all outcomes reported within studies were extracted to gain a comprehensive overview of all
commonly reported outcomes.
Primary outcomes
l Reduction in severity of traumatic stress symptoms as measured using a validated and standardised
clinician-rated scale.
l Reduction in symptoms of difficulties with emotion regulation (e.g. Difficulties with Emotion
Regulation Scale35) and interpersonal relationship problems (e.g. Inventory of Interpersonal Problems36).
Secondary outcomes
l Severity of self-reported traumatic stress symptoms using a standardised measure (e.g. Modified
PTSD Symptom Scale37).
l Reduction in depressive and/or anxiety symptoms measured using validated clinician-rated
instruments (e.g. Hamilton Depression Rating Scale38) or validated patient self-reported instruments
(e.g. Hospital Anxiety and Depression Scale39).
l Reduction in symptoms of panic disorder.
l Reduction in symptoms of disassociation.
l Reduction in symptoms of functional somatic syndromes.
l Reduction in substance misuse.
l Acceptability measured in terms of intervention uptake, adherence and withdrawal (dropouts).
l Adverse events and harms from trial data (e.g. worsening of traumatic stress symptoms).
l Suicidal ideation, attempts and completion.
l Functioning, disability and quality of life measured by validated clinician-rated scales (e.g. Global
Assessment of Functioning) or validated self-reported scales (e.g. Short Form questionnaire-36 items).
l Study designs.
l RCTs and cluster RCTs (where relevant).
Because CPTSD and complex trauma make up an emerging and relatively new diagnostic category,
we proposed to also identify and include non-randomised controlled studies so as to capture data on
emerging treatments and treatments tested in more pragmatic settings that might not have been
tested in the context of a RCT. Studies undertaken in any country and setting (i.e. both low and
middle-income countries and high-income countries) were included. Single-group before-and-after
studies, uncontrolled observational studies, single-subject designs, case studies, opinion papers,
descriptive studies and editorials were excluded.
Study selection
The selection criteria and process were independently checked by an advisory group (see Advisory
group). Three researchers (Julie Jones-Diette, Hollie Melton and Holly Dale) independently screened
titles and abstracts. The EndNote library was split evenly between those involved in screening, but,
to ensure the distribution was not weighted to any particular year or author groups, each reviewer
screened a cross-section of the library across dates and authors. To ensure that the inclusion criteria
were consistently applied, a 10% sample of records was first double screened based on the title and
abstract by pairs of researchers. Consensus meetings with the rest of the research team were held at
regular intervals to resolve unclear decisions at the title and abstract screening phase. Full-text records
were similarly screened with consensus meetings used to resolve disagreements.
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Advisory group
We convened a study advisory group that comprised the principal investigator (Peter Coventry) and
co-investigator (Rachel Churchill), along with content and clinical experts in trauma studies, PTSD and
CPTSD. The advisory group provided independent advice about the strategic direction and scientific
and policy relevance of the research undertaken by the INCiTE (INterventions for Complex Traumatic
Events) review team. The broad aim of the advisory group was to ensure that the INCiTE study met its
objectives and to maximise the impact and benefit of the review to end-users. The chairperson of the
advisory group shared with the INCiTE team search terms and preliminary results associated with an
update of a review of treatments for PTSD. Our search was shared with the advisory group and vetted
for accuracy and credibility. Following the first advisory group meeting, the INCiTE team was advised
to modify the inclusion criteria to include populations with a history of complex traumatic events who
also had psychosis. In addition, feedback from the clinical content experts suggested that screening
decisions should include combat trauma of all kinds because of the increased likelihood that veterans
who present with PTSD may have encountered other traumatic events prior to military service and
that it is the experience of multiple forms of trauma resulting in symptoms associated with CPTSD.
Data extraction
Data extraction was piloted on a small sample of studies by three researchers independently. Both
RCTs and non-RCTs were extracted using the same template and were managed in separate Microsoft
Excel® (Microsoft Corporation, Redmond,WA, USA) spreadsheets. After consensus checking, the included
records were split between three reviewers to singly extract, owing to the volume of evidence. Uncertainties
were resolved by consultation between reviewers tasked with data extraction or by deferring to the
wider review team. Extracted data across domains related to study and participant characteristics and
outcomes were compiled in a spreadsheet. When they were presented, intention-to-treat data were
extracted instead of complete cases.
If an included study was published across multiple manuscripts, we used the primary publication as the
main source of information. New and follow-up data were taken from subsequent publications but the
unit of allocation remained the study rather than numbers of publications.
Risk of bias
Randomised controlled studies of clinical effectiveness
Studies were evenly distributed between researchers tasked with data extraction and each study was
singly assessed for risk of bias. A subset of studies was used to pilot the Cochrane risk-of-bias tool.
This tool assessed each study against domains known to be associated with bias in RCTs: selection,
performance, detection, attrition, reporting and other biases (which were applied based on the specific
context). Each study was assessed as being at ‘low’, ‘unclear’ or ‘high’ risk of bias across each of these
domains. Attrition bias was used as an independent variable in the sensitivity analysis; this domain was
checked by a further reviewer after all of the original appraisals had been made.
Selection bias was assessed by considering random sequence generation and allocation concealment;
when these were not reported with sufficient detail, they were graded as at unclear risk. Performance
bias considered the blinding of participants and personnel; when this was not possible owing to
intervention type (e.g. comparing a psychological intervention with a waitlist), studies were graded as
high risk. Detection bias was assessed by considering the blinding of outcomes assessors. The attrition
bias domain took account of incomplete outcome data and how they were managed. When attrition
was unequal, in high frequency or not appropriately managed by study authors, this was graded as high
risk. Reporting bias was appraised by considering the risk of selective reporting. Generally, studies
without a registered protocol were graded as being an unclear risk, while studies that favoured
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significant outcomes or obscured results were graded as high risk. Finally, other biases were assessed and
descriptively reported if there were possible concerns not addressed by the existing domains of the tool.
Non-randomised controlled intervention studies
Non-randomised controlled intervention studies that were subject to the same piloting and agreement
process as RCTs were included. Two reviewers piloted the Risk Of Bias In Non-randomized Studies – of
Interventions (ROBINS-I),40 the Newcastle–Ottawa Scale41 and the NICE quality appraisal checklist.42
After piloting these tools, the pragmatic decision was taken to use a modified version of the NICE quality
appraisal checklist42 used in public health guidance. There were few non-randomised controlled studies
but the resources needed to use the ROBINS-I tool would have outstripped capacity in the team and
compromised the schedule allocated for extracting data from the large volume of included RCTs.
Reviewers singly appraised the quality of each included non-randomised controlled intervention study.
The checklist was originally developed based on the ‘Graphical Appraisal Tool for Epidemiological
studies’ (GATE) tool43 and includes domains of population bias, allocation, outcomes and analyses, as
well as summary judgements for internal and external validity. Ten items were not directly relevant to
the included studies, so were graded as ‘not applicable’ (items 2.3, 2.5, 3.2, 3.4, 3.5, 3.6, 4.3, 4.5 and 4.6).
Each study was graded ‘++’ indicating minimal risk of bias, ‘+’ indicating potential sources of bias or ‘–’
indicating significant sources of bias. The additional grade ‘NR’ was used when studies did not report
information and ‘NA’ was used when an item was not applicable to the given study design.
Data analysis
Meta-analyses of clinical effectiveness and attrition
Random-effects pairwise meta-analyses were conducted using Stata® 15 (StataCorp LP, College Station,
TX, USA). We decided to use a frequentist approach for the pairwise meta-analyses, as this remains the
standard approach in the literature.
Control conditions were grouped into two categories: controls (which included a waitlist or other
controls with no or minimal therapeutic input) and active controls (including attention controls or
treatment as usual with non-systematic psychological intervention input).
If multiple intervention groups were included in the study, we analysed the data in the following way:
l If one of the groups did not meet criteria for our review, we did not combine across groups but
used data from the group that met our review criteria.
l If studies included two intervention groups that met criteria for the same intervention
classification, we combined them together. For example, if a study included a prolonged exposure
group and a cognitive processing therapy group, we combined them together into one group for the
trauma-focused CBT analyses.
l However, of course, if a study included a mindfulness arm and a trauma-focused CBT arm, we did
not combine them but included them in their appropriate subgroups.
Most outcomes were continuous. If all studies used the same scale, we calculated mean differences
and their 95% confidence interval (CI). If studies used different scales to measure a particular outcome,
we calculated standardised mean differences (SMDs) and their 95% CI. In keeping with established
cut-off points of effect in behavioural medicine, SMDs of 0.56 to 1.2 were categorised as large, effect
sizes of 0.33 to 0.55 were categorised as moderate and effect sizes ≤ 0.32 were categorised as small.
For dichotomous outcomes, such as attrition, we calculated odds ratios (ORs) and their 95% CI.
Heterogeneity assessment was based on visual inspection of forest plots and the I2 statistic.44 A Q-value
(approximating chi-squared distribution) of p < 0.1 indicated statistically significant heterogeneity.
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Statistical heterogeneity was explored using subgroup analyses, meta-regression and components
network meta-analyses.
Subgroup analyses: categorising interventions
Given the substantial and inherent heterogeneity expected from our broad research questions, we
conducted a range of subgroup analyses.
First, we conducted meta-analyses including all psychological interventions versus controls or active
controls in all populations.
Second, we grouped these meta-analyses of all psychological interventions into the following
populations based on descriptions in the study and through discussion with clinical experts: veterans,
people who had experienced childhood sexual abuse, refugees, people who had experienced domestic
violence and war-affected civilians.
Third, we grouped the data according to intervention categories commonly reported in the literature
based on reporting from the original papers and discussion with clinical experts: trauma-focused CBT,
EMDR therapy, non-trauma-focused CBT, mindfulness, dialectical behaviour therapy (DBT) and IPT.We
assessed the effectiveness of these intervention categories in the same populations as described above:
all psychological interventions, veterans, childhood sexual abuse, refugees, domestic violence and war.
Fourth, we further grouped the data into three superordinate intervention categories:
1. single-component trauma-focused interventions: any trauma-focused intervention that includes a
single therapeutic approach (e.g. trauma-focused CBT, EMDR)
2. multicomponent trauma-focused interventions: any intervention that is primarily trauma-focused
but also includes elements of other theoretical approaches, such as mindfulness, present-centred
therapy or counselling [e.g. Skills Training in Affect and Interpersonal Regulation (STAIR)]
3. single-component non-trauma-focused interventions: any non-trauma-focused intervention including
a single theoretical approach (e.g. non-trauma-focused CBT, mindfulness, IPT, present-centred therapy).
These intervention categories were then grouped according to the populations listed above (i.e. all
psychological interventions, veterans, childhood sexual abuse, refugees, domestic violence and war).
Meta-regression analyses: predictors of treatment effectiveness
Mixed-effects meta-regression analyses were conducted using the ‘metareg’ package in Stata 15 to
examine the impact of differences in population and intervention components on the effectiveness of
psychological interventions (using SMD as the outcome measure) for reducing trauma outcomes in all
populations (number of trials = 46). We used a frequentist approach to supplement and compare with
the more complex Bayesian approach used for the components network meta-analyses.
The impact of the following populations was explored based on the same categories described above
for the subgroup analyses: veterans, people who had experienced childhood sexual abuse, refugees,
people who had experienced domestic violence and war-affected civilians.
Intervention components were identified on the basis of study descriptions in the published manuscripts,
accessing treatment manuals where available, and in discussion with clinical experts with experience of
delivering these types of interventions. The following intervention components were included, as long
as they had sufficient data to be included as covariates in the meta-regression: support, psychoeducation,
relaxation, cognitive restructuring, in vivo exposure, imaginal exposure, virtual reality exposure,
mindfulness and phased based.
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We also assessed the impact of the following methods of intervention delivery on effectiveness:
individual versus group, face to face versus other and duration of intervention (< 12 weeks, 12 weeks,
> 12 weeks).
Components network meta-analyses
We sought to further explore the impact of different combinations of intervention components using
network meta-analyses. We used a Bayesian approach, as this allows greater flexibility in fitting more
complex models and, therefore, a more thorough exploration of heterogeneity.
As with the meta-regression analyses above, we began by conducting the component network
meta-analyses using SMDs that combined different trauma outcomes and all populations. However, there
were difficulties with compiling the model. Given the greater complexity of the network meta-analysis
models, we judged that it would be appropriate to simplify the analyses by focusing on mean differences
for the Clinician-Administered PTSD Scale (CAPS; i.e. the most frequently reported trauma outcome
reporting scale; number of trials = 16) in all populations for this outcome.
We fitted models using WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) based on the
components network meta-analyses approach proposed by Welton et al.45 and an adaptation of the
WinBUGS code reported in Freeman et al.46 All models used a normal likelihood for continuous
outcomes and vague priors for treatment effect and between-trial standard deviation. Convergence
was assessed based on visual assessment of trace plots, the Brooks–Gelman–Rubin statistic and
autocorrelation plots using three Markov chain Monte Carlo methods. All models were judged to have
reached convergence after 50,000 iterations. These iterations were then discarded and all results were
based on a further 50,000 iterations.
Goodness of fit to the observed data was assessed using total residual deviance and the deviance
information criterion (DIC). Total residual deviance approximately equal to the number of data points
was considered to indicate acceptable fit.47 Greater than 5 points on the DIC was considered a
substantial difference in goodness of fit between models.48
We compared four models:
1. Model 1 included the intervention categories used in the pairwise meta-analyses (trauma-focused
CBT, EMDR, non-trauma-focused CBT, mindfulness and IPT) compared with either control or
active control.
2. Model 2 included all intervention components originally assessed in the meta-regression analyses
discussed above (support, psychoeducation, relaxation, cognitive restructuring, in vivo exposure,
imaginal exposure, virtual reality exposure, mindfulness and phased based). In addition to these, it
was also assumed that all active treatments and attention controls included a placebo component.
We also took into account the effect of the control group (waitlist vs. active control). Each
component had a separate effect and assumed the total effect of the intervention was a sum of
these separate effects.
3. Model 3 included all intervention components in model 2 plus all available pairs of components.
Seven pairs of intervention components were reported in two or more included studies and were
therefore included in the analyses: support + psychoeducation, psychoeducation + relaxation,
psychoeducation + cognitive restructuring, psychoeducation + imaginal exposure, relaxation +
mindfulness, relaxation + cognitive restructuring and relaxation + imaginal exposure. This model
allowed for interactions between pairs of interventions above or below what would be expected
from the sum of their components.
4. Model 4 included all possible combinations of intervention components.
METHODS OF THE EFFECTIVENESS REVIEW AND META-ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Acceptability sensitivity analyses
For the attrition outcome, we were concerned that any differences between interventions and the
control may be confounded by study design characteristics. Therefore, we conducted sensitivity
analyses on attrition outcomes including only studies with a low risk of attrition bias and compared
these findings with all included studies.
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Chapter 3 Methods of the qualitative
acceptability review
Objective
The aim of this element of the review was to identify, appraise and synthesise narratively qualitative
data that addressed service user and provider perspectives about the acceptability and feasibility of
using psychological and/or pharmacological interventions to treat mental health problems after
complex traumatic events.
Literature searches
Literature searches of the following databases were conducted: CINAHL, EMBASE, MEDLINE and
PsycINFO. The searches identified 4289 records, which were downloaded, imported into EndNote
[Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA] bibliographic software and
de-duplicated to leave 1574 unique records. The full qualitative search strategy is available in Appendix 2.
Study selection
Qualitative research was defined as those studies that collected data using specific qualitative techniques
such as unstructured interviews, semistructured interviews or focus groups, either as a stand-alone
methodology or as a discrete part of a larger mixed-method study, and analysed qualitatively. Studies
that collected data using qualitative methods but then analysed these data using quantitative methods
were therefore excluded.
For qualitative evaluations, the inclusion criteria for population, intervention and comparisons were
largely unchanged from those used to identify studies for the effectiveness syntheses. In addition, to
ensure that we identified non-trial-based qualitative evaluations of acceptability of psychological and/or
pharmacological interventions, we also included stand-alone studies not specifically linked to RCTs.
Population
As per the effectiveness review.
Interventions
As per the effectiveness review.
Comparators
As per the effectiveness review.
Outcomes
The outcomes were qualitative thematic and verbatim data related to service user and/or provider
experiences of psychological and/or pharmacological interventions for mental health problems in the
presence of complex trauma histories.
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Data extraction
The findings and supporting quotations from the nine qualitative studies included were extracted into
a standardised template designed for the purpose of the review. For each study, the key themes, as
reported by the study authors, were first categorised according to whether they addressed issues
related to the ‘acceptability’ or ‘feasibility’ of interventions. Themes were then further coded into three
subcategories: (1) uptake and adherence, (2) service experience and (3) professional competencies/
training. New thematic categories were created, where necessary, for any data that did not fit into the
three main groupings.
Quality assessment
Following the lead established by the GRADE Working Group49 and the Cochrane Qualitative and
Implementation Methods Group,50 we used the CERQual (certainty of the qualitative evidence) approach51
to assess both the methodological limitations of individual studies and the coherence of our review findings.
CERQual assessment offers a framework to evaluate the certainty of evidence, addressing questions
beyond the effectiveness of interventions, such as acceptability. Methodological limitations were assessed
with the Critical Appraisal Skills Programme (CASP) checklist.52 The elements of the CASP assessment,
questions 1 to 9, were assessed and scored as either ‘yes’, ‘no’ or ‘cannot say’. When a question was
assessed as meeting the criteria describing a suitable methodological rigour, the question was scored
as ‘yes’; conversely, if the methodology did not meet the expected level of methodological rigour or the
information was not apparent from the methods, the study was scores as ‘no’ or ‘cannot say’, respectively.
A ‘yes’ received a numeric score of 1.0, a ‘no’ scored 0 and ‘cannot say’ scored 0.5. Therefore, the maximum
score, namely if each of the nine questions was allocated a ‘yes’ for methodological rigour, would be 9.0.
The coherence of the review was assessed by identifying patterns across the data that were
contributed to by each of the individual included studies, for example by combining findings across
multiple settings or different subgroups. The certainty of the evidence in each individual study was
rated as ‘no concerns’, ‘minimal concerns’, ‘moderate concerns’ or ‘significant concerns’ by considering
the CASP assessment and ranked according to the methodological limitations and coherence of
each finding.
Data analysis
A narrative synthesis approach was used to summarise the research findings of the studies included.
This approach allows the creation of a description and map of findings from the studies included for
interpretation, but also allows the identification of both common and emergent themes (a thematic
analysis) within and between studies. This methodology provides a broader perspective on solutions
and recommendations that are relevant to end-users.
METHODS OF THE QUALITATIVE ACCEPTABILITY REVIEW
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Chapter 4 Results of the effectiveness review
Flow of the studies included
The searches identified 16,552 records, which were downloaded, imported into EndNote bibliographic
software and de-duplicated to leave 10,212 unique records. In addition, 42 records were identified
from International Pharmaceutical Abstracts. A total of 10,254 titles and/or abstracts were screened.
Approximately 10% of the titles and abstracts were pilot screened to achieve consistency and
agreement between researchers. Full-text records were double screened at the following stage,
and 328 were excluded for the reasons summarised in Figure 1.
Studies included
Overall, we included 105 papers, comprising 96 reports53–147 of RCTs (95 unique trials) and nine
non-randomised trials.148–156 A table of the studies excluded, with rationale for their exclusion, can be
found in Appendix 3.
Characteristics of the randomised controlled trials included
Of the RCTs, the vast majority of trials were conducted in the USA (n = 6258–60,64,66,68–76,78,79,81,82,84,85,87,89–91,
93–95,97–102,104–107,109,110,112,115–117,120–133,135,137,140–142,146), followed by countries in Europe [Germany (n = 455,88,92,136),
Denmark (n= 363,77,103,134), the Netherlands (n= 2138,139), Croatia (n= 180), Kosovo (n= 1143), Portugal (n= 183),
Romania (n= 161) and Sweden (n= 1119)], countries in the Middle East [Iran (n= 456,57,111,118), Iraq/Iraqi
Records identified through database
searching
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FIGURE 1 The PRISMA flow diagram indicating the flow of studies through the review process.
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Kurdistan (n= 362,144), Turkey/Syria (n= 353,54,65), Egypt (n= 1108) and Israel (n= 1147)] and countries in Africa
[Uganda (n= 2113,114), Burundi (n= 1145) and the Democratic Republic of the Congo (n= 186)]. One study took
place in South Korea67 and another took place remotely in Germany96 while its participants were located
in Iraq. No studies were conducted in the UK. Appendix 3 details the comparisons in each study, as well as
their characteristics.
In terms of the types of trauma that participants were exposed to, the vast majority of participants’
exposure related to their status as veterans (n = 47 studies56,58–60,64,65,67,71–74,78,80–85,88,91,94,95,97,99,102,104,105,107,
110–112,115,118,120–124,126,128–130,135,137,140,142,147), followed by refugees (n = 1753–55,63,87,89,90,108,113,114,116,119,133,134,136,138,139),
those who experienced childhood sexual abuse (n = 1466,68–70,75–77,92,98,103,106,117,127,131,132,146), those who
experienced war-related trauma (n = 1057,61,62,86,96,109,143–145), those who experienced mixed trauma
(n = 379,93,141) and those who experienced domestic violence (n = 3100,101,125).
Of the 95 trials included, all trial arms with active interventions were categorised for analysis. For
psychological interventions this included trauma-focused CBT (n= 4155,60–63,66,71,79,81,83,84,86,87,89,90,92–94,96,100,101,
105–107,109,113,114,117,119,124,126,128,136,140,143,144), EMDR (n = 1153,54,64,74,76,88,91,130,138,139), mindfulness (n = 757,95,115,120,121,142),
non-trauma-focused CBT (n = 662,78,131,132,137), DBT (n= 469,70), other psychotherapy (n = 1293,103,106,114,120,124,125,
128,145,146), exposure only (n= 360,119,130) and IPT (n = 2,98,108 n = 2 for each non-trauma-focused non-CBT64,111
and stabilisation,138,139 and n = 1 for both biofeedback102 and other psychological interventions).142 Classen
et al.68 conducted a trial in two interventions (trauma-focused therapy and psychotherapy) but presented
combined results, so these were not included in the categorisation. The pharmacological interventions
compared in the studies included were categorised as antidepressant (n = 15,59,65,67,73,82,112,116,118,133,141,147 of
which 10 were SSRIs65,67,82,112,116,118,133,141,147), antipsychotic (n= 658,85,99,110,127,135) and anticonvulsant (n = 272,104),
as well as prazosin (n = 384,122,123) and rivastigmine (n = 156). There were also a number of combined
treatments: antidepressant and trauma-focused CBT (n= 6,63,97,116,134 of which there were three SSRI and
trauma-focused CBT interventions63,116,134), SSRI and other psychotherapy (n = 263,80), antidepressant
and other psychotherapy (n = 180), benzodiazepine and trauma-focused CBT (n = 1129) and d-cycloserine
and trauma-focused CBT (n = 1129).
Psychological interventions were then grouped into superordinate classifications (as described in the
methods), which were single-component trauma-focused (n = 4153–55,60–62,64,74,76,79,81,83,86,87,89–91,93,94,96,106,107,
109,113,114,117,119,124,126,128,136,138,139,144,145), single-component non-trauma-focused (n = 2757,62,64,78,95,98,106,108,111,114,
115,120,121,124,125,128,131,132,137–139,142,146), multicomponent trauma-focused (n = 1760,66,69–71,84,88,92,100,101,105,130,140,
143–145) and multicomponent non-trauma-focused (n = 470,93,103).
Characteristics of the non-randomised controlled trials included
A total of nine non-RCTs were included in the review; eight compared psychological interventions
with a control group148–153,155,156 and one compared a pharmacological intervention with placebo154
(see Appendix 6). Studies were conducted in a range of regions [Canada (n = 2152,156), Croatia (n = 1154),
Germany (n = 1149), Iran (n = 1153), Israel (n = 1150), Palestine (n = 1155), Sweden (n = 1151) and the USA
(n = 1148)], presenting a diverse selection of health-care systems that may differ from that in the UK.
Studies were published between 1999152,153,156 and 2016,150 with one-third being published in 1999.
The population subgroups included in the non-RCTs were veterans (n = 3148,150,154), childhood sexual
abuse (n = 3151,152,156), war affected (n = 2153,155) and refugees (n = 1149). When reported, the mean age
of participants ranged from 30 to 60 years old. Across studies, there was largely equal representation
of majority female149,151,152,156 and majority male populations.150,154,155 Further detail about the
characteristics of populations of the studies included can be found in Appendix 7.
The majority of studies were compared with an inactive control (no intervention, waitlist or placebo),
with the exception of two direct comparison studies,150,154 and effect sizes were not calculated for these.
RESULTS OF THE EFFECTIVENESS REVIEW
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Another study included treatment as usual, which was considered to be an alternative active
psychological intervention and so was narratively synthesised as a direct comparison.148 Intervention
details are outlined in Appendix 4.
Quality of the studies included
Randomised controlled trials
The quality of the RCTs included was assessed using the Cochrane Collaboration’s risk-of-bias tool,
as described in Chapter 2, Randomised controlled studies of clinical effectiveness. The grading of each
study across six domains can be found in Appendix 8.
Overall, reporting was quite variable, with a large proportion of responses being graded as ‘unclear’. Five of
the six domains were largely assessed as being at an unclear or high risk of bias. This indicated that studies
reported insufficient detail to make a clear decision about the risk of bias across these domains or, in most
cases, that the study designs did not appropriately account for sources of bias. The exception to this was
the domain of ‘other bias’, which was graded as a low risk of bias for over 80% of studies.
A small proportion of trials were rated as being at a high risk of selection bias. The majority of studies
were unclear in reporting on selection bias (Figure 2). However, less than 20% were considered as at a
low risk of bias based on allocation concealment and less than 50% were at a low risk based on random
sequence generation.
Over half of the trials were rated as being at high risk of performance bias because the blinding of
participants and personnel was inadequate or infeasible. The latter was especially true in the case of
most psychological interventions, in which the nature of the allocated intervention could not easily
be disguised.
Detection bias was generally considered as low risk or unclear for the majority of trials, with a slightly
larger proportion being rated as unclear than low risk. This was indicative of the outcome assessment
being blinded effectively or reported unclearly. Approximately 10% of studies were considered as being
at high risk of detection bias.
In terms of attrition bias, gradings of low risk, high risk or unclear bias were almost equally prevalent
across studies. This suggested that the majority of studies experienced high dropout and did not handle
it appropriately or did not report sufficiently on the number of participants and withdrawals.
0
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel
(performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)









FIGURE 2 Proportional distribution of the risk-of-bias grades across the RCTs included per domain of bias.
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Selective reporting was assessed via the reporting bias domain, for which a large majority of studies
were graded as being unclear, typically owing to a lack of preregistration (see Figure 2). Close to 10%
were considered as low risk in this domain of bias, and nearly 20% were considered as high risk.
Finally, there was generally a low risk of bias from other sources across the large majority of studies.
The remainder of studies were graded as having an unclear risk of bias from sources not covered
within the other domains. Just one study was graded as high risk from other sources of bias.100
Non-randomised controlled trials
The quality of the nine non-randomised trials included was assessed using the NICE (2012)42 tool as
described in Chapter 2, Methods, Non-randomised controlled intervention studies; the grading is presented
in Table 1. Overall, methods were reported adequately to make summary judgements on studies.
Notable exceptions were the availability of information to grade contamination (domain 2.6; present in
only three studies148,152,156) and information regarding the similarity of other interventions across study
arms (domain 2.7; clearly reported in four studies148,149,151,156).
Generally, population bias domains were well reported, with minimal or some potential sources of bias.
Allocation bias domains presented the largest subset of quality assessment and were also the most
poorly reported. Investigator blinding (domain 2.4) was the highest risk domain, with a high risk of bias
across all studies that reported sufficient detail to make a judgement.148,150–152,154,156
Outcome domains were also well reported, with most studies attaining a ‘+’ grading indicating some
potential sources of bias, but not high risk.
Domains regarding analyses were mostly well reported, with baseline similarities between study arms
(domain 4.1) and estimates of effect being given or calculable (domain 4.4), mostly showing low or
some sources of bias.
Finally, summary grades of the overall risk of bias were mostly indicative of designs attempting to
address sources of bias, with some potential risks. External validity showed minimal risk of bias; just
one study was graded as high risk.153 By contrast, internal validity was not considered low risk in any
study; three trials were judged to be high risk150,151,156 and one did not report sufficient detail.154
Meta-analyses of clinical effectiveness
Of the 104 RCTs and non-RCTs included in the systematic review, 79 included effectiveness data that
could be meta-analysed.53–56,58,59,62,64–67,69,71–74,76,78,79,81,82,84–92,94–96,98–101,104–113,115,118,121–123,125–127,131,132,135,137–140,142–147
All of these studies were RCTs. We conducted a series of meta-analyses to investigate the effectiveness
of psychological and pharmacological interventions on the primary outcome and, when the data permitted,
a number of secondary outcomes. In summary, the comparisons that were meta-analysed were:
l psychological interventions versus control for all populations combined
l psychological interventions versus control in veteran populations
l psychological interventions versus control in war-affected populations
l psychological interventions versus control in childhood sexual abuse populations
l psychological interventions versus control in refugee populations
l psychological interventions versus control in domestic violence populations
l pharmacological interventions versus placebo in veteran and childhood sexual abuse populations.
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TABLE 1 Risk-of-bias gradings for the non-randomised controlled studies included
Authors (year)
Population bias Allocation














































King et al. (2013)148 ++ ++ + + ++ – ++ ++ ++
Levi et al. (2016)150 ++ ++ + – ++ – NR NR +
Morgan and
Cummings (1999)152
+ + + + – ++ NR ++
Saxe and Johnson
(1999)156
+ + ++ + + – ++ – +
Pivac et al. (2004)154 + + NR NR + – NR NR NR
Lundqvist et al.
(2006)151
+ + + – – – NR – +
Salo et al. (2008)155 ++ + ++ – + NR NR NR –
Narimani et al.
(2008)153
– + ++ + ++ NR NR NR –













































































































































































































































































































































































































































TABLE 1 Risk-of-bias gradings for the non-randomised controlled studies included (continued )
Authors (year)
































King et al. (2013)148 NA + + ++ + ++ + +
Levi et al. (2016)150 NA + + ++ + ++ – +
Morgan and
Cummings (1999)152
NA + – + + + + +
Saxe and Johnson
(1999)156
NA + – ++ – ++ – +
Pivac et al. (2004)154 NA + + + NR – NR +
Lundqvist et al.
(2006)151
NA + – + – + – +
Salo et al. (2008)155 ++ ++ ++ – – ++ + ++
Narimani et al.
(2008)153
++ + + NR NR – + –
































































l quality of life
l sleep quality.
All populations and trauma exposure combined
Post-traumatic stress disorder total symptoms
A summary of meta-analyses of the effectiveness of psychological interventions across all populations
for PTSD symptoms is shown in Appendix 9, Table 34. Overall, when all eligible trials were combined
(39 trials, n = 2506)53–55,62,66,69,74,76,78,81,86,88,89,91,92,94–96,98,100,101,106–109,121,126,131,132,140,142–146,157–159 across all
populations, psychological interventions were associated with a large and significant post-treatment
effect in favour of a reduction in PTSD total symptoms (Figure 3).
Of the six trials (n = 259)71,84,87,113,137–139,160 that compared psychological interventions with an active
control, the post-treatment effect size was smaller and in favour of a reduction in total PTSD symptoms,
but not significantly (SMD –0.35, 95% CI –0.72 to 0.03; I2 = 47.0%). Ten trials (n = 738)78,81,92,95,98,121,132
measured outcomes after < 6 months and showed that psychological interventions were associated with
a medium and significant effect in favour of a reduction in PTSD total symptoms (SMD –0.38, 95% CI
–0.68 to –0.08; I2 = 79.4%).
When treatment effects were meta-analysed by intervention type, we showed that IPT was associated with
the largest post-treatment effect on total PTSD symptoms (SMD –1.41, 95% CI –1.97 to –0.85; I2= 0%).
This result is based on two small studies (n= 66)98,108 and associated with a high degree of uncertainty, as
indicated by the wide CIs for the individual and combined point estimates (see Appendix 10, Figure 27).
There was strong evidence from 21 trials (n = 1283)55,62,66,81,86,92,94–96,100,101,106,107,109,126,140,143,144,158,159 that
trauma-focused CBT is effective for reducing PTSD total symptoms (see Appendix 10, Figure 28).
Four trials (n = 206)81,87,92,113 that tested trauma-focused CBT measured outcomes at follow-up after
< 6 months and were associated with a large and significant treatment effect (SMD –0.64, 95% CI
–1.10 to –0.18; I2 = 44.9%). However, we did not find evidence of the effectiveness of trauma-focused
CBT versus active controls.
Evidence from seven trials (n = 244)53,54,74,76,88,91,157 showed that EMDR was similarly effective at
reducing PTSD symptoms post treatment (see Appendix 10, Figure 29). Two trials (n = 71)138,139
compared EMDR with an active control. Post-treatment effects were in favour of a small reduction in
PTSD total symptoms, but this result was non-significant (SMD –0.15, 95% CI –0.62 to 0.32; I2 = 0%).
Mindfulness (three trials, n = 183)95,121,142 was associated with a small non-significant effect in favour of
symptom reduction when compared with control post treatment (see Appendix 10, Figure 30). In two
trials95,121 that measured outcomes at follow-up after < 6 months, mindfulness was not effective for
PTSD symptoms (SMD –0.08, 95% CI –1.56 to –0.32; I2 = 59%).
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Intervention (n) Control (n) ES (95% CI) Weight (%)
15 14 –1.70 (–2.56 to –0.84) 2.31
Acarturk (2016)54 37 33 –2.17 (–2.77 to –1.58) 2.74
Adenauer (2011)55 11 8 –1.88 (–2.99 to –0.77) 1.92
Bolton (2014)62 215 66 –0.33 (–0.61 to –0.05) 3.16
Carlson (1997)64 10 11 –0.94 (–1.85 to –0.04) 2.23
Chard (2005)66 36 37 –2.33 (–2.93 to –1.73) 2.73
Cloitre (2002)69 22 24 –1.30 (–1.93 to –0.66) 2.67
Devilly (1998)74 12 10 –0.03 (–0.87 to 0.81) 2.34
Edmond (1999)76 20 19 –1.09 (–1.77 to –0.42) 2.61
Engel (2015)78 29 29 0.13 (–0.38 to 0.65) 2.86
Franklin (2017)81 6 7 –1.05 (–2.22 to 0.13) 1.83
Hermenau (2013)86 15 15 –0.41 (–1.13 to 0.31) 2.53
Himmerich (2016)88 21 17 –0.47 (–1.12 to 0.18) 2.65
Hinton (2005)89 20 20 –2.17 (–2.96 to –1.38) 2.42
Hinton (2004)90 6 6 –2.40 (–3.94 to –0.85) 1.38
Jensen (1994)91 13 12 –1.00 (–1.84 to –0.17) 2.34
Jung (2013)92 14 14 –0.83 (–1.61 to –0.06) 2.45
Keane (1989)94 11 31 –0.24 (–0.93 to 0.45) 2.59
Kearney (2013)95 25 22 –0.50 (–1.08 to 0.08) 2.76
Knaevelsrud (2015)96 79 80 –0.92 (–1.25 to –0.59) 3.11
Krupnick (2008)98 32 16 –1.37 (–2.03 to –0.71) 2.63
Kubany (2003)100 18 14 –2.99 (–4.02 to –1.96) 2.04
Kubany (2004)101 45 40 –2.89 (–3.51 to –2.28) 2.71
Margolies (2011)105 15 12 –1.12 (–1.94 to –0.30) 2.37
McDonagh (2005)106 51 23 –0.62 (–1.12 to –0.12) 2.88
McLay (2011)107 10 9 –0.68 (–1.61 to 0.25) 2.20
Meffert (2014)108 10 8 –1.51 (–2.58 to –0.44) 1.98
Miyahira (2012)109 10 12 –0.50 (–1.35 to 0.35) 2.32
Possemato (2016)121 36 26 –0.05 (–0.55 to 0.45) 2.88






Weiss (2015) trial 1: CETA144
Weiss (2015) trial 2: CPT144
48 0.09 (–0.27 to 0.45) 3.07
124 123 –0.03 (–0.28 to 0.22) 3.19
12 9 –1.81 (–2.85 to –0.77) 2.03
52 25 –0.27 (–0.75 to 0.20) 2.92
13 15 0.01 (–0.74 to 0.75) 2.50
99 50 –0.70 (–1.05 to –0.35) 3.09
124 64 –0.26 (–0.56 to 0.05) 3.14
Yeomans (2010)145
Zlotnick (1997)146
38 38 –0.28 (–0.73 to 0.17) 2.95
16 17 –0.85 (–1.57 to –0.14) 2.54
Overall (I2 = 85.3%; p = 0.000)
NOTE: weights are from random-effects analysis
–0.90 (–1.14 to –0.66) 100.00
–3 –2 –1 0 1 32
Favours intervention Favours control
FIGURE 3 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all psychological
interventions with control. CETA, common elements treatment approach; CPT, cognitive processing therapy.
RESULTS OF THE EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Non-trauma-focused CBT (three trials, n = 548)62,78,131,132 was associated with small non-significant effects
in favour of symptom reduction when compared with control post treatment (see Appendix 10, Figure 31).
Treatment effects were also non-significant for non-trauma-focused CBT for PTSD outcomes in two
trials78,132 that measured outcomes after < 6 months (SMD –0.02, 95% CI –0.25 to 0.20; I2 = 0%).
When interventions from 22 trials (n = 1191)53–55,62,66,74,76,81,86,89,91,92,94,96,100,101,106,107,109,126,144,157,158 were
grouped using composite intervention categories, we showed that single-component and trauma-
focused interventions based on a single theoretical approach were associated with a large and
significant treatment effect in favour of a reduction in PTSD symptoms (see Appendix 10, Figure 32).
A large effect was also observed in a meta-analysis of five trials (n = 276)54,78,81,95,98,132 that measured
outcomes at follow-up after < 6 months (SMD –0.94, 95% CI –1.56 to –0.32; I2 = 77.6%).
Seven trials (n = 440)69,88,140,143–145,159 delivered multicomponent and trauma-focused interventions
(DBT, EMDR, trauma-focused CBT and other psychotherapeutic approaches) and were associated with
a large and significant effect in favour of a reduction in PTSD symptoms (see Appendix 10, Figure 32).
There was evidence (11 trials, n = 936)62,78,95,98,106,108,121,131,132,142,146 that single-component non-trauma-
focused interventions (CBT, mindfulness, counselling, IPT and other psychotherapeutic approaches)
were associated with a significant and moderate treatment effect in favour of a reduction in PTSD
symptoms post treatment (see Appendix 10, Figure 34). In five trials (n = 462)78,95,98,121,132 that measured
outcomes after < 6 months, the treatment effect for single-component non-trauma-focused interventions
was small and non-significant (SMD –0.05, 95% CI –0.23 to 0.14; I2 = 0%).When compared with an active
control (two trials, n = 62),137,160 single-component non-trauma-focused interventions were associated
with a non-significant large treatment effect in favour of a reduction in PTSD symptoms (SMD –0.64,
95% CI –1.82 to 0.53; I2 = 76.9%).
Figure 4 shows the results of a meta-analysis that compared phase-based psychological interventions
with control. Only six studies (n = 190)69,88,98,107,108,140 were coded as phased based for PTSD outcomes.
The results show that a variety of trauma- and non-trauma-focused interventions (DBT, EMDR, IPT
and trauma-focused CBT) are associated with a large and significant improvement in PTSD symptoms
when delivered as part of a phase-based approach with a stabilisation component.
First author (year)
Cloitre (2002)69
Intervention (n) Control (n) ES (95% CI) Weight (%)
22 24 –1.30 (–1.93 to –0.66) 21.72
Himmerich (2016)88 21 17 –0.47 (–1.12 to 0.18) 21.36
Krupnick (2008)98 32 16 –1.37 (–2.03 to –0.71) 20.87
McLay (2011)107 10 9 –0.68 (–1.61 to –0.25) 13.53
Meffert (2014)108
Overall (I2 = 35.9%; p = 0.168)





–1.51 (–2.58 to –0.44)
–1.81 (–2.85 to –0.77)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 4 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing phase-based
psychological interventions with control.
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Complex post-traumatic stress disorder symptoms
A summary of meta-analyses of the clinical effectiveness of psychological interventions across all
populations for CPTSD symptoms is shown in Appendix 9, Table 35.
Emotional dysregulation
Seven studies (n = 289)69,79,86,98,106,108,142 included data about symptoms of emotional dysregulation that
could be meta-analysed across populations and trauma exposure. Figure 5 shows the results of a
meta-analysis that compared all psychological interventions with control as regards a reduction in
symptoms of emotional dysregulation at the end of treatment. The results favoured the interventions
but did not reach statistical significance.
Of these seven trials, three compared trauma-focused CBT with control.79,86,106 At the end of treatment,
trauma-focused CBTwas associated with a small effect in favour of a reduction in symptoms of emotional
dysregulation, but this result did not reach statistical significance (see Appendix 10, Figure 35). Two small
studies (n = 51)79 that compared trauma-focused CBTwith control measured outcomes after < 6 months
and were associated with a medium but non-significant treatment effect (SMD –0.42, 95% CI –1.53 to
0.69; I2 = 72.3%).
Four studies (n = 163)98,106,108,142 compared single-component and non-trauma-focused interventions
with control. At the end of treatment, the meta-analysis showed that single-component and non-
trauma interventions were not significantly associated with a reduction in symptoms of emotional
dysregulation (see Appendix 10, Figure 36).
The largest treatment effect for emotional dysregulation was associated with three studies (n = 112)69,98,108
that tested interventions that can be characterised as phased based. However, while the large treatment




Intervention (n) Control (n) SMD (95% CI) Weight (%)
22 24 –1.45 (–2.10 to –0.80) 14.82
Feske (2008)79 9 12 –1.02 (–1.95 to –0.10) 11.83
Hermenau (2013)86 15 15 0.11 (–0.61 to 0.83) 14.09
Krupnick (2008)98 32 16 0.09 (–0.51 to 0.69) 15.42
Meffert (2014)108 10 8 –0.97 (–1.96 to 0.02) 11.17
Wahbeh (2016)142
Overall (I2 = 74.5%; p = 0.001)





0.09 (–0.46 to 0.63)
0.12 (–0.37 to 0.61)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 5 Meta-analysis of post-treatment SMD for emotional dysregulation, comparing all psychological interventions
with control.
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Negative self-concept
Five studies (n = 215)92,100,101,125,142 included data about symptoms of negative self-concept that could
be meta-analysed. Figure 7 shows the results of a meta-analysis that compared all psychological
interventions with control as regards a reduction in symptoms of negative self-concept at the end of
treatment. When combined, psychological interventions were associated with a large treatment effect
in favour of a reduction in symptoms of negative self-concept, albeit with a high degree of uncertainty
and heterogeneity.
Figure 37 (see Appendix 10) shows that, when only the trauma-focused CBT studies were meta-analysed
(three trials, n = 145),92,100,101 the effect size was very large and significant but with high degree of
uncertainty about the combined point estimate and high levels of heterogeneity (SMD 2.22, 95% CI




SMD (95% CI) Weight (%)
14 14 0.76 (–0.01  to 1.53) 20.31
Kubany (2003)100 18 14 3.07 (2.03 to 4.12) 18.68
Kubany (2004)101 45 40 2.88 (2.27 to 3.49) 21.11
Reed (2006)125
Overall (I2 = 90.0%; p = 0.000)





1.81 (0.75 to 2.87)
0.64 (0.07 to 1.21)




 –3  –2  –1 0 1 2 3
Intervention (n) Control (n)
FIGURE 7 Meta-analysis of post-treatment SMD for negative self-concept, comparing all psychological interventions with
control (positive SMD equals improvement in symptoms).
First author (year)
Cloitre (2002)69
Intervention (n) Control (n) SMD (95% CI) Weight (%)
22 24 –1.45 (–2.10 to –0.80) 34.85
Krupnick (2008)98
Overall (I2 = 83.4%; p = 0.002)





0.09 (–0.51 to 0.69)
–0.97 (–1.96 to 0.02)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 6 Meta-analysis of post-treatment SMD for emotional dysregulation, comparing phase-based psychological
interventions with control.
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A more homogeneous and significantly large treatment effect was associated with the two studies
(n = 117)100,101 that were characterised as comparing multicomponent and trauma-focused interventions
with control (SMD 2.93, 95% 2.40 to 3.45; I2 = 0%; see Appendix 10, Figure 38).
Single-component non-trauma-focused interventions (two studies; n = 70)125,142 were also associated
with large and significant effects in favour of improvement in negative self-concept, but the overall
point estimate had a high degree of uncertainty (SMD 1.14, 95% CI 0.01 to 2.27; I2 = 72.6%; see
Appendix 10, Figure 39).
Interpersonal problems
Only two studies (n = 94),69,98 both testing phase-based interventions, were identified that included
outcome data for interpersonal problems that could be meta-analysed. The overall treatment effect
was large and in favour of a reduction in symptoms associated with interpersonal problems, but did not
reach significance (SMD –0.59, 95% CI –1.28 to 0.11; I2 = 61.9%; see Appendix 10, Figure 40).
Depression symptoms
A summary of meta-analyses of the clinical effectiveness of psychological interventions across all
populations for depression symptoms is shown in Appendix 9, Table 36. Figure 8 shows the results of
the meta-analysis of the 31 studies (n = 1866)53–55,62,69,74,76,81,92,95,96,98,100,101,106,108,109,111,121,125,137,140,142,144,157–159
that compared all psychological interventions with control post treatment for depression symptoms.
The results show that interventions were associated with a large effect in favour of a reduction in
depression symptoms. When all psychological interventions were compared with control at follow-up
after < 6 months, there was a medium and still significant effect in favour of a reduction in depression
symptoms (SMD –0.51, 95% CI –0.80 to –0.22; I2 = 48%; nine trials, n = 410).54,78,81,87,92,95,98,111,121
When interventions were meta-analysed by type, studies that tested trauma-focused CBT were the
most numerous. Fifteen studies (n = 1115)62,81,92,96,100,101,106,109,126,140,143,144,159 compared trauma-focused
CBT with control post treatment. Figure 41 (see Appendix 10) shows that trauma-focused CBT was
associated with a large and significant effect in favour of a reduction in depression symptoms. There
was also a positive effect in the three studies (n = 104)81,87,92 that compared post-treatment outcomes
at follow-up after < 6 months, although the point estimate was associated with considerable
uncertainty (SMD –0.72, 95% CI –1.43 to –0.01; I2 = 56.6%).
Large and significant treatment effects in favour of a reduction of depression symptoms were also
similarly observed in a meta-analysis (five trials, n = 182)53,54,74,76,157 that compared EMDR with control
post treatment (see Appendix 10, Figure 42). In the two studies (n = 72)138,139 that compared EMDR with
an active control, at the end of treatment the effect on depression symptoms favoured the intervention,
but did not reach significance (SMD –0.32, 95% CI –1.23 to 0.59; I2 = 47.8%).
There was also some evidence from two small studies (n = 66)98,108 that IPT compared with control was
effective at reducing symptoms of depression (see Appendix 10, Figure 43).
Three studies (n = 186),95,121,142 all of which included veteran populations, compared mindfulness with
control post treatment. Mindfulness interventions were associated with a medium effect size in favour
of a reduction in depression symptoms (see Appendix 10, Figure 44). In the two studies95,121 that
measured outcomes at follow-up after < 6 months, mindfulness was also associated with a medium and
significant treatment effect (SMD –0.41, 95% CI –0.79 to –0.02; I2 = 0%).
Non-trauma-focused interventions78,137 were not effective in reducing depression symptoms
(see Appendix 10, Figure 45).
Using composite intervention categories, we showed that single-component and trauma-focused
interventions (17 studies; n = 1034)53–55,62,74,76,81,92,96,100,101,106,109,126,144,157,158 based on a single theoretical
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approach were associated with a large and significant treatment effect in favour of a reduction in
depression symptoms (see Appendix 10, Figure 46). A large and significant effect was also observed in
the four studies (n = 174)53,81,87,92 that compared outcomes at follow-up after < 6 months (SMD –0.85,
95% –1.42 to –0.29; I2 = 62.5%).
First author (year)
Acarturk (2015)53
ES (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 3.05
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 3.60
Adenauer (2011)55 11 8 –2.05 (–3.19 to –0.91) 2.34
Bolton (2014)62 215 66 –0.30 (–0.58 to –0.03) 4.10
Carlson (1997)64 10 11 –1.64 (–2.64 to –0.64) 2.61
Chard (2005)66 36 37 –2.00 (–2.57 to –1.44) 3.57
Cloitre (2002)69 22 24 –1.22 (–1.85 to –0.59) 3.42
Devilly (1998)74 13 10 –0.23 (–1.06 to –0.59) 2.98
Edmond (1999)76 20 19 –0.74 (–1.39 to –0.09) 3.38
Engel (2015)78 29 29 0.13 (–0.39 to 0.64) 3.68
Franklin (2017)81 6 7 –1.60 (–2.88 to –0.32) 2.09
Hinton (2004)90 6 6 –1.99 (–3.42 to –0.56) 1.85
Jung (2013)92 14 14 –0.49 (–1.25 to 0.26) 3.15
Kearney (2013)95 25 22 –0.62 (–1.21 to –0.03) 3.52
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 4.02
Krupnick (2008)98 32 16 –1.06 (–1.70 to –0.42) 3.41
Kubany (2003)100 18 14 –3.97 (–5.19 to –2.75) 2.19
Kubany (2004)101 45 40 –2.77 (–3.37 to –2.17) 3.50
Margolies (2011)105 14 9 –1.40 (–2.33 to –0.46) 2.74
McDonagh (2005)106 51 22 –0.62 (–1.13 to –0.11) 3.69
Meffert (2014)108 10 8 –1.46 (–2.52 to –0.40) 2.50
Miyahira (2012)109 10 12 0.09 (–0.75 to 0.93) 2.96
Moradi (2014)111 12 12 –0.72 (–1.55 to 0.11) 2.98
Possemato (2016)121 36 26 –0.28 (–0.78 to 0.23) 3.69
Reger (2016)126 30 46 –0.56 (–1.03 to –0.09) 3.77
Teng (2008)137 18 17 –0.33 (–0.99 to 0.34) 3.34
Ulmer (2011)140 12 9 –0.34 (–1.22 to 0.53) 2.89
Wahbeh (2016)142 52 25 –0.43 (–0.92 to 0.05) 3.74
Wang (2016)143 13 15 0.08 (–0.67 to 0.82) 3.17
Weiss (2015) trial 1: CETA144 99 50 –0.84 (–1.20 to –0.49) 3.99
Overall (I2 = 82.8%; p = 0.000)
NOTE: weights are from random-effects analysis
124Weiss (2015) trial 2: CPT144 64 –0.28 (–0.59 to 0.02)
–0.94 (–1.20 to –0.68)
4.07
100.00
–3 –2 –1 0 1 32





FIGURE 8 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all psychological
interventions with control. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Six studies (n = 340)69,140,143,144,159 compared multicomponent and trauma-focused interventions with
control and were associated with a similarly large and significant effect in favour of a reduction in
depression symptoms (see Appendix 10, Figure 47).
A smaller but still significant and favourable treatment effect was observed in the 10 studies (n= 594)62,78,95,98,
106,108,111,121,137,142 that compared single-component and non-trauma-focused interventions with control post
treatment (see Appendix 10, Figure 48). There was a small and non-significant effect in the five studies
(n = 236)78,95,98,111,121 that measured outcomes at follow-up after < 6 months (SMD –0.30, 95% –0.56 to
0.04; I2 = 0%).
Figure 9 shows that, post treatment, compared with control, phase-based interventions were associated
with a large and significant treatment effect in favour of a reduction in depression symptoms, although
this result is based on just four small studies.69,98,108,140
Anxiety symptoms
A summary of meta-analyses of the clinical effectiveness of psychological interventions across all
populations for anxiety symptoms is shown in Appendix 9, Table 37. Figure 10 shows the result of
a meta-analysis of 13 studies (n = 1136)62,69,74,76,81,91,96,126,143,144,157 that compared all psychological
interventions with control post treatment. Interventions were associated with a large and significant
treatment effect in favour of a reduction in anxiety symptoms.
The majority of the studies (eight studies; n = 7)62,81,96,106,126,143,144 that included data about anxiety
symptoms tested trauma-focused CBT. When compared with control post treatment, meta-analysis
showed that trauma-focused CBT was associated with a large and significant effect in favour of a
reduction in anxiety symptoms (Figure 11).
The largest effects in favour of a reduction in anxiety symptoms were observed in a meta-analysis of
four studies (n = 102)74,76,91,157 that compared EMDR with control post treatment (see Appendix 10,
Figure 49).
There were no data that could be meta-analysed that compared mindfulness or non-trauma-focused
CBT with either control or an active control.
First author (year)
Cloitre (2002)69
ES (95% CI) Weight (%)
22 24 –1.22 (–1.85 to –0.59) 33.94
Krupnick (2008)98 32 16 –1.06 (–1.70 to –0.42) 33.40
Meffert (2014)108
Overall (I2 = 10.9%; p = 0.339)





–1.46 (–2.52 to –0.40)
–0.34 (–1.22 to 0.53)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 9 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing phase-based
interventions with control.
RESULTS OF THE EFFECTIVENESS REVIEW




ES (95% CI) Weight (%)
215 66 –0.19 (–0.46 to 0.09) 10.64
Carlson (1997)64 10 11 –1.39 (–2.36 to –0.43) 6.35
Cloitre (2002)69 22 24 –1.54 (–2.21 to –0.88) 8.27
Devilly (1998)74 13 10 –0.43 (–1.27 to 0.40) 7.13
Edmond (1999)76 20 19 –1.35 (–2.05 to –0.65) 8.02
Franklin (2017)81 6 7 –1.39 (–2.63 to –0.16) 4.95
Jensen (1994)91 11 8 –0.99 (–1.96 to –0.02) 6.32
Knaevelsrud (2015)96 79 80 –1.55 (–1.90 to –1.19) 10.24
Reger (2016)126 30 47 –0.14 (–0.59 to 0.32) 9.62
Wang (2016)143 13 15 0.06 (–0.68 to 0.80) 7.73
Weiss (2015) trial 1: CETA144
Overall (I2 = 83.4%; p = 0.000)
NOTE: weights are from random-effects analysis
99
124Weiss (2015) trial 2: CPT144
50
64
–0.98 (–1.34 to –0.62)
–0.33 (–0.63 to –0.03)




–3 –2 –1 0 1 2 3





FIGURE 10 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing all psychological
interventions with control. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
First author (year)
Bolton (2014)62
ES (95% CI) Weight (%)
101 66 –0.25 (–0.56 to 0.06) 14.56
Franklin (2017)81 6 7 –1.39 (–2.63 to –0.16) 6.50
Knaevelsrud (2015)96 79 80 –1.55 (–1.90 to –1.19) 14.20
McDonagh (2005)106 29 22 –0.43 (–0.99 to 0.13) 12.25
Reger (2016)126 30 47 –0.14 (–0.59 to 0.32) 13.26
Wang (2016)143 13 15 0.06 (–0.68 to 0.80) 10.44
Weiss (2015) trial 1: CETA144
Overall (I2 = 85.5%; p = 0.000)
NOTE: weights are from random-effects analysis
99
124Weiss (2015) trial 2: CPT144
50
64
–0.98 (–1.34 to –0.62)
–0.33 (–0.63 to –0.03)
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FIGURE 11 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing trauma-focused CBT with
control. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Using composite intervention categories, we showed in a meta-analysis that single-component and
trauma-focused interventions (10 studies; n = 757)62,74,76,81,91,96,106,126,144,157 were associated with a large
and significant treatment effect in favour of a reduction in anxiety symptoms (see Appendix 10,
Figure 50).
Compared with control, multicomponent and trauma-focused interventions were associated with the
largest treatment effect in favour of a reduction of anxiety symptoms (SMD –0.85, 95% CI –1.60 to
–0.10; I2 = 80.4%).69,143,144 This meta-analysis included studies that tested a phase-based intervention
and trauma-focused CBT (see Appendix 10, Figure 51).
Only two studies (n = 225)62,106 compared single-component and non-trauma-focused interventions with
control post treatment: one tested a counselling intervention and one tested non-trauma-focused CBT.
Although the treatment effect favoured a reduction in anxiety symptoms, the effect was small and did
not reach significance (see Appendix 10, Figure 52).
Quality of life
A summary of meta-analyses of the clinical effectiveness of psychological interventions across all
populations for quality of life is shown in Appendix 9, Table 38. We identified five trials (n = 307)95,96,106,109,143
that included quality-of-life data that could be meta-analysed. Figure 12 shows the result of a meta-analysis
that compared all psychological interventions with control post treatment.
Four of these five studies (n = 260)96,106,109,143 compared trauma-focused CBTwith control post treatment.
Although interventions favoured a small improvement in quality of life, the effect size did not reach
significance (SMD 0.23, 95% CI –0.33 to 0.79; I2 = 73.9%; see Appendix 10, Figure 53).
Sleep quality
A summary of meta-analyses of the clinical effectiveness of psychological interventions across all
populations for sleep quality is shown in Appendix 9, Table 39. Only three studies (n = 111)140,142,159
included data about sleep quality that could be meta-analysed. When compared with control post
treatment, all psychological interventions were associated with a large and significant effect on sleep
First author (year)
Kearney (2013)95
ES (95% CI) Weight
(%)
25 22 0.38 (–0.19 to 0.96) 20.34
Knaevelsrud (2015)96 79 80 0.84 (0.51 to 1.16) 27.16
McDonagh (2005)106 29 23 0.14 (–0.40 to 0.69) 21.14
Miyahira (2012)109
Overall (I2 = 65.5%; p = 0.021)





–0.23 (–1.08 to 0.61)
–0.12 (–0.84 to 0.60)










FIGURE 12 Meta-analysis of post-treatment effect size (ES) for quality of life, comparing all psychological interventions
with control (positive ES favours intervention).
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quality (SMD –1.00, 95% CI –1.49 to –0.51; I2 = 28.8%; see Appendix 10, Figure 54). A larger and
significant treatment effect in favour of improved sleep quality was observed in a meta-analysis of just
two small studies140,159 that compared trauma-focused CBT with control post treatment (SMD –1.30,
95% CI –1.87 to –0.73; I2 = 0%; see Appendix 10, Figure 55).
Psychological interventions versus control
A summary of all of the clinical effectiveness meta-analyses undertaken within each trauma exposure
can be found in Appendix 9.
Veterans
A summary of meta-analyses of the clinical effectiveness of psychological interventions in veterans
for PTSD, depression and anxiety symptoms is shown in Appendix 9, Table 40. Twenty-three trials
were identified that included data about veteran populations. Five trials were not included in the
meta-analysis: three compared head-to-head interventions,120,124,128 one compared trauma-focused
CBT with exposure alone60 and one did not include extractable data.83
Post-traumatic stress disorder symptoms
Figure 13 shows the result of a meta-analysis (14 trials, n = 502)74,78,81,88,91,94,95,107,121,126,140,142,157,159 that
compared all psychological interventions with control post treatment. The medium treatment effect
favours a significant reduction in PTSD symptoms.
Four trials (n = 180)78,95,121 measured PTSD outcomes at follow-up after < 6 months and, while
psychological interventions were associated with a small treatment effect in favour of interventions,
this did not reach significance (SMD –0.20, 95% –0.72 to 0.33; I2 = 63.1%).
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –0.94 (–1.85 to –0.04) 5.06
Devilly (1998)74 12 10 –0.03 (–0.87 to 0.81) 5.65
Engel (2015)78 29 29 0.13 (–0.38 to 0.65) 9.91
Franklin (2017)81 6 7 –1.05 (–2.22 to 0.13) 3.40
Himmerich (2016)88 21 17 –0.47 (–1.12 to 0.18) 7.83
Jensen (1994)91 13 12 –1.00 (–1.84 to –0.17) 5.67
Keane (1989)94 11 31 –0.24 (–0.93 to 0.45) 7.28
Kearney (2013)95 25 22 –0.50 (–1.08 to 0.08) 8.80
Margolies (2011)105 15 12 –1.12 (–1.94 to –0.30) 5.83
McLay (2011)107 10 9 –0.68 (–1.61 to 0.25) 4.89
Possemato (2016)121 36 26 –0.05 (–0.55 to 0.45) 10.10
Reger (2016)126 30 47 –0.40 (–0.86 to 0.07) 10.88
Ulmer (2011)140
Overall (I2 = 41.7%; p = 0.051)
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FIGURE 13 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing all psychological interventions
with control in veteran populations.
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Six trials (n = 106)81,94,100,107,126,159 compared trauma-focused CBT with control post treatment. Trauma-
focused CBT was associated with a large and significant treatment effect in favour of a reduction in
PTSD total symptoms (SMD –0.77, 95% CI –1.20 to –0.33; I2 = 44.6%; see Appendix 10, Figure 56).
A meta-analysis of four trials (n = 106)74,88,91,157 showed that EMDR was associated with a smaller but
still significant treatment effect when compared with control post treatment (see Appendix 10, Figure 57).
Studies that included veterans95,121,142 provided all of the data in the previous meta-analysis that compared
mindfulness with control post treatment and at follow-up after < 6 months (see Appendix 10, Figure 58).
No studies that included veterans compared non-trauma-focused CBT with either a control or an active
control group.
Figure 59 (see Appendix 10) shows the results of a meta-analysis (seven trials, n = 219)74,81,91,94,107,157
that compared single-component and trauma-focused interventions with control post treatment. This
shows that single-component and trauma-focused interventions were associated with a medium and
significant effect in favour of a reduction in PTSD symptoms. The size of the effect was about half that
observed in the equivalent analysis for all populations and trauma exposures pooled.
The largest effect was observed in a meta-analysis of three small studies (n= 86)88,140,159 that compared
multicomponent and trauma-focused interventions with control post treatment (see Appendix 10, Figure 60).
Single-component and non-trauma-focused interventions were not associated with a significant
treatment effect in favour of a reduction in PTSD symptoms post treatment in veterans (see Appendix 10,
Figure 61).78,95,121,142
Four trials compared psychological interventions with active control (sleep and nightmare management,
placebo and psychoeducation).71,84,137,160 It was unclear if psychological interventions as a whole (SMD
–0.44, 95% CI –0.98 to 0.10; I2 = 64%; four trials, n = 188) or trauma-focused CBT (SMD –0.26, 95% CI
–0.88 to 0.35; I2 = 51.1%; two trials, n = 126) were effective for PTSD symptoms.
Depression
Figure 14 shows the results of a meta-analysis (11 trials; 445)74,78,81,95,111,121,126,137,140,142,157,159 that
compared all psychological interventions with control post treatment. The size of the treatment effect
is smaller than the effect observed in the equivalent analysis that pooled PTSD outcomes across all
populations and trauma exposures. In five studies (n = 201)78,81,95,111,121 that measured outcomes at
follow-up after < 6 months, all psychological interventions were associated with a medium effect in
favour of a reduction in depression symptoms, but this effect was not significant (SMD –0.38, 95% CI
–0.78 to 0.01; I2 = 42.3%).
When only those studies that compared trauma-focused CBT with control post treatment were
considered, the meta-analysis (three trials, n = 112)81,126,159 showed that interventions were associated
with a large and significant treatment effect in favour of a reduction of depression symptoms (see
Appendix 10, Figure 62). There was, however, no evidence of a significant difference between trauma-
focused CBT and active control (SMD –0.04, 95% CI –0.55 to 0.48; I2 = 38.7%; two trials, n = 128).71,84
Compared with control post treatment, EMDR was similarly associated with large effects in favour of a
reduction in depression symptoms, but the overall point estimate was non-significant and associated
with considerable uncertainty (see Appendix 10, Figure 63).74,157
The pooled population meta-analysis that compared mindfulness with control post treatment and after
< 6 months included only studies with veterans and is shown in Appendix 10, Figure 64.95,121,142
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No studies that included veteran populations compared non-trauma-focused CBT with control for
depression symptoms.
Single-component and trauma-focused interventions were associated with large and significant effects
in favour of a reduction in depression symptoms (see Appendix 10, Figure 65).74,81,126,157
There was less evidence in favour of multicomponent and trauma-focused interventions, which were
not significantly associated with a reduction in depression symptoms in a meta-analysis that included
only two small trials (see Appendix 10, Figure 66).140,159
By contrast, a meta-analysis that included five studies (n = 268)78,95,111,121,142 that compared single-
component and non-trauma-focused interventions showed that interventions were associated with a
medium but significant effect in favour of a reduction in depression symptoms (see Appendix 10,
Figure 67). Four of these studies (n = 188)78,95,111,121 measured outcomes after < 6 months, but the
effect was not significant (SMD –0.27, 95% CI –0.56 to 0.02; I2 = 0%).
Anxiety
There was less evidence for using psychological interventions for managing anxiety symptoms than other
symptoms in veteran populations. We identified five studies (n = 153)74,81,91,126,157 that showed, in a meta-
analysis, that overall, when pooled together, psychological interventions compared with control were
associated with a large and significant effect in favour of a reduction in anxiety symptoms (Figure 15).
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –1.64 (–2.64 to –0.64) 5.75
Devilly (1998)74 13 10 –0.23 (–1.06 to 0.59) 7.47
Engel (2015)78 29 29 0.13 (–0.39 to 0.64) 12.33
Franklin (2017)81 6 7 –1.60 (–2.88 to –0.32) 3.95
Kearney (2013)95 25 22 –0.62 (–1.21 to –0.03) 10.98
Margolies (2011)105 14 9 –1.40 (–2.33 to –0.46) 6.32
Moradi (2014)111 12 12 –0.72 (–1.55 to 0.11) 7.47
Possemato (2016)121 36 26 –0.28 (–0.78 to 0.23) 12.49
Reger (2016)126 30 46 –0.56 (–1.03 to –0.09) 13.27
Ulmer (2011)140
Overall (I2 = 46.8%; p = 0.043)
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FIGURE 14 Meta-analysis of post-treatment SMD for total depression symptoms, comparing all psychological
interventions with control in veteran populations.
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Only two studies (n = 90)81,126 compared trauma-focused CBT with control post treatment in veterans.
Meta-analysis showed that interventions favoured a reduction in anxiety symptoms, but this effect was
not significant and was associated with a high degree of uncertainty (see Appendix 10, Figure 68).
By contrast, EMDR compared with control was associated in a meta-analysis (three trials, n = 63)74,91,157
with a large treatment effect in favour of a reduction in anxiety symptoms post treatment (see Appendix 10,
Figure 69). The size of this effect was marginally smaller than that observed in the meta-analysis that
pooled all populations and that included more studies.
War-affected populations
A summary of meta-analyses of the clinical effectiveness of psychological interventions across
war-affected populations for PTSD, depression and anxiety symptoms is shown in Appendix 9, Table 41.
Ten studies that included war-affected populations were identified; eight were included in the meta-analyses.
Azad Marzabadi and Hashemi Zadeh57 did not report outcomes that were sufficiently similar to other
studies (i.e. they only reported on the WHO Quality of Life questionnaire) and Bichescu et al.61 compared
head-to-head interventions; therefore, these were not meta-analysed.
Post-traumatic stress disorder total symptoms
Figure 16 shows the results of a meta-analysis that compared all psychological interventions
(eight trials, n = 933)62,86,96,109,143–145 with control post treatment. The results show that psychological
interventions were associated with a medium effect size in favour of a reduction in total PTSD
symptoms. The size of this effect was comparable to that observed for veteran populations.
The majority of the studies (seven trials, n = 743)62,86,96,109,143,144 in war-affected populations compared
trauma-focused CBT with control post treatment. Figure 70 (see Appendix 10) shows that trauma-
focused interventions were associated with a medium and significant effect in favour of reducing PTSD
symptoms in war-affected populations.
A very similar result was found when single-component and trauma-focused interventions were
compared in a meta-analysis (five trials, n = 566)62,86,96,109,144 with control post treatment (SMD –0.51,
95% CI –0.80 to –0.23; I2 = 55.9%).
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –1.39 (–2.36 to –0.43) 17.82
Devilly (1998)74 13 10 –0.43 (–1.27 to 0.40) 20.61
Franklin (2017)81 6 7 –1.39 (–2.63 to –0.16) 13.23
Jensen (1994)91
Overall (I2 = 54.0%; p = 0.069)
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FIGURE 15 Meta-analysis of post-treatment SMD for total anxiety symptoms, comparing all psychological interventions
with control in veteran populations.
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Three studies delivered therapies as part of a multicomponent and trauma-focused intervention.143–145
When meta-analysed, these three studies (n = 253) showed that multicomponent and trauma-focused
interventions were associated with a medium effect size in favour of a reduction in PTSD symptoms
post treatment, but the overall point estimate was more uncertain than in the other meta-analyses in
this population subgroup (see Appendix 10, Figure 71).
Depression symptoms
Six trials (n = 827)62,96,109,143,144 were identified that included data that could be meta-analysed for
depression symptoms in the war-affected subgroup. All of these studies compared trauma-focused CBT
with control post treatment. When meta-analysed together, Figure 17 shows that trauma-focused CBT is
associated with a medium and significant effect size in favour of a reduction in depression symptoms.
When trauma-focused CBT was delivered as part of a single-component intervention and compared
with control, the meta-analysis (four trials, n = 536)62,96,109,144 shows that the intervention was associated
with a similarly medium and significant effect size in favour of a reduction in depression symptoms
(see Appendix 10, Figure 72). However, in the two studies that tested trauma-focused CBT as part of a
multicomponent intervention, the meta-analysis (n = 177)143,144 shows that the treatment effect favoured
a reduction in depression symptoms but did not reach significance (see Appendix 10, Figure 73).
Anxiety symptoms
Five trials (n = 691)62,96,143,144 were identified that included data that could be meta-analysed for
depression symptoms in the war-affected subgroup. All of these studies compared trauma-focused CBT
with control post treatment. When meta-analysed together, Figure 18 shows that trauma-focused CBT
is associated with a large and significant effect size in favour of a reduction in anxiety symptoms.
First author (year)
Bolton (2014)62
ES (95% CI) Weight (%)
215 66 –0.33 (–0.61 to –0.05) 18.85
Hermenau (2013)86 15 15 –0.41 (–1.13 to 0.31) 6.68
Knaevelsrud (2015)96 79 80 –0.92 (–1.25 to –0.59) 16.79
Miyahira (2012)109 10 12 –0.50 (–1.35 to 0.35) 5.16
Wang (2016)143 13 15 0.01 (–0.74 to 0.75) 6.42
Weiss (2015) trial 1: CETA144 99 50 –0.70 (–1.05 to –0.35) 15.92
Weiss (2015) trial 2: CPT144
Overall (I2 = 50.4%; p = 0.049)





–0.26 (–0.56 to 0.05)
–0.28 (–0.73 to 0.17)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 16 Meta-analysis of post-treatment effect size (ES) for total PTSD symptoms, comparing all psychological
interventions with control in war-affected populations. CETA, common elements treatment approach; CPT, cognitive
treatment therapy.
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When trauma-focused CBT was delivered as part of a single-component intervention and compared
with control, the meta-analysis (three trials, n = 514)62,96,144 shows that the intervention was associated
with a large effect size in favour of a reduction in anxiety symptoms, but this effect did not reach
significance (see Appendix 10, Figure 74). Similarly, in the two studies143,144 that tested trauma-focused
CBT as part of a multicomponent intervention, the meta-analysis (n = 177) shows that the treatment
effect favoured a reduction in depression symptoms but did not reach significance and was associated
with considerable uncertainty (see Appendix 10, Figure 75).
First author (year)
Bolton (2014)62
ES (95% CI) Weight 
(%)
101 66 –0.25 (–0.56 to 0.06) 21.22
Knaevelsrud (2015)96 79 80 –1.55 (–1.90 to –1.19) 20.79
Wang (2016)143 13 15 0.06 (–0.68 to 0.80) 15.94
Weiss (2015) trial 1: CETA144
Overall (I2 = 90.4%; p = 0.000)
NOTE: weights are from random-effects analysis
99
124Weiss (2015) trial 2: CPT144
50
64
–0.98 (–1.34 to –0.62)
–0.33 (–0.63 to –0.03)
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FIGURE 18 Meta-analysis of post-treatment effect size (ES) for total anxiety symptoms, comparing trauma-focused CBT
with control in war-affected populations. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
First author (year)
Bolton (2014)62
ES (95% CI) Weight 
(%)
101 66 –0.38 (–0.69 to –0.06) 20.11
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 19.69
Miyahira (2012)109 10 12 0.09 (–0.75 to 0.93) 9.62
Wang (2016)143 13 15 0.08 (–0.67 to 0.82) 11.08
Weiss (2015) trial 1: CETA144
Overall (I2 = 74.8%; p = 0.001)
NOTE: weights are from random-effects analysis
99
124Weiss (2015) trial 2: CPT144
50
64
–0.84 (–1.20 to –0.49)
–0.28 (–0.59 to 0.02)
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FIGURE 17 Meta-analysis of post-treatment effect size (ES) for total depression symptoms, comparing all trauma-focused
CBT interventions with control in war-affected populations. CETA, common elements treatment approach; CPT, cognitive
treatment therapy.
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Childhood sexual abuse
A summary of meta-analyses of the clinical effectiveness of psychological interventions across populations
exposed to childhood sexual abuse for PTSD, depression and anxiety symptoms is shown in Appendix 9,
Table 42. Thirteen of these studies included data that could be meta-analysed in the childhood sexual abuse
subgroup; nine studies (n = 687)66,69,76,92,98,106,131,132,146 were included in the meta-analyses. Those excluded
from the meta-analyses were Cloitre et al.,69 which was a deconstruction trial; Lau and Kristensen,103 which
compared analytic with systemic group therapy; Classen et al.,68 which combined data from trauma-focused
CBT and present-centred therapy groups, making it difficult to separate out and interpret the intervention
effects; and Owens et al.,117 which only reported loss of PTSD diagnosis (an outcome not reported in any
other study in this population).
Post-traumatic stress disorder total symptoms
Figure 19 shows the results of a meta-analysis (nine trials, n = 687)66,69,76,92,98,106,131,132,146 that compared
all psychological interventions with control post treatment. The treatment effect was large and
significant and about twice the size of the comparable result in the meta-analysis that assessed the
effectiveness of all psychological interventions across all populations. Three studies (n = 323)92,98,132
measured outcomes at follow-up after < 6 months. The meta-analysis of these three studies showed
that the treatment effect still favoured a reduction in PTSD symptoms, but it did not reach significance
(SMD –0.27, 95% CI –0.71 to 0.17; I2 = 53.6%).
Three studies (n = 153)66,92,106 compared trauma-focused CBT with control post treatment. The
meta-analysis shows that trauma-focused CBT was the most effective intervention in this subgroup.
Figure 76 (see Appendix 10) shows that this intervention was associated with a large effect in favour
of a reduction in PTSD symptoms, but the wide CIs suggest that this result is particularly uncertain.
First author (year)
Chard (2005)66
SMD (95% CI) Weight (%)
36 37 –2.33 (–2.93 to –1.73) 11.06
Cloitre (2002)69 22 24 –1.30 (–1.93 to –0.66) 10.84
Edmond (1999)76 20 19 –1.09 (–1.77 to –0.42) 10.64
Jung (2013)92 14 14 –0.83 (–1.61 to –0.06) 10.09
Krupnick (2008)98 32 16 –1.37 (–2.03 to –0.71) 10.71
McDonagh (2005)106 51 23 –0.62 (–1.12 to –0.12) 11.54
Sikkema (2007)131 73 48 0.09 (–0.27 to 0.45) 12.15
Sikkema (2013)132
Overall (I2 = 89.6%; p = 0.000)
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FIGURE 19 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing all psychological interventions
with control in childhood sexual abuse populations.
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By contrast, non-trauma-focused CBT, meta-analysed in two studies (n = 368),131,132 did not favour the
intervention when compared with control post treatment (see Appendix 10, Figure 77).
When studies (three trials, n = 119)66,76,92,106 were grouped using the composite categories, we showed
that single-component and trauma-focused interventions were associated with a large and significant
effect in favour of a reduction in PTSD symptoms (see Appendix 10, Figure 78).
Larger and significant effects in favour of a reduction in PTSD symptoms were observed in the meta-
analysis that compared multicomponent and trauma-focused interventions with control post treatment,
but the treatment estimate was associated with considerable uncertainty (SMD –1.82, 95% CI –2.83
to –0.81; I2 = 81.3%; two trials, n = 122). Single-component and non-trauma-focused interventions
(five trials, n = 494)98,106,131,132,146 were shown, in a meta-analysis, to be associated with a medium and
significant effect that favoured a reduction in PTSD symptoms (see Appendix 10, Figure 79). This
analysis included a phase-based study of IPT that was associated with a large and significant effect.98
Two of these trials measured outcomes at follow-up after < 6 months and a meta-analysis shows that
there was no significant difference between interventions and control (SMD –0.08, 95% CI –0.31 to
0.15; I2 = 0%).98,132
Depression
Figure 20 shows the result of a meta-analysis (six trials, n = 307)69,76,92,98,106 that compared all
psychological interventions with control post treatment. Psychological interventions were associated
with a large and significant effect in favour of a reduction in depression symptoms.
Two of these six trials measured outcomes at follow-up after < 6 months; the treatment effect still
favoured interventions and was significant (SMD –0.52, 95% CI –0.99 to –0.04; I2 = 0%).92,98
Figure 80 (see Appendix 10) shows that trauma-focused CBT, when compared with control post
treatment, is associated with a large but non-significant effect size in favour of a reduction in
depression symptoms. This analysis was based on three small studies (n = 152) and there is
considerable uncertainty regarding the overall point estimate.
First author (year)
Chard (2005)66
SMD (95% CI) Weight (%)
36 37 –2.00 (–2.57 to –1.44) 17.62
Cloitre (2002)69 55 24 –1.22 (–1.85 to –0.59) 16.53
Edmond (1999)76 20 19 –0.74 (–1.39 to –0.09) 16.25
Jung (2013)92 14 14 –0.49 (–1.25 to 0.26) 14.65
Krupnick (2008)98
Overall (I2 = 70.5%; p = 0.005)
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FIGURE 20 Meta-analysis of post-treatment SMD for depression symptoms, comparing all psychological interventions
with control in childhood sexual abuse populations.
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There was some tentative evidence from a meta-analysis of three studies (n = 118)76,92,106 that single-
component and trauma-focused interventions were similarly associated with a large and significant
effect size (see Appendix 10, Figure 81).
Single-component and non-trauma-focused interventions were associated with a medium and
significant effect in favour of a reduction in depression symptoms in this subgroup (see Appendix 10,
Figure 82). This analysis was based on three small studies (n = 118).76,92,106
Larger and significant effects in favour of a reduction in depression symptoms were observed in the
meta-analysis that compared multicomponent and trauma-focused interventions with control post
treatment, but the treatment estimate was associated with considerable uncertainty (SMD –1.63,
95% CI –2.40 to –0.85; I2 = 69.7%; two trials, n = 122).
Anxiety symptoms
Only two studies (n = 90)76,106 included anxiety outcome data that could be meta-analysed. Figure 83
(see Appendix 10) shows that single-component and trauma-focused interventions (one testing EMDR,
one testing trauma-focused CBT) are associated with a large effect in favour of a reduction in anxiety
symptoms, but the effect did not reach significance.
Refugee populations
A summary of meta-analyses of the clinical effectiveness of psychological interventions across
refugee populations for PTSD, depression and anxiety symptoms is shown in Appendix 9, Table 43.
Twelve studies that included refugee populations were identified; however, few meta-analyses were
possible. The following trials did not appear in any meta-analyses:
l Neuner et al.114 compared trauma-focused CBT, supportive counselling and psychoeducation and
there was no comparison with a control group.
l Paunovic and Ost119 compared trauma-focused CBT with an exposure-only intervention.
l In Stenmark et al.,136 trauma-focused CBT data were not extractable.
Post-traumatic stress disorder symptoms
Figure 21 shows the results of a meta-analysis (six trials, n = 188)53–55,89,108,136,158 that compared all
psychological interventions with control post treatment. Interventions were associated with a very large
and significant effect size in favour of a reduction in PTSD symptoms. Three studies (n = 235)54,87,113
measured outcomes at follow-up after < 6 months and, in the meta-analysis, the treatment effect was
large and significant at follow-up (SMD –0.66, 95% CI –1.22 to –0.09; I2 = 72.7%).
Three small studies (n = 71)55,89,158 compared trauma-focused CBT with control post treatment and
were associated in a meta-analysis with a very large and significant treatment effect in favour of
a reduction in PTSD symptoms (see Appendix 10, Figure 83). Two larger studies (n = 165)87,113 that
compared trauma-focused CBT with control measured outcomes at follow-up after < 6 months. The
meta-analysis of these two studies showed that the treatment effect favoured interventions but did
not reach significance (SMD –0.40, 95% CI –0.87 to 0.06; I2 = 86.3%).
There was some evidence, based on two small trials (n = 99),53,54 that EMDR, when compared with
control post treatment, was effective at reducing total PTSD symptoms (see Appendix 10, Figure 85).
A large and significant effect in favour of a reduction in total PTSD symptoms was observed in a
meta-analysis (five trials, n = 170)53–55,89,158 that compared single-component and trauma-focused
interventions with control post treatment (see Appendix 10, Figure 86). Two studies (n = 133)54,87
measured outcomes at follow-up after < 6 months and, in a meta-analysis, the treatment effect
favoured the interventions but did not reach significance (SMD –0.67, 95CI% –1.65 to 0.32; I2 = 86.3%).
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In addition to the comparisons with control, two studies (n = 71)138,139 compared EMDR with
stabilisation only. There was insufficient evidence to conclude that EMDR was more effective post
treatment (SMD –0.15, 95% CI –0.62 to 0.32; I2 = 0%) and at follow-up after < 6 months (SMD –0.15,
95% CI –0.80 to 0.49; I2 = 22.4%).
Depression symptoms
Figure 22 shows the results of a meta-analysis (five trials, n = 148)53–55,108,158 that compared all
psychological interventions with control post treatment. There is evidence that psychological
interventions are effective in reducing symptoms of depression in refugee populations.
First author (year)
Acarturk (2015)53
SMD (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 21.99
Acarturk (2016)54 37 33 –1.57 (–2.11 to –1.03) 48.06
Adenauer (2011)55 11 8 –2.05 (–3.19 to –0.91) 10.70
Hinton (2004)90
Overall (I2 = 0.0%; p = 0.764)





–1.99 (–3.42 to –0.56)
–1.46 (–2.52 to –0.40)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 22 Meta-analysis of post-treatment SMD for depression symptoms, comparing all psychological interventions
with control in refugee populations.
First author (year)
Acarturk (2015)53
SMD (95% CI) Weight (%)
15 14 –1.70 (–2.56 to –0.84) 16.27
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 39.21
Adenauer (2011)55 11 8 –1.88 (–2.99 to –0.77) 9.74
Hinton (2005)89 20 20 –2.17 (–2.96 to –1.38) 19.25
Hinton (2004)90
Overall (I2 = 0.0%; p = 0.879)





–2.40 (–3.94 to –0.85)
–1.51 (–2.58 to –0.44)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 21 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing all psychological interventions
with control in refugee populations.
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There was only modest evidence from a meta-analysis of two small trials (n= 31)55,158 that trauma-focused
CBTwhen compared with control is associated with large and significant treatment effects in favour of a
reduction in depression symptoms; the wide CIs suggest this result is uncertain (see Appendix 10, Figure 87).
Two other trials (n= 133)54,87 measured outcomes at follow-up after < 6 months and a meta-analysis shows
that the treatment effect favoured interventions but did not reach significance (SMD –0.73, 95% CI –1.57
to 0.10; I2= 81.3%).
Evidence to support the use of EMDR for managing depression in this population was also based only
on data from two small trials (n = 99).53,54 When compared with control post treatment, EMDR was
associated with a large and significant treatment effect in favour of a reduction in depression
symptoms (see Appendix 10, Figure 88).
Taken together, single-component and trauma-focused interventions that included trauma-focused CBT
and EMDR were effective at reducing depression in refugee populations. A meta-analysis (four trials,
n = 130)53–55,158 showed that, overall, these interventions are associated with a large and significant
treatment effect (see Appendix 10, Figure 89).
Two studies also compared EMDR with stabilisation only.138,139 There was insufficient evidence to
conclude that EMDR was more effective post treatment (SMD –0.32, 95% CI –1.23 to 0.59; I2 = 47.8%;
two trials, n = 72) or at follow-up after < 6 months (SMD –0.01, 95% CI –0.47 to 0.45; I2 = 0%; two
trials, n = 73).
Anxiety symptoms
Only data from two studies that compared EMDR with stabilisation included data on anxiety symptoms
that could be extracted.138,139 There was no evidence that EMDR was effective in reducing anxiety
symptoms in refugee populations post treatment (SMD –0.36, 95% CI –0.82 to 0.11; I2 = 0%; two trials,
n = 73) or at follow-up after < 6 months (SMD –0.43, 95% CI –1.21 to 0.35; I2 = 35.1%; two trials, n = 73).
Domestic violence
A summary of meta-analyses of the clinical effectiveness of psychological interventions across
populations exposed to domestic violence for PTSD, depression and anxiety symptoms is shown in
Appendix 9, Table 44.
Post-traumatic stress disorder symptoms
Three trials were identified that measured PTSD symptoms in populations affected by domestic
violence. Two of the three trials were included in the meta-analyses that compared trauma-focused
CBT with control post treatment and interventions were associated with a large and significant
treatment effect (SMD –2.92, 95% CI –3.45 to –2.39; I2 = 0%; two trials, n = 117).100,101
The other trial in this subgroup compared forgiveness therapy with an alternative treatment including
anger validation, assertiveness and interpersonal skills training and could not be meta-analysed.125
Depression symptoms
The same two trials that compared trauma-focused CBT with control also reported post-treatment
outcomes for depression. A meta-analysis showed that interventions were associated with a large and
significant treatment effect, but there is a high degree of uncertainty about the overall point estimate
(SMD –3.24, 95% CI –4.40 to –2.09; I2 = 66.6%; two trials, n = 117).125
Pharmacological interventions versus placebo
Nineteen trials were identified that compared pharmacological interventions with placebo. Rezaei
Ardani et al.56 tested rivastigmine augmentation and this study was not included in the meta-analyses
because there were no other comparable interventions to combine it with. Two other studies were
excluded from the meta-analyses because they compared head-to-head interventions, with no placebo
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group.65,67 All the trials (n = 16)58,59,72,73,82,84,85,99,104,110,112,118,122,123,135,147 included in the meta-analyses, except
one trial in childhood sexual abuse, were in veteran populations.
Total post-traumatic stress disorder symptoms
A summary of meta-analyses of the clinical effectiveness of pharmacological interventions for PTSD
symptoms is shown in Appendix 9, Table 45. A meta-analysis of six trials (n = 338)59,73,82,112,118,147 compared
antidepressants with placebo post treatment. The results show that there was a medium treatment
effect in favour of antidepressants, but this did not reach significance (see Appendix 10, Figure 90).
Four trials (n = 293)82,112,118,147 were included in a meta-analysis that compared SSRIs with placebo.
Figure 91 (see Appendix 10) shows that SSRIs were associated with a large effect in favour of a
reduction in total PTSD symptoms, but this did not reach significance.
Data about the effectiveness of antipsychotics were meta-analysed in five trials (n = 365).58,85,99,110,135
Antipsychotics were associated with a medium and significant treatment effect in favour of a reduction
in total PTSD symptoms post treatment (see Appendix 10, Figure 92).
Only two trials that compared anticonvulsants with placebo were meta-analysed and there was little
evidence that these classes of drugs were effective at reducing total PTSD symptoms (see Appendix 10,
Figure 93).72,104
Three trials (n = 110) compared prazosin with placebo and a meta-analysis showed that this
sympatholytic medication is associated with a medium treatment effect post treatment in favour
of reducing total PTSD symptoms (see Appendix 10, Figure 94).84,122,123
Depression symptoms
A summary of meta-analyses of the clinical effectiveness of pharmacological interventions for
depression symptoms is shown in Appendix 9, Table 46. Antidepressant medication was compared with
placebo post treatment in a meta-analysis that included three trials (n = 220).59,73,82 The results were
inconclusive, with no evidence that these classes of drugs were effective in reducing depression
symptoms in veteran populations (see Appendix 10, Figure 95).
There was some evidence drawn from two trials (n = 266)99,135 that antipsychotic medication compared
with placebo post treatment favoured the intervention, but the treatment effect did not reach
significance (see Appendix 10, Figure 96).
There was very little evidence that anticonvulsants compared with placebo post treatment were
effective in reducing depression symptoms. A meta-analysis of two trials (n = 106)72,104 showed that the
treatment effect marginally favoured the placebo group (see Appendix 10, Figure 97).
In a meta-analysis of two trials (n = 76)84,123 that compared prazosin with placebo post treatment, the
treatment effect favoured prazosin but did not reach significance.
There were insufficient data to assess the effectiveness of SSRIs. Only one study that compared SSRIs
with placebo reported a depression outcome.82 Among the other studies that tested SSRIs, one study
did not report depression outcomes separately and instead presented combined depression and
anxiety data using the Hospital Anxiety and Depression Scale total,112 and two other trials did not
report any depression outcome data.118,147
Anxiety symptoms
No meta-analyses were possible for anxiety outcomes.
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Psychosis symptoms
A summary of meta-analyses of the clinical effectiveness of pharmacological interventions for
psychosis symptoms is shown in Appendix 9, Table 47. All of the trials included in the meta-analyses
that compared antipsychotic medication with placebo tested risperidone. Three trials were identified
that included post-treatment outcome data related to symptoms of psychosis; all used the Positive and
Negative Syndrome Scale (PANSS).58,85,99
There was no good evidence that antipsychotic medication reduces symptoms of psychosis in veteran
and childhood sexual abuse populations.
In a meta-analysis of three trials (n = 329),58,85,99 risperidone was associated with a reduction in positive
psychotic symptoms on the PANSS, but the treatment effect did not reach significance and the overall
point estimate was very uncertain (see Appendix 10, Figure 98).
In a meta-analysis of one small and one medium-sized trial, the treatment effect did not favour
risperidone for either negative or total scores on the PANSS, although the effects were not significant
(see Appendix 10, Figures 99 and 100).85,99 In the same meta-analysis, there was some evidence that
risperidone favoured an improvement on the general psychopathology scale of the PANSS, but the
effect did not reach significance (see Appendix 10, Figure 101).
Sleep quality
A summary of meta-analyses of the clinical effectiveness of pharmacological interventions for sleep
quality is shown in Appendix 8, Figure 26. Prazosin was the only pharmacological intervention with
sufficient data to conduct meta-analyses; it was more effective than placebo (mean difference –2.53,
95% CI –3.82 to 1.23; I2 = 0%; three trials, n = 109).84,122,123
Meta-analysis of attrition
Of the RCTs included, 46 studies representing 47 trials in psychological interventions reported attrition
data.53,55,62,64,66,69,71,76,78,79,81,83,84,86–92,94–96,98,100,105–109,111,115,121,125,126,128,131,132,135–140,144,145 Thirteen RCTs reported
attrition data for pharmacological interventions.56,58,72,73,82,84,85,99,104,110,118,127,141 We conducted meta-analyses
to investigate the odds of attrition from psychological and pharmacological interventions. Owing to a
subset of trials reporting zero attrition, ORs were not calculable for eight trials;88–91,94,111,125,138 therefore,
these were excluded from the analyses presented. The comparisons meta-analysed for odds of attrition
from psychological interventions were considered two ways:
1. psychological interventions versus control for all populations combined, reported by
intervention category
2. all psychological interventions versus control, reported by trauma experience.
All pharmacological interventions included in this analysis were in veteran populations, with the
exception of one study in individuals with a history of childhood sexual abuse;127 therefore, veterans-only
pharmacological intervention attrition meta-analyses were undertaken (see Veterans).
Intervention categories
Trauma-focused cognitive–behavioural therapy
Twenty-one studies (n = 1557)55,62,66,79,81,83,86,87,92,96,100,105–107,109,126,128,136,140,144 reported attrition figures in
trauma-focused CBT across all populations, and indicated participation in a trauma-focused CBT
intervention was significantly associated with a reduction in the odds of dropout compared with
controls (Figure 23).
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Four trials stood out owing to ORs that favoured increased attrition from the intervention; these had
smaller sample sizes (< 20 participants per arm) and did not have a common trauma population
(including veterans,105,107 domestic violence populations100 and refugees55).
Eye movement desensitisation and reprocessing
Few controlled EMDR trials reported attrition data (three trials, n = 179).53,64,76 All favoured increased
odds of attrition in the intervention group, with a non-significant pooled estimate suggesting
uncertainty (OR 1.79, 95% CI 0.79 to 4.07; I2 = 0.0%). Trials included within this analysis were each
from different populations (refugees,53 veterans64 and those with a history of childhood sexual abuse76).
Mindfulness
There were also few mindfulness trials reporting attrition (three trials, n = 141).57,95,121 The pooled estimate
suggested that the odds of attrition of individuals in mindfulness interventions were one-third those of
individuals on a waitlist, but this finding did not reach significance (OR 0.29, 95% CI 0.05 to 1.74; n = 141).
There was also moderate heterogeneity in the sample with the CI including 1, suggesting mindfulness







OR (95% CI) Weight (%)
16 18 2.75 (0.67 to 11.24) 5.66
Bolton (2014)62 101 66 0.35 (0.16 to 0.77) 9.33
Chard (2005)66 36 35 1.04 (0.34 to 3.16) 7.21
Feske (2008)79 13 14 0.38 (0.06 to 2.52) 3.84
Franklin (2017)81 19 8 0.04 (0.00 to 0.70) 1.88
Gamito (2010)83 7 3 0.62 (0.02 to 19.58) 1.46
Hermenau (2013)86 19 19 0.18 (0.01 to 4.00) 1.76
Hijazi (2014)87 41 22 0.93 (0.08 to 10.85) 2.60
Jung (2013)92 17 17 1.00 (0.17 to 5.83) 4.27
Knaevelsrud (2015)96 79 80 1.03 (0.55 to 1.94) 10.44
Kubany (2003)100 19 18 5.14 (0.52 to 51.29) 2.89
Margolies (2013)105 20 20 171 (0.40 to 7.34) 5.45
McDonagh (2005)106 51 23 0.40 (0.10 to 1.55) 5.88
McLay (2011)107 10 10 3.32 (0.12 to 91.60) 1.57
Miyahira (2012)109 29 13 0.21 (0.05 to 0.94) 5.31
Reger (2016)126 108 54 0.20 (0.08 to 0.48) 8.70
Resick (2015)128 56 52 043 (0.16 to 1.15) 7.96
Stenmark (2013)136 51 30 0.79 (0.30 to 2.07) 8.11
Ulmer (2011)140 12 9 0.10 (0.00 to 2.13) 1.80
Weiss (2015) trial 1:
CETA144
99 50 0.39 (0.02 to 8.20) 1.81
Overall (I2 = 44.1%; p = 0.016)
NOTE: weights are from random-effects analysis
129Weiss (2015) trial 2:
CPT144
64
0.04 (0.00 to 0.62)
0.57 (0.36 to 0.88)
2.08
100.00
0.1 0.2 0.3 0.5 1.02.0 3.05.0 10.0
Favours intervention Favours control
FIGURE 23 Meta-analysis of ORs of attrition for trauma-focused CBT interventions compared with control.
CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Non-trauma-focused cognitive–behavioural therapy
There were insufficient data comparing non-trauma-focused CBT with an inactive control to perform
analyses.
Trauma populations
Meta-analyses were carried out according to each intervention category within populations in which
there were multiple studies present. The results for each of these can be found in Appendix 10.
The following sections give the results of attrition from any psychological intervention within each
population and highlight notable contrasts due to the sparsity of data in grouped meta-analyses.
Veterans
Twelve trials (n= 616)66,78,81,83,95,105–107,109,121,128,157 were included in this meta-analysis, which compared
psychological intervention with a control (see Appendix 10, Figure 102). Veterans receiving any psychological
intervention had less than half the odds of attrition as those on a waitlist (OR 0.49, 95% CI 0.26 to 0.92;
I2= 41.8%), a statistically significant result. This suggests that it is likely that psychological therapies
experience favourable dropout in comparison with waitlists or non-interventions in veteran populations.
Four trials (n = 225) compared psychological interventions with an active control71,84,115,137 and also
showed reduced attrition among veterans receiving psychological intervention (OR 0.34, 95% CI
0.17 to 0.68; I2 = 0.0%; see Appendix 10, Figure 103).
Pharmacological interventions
A sufficient number of pharmacological trials in veterans reported attrition to analyse the odds of
dropout in antidepressant intervention, including three studies of SSRIs82,118,141 (OR 0.56, 95% CI 0.29
to 1.07; I2 = 24.9%; four studies, n = 345; see Appendix 10, Figure 104)73,82,118,141 and antipsychotics
(OR 0.46, 95% CI 0.14 to 1.56; I2 = 56.5%; four studies, n = 414; see Appendix 10, Figure 105).58,85,99,110
Two studies reported attrition for the use of anticonvulsants72,104 (see Appendix 10, Figure 106).
Although all had an OR that favoured reduced attrition in the intervention group, none was significant.
Childhood sexual abuse
Based on five trials (n = 414),69,92,98,131,140 individuals with experience of childhood sexual abuse and
receiving psychological therapy had almost one-quarter the odds of dropout as inactive controls
(OR 0.24, 95% CI 0.08 to 0.75; I2 = 26.5%; see Appendix 10, Figure 107). Three of the five studies in the
analysis were also phased based.69,98,140
One trial reported attrition data for a pharmacological intervention, comparing antipsychotics with
placebo; therefore, an OR was not calculated for these data.127
Refugee populations
Evidence for attrition in refugee populations was mixed. Five studies (n= 298)53,55,87,108,136 were associated with
psychological intervention having greater odds of attrition than controls, a finding that was not significant
(OR 1.21, 95% CI 0.69 to 2.12; I2= 0.0%; see Appendix 10, Figure 108). Across trials, odds were not consistent
in favouring increased or decreased odds of attrition, resulting in a wide CI for the pooled estimate.
Domestic violence
There were only two studies on psychological interventions for individuals exposed to domestic
violence.62,100 Both investigated individual therapies and they had opposing directions of effect for
attrition (see Appendix 10, Figure 109).
War-affected populations
Six trials of psychological interventions gave a pooled OR that suggested reduced attrition for psychological
intervention (when compared with inactive controls) in war-related trauma populations (OR 0.66, 95% CI
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
47
0.27 to 1.60; I2= 36.7%; n= 695).57,86,96,144,145 However, the CI includes 1, while an equivalent number of
trials favour both reduced and increased odds of attrition. There is large uncertainty as regards the
direction of effect, despite low to moderate heterogeneity (see Appendix 10, Figure 110).
Meta-regression analyses: predictors of treatment effectiveness
We conducted meta-regression analyses for any validated trauma outcome measure (using SMDs) and
in all populations.
Model 1: predictors of treatment effectiveness by population type
Table 2 shows the results of the univariable analyses. Interventions delivered in studies that included
veterans were less likely to be effective than interventions delivered in studies in other populations.
In addition, interventions delivered in studies that included people who had experienced domestic
violence were more effective than studies that included other populations. However, there were
few studies of people exposed to domestic violence and therefore it is unclear if further studies
will consistently show greater effectiveness for people who have experienced domestic violence.
In multivariable analyses both remained statistically significant: studies of veterans [coefficient 0.41,
standard error (SE) 0.20; p = 0.049] and studies of people experiencing domestic violence (coefficient
–2.01, SE 0.51; p < 0.001). The multivariable model was statistically significant [F2,42 = 11.51; p < 0.001)
and explained some of the heterogeneity (adjusted R2 = 38.96%); however, a substantial proportion of
heterogeneity remained unexplained (I2 residual = 79%).
Model 2: predictors of treatment effectiveness by intervention components
When covariates for intervention content were assessed, only imaginal exposure was found to have a
statistically significant association with effectiveness, but psychoeducation had a borderline statistically
significant effect (Table 3). Therefore, both covariates were included in the multivariable analysis;
psychoeducation was no longer statistically significant (coefficient –0.39, SE 0.23; p = 0.1) and imaginal
exposure was borderline statistically significant (coefficient –0.44, SE 0.24; p = 0.07). The multivariable
model as a whole was statistically significant (F2,42 = 3.88; p = 0.03) and explained some of the
heterogeneity (adjusted R2 = 15.78%), but a substantial proportion of heterogeneity remained
unexplained (I2 residual = 81.19%).
Model 3: treatment effectiveness by delivery method
Studies that tested individually delivered interventions reported improved outcomes compared with
studies that tested interventions delivered in a group (Table 4). Since almost all interventions were
delivered face to face, it was not possible to confirm if there was a difference in effectiveness
compared with other modalities. There was no evidence that the duration of intervention had an
impact on effectiveness.
TABLE 2 Predictors of effectiveness of psychological interventions by population type (univariable analyses)
Populations Coefficient (standard error) p-value
Veterans 0.56 (0.23) 0.02
Childhood sexual abuse –0.04 (0.30) 0.89
Refugees –0.36 (0.28) 0.21
Domestic violence –2.19 (0.52) < 0.001
War affected 0.25 (0.45) 0.59
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Only studies that used individually delivered psychological interventions were statistically significantly
associated with greater effectiveness compared with group-delivered psychological interventions explaining
a small proportion of the heterogeneity (adjusted R2 = 12.72%; I2 residual = 81.54%). No multivariable
analyses were conducted.
Components network meta-analyses
We fitted four models to assess the impact of different combinations of interventions on reducing
trauma. Owing to the instability of models when assessing different trauma scales combined, we
conducted all analyses on the CAPS (the most frequently reported trauma scale). Figure 24 shows all
of the combinations of intervention components extracted from the studies included. The thickness
of the lines for each node are weighted by the number of studies (i.e. the thicker the line, the more
studies comparing a particular combination of components with an active control or a waitlist).
Model selection
Models 1, 2 and 4 did not fit the data well, reflected by the very high total residual deviance found for
each of these models. Model 3 had an acceptable goodness of fit (total residual deviance = 36.33) and
the DIC was substantially lower than in other models. Therefore, further analyses were conducted
using model 3 (Table 5).
TABLE 4 Predictors of treatment effectiveness by delivery method
Delivery method Coefficient (SE) p-value
Face to face vs. other –0.47 (0.39) 0.74
Individual vs. group –0.67 (0.28) 0.02
< 12 weeks vs. 12 weeks 0.12 (0.32) 0.70
> 12 weeks vs. 12 weeks 0.20 (0.44) 0.66
TABLE 3 Univariable predictors of treatment effectiveness by intervention component
Components Coefficient (SE) p-value
Support –0.12 (0.33) 0.71
Psychoeducation –0.47 (0.23) 0.052
Relaxation –0.06 (0.27) 0.83
Mindfulness –0.13 (0.36) 0.73
Cognitive –0.03 (0.25) 0.91
In vivo exposure –0.04 (0.45) 0.92
Virtual reality exposure 0.36 (0.49) 0.47
Imaginal exposure –0.51 (0.24) 0.04
Phased based –0.36 (0.37) 0.33
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Findings from the intervention component network meta-analysis (model 3)
The intervention components with evidence of effectiveness and sufficiently precise credible intervals
were mindfulness, cognitive restructuring, phase-based approaches, relaxation + imaginal exposure and
relaxation + cognitive restructuring (Table 6).






Model 1: waitlist, active control, trauma-
focused CBT, EMDR, mindfulness, DBT, IPT
25.72 252.99 70.03 0.043
Model 2: waitlist, placebo, support,
psychoeducation, relaxation, cognitive
restructuring, in vivo exposure, imaginal
exposure, virtual reality exposure, mindfulness,
phased based
28.60 267.93 70.57 0.042
Model 3: waitlist, placebo, support,
psychoeducation, relaxation, cognitive
restructuring, in vivo exposure, imaginal
exposure, virtual reality exposure, phased
based, support+ psychoeducation,
psychoeducation + relaxation,
psychoeducation + cognitive restructuring,
psychoeducation + imaginal exposure,
relaxation +mindfulness, relaxation + cognitive
restructuring, relaxation + imaginal exposure
30.94 235.45 36.33 0.13

















AC = active control
C = cognitive
IE = imaginal exposure
IV = in vivo exposure
M = mindfulness
PE = psychoeducation
PH = phase based
R = relaxation
S = support
VR = virtual reality exposure
WL = waitlist
FIGURE 24 Network plot for all combinations of components extracted from the studies included.
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Acceptability sensitivity analyses
Estimates of attrition in intervention and control groups are likely to be effected by both the
acceptability of the intervention and attrition bias. To try to disentangle these factors, we conducted
sensitivity analyses including only studies judged to be at a low risk of attrition bias. Table 7 shows
the OR of attrition for psychological interventions compared with controls, as presented in Trauma
populations earlier, and the OR of attrition for psychological interventions compared with controls for
only those trials graded as at a low risk of attrition bias.
Overall, studies with a low risk of attrition bias were associated with reduced odds of dropout from
psychological interventions in comparison with controls in all populations combined (14 trials).55,62,64,78,87,
92,98,121,126,131,132,140,144 This trend was seen across trauma experiences (when data were available), although
differences between interventions and controls were not always statistically significant. The exception
was refugee populations, in which people assigned to psychological interventions were more likely to
drop out than those in controls.
Trauma populations that demonstrated a reduced likelihood of dropout in psychological interventions
saw a further decrease in the likelihood of dropout when considering only those trials with a low risk of
attrition bias. These populations were veterans (three trials),64,78,121 childhood sexual abuse populations
(four trials)92,98,131,140 and war-affected populations (two trials),144 but none was statistically significant.
In the case of veterans and childhood sexual abuse populations, the reduced odds of dropout were
TABLE 6 Mean difference for outcomes by intervention component
Intervention component Mean difference vs. waitlist (95% CI)
Active control –0.07 (–61.71 to 62.21)
Placebo –27.6 (–57.76 to 2.60)
Support 16.78 (–13.07 to 47.08)
Psychoeducation –0.24 (–30.23 to 29.76)
Relaxation 24.32 (–12.12 to 60.56)
Mindfulness –32.22 (–53.18 to –10.52)
Cognitive restructuring –39.24 (–54.05 to –23.88)
Virtual reality exposure –8.6 (–42.08 to 25.84)
Imaginal exposure –1.18 (–32.16 to 29.76)
Phased based –26.95 (–41.59 to –11.96)
In vivo exposure 14.45 (–32.74 to 61.39)
Support+ psychoeducation 21.3 (–10.29 to 52.64)
Psychoeducation + relaxation 32.09 (–6.64 to 70.77)
Psychoeducation + cognitive restructuring 10.56 (–8.07 to 29.29)
Psychoeducation + imaginal exposure 18.28 (–13.0 to 49.48)
Relaxation +mindfulness 28.03 (–17.44 to 73.86)
Relaxation + cognitive restructuring –28.29 (–47.56 to –8.79)
Relaxation + imaginal exposure –45.34 (–70.86 to –19.52)
Mindfulness + cognitive restructuring 28.41 (–16.96 to 74.14)
Cognitive restructuring + in vivo exposure 14.31 (–32.8 to 61.41)
In vivo exposure + imaginal exposure 15.42 (–18.72 to 49.73)
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
51
statistically significant when considering trials of all risk-of-bias gradings. Therefore, the lack of
statistical significance is most likely explained by the reduced statistical power resulting from including
only a subset of the data.
In refugee populations, the odds of dropout from psychological interventions were greater than from
controls and increased when considering only those trials with a low risk of attrition bias (based on
two trials);55,87 however, neither of the pooled ORs was statistically significant.
Adverse events for pharmacological interventions
All of the data relating to adverse events and pharmacological interventions were collated (Table 8).
All reporting of further information regarding reasons for withdrawal and adverse events were from
veteran populations. Withdrawal owing to adverse events was common across studies, but with
relatively small numbers. Practical issues resulting in withdrawal were more frequently reported; there
was insufficient detail to infer acceptability from this.
TABLE 7 Odds ratios of attrition per population shown across all studies and across only those trials rated as being at a
low risk of attrition bias
Population
OR (95% CI)
All studies Low risk of attrition bias
All 0.56 (0.40 to 0.80) 0.39 (0.21 to 0.73)
Veterans 0.49 (0.26 to 0.92) 0.44 (0.06 to 3.54)
Childhood sexual abuse 0.24 (0.08 to 0.75) 0.18 (0.03 to 1.00)
Refugee 1.21 (0.69 to 2.12) 2.10 (0.62 to 7.14)
Domestic violence Insufficient data Insufficient data
War affected 0.66 (0.27 to 1.60) 0.11 (0.01 to 1.27)
Mixed Insufficient data Insufficient data











Bupropion and control overall: allergic
reaction (n = 1), transportation difficulties
(n= 1), no further interest (n = 1), lost to
contact (n= 2)




Mirtazapine: lack of efficacy (n = 3),
personal reasons (n = 3), side effects (n = 1)






Nefazodone: adverse effects (n = 5),
medication ineffective (n = 2), lost to
follow-up (n= 4), non-compliance (n= 1)
Placebo: adverse effects (n = 1), medication
ineffective (n= 2), lost to follow-up (n = 1),
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Sertraline: adverse events (n = 2), protocol
violation (n = 1)
Placebo: adverse event (n= 1), protocol
violation (n = 2), other (of own accord)
(n = 2)
Sertraline: headache (31%), insomnia
(31%), nausea (31%), restlessness (25%),
diarrhoea (22%), dry mouth (19%),
drowsiness (16%), asthenia (16%),
decreased appetite (16%), constipation
(16%), decreased libido (13%)
Placebo: headache (20%), insomnia
(13%), nausea (17%), restlessness (17%),
diarrhoea (13%), dry mouth (17%),
drowsiness (7%), asthenia (7%),
decreased appetite (10%), constipation




NR Sertraline: nausea (35%), headache
(26%), drowsiness (26%), asthenia
(17%), increased appetite (13%), dry
mouth (13%), decreased appetite (13%)
Placebo: nausea (21%), headache (16%),
drowsiness (16%), asthenia (15%),
increased appetite (10%), dry mouth




Risperidone: adverse effects (n = 11),
unrelated medical condition (n= 1), alcohol
abuse (n = 1), discontinuing medication
(n = 1), lost to follow-up (n = 5)
Placebo: adverse effects (n = 6), alcohol





Risperidone: episode of urinary retention
(n = 1)
Risperidone: mild adverse event (n= 4)
Placebo: mild adverse event (n= 2),




Olanzapine: (early protocol terminations)
somnolence (n= 2), unspecified (n = 1)
Placebo: lack of efficacy (n= 1)
Olanzapine: weight gain change of
+13.2 lb (SD 5.9 lb)
Placebo: –3 lb (SD 6.5 lb)
Anticonvulsants Davis et al.
(2008),72
veterans
Divalproex: adverse events (n = 3), serious
but unrelated adverse event (n= 1), failure
to return (n= 2), lost to follow-up (n = 4)
Placebo: adverse event (n= 1), lack of





Topiramate: adverse events (n = 6),
clinician withdrew because of adverse
event (n = 2), significant worsening of
symptoms (n = 1), left residential treatment
(n = 1), discharged by clinical staff owing to
behaviour (n = 1)
Placebo: adverse event (n= 1), clinician
withdrew because of adverse event (n = 1),
left residential treatment (n= 12),
discharged by clinical staff owing to
behaviour (n = 1)
Topiramate: reported in 17 patients
Placebo: reported in 16 patients
continued
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Non-randomised studies of clinical effectiveness
Post-traumatic stress disorder symptoms
Six of the nine non-randomised studies reported PTSD outcomes.148–150,152,155,156 Effect sizes were
calculated for four of these studies (representing five interventions), as they used inactive control
comparators (Table 9).149,152,155,156




population Reasons for withdrawal Adverse events
Prazosin Raskind et al.
(2013),123
veterans
Prazosin: adverse event (n = 1), opted for
open-label prazosin (n= 1), too busy (n= 1),
lost contact (n= 1)
Placebo: opted for open-label prazosin (n= 1),
too busy (n= 2), lost contact (n= 3)
Prazosin: hospitalisation for suicidal
ideation (n= 1), suicide attempt with
non-lethal overdose of oxycodone/
acetaminophen (n= 1); syncope (3%),
light-headedness (25%), nasal
congestion (22%), palpitations (6%),
drowsiness (3%), muscle weakness (3%),
headaches (3%)
Placebo: light-headedness (20%), nasal
congestion (11%), lack of energy (3%),
palpitations (3%), drowsiness (9%),
depression (6%), headaches (23%)
SD, standard deviation.
TABLE 9 Non-randomised trial intervention characteristics and effects on PTSD outcomes
Authors






















































































HTQ, Harvard Trauma Questionnaire; IES, Impact of Events Scale.
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Trauma-focused interventions
Two studies in trauma-focused CBT saw a significant reduction in PTSD avoidance symptoms.155,156
One study investigated ‘victim to survivor’ group therapy in a childhood sexual abuse population156
(SMD –1.01, 95% CI –1.53 to –0.48; n = 63) and the other investigated individual therapy in a
war-affected population155 (SMD –1.22, 95% CI –1.75 to –0.69; n = 95). Individual therapy in a
war-affected population also showed a large and significant effect in reducing PTSD hyperarousal
symptoms (SMD –1.50, 95% CI –2.04 to –0.95; n = 95), but was equivalent to the waitlist at reducing
PTSD re-experiencing symptoms.155
One study examined a multicomponent trauma-focused intervention delivered in a group format to a
childhood sexual abuse population.152 A small reduction in PTSD symptoms was found, but this was
not significant.
Non-trauma-focused interventions
Non-trauma-focused CBT was investigated in one study in a refugee population and showed a large
and significant effect favouring group intervention for reducing PTSD symptoms (SMD –2.54, 95% CI
–3.21 to –1.88; n = 64).149
Multicomponent non-trauma-focused therapy was investigated in just one study of war-affected
individuals155 and showed significant effects favouring controls for PTSD hyperarousal (SMD 0.74,
95% CI 0.24 to 1.25; n = 96) and avoidance symptoms (SMD 2.66, 95% CI 2.04 to 3.28; n = 96).
A small, insignificant effect on PTSD re-experiencing symptoms also favoured the control group.
Head-to-head comparisons
Two148,150 of the non-randomised studies reporting PTSD outcomes were head-to-head comparisons
conducted in veteran populations.
One comparison of trauma-focused CBT versus psychodynamic psychotherapy reported a significant
reduction in PTSD symptoms (clinician- and patient-rated), with no significant difference
between interventions.150
A comparison of mindfulness-based cognitive therapy with a mixed comparator of active interventions
reported a significant reduction in PTSD symptoms for those undergoing mindfulness-based cognitive
therapy, but not the mixed comparator.148
Depression
Five non-randomised studies150–153,156 reported depression outcomes. Of these, four studies150–152,156 used
inactive comparators. Effect sizes were calculated for three studies (constituting four interventions);
outcome reporting prohibited this for one study,153 so it is described as published (Table 10).
Trauma-focused interventions
All studies for which SMDs were calculated were trauma-focused interventions, delivered in a group
format, to childhood sexual abuse populations.
Two studies reported depression outcomes for three trauma-focused CBT interventions. In one
study,151 a short-term therapy demonstrated an insignificant and small effect of increasing depression
(compared with control); the same study found an insignificant and small effect of group therapy
reducing depression. Another study156 of trauma-focused CBT in group therapy showed a large and
significant effect for decreasing depression symptoms on two scales: the Beck Depression Inventory
(–1.53, 95% CI –2.09 to –0.97; n = 63) and the Center for Epidemiologic Studies Depression Scale
(–1.19, 95% CI –1.73 to –0.65; n = 63).
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Based on one study,152 multicomponent trauma-focused group therapy was associated with a moderate
treatment effect in favour of a reduction of depression and this was of borderline significance (SMD –0.43,
95% CI –0.88 to 0.01; n = 80).
In one study,153 a SMD was not calculated owing to outcome reporting. This compared both EMDR and
trauma-focused CBT with a control in a war-affected population. The reported results stated that both
interventions significantly reduced depression symptoms with no significant difference between EMDR
and CBT, suggesting effectiveness.
Head-to-head comparisons
One study150 reported a direct comparison of trauma-focused CBT with psychodynamic therapy in
veterans. A significant reduction in depression symptoms was reported following treatment, with
equivalent effectiveness between therapies.
Anxiety
One151 of the nine non-randomised studies included in this review reported anxiety outcomes for two
interventions. The findings are presented in Table 11.
TABLE 11 Non-randomised trial intervention characteristics and effects on anxiety outcomes


















SCL-90, Symptom Checklist 90.
TABLE 10 Non-randomised trial intervention characteristics and effects on depression outcomes


















































BDI, Beck Depression Inventory; CES-D, Center for Epidemiologic Studies Depression Scale; SCL-90, Symptom
Checklist 90.
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Trauma-focused interventions
Two trauma-focused CBT interventions were both compared with control in a childhood sexual abuse
population.151 Group therapy was associated with a small reduction in anxiety symptoms, while short-term
therapy was associated with a small increase compared with control. Neither finding was significant.
Quality of life
None of the non-randomised studies included reported quality-of-life outcomes.
Sleep quality
None of the non-randomised studies included reported sleep quality outcomes.
Attrition
Six148–151,155,156 of the non-randomised trials included reported attrition data for eight comparisons.
All were compared with a control group, with the exception of one active control trial148 and one
head-to-head comparison.150 ORs were calculated for all controlled trials and are presented in Table 12.
Only one trial,155 investigating two interventions, reached significance. There was a reduced likelihood
of dropout in both the trauma-focused CBT and the multicomponent non-trauma-focused intervention
compared with control in a war-affected population.
Three trauma-focused CBT interventions in a childhood sexual abuse population had reduced odds of
attrition among those receiving the intervention, but large CIs resulting in uncertain estimates.151,156
A non-trauma-focused CBT intervention in a refugee population showed increased odds of dropout
among those receiving the intervention compared with those in the control; this finding also had wide
CIs and was not significant.149
TABLE 12 Odds ratios of attrition for each trial reporting data
Authors (year)
Trauma
population Intervention category vs. control
OR of attrition
(95% CI) n
Kruse et al. (2009)149 Refugees Non-trauma-focused CBT 2.06 (0.19 to 23.83) 70
Lundqvist et al. (2006)151 Childhood
sexual abuse
(Group) trauma-focused CBT 0.58 (0.03 to 12.08) 55
(Short-term) trauma-focused CBT 0.20 (0.01 to 4.01) 32
Salo et al. (2008)155 War affected Trauma-focused CBT 0.02 (0.00 to 0.36) 106
Multicomponent non-trauma-focused
intervention
0.00 (0.00 to 0.08) 106
Saxe and Johnson (1999)156 Childhood
sexual abuse
Trauma-focused CBT 0.51 (0.16 to 1.61) 108
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Chapter 5 Results of the qualitative
acceptability review
Studies included
In total, 1609 titles and abstracts were screened and 1560 were excluded. In addition, 49 full-text
papers were screened and 41 were excluded, with the reasons summarised in Figure 25. We included
nine papers, constituting eight unique studies, that were found to use qualitative methods or a
mixed-methods approach with a strong qualitative component. Qualitative components included data
collection using interviews (unstructured or semistructured) and focus groups, and the data were
analysed following a qualitative methodology, with methods such as thematic analysis, ethnography
or a phenomenological approach.
Of the studies selected for inclusion in the qualitative review, the majority were from North America
(n = 7); two studies were performed in Canada but most of the research was performed in the USA
(n = 5). The other studies were performed in Bangladesh (n = 1) and the UK (n = 1).
In terms of the types of trauma that participants were exposed to, four studies involved participants
exposed to intimate partner violence,161–164 of which two are linked.163,164 Two studies involved
veterans,165,166 two studies involves participants exposed to childhood sexual abuse167,168 and one study
involved asylum seekers.169
The intervention classifications include group mindfulness-based stress reduction (MBSR; n = 3163–165),
motivational interviewing (n = 1162), prolonged exposure (n = 1166), mental health counselling (n = 1161),
group healing or group treatments (n = 2167,168) and trauma-focused CBT (n = 2166,169), which, in one
case, was a combined treatment with prolonged exposure (n = 1166). Table 13 provides details of all of
the studies included.
Records identified through database
searching




Records after duplicates removed








• Population, n = 8
• Intervention, n = 13
• Outcome(s), n = 8
• Study design, n = 10
• Language, n = 1







FIGURE 25 The PRISMA diagram of the flow of records through the review process.
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1. Was there a clear statement of the aims of
the research?
Y Y Y Y Y Y Y Y Y
2. Was a qualitative methodology appropriate? Y Y Y Y Y Y Y Y Y
3. Was the research design appropriate to
address the aims of the research?
Y Y Y Y Y C Y Y Y
4. Was the recruitment strategy appropriate to
the aims of the research?
Y Y Y Y N N C Y Y
5. Were the data collected in a way that
addressed the research issue?
Y Y Y Y Y Y Y Y Y
6. Has the relationship between researcher and
participants been adequately considered?
C C C Y Y Y Y Y C
7. Have ethical issues been taken into
consideration?
Y Y Y C Y Y C Y Y
8. Was the data analysis sufficiently rigorous? Y Y Y Y C C Y Y C
9. Is there a clear statement of findings? Y Y Y Y Y Y Y Y Y
10. How valuable is the research? Score 8.5 Score 8.5 Score 8.5 Score 8.5 Score 7.5 Score 7.5 Score 8.0 Score 9.0 Score 8.0

































































Quality of the studies included: Critical Appraisal Skills Programme assessment
Methodological limitations were assessed with the CASP qualitative checklist to facilitate the assessment
of both study design and implementation, as described in the GRADE-CERQual recommendations.51
The studies included were assessed for methodological limitations using a modified version of the CASP
in which the individual elements for the quality assessment (see Table 13 for the CASP checklist) were
used in conjunction with a scoring system. A full score of 9.0 for the CASP assessment allowed a CERQual
score of ‘no concerns’ as regards the methodological limitations of the studies included, as well as the
relevance and coherence of data with regard to integration across the review themes.
The majority of the studies were allocated less than the maximum score of 9.0, as information was not
clearly apparent in the methods of the paper. This contributed to a CERQual assessment of ‘minimal
concerns’ for the integration of research findings for this review. When no score was given, the
CERQual score was registered as ‘significant concerns’; the only instance of this was attributed to
selection bias for the participant selection, as many studies experienced difficulties in recruiting
participants and, as such, studies enrolled a small number of participants or a convenience sample.
Table 13 presents the findings of the CASP assessment and the tables in Appendix 9 provides additional
information on the study details and their methodological assessments.
Narrative synthesis
All of the studies included offered in-depth accounts of service user experiences of psychological
interventions either delivered in health- or social-care or settings or by voluntary agencies. Population
subgroups included veterans, people with a history of childhood sexual abuse, people with a history of
domestic violence and asylum seekers. Using acceptability and feasibility as organising meta-themes,
we identified three core subthemes across these populations:
1. therapeutic context
2. skills strengthening
3. self-efficacy and reward.
Therapeutic context
Group-based therapies
This theme captured data that spoke to service users’ perspectives on the merits of engaging in
therapeutic interventions in groups and how feasibly these group-based approaches aligned with the
therapeutic orientation and goals of the intervention. For non-trauma-focused interventions such as
mindfulness, there was an understanding that delivering interventions in groups was potentially a safe
and advantageous way to connect with others who have had similar traumatic experiences without
fear of re-traumatisation. This was especially true of women with a history of domestic violence:
‘Having had common traumas made it easy to relate to other participants. I was able to revisit
traumatic situations without judgement.’163
However, this perspective was not universally shared, with a contrary finding among veterans, whose
overall perception of mindfulness was positive but was layered with misgivings about taking part in
groups. For some participants, groups were less acceptable because their PTSD symptom profile made
them feel ‘uncomfortable in groups’, with the risk that interactions with other group members were
counterproductive to the therapeutic goals of achieving serenity and non-judgemental self-awareness:
‘I had such issues with certain people and one of them couldn’t sit still. I would turn around and he
kept staring at me. I was not comfortable.’165
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Women with a history of childhood sexual abuse also voiced similar concerns about the negative
impact of taking part in groups as part of more trauma-focused interventions:
[I] found it hard to break through the barriers that I’d already set up . . . a lot of trust issues with the
group . . . I was still just breaking the ice . . . about my sexuality . . . I saved it right up to the very last day.
Palmer et al.167
The idea that group approaches were not always an acceptable platform to engage people with
complex trauma histories was also linked to concerns that group-based activities that focused on
trauma experiences risked re-traumatising participants: ‘I would come out of [the process groups]
exhausted, even if I didn’t say anything . . . just listening to other people’s stories was very draining.’167
Scheduling and setting
Another key feature of the therapeutic context that underpinned perceptions about the acceptability
and feasibility of interventions was that scheduling and the setting of treatments were important
determinants of participants’ satisfaction and engagement with therapy. Veterans that were signed up
to mindfulness noted that scheduling could be a practical barrier to attendance.165 More critically,
among women with a history of domestic violence, there were widely voiced concerns that waiting
times and the length of treatment sessions for counselling could increase the risk of further abuse at
home if they returned late.161 This highlighted the importance of providing treatment in a safe and
caring environment that offered participants sanctuary and the security to engage in treatment, as
reported by women with a history of domestic violence who were given classes in motivational
interviewing at a shelter: ‘You deserve the caring, and you deserve to be treated well.’162
The need for additional wraparound care to help facilitate engagement with treatment was especially
salient among women exposed to domestic violence who had children and felt frustrated that their
family needs were not often met:
I was takto [irritated/annoyed] . . . I was annoyed that I left my child in the corridor. They took me to
another room . . . The child was crying.
Naved et al.161
Skills strengthening
Participants’ ratings about the acceptability of interventions were also associated with the extent to
which they perceived interventions as strengthening their personal and interpersonal skills. This was
especially true among participants who had experience of non-trauma-focused interventions such as
mindfulness and motivational interviewing. MBSR was particularly earmarked by women with a history
of domestic violence as conferring opportunities to use newly acquired skills in self-compassion and
self-awareness to regulate their emotions and manage their stress more effectively, because they
‘felt they had learned how to quiet their minds’.163,164
Beyond the recognition that non-trauma-focused interventions can bring about positive steps towards
self-actualisation through personal development, there were also signals that treatment acceptability
hinged on the broader impact on participants’ interpersonal skills. Women with a history of domestic
violence voiced how taking part in motivational interviewing had enabled them to more effectively
engage in other treatment services. In addition, for some participants, these interpersonal benefits
spilled over into the domestic sphere, positively affecting the way that they interacted with partners
and underpinning a newly derived confidence to engage in family life:
My confidence has gone up a great deal . . . Even though I came in self-confident in some areas of my life,
I think that when it comes to specifically how I relate with my husband in that area, it’s boosted it up
completely. I think that I’m capable.
Hughes and Rasmussen162
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Self-efficacy and reward
Related to the notion that interventions were more acceptable if they led to strengthening of
personal and interpersonal skills was the finding that participants tended to favour interventions
that made intuitive sense, rewarded persistence and were demonstrably effective. In this sense, the
more self-efficacious participants felt about fulfilling the requirement of treatment sessions, the more
likely they were to persist with treatment; this bi-directional relationship was also reinforced by visible
signs of recovery. Dropout and attrition were more common among participants who engaged in
interventions that they struggled to identify with and master, with mindfulness being singled out by
veterans, among the non-trauma-focused interventions, as challenging:
I just didn’t get it. I was so stupid when I first went to it the last time. I didn’t even realise what I was
supposed to be doing . . . I felt ignorant and embarrassed so that’s why I quit.
Martinez et al.165
By contrast, although trauma-focused interventions such as prolonged exposure and cognitive
processing therapy could initially lead to a worsening of symptoms, veteran participants recognised
that it was likely to be ultimately effective and ‘worth it’.166
In part, participants’ willingness to stay the course in trauma-focused treatment stemmed from a
‘commitment to finish’, born from a realisation that their time had come to ‘turn things around’,
to paraphrase a male veteran, a theme that was voiced by other veterans engaged in cognitive
processing therapy:
Yes, I did [consider dropping out] because I was avoiding having to write out my traumatic experience but
I knew I had to do it . . . I can’t keep burying my head in the sand.
Hundt et al.166
For others, participation in trauma-focused work was made feasible only through engagement with a
supportive therapist. In this context, a positive therapeutic alliance conferred the means to stay
focused on treatment goals:
I loved [therapist name]; she was great and she was patient and she helped keep me focused . . . that
made it a little bit easier to show up.
Hundt et al.166
The tone of participants’ ratings about trauma-focused interventions differed depending on their
circumstances, with asylum seekers, who feared deportation, more likely push themselves to take up
treatment on the grounds that it will be effective:
I used to force myself to do it just because I feel that it’s going to help me.
Vincent et al.169
Despite ongoing fears of repatriation and a sense of creeping fatalism among asylum seekers, there
were participants whose ability to see signs of progress encouraged them to continue to push
themselves to take up therapy:
. . . I started maybe feeling a bit of difference. That’s when I used to force myself ‘You have to go. No, be
strong, go and they are helping you’, so I end up going.
Vincent et al.169
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Summary
In summary, the acceptability of interventions was associated with how congruent they were with
participants’ therapeutic needs and social contexts, and the means by which the interventions were
able to provide participants with opportunities to engage in personal and interpersonal improvement
and confer demonstrable improvements. The feasibility of interventions hinged on more instrumental
features, such as the scheduling and timing of treatment sessions.
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Chapter 6 Patient and public involvement and
the research prioritisation exercise
A lthough the overarching focus and framework of the current review was prespecified by thecommissioned brief, we recognise that patient and public involvement (PPI) in systematic reviews
is a critical means to ensure that the research process and products are more accessible, relevant and
meaningfully used through active involvement of service users (known as ‘experts by experience’) and
key stakeholders.170 However, there is a broad range of conceptual models of service user involvement
in systematic reviews, from one-off consultation to ongoing collaboration, and early engagement with
potential contributors at a conceptual level is likely to shape the content and style of user involvement.171
Our strategy was informed by an understanding that knowledge mobilisation is a dynamic and
interactive process that is reliant on forming equitable transactional relationships with patients, the
public and stakeholders.172 Our user engagement strategy was informed by an understanding that
experts by experience can bring critical insights and perspectives that can add value to contextualising
the findings of our review and contribute to enhancing the reach of dissemination activities, especially
in relation to setting future research priorities.
Aims
Our PPI strategy had three broad aims:
1. to consult with experts by experience about the focus and design of the review
2. to contribute to identifying research priorities
3. to contribute to dissemination of the findings of the review, including the research priorities.
Aim 1: consultation on the overall aims and design of the review
Methods
To identify people with a history of complex traumatic events, we approached The Retreat hospital,
York, or service user groups that were known to us through our clinical experience of working in the
field. We have not named the groups involved in this consultation exercise to protect the identity of
the service users.
Participants
Ten people (six women and four men) who had used inpatient and secondary care mental health
services, all with a history of complex trauma, took part in the focus groups. Trauma histories included
childhood sexual abuse, sexual assault as adults, self-harm and domestic violence. Some had experienced
homelessness and had been offenders; comorbidities and symptom profiles included drug and alcohol
addictions, suicidality and dissociated identities. All of the service users identified were all currently
using or had recently used NHS mental health services and/or third-sector mental health services.
None of the subjects was approached within an NHS setting or directly through NHS services.
Research governance approval to contact and identify eligible service users who had been patients
at The Retreat was granted on 31 July 2017 by Dr Mark McFetridge, Chairperson of the Clinical
Governance Group at The Retreat, York.
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Format and timing of focus groups
Interviewing people who are currently using mental health services or who are still acutely affected by
their symptoms is difficult owing to the sometimes chaotic nature of engagement with services, as well
as the sensitivity and care needed to avoid causing harm to these subjects. An expert by experience
(the Involvement Lead at The Retreat) and a specialist trauma psychotherapist (IS) carried out the
interviews so that the risk of re-traumatisation was minimised. Following the interviews, all of the
subjects had access to mental health nursing staff or support workers with whom they had an
existing relationship.
Four focus groups were conducted between May and July 2018. Where possible, focus groups were
carried out at times when the service users were already planning to meet so that the researchers
could align the focus groups with an existing structured timetable, thereby minimising disturbance to
the service users’ schedule.
Topic guide
A structured topic guide was used to ensure that each focus group addressed similar issues pertinent
to the review process. Participants were given copies of lay summaries of the project protocol that
specified and explained the criteria for the population, interventions, comparisons and outcomes
used to determine inclusion within and exclusion from the eligible studies. In addition, participants
were given lay summaries of the descriptive results of the effectiveness review that characterised
the number of studies included, the types of populations included and the characteristics of the
interventions included. The following questions and prompts were used to elicit responses about the
aims and focus of the review, with a view to generating feedback about the scope of the current
review and future research priorities:
1. Which populations should be included in the study?
l Do you feel this is an accurate representation of populations with a history of trauma?
l What other groups do you think should be included?
l Do you think this is the right balance of studies on each population?
2. What types of therapies should be included in the review?
l Is this an accurate representation of the therapies available for people with a history of trauma?
l Do you know of any therapies for trauma that have not been included here?
l Do you think this is a good balance of therapies included in the systematic review?
l Are there any additional psychological interventions that should be included?
l Do you think any of the therapies included to date require further research?
3. Which medicines should be included in the review?
l What other types of medicine are prescribed to individuals with complex trauma?
l What do you think about the balance of studies on each type of medication included in the
systematic review?
Results
Theme 1: under- or over-representation of populations of interest
There were a number of responses that clustered around discussions of certain population groups
exposed to complex trauma being either under- or over-represented in the review: ‘It’s important to
include all populations to get the scale of it’.
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In general, participants suggested that female populations were seen as under-represented within
population groups that might typically be associated with males, such as veterans: ‘. . . it’s strange; it’s
[the review] so male dominated because most domestic abuse happens to women’.
Respondents suggested that groups such as people in drug and alcohol services and those that foster
children should be included. In addition, participants who had experienced treatment in inpatient
settings suggested that studies that evaluated treatments among inpatients were under-represented
and pointed to the complexity of their symptoms as indicative of the need for a broader formulation of
what complex trauma is: ‘. . . people associate trauma with war, but PTSD is not the same as complex
trauma’ and ‘. . . it can be a fine line between stress and trauma’.
Theme 2: mind and body separation
Participants highlighted that the review was possibly focused on a narrow range of symptoms
associated with mental health alone, with too little focus on understanding the impact of complex
trauma on physical functioning: ‘why does it just include psychological therapies? There is a mind–body
separation here’.
This awareness of a mind–body separation was reflected by participants acknowledging that the
therapies included in the review were prescriptive and manualised psychological interventions, with a
focus on mental health symptom management rather than more humanistic and integrative therapies,
such as transactional analysis and Gestalt, which look to overcome such mind–body dualism: ‘. . . are
trauma-focused CBT and exposure therapies really integrative therapies? . . . humanistic therapies
should be added as a category of their own’.
Similarly, participants noted that there is also scope to learn more about the effectiveness of therapies
that address the somatic impact of complex trauma, such as alternative and complimentary therapies
such as yoga and kinesiology: ‘. . . lots of trauma relates to the body’.
There was also a sense that future research should address the effectiveness of therapies for people
who had limited access to existing evidence-based treatments owing to learning difficulties and
language barriers.
Theme 3: further work on pharmacological therapies
Fewer studies about pharmacological interventions have been included in the current review and
service users’ own experiences were predominantly drawn from their experience of psychological
interventions. However, there was an awareness that, in the current review, many of the studies that
evaluated the effectiveness of medications were focused on medications used for severe and enduring
mental health problems (such as personality disorder rather than PTSD) and it was not clear if there
was sufficient understanding about the role of a broader range of medications in managing symptoms
across the complex trauma experience.
Aims 2 and 3: setting research priorities and disseminating findings
Process
A stakeholder research prioritisation day was held on 9 July 2018 to present preliminary quantitative
and qualitative findings. The goal was to identify research priorities and co-produce with stakeholders
a ranked list of future research questions. Attendees were practitioners with interest and experience
in complex trauma, voluntary and third-sector providers of services to people affected by complex
trauma, and experts by experience.
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The team from Beyond The Room (http://beyondtheroom.net/) facilitated online voting and online
public engagement via social media. A Twitter account was set up (@UoY_INCiTE) and a hashtag for
the project (#INCiTEstudy) was also active throughout the day, alongside the Beyond The Room social
media account, to disseminate information being shared at the event and to invite non-participants on
the day to engage in the voting.
Future research priorities were co-produced in a workshop format, following the presentation of
results. Three break-out groups discussed their perspectives on the range of evidence presented
and identified important unanswered questions. The role of the review team was to help facilitate
development of research questions and offer guidance about appropriate methodologies that could be
feasibly used to address the questions identified within the groups.
Research priorities were then collated online using MentiMeter (www.mentimeter.com), an online
voting platform provided by the Beyond The Room team. This platform enabled online voting among
participants in the room but also facilitated wider engagement with voting on research priorities from
those not present but following the discussions on the INCiTE Twitter account. Each participant was
awarded 100 points to allocate to the long-list of research questions.
Participants were encouraged to promote further engagement in the voting exercise by advertising the
voting link with interested people in their networks. Voting was open for 1 week following the event
and closed on 16 July 2018.
Results
On the day, there were 16 attendees (plus the review team) who were from:
l The Retreat, York
l Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington
l Combat Stress, Surrey
l Home-Start, York
l IDAS (Independent Domestic Abuse Services), York
l University of Manchester, Manchester
l University of York, York.
The research priorities developed during the prioritisation event are listed in Table 14. A total of
68 people took part in the online vote. The proportional share of points awarded to each priority is
also shown.
A majority of the points were awarded to just 4 of the 13 research priorities, accumulating over 10%
each. A definitive trial of the effectiveness of interventions with a long-term follow-up and a peer
researcher exercise to understand the lived experience of people with experience of complex trauma
were the two most favoured priorities, with both having a similar percentage of vote share.
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TABLE 14 Research priorities developed from research prioritisation exercise attendees and the share of the online vote
Research priority Vote share (%)
Conduct a definitive trial of the effectiveness of interventions in complex trauma, with long-term
follow-up (e.g. 24 months)
15.91
Understand the lived experience of people with experience of complex traumatic events: a peer
researcher exercise
14.80
Conduct a qualitative study exploring the patient perspective on key outcomes, preferred therapies,
acceptability and delivery format of interventions (e.g. group or individual)
12.48
Develop holistic and biopsychosocial assessment, prioritising a mind–body approach 10.46
Understand what the core outcomes for patients, families and health-care providers are
(e.g. appropriate outcome domains and measures, including adverse outcomes)
7.55
Understand how best you engage populations with experience of complex traumatic events 6.43
Understand what the key outcomes that should be included in trials are 6.28
What are the key components of an effective multicomponent intervention? (e.g. support in
engaging in work, debt management)
5.83
Test the feasibility of social prescribing for wraparound care for people with complex traumatic
experiences
5.68
Understand what the core components and domains of interventions and integrated approaches are
(e.g. individual vs. group plus individual therapy)
4.71
Understand how we can define good practice. Use a Delphi survey to capture perspectives on
positive recovery stories and barriers to and facilitators of retaining patients in care
3.74
Understand how we best taper off psychological interventions 3.14
Understand what the optimal duration of treatment is 2.99
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Summary of results across all populations with complex trauma for post-traumatic
stress disorder
We included 104 studies in the effectiveness review and reported 37 comparisons using meta-analysis
across 79 RCTs. There were a total of nine non-RCTs that included five comparisons for PTSD, four
comparisons for depression and two comparisons for anxiety. The number of non-RCTs included in the
review was much lower than anticipated and we identified a greater volume of trial evidence than was
anticipated. This may have been because we adopted a strategy that favoured including studies based
on trauma exposure rather than diagnostic criteria and thereby we were able to identify a much
broader range of studies pertaining to complex trauma. However, the merit of including data from
non-RCTs was diminished by the fact that these studies rarely reported the same intervention types
or outcomes, making meta-analyses less possible. Overall, the quality of the available evidence was
unclear, with the lowest risk observed in domains related to detection bias, random sequence
generation and other risks of bias and the highest risk of bias observed in performance bias and
attrition domains. The majority of studies were at high risk of performance bias, partially explained by
the predominance of psychological interventions included in the review and the challenges of blinding
their delivery. When pooled across all populations with complex trauma, psychological interventions
were proven to be effective at reducing PTSD symptoms when compared with control post treatment.
There was less evidence that this finding held when treatment effects were measured up to 6 months
post treatment, with only trauma-focused CBT and single-component trauma-focused interventions
showing positive effects over the longer term. There was no significant difference in the effectiveness
of psychological interventions for PTSD symptoms when compared with active controls.
The bulk of the evidence across all populations for reducing PTSD symptoms favoured trauma-focused
CBT when compared with control post treatment and at follow-up after up to 6 months. There was
no evidence of the effectiveness of trauma-focused CBT versus active controls and this is a weakness
of the set of trials analysed. IPT and EMDR were also superior to control post treatment but there
was less evidence that mindfulness improves PTSD symptoms in the presence of complex trauma.
Non-trauma-focused CBT was not effective at any time point. These findings were reflected in the
meta-analysis that showed that single-component and trauma-focused interventions were more effective
than control post treatment and at follow-up and outperformed multicomponent and trauma-focused
interventions post treatment. Collectively, single-component non-trauma-focused interventions that
included approaches beyond CBT were effective post treatment, but these approaches were the least
best option for managing PTSD symptoms across all populations.
Few studies addressed the symptom cluster associated with CPTSD and, of those that did, the majority
focused on emotional dysregulation.We found no evidence that either trauma- or non-trauma-focused
psychological interventions were superior to control in improving emotional dysregulation or interpersonal
problems post treatment. By contrast, psychological interventions post treatment were associated with
large and positive effect sizes for improving negative self-concept, with multicomponent trauma-focused
interventions outperforming all other approaches. There was some evidence that phase-based approaches
that allow for stabilisation work to be done before exposure to trauma-focused interventions are the most
promising candidate intervention for managing emotional dysregulation and interpersonal problems,
although the superiority of these approaches over control was not statistically significant.
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Summary of results for psychological interventions across populations for depression and anxiety
Collectively, psychological interventions were shown to be superior to control, but not to active
control, both post treatment and at follow-up for managing associated symptoms of depression in all
populations with complex trauma. There was strong evidence that trauma-focused CBT post treatment
was a highly effective treatment for managing depression in people exposed to complex trauma,
but there was less evidence that these effects are present at 6 months’ follow-up. IPT and EMDR
were similarly associated with large treatment effects for reducing depression when compared with
control, but not active control, post treatment, but evidence in favour of these approaches was thin.
Mindfulness was also superior to control post treatment; it was also effective at 6 months’ follow-up,
but evidence for this finding is inconclusive. While single-component non-trauma-focused interventions
that included mindfulness-based approaches were effective in reducing depression symptoms post
treatment, the most consistent and largest effects for depression post treatment and at 6 months’
follow-up were observed in trials that tested single-component and trauma-focused interventions.
A similar set of results were returned in the meta-analyses that assessed the effectiveness of
psychological interventions across all populations for reducing associated symptoms of anxiety.
All analyses for this outcome were conducted post treatment. Trauma-focused CBT emerged as a
leading candidate intervention for reducing anxiety symptoms in the presence of any type of complex
trauma, with interventions associated with medium to large effect sizes. The largest effects were
observed in trials that compared EMDR with control, albeit this finding was based on relatively few
trials. In summary, trauma-focused approaches, when delivered as either a single-component or a
multicomponent intervention, were superior to control for anxiety symptoms when effects were
pooled across all populations.
We found no evidence that psychological interventions in general, and trauma-focused CBT in
particular, were effective in improving quality of life across all populations. There was a modest amount
of evidence in favour of trauma-focused CBT for managing sleep problems when results were pooled
across all populations.
Summary of population subgroup analyses
Veterans
Among veterans, psychological trauma-focused CBT and EMDR emerged as the most effective
individual psychological interventions for reducing PTSD symptoms post treatment. There was little
evidence to show that mindfulness was an effective therapeutic strategy in this group and, overall,
single-component non-trauma-focused interventions were not superior to control either post
treatment or at follow-up. Multicomponent and trauma-focused interventions were the most effective
approaches among veterans for managing PTSD symptoms.
Psychological interventions, in general, are effective for managing depression in veterans exposed to
complex trauma.When effects were pooled across all interventions, the SMD post treatment represented
a medium and positive effect in favour of reducing depression, but this effect was about half the size
observed in the analysis across any type of trauma exposure. The most effective interventions for
depression among veterans were trauma-focused CBT and EMDR, and these positive and large effects
held when trauma-focused interventions were delivered as either a single-component or a multicomponent
approach. Limited evidence from non-RCTs suggested that trauma-focused CBT and psychodynamic
therapy had equivalent positive effects for depression in veterans. The least effective but still positive
approaches for depression in veterans were mindfulness and single-component non-trauma-focused
interventions, which yielded moderate treatment effects.
Similarly, psychological interventions were, on the whole, effective at reducing associated anxiety
symptoms in veterans exposed to complex trauma post treatment. There was less evidence to draw on
by comparison with studies that measured depression. However, EMDR and trauma-focused CBT were
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superior to control post treatment and were associated with large and positive effects in favour of
reducing anxiety.
Childhood sexual abuse
People exposed to childhood sexual abuse formed the next largest complex trauma subgroup. We
showed that psychological interventions overall were associated with large and positive treatment
effects for reducing PTSD in this subgroup post treatment only. As was the case with veterans, individual
trauma-focused CBTwas the most effective individual treatment for PTSD in people exposed to
childhood sexual abuse. In addition, evidence gleaned from the non-RCTs showed that trauma-focused
CBTwas superior to control in reducing PTSD avoidance symptoms, suggesting that this approach
was among the most effective in this group. Moreover, while single-component and trauma-focused
interventions were collectively superior to control post treatment, it is clear that larger and positive
effects were observed in trials that tested multicomponent and trauma-focused interventions in the
childhood sexual abuse subgroup.
A similar pattern emerged for associated depression symptoms in this subgroup. When pooled
together, psychological interventions in general were associated with large and positive effects for
reducing depression post treatment; there was only modest evidence that these effects were positive
at follow-up. Individual trauma-focused CBT and, collectively, single-component and trauma-focused
interventions were superior to control for reducing depression post treatment. Consistent with the
findings for veterans, the single-component and non-trauma-focused interventions were also superior
to control post treatment for depression. Furthermore, the largest treatment effects for depression
symptoms observed in the childhood sexual abuse subgroup were associated with multicomponent and
trauma-focused interventions. With veteran and childhood sexual abuse being prototypical exposures
for CPTSD, it might be that, among these populations, PTSD and associated depression symptoms are
more effectively managed with multicomponent approaches that also include non-trauma-focused
work. There was, however, no strong evidence in any direction for which types of psychological
interventions might be most effective for reducing anxiety symptoms in this subgroup.
War-affected populations
War-affected populations comprised the next largest subgroup. All analyses in this subgroup were
conducted post treatment. Although psychological interventions of any type were superior to control
for PTSD symptoms, the sizes of the SMDs were small in comparison with all other subgroups except
for veterans. Individual trauma-focused CBT interventions were the most efficacious for reducing
PTSD symptoms in war-affected populations. In addition, evidence gleaned from the non-RCTs showed
that trauma-focused CBT was superior to control in reducing PTSD avoidance symptoms, suggesting
that this approach was among the most effective in this group. Single-component and trauma-focused
interventions were marginally more effective than multicomponent and trauma-focused interventions,
but both approaches yielded medium and positive treatment effects in favour of reducing PTSD
symptoms. Evidence from non-RCTs suggested that multicomponent interventions were in fact inferior
to control for PTSD symptoms, but this finding was not endorsed by the meta-analyses of trials.
Comparable medium and positive treatment effects were observed for individual trauma-focused CBT
in this subgroup for associated depression symptoms. Single-component, but not multicomponent,
trauma-focused interventions were superior to control post treatment for depression symptoms. There
was less evidence to judge the effectiveness of psychological interventions for anxiety symptoms in
war-affected populations. Individual trauma-focused CBT was the only class of intervention associated
with significant and positive effects in favour of reducing anxiety.
Refugees
Few meta-analyses were possible among studies that included refugees. Any psychological intervention
was vastly superior to control post treatment and also at follow-up for PTSD symptoms in refugees.
In keeping with a recent review of treatments in refugees and asylum seekers,173 we found that very
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large and positive treatment effects for PTSD were observed in studies that compared trauma-focused
CBT and EMDR with control post treatment, but these effects were not sustained at follow-up. A
similar picture was shown when psychological interventions were compared with control for associated
depression symptoms: trauma-focused CBT and EMDR emerged as being better than control post
treatment, but these findings were based on scarce evidence and it is not possible to judge if these
effects are maintained at follow-up. Based on limited evidence from non-RCTs, it is possible that
non-trauma-focused interventions could be effective for PTSD in refugees, but this finding was
not observed in the meta-analyses of the trials. There was insufficient evidence to determine if
psychological interventions were effective for anxiety symptoms in refugees.
Domestic violence
There was very limited evidence to draw on to make firm conclusions about the effectiveness of
psychological interventions in the subgroup of trials that included people exposed to domestic violence.
Individual trauma-focused CBTwas associated with very large and positive effects in favour of reducing
PTSD and associated depression symptoms in this subgroup post treatment only. However, these
findings were associated with high levels of uncertainty and based on few studies of variable quality.
Summary of results of pharmacological interventions
The pooled results for pharmacological interventions in veterans showed that only antipsychotic
medication was effective in reducing PTSD symptoms post treatment. The SMD for antipsychotics
was equivalent to that observed in a comparable analysis in veterans that compared psychological
interventions as a whole with control, but less than half the size of that observed in the analysis that
compared multicomponent and trauma-focused interventions with control. There was also a small
amount of evidence to signal that blood pressure medicine (prazosin) can reduce PTSD symptoms in
veterans. Curiously, in veterans, antipsychotic medication was not effective in reducing symptoms
of psychosis.
These findings might suggest that, in veterans at least, pharmacological interventions alone are not as
effective as using multicomponent and trauma-focused interventions for PTSD symptoms. Moreover,
additional strategies might be warranted to more effectively manage symptoms of psychosis in
veterans in the presence of complex trauma.
Heterogeneity
The I2 statistic and chi-squared tests for the pooled results across all populations demonstrated
substantial and significant heterogeneity at the 0.10 level for all classes of psychological interventions
for PTSD symptoms. A similar picture was seen in the forest plots for the pooled results across
all populations for associated symptoms of depression and anxiety. Although this might be mainly
attributed to clinical diversity among the populations, it is also known that there is a link between
meta-analysis size and heterogeneity levels and the high levels detected in our review might also thus
be a function of the size of the review.
We explored these high levels of heterogeneity by undertaking subgroup analyses of the effectiveness
of interventions by population. For the primary outcome, the pooled results for psychological
interventions as a whole were associated with much less heterogeneity in the veteran and war-affected
subgroups, with I2 results (between 42 and 50%) suggesting lower levels of between-study variability,
but chi-squared results were still significant suggesting inconsistency between study results.
However, the pooled results for PTSD symptoms by intervention type among the veteran and war-affected
subgroups returned considerably lower levels of heterogeneity. It might be that subgrouping by population
and then by intervention appears to explain much of the heterogeneity in veteran and war-effected groups
but not in others (e.g. childhood sexual abuse groups). This trend was not duplicated in the childhood
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sexual abuse subgroup, in which the pooled results across all psychological interventions and for specific
classes of psychological interventions were still associated with high and significant levels of heterogeneity,
making it more difficult to be confident about the true size and direction of effects in this subgroup. There
was negligible and non-significant levels of heterogeneity for the pooled results for PTSD for all and any
class of psychological intervention in the refugee and domestic violence subgroups.We might suggest
that the lower and nil levels of heterogeneity returned in the subgroup analyses can partly be explained by
less clinical variability and fewer trials within each subgroup. However, it is worth noting that, among the
veteran, war-affected and childhood sexual abuse subgroups, heterogeneity was still more apparent in the
pooled results that compared composite intervention categories with control. This was especially true for
the pooled results that compared multicomponent and trauma-focused interventions with control and it
might be that, in these analyses, heterogeneity was partly driven by variability among intervention
components as well as by any residual clinical diversity.
In addition, we can conclude on the basis of the meta-regression results that population type partly
moderated the effectiveness of psychological interventions for PTSD symptoms, with interventions
doing less well in veterans and war-affected populations and significantly better in those exposed to
domestic violence. In this sense, clinical diversity accounted for a modest amount of the heterogeneity
observed in the pooled results across all populations, but there was still significant levels of residual
heterogeneity that remained unexplained. Similarly, while the meta-regression was able to model the
moderating effects of intervention content on the effectiveness for PTSD symptoms, results were fairly
inconclusive, with the multivariable model that included only imaginal exposure and psychoeducation
accounting for a fraction of heterogeneity and between-study inconsistencies.
Component network meta-analysis
We further explored the treatment effects of different components of the composite complex
interventions included by using component network meta-analysis. The results of the component
network meta-analysis showed that the components of standard trauma-focused CBT – cognitive
restructuring, imaginal exposure and relaxation – appear to be effective for PTSD symptoms. This is
consistent with the results of the population subgroup analyses. There were strong interaction effects
between relaxation, cognitive restructuring and imaginal exposure in part because most of these
components were used together.
Mindfulness was treated as a component and, in that sense, it was an approach identified in studies
that primarily tested a mindfulness intervention as well as in studies in which mindfulness was a
component of a broader CBT intervention. However, there were limitations to categorising mindfulness
interventions owing to the variability of reporting, especially when mindfulness was but one of several
components as part of a broader CBT package. There is scope here for future work to tease apart
differences in the effectiveness of mindfulness when delivered as a stand-alone therapy and
mindfulness as part of a composite psychological intervention.
The analyses of phase-based approaches presented even greater challenges. The phase-based
approaches included in this review comprised combinations of multicomponent trauma-focused CBT,
DBT, EMDR and IPT. Pragmatically, these approaches were categorised for the network meta-analysis
in terms of the components included, for example imaginal exposure or mindfulness. However, we
also coded these interventions as phased based if the components were phased in such a way that
allowed for stabilisation before working on the trauma. It is unclear if the phasing itself constitutes
an intervention or if it is a higher order theoretical construct, but phasing of these components,
as well as the intervention content, appears to be one of the factors having an impact on effectiveness.
There is a need for future work on phase-based approaches to reach a consensus on how phasing is
conceptualised in the presence of composite interventions.
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Attrition
Across all populations, trauma-focused CBTwas associated with reduced odds of attrition compared with
control. There was less evidence to draw firm conclusions about the attrition rate for other interventions,
although there was some suggestion that across all populations EMDR incurred a greater attrition rate
than control. When attrition was analysed across population subgroups, we found that veterans who
received any type of psychological intervention were half as likely to drop out than those on a waitlist or
in the active control. In studies that tested psychological interventions in people exposed to childhood
sexual abuse, the attrition rate for any psychological intervention was one-quarter of that observed in
the control groups. There was a mixed picture among studies that included refugees, with some evidence
that there were greater rates of attrition among those given a psychological intervention than in the
control, suggesting that it is a challenge for displaced populations to adhere to psychological treatment
protocols. Why this might be is not clear and future work could focus on the acceptability and feasibility
of psychological interventions in this group. There was insufficient evidence to determine the odds of
attrition in war-affected and domestic abuse populations.
Acceptability and feasibility of interventions: qualitative findings
The narrative synthesis of the subset of qualitative studies identified three core themes related to patient
ratings about the acceptability and feasibility of interventions: therapeutic context, skills strengthening,
and self-efficacy and reward. These themes cut across patient perceptions about both trauma- and
non-trauma-focused therapies. Specifically, where and how interventions were delivered were seen to
be important factors that determined acceptability and feasibility. Group delivery could be advantageous
in some contexts, for example for the delivery of non-trauma-focused interventions such as mindfulness,
but there were risks of vicarious re-traumatisation for those attending group-based therapies with a
focus on trauma reprocessing. Perceptions about the acceptability of different therapeutic approaches
were split between instrumental perceptions about the capacity for interventions to confer life skills
and perceptions about how likely interventions were to aid symptomatic recovery. For those primarily
engaged with non-trauma-focused interventions, there was a sense of these approaches equipping them
with practical skills that made using other health- and social-care services more feasible. By contrast,
among those who had experience of trauma-focused interventions, their willingness to persist with
treatment was linked with their belief that they were going to feel better and the emergence of vital
signs that were indeed feeling better.
Comparison with other reviews and guidance
We have shown that existing psychological treatments for PTSD are effective for people with a
history of complex traumatic events. The strongest evidence was in favour of trauma-focused therapies
such as trauma-focused CBT and EMDR delivered either as stand-alone therapies or as part of
single-component and trauma-focused interventions. This finding mirrors that of a Cochrane review for
psychological therapies for the treatment of chronic PTSD and is consistent with the NICE guideline
that recommends the use of trauma-focused psychological treatment for PTSD for ≥ 3 months.20,174
While there was less good evidence in favour of non-trauma-focused interventions, we did show that
IPT and mindfulness were effective, to varying degrees, across all populations for PTSD symptoms
and to a lesser extent for depression too. This breaks with the NICE guideline, which suggests that
non-trauma-focused interventions should not be routinely offered to people with chronic PTSD for
> 3 months. We were not able to identify sufficient evidence about adverse events associated with
psychological treatments to make judgements about the safety of these approaches in people with
complex trauma. However, we showed that dropout was lower in people offered psychological
interventions and this might suggest that existing trauma-focused interventions are at least
acceptable and feasible, as well as effective, in the presence of complex trauma.
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Consistent with the International Society for Traumatic Stress Studies (ISTSS) expert consensus
guidelines for CPTSD, we also showed that phase-based interventions that drew on a variety of
trauma-focused (CBT, EMDR) and non-trauma-focused (DBT, IPT) approaches and included
stabilisation and skills strengthening were effective across all populations for PTSD symptoms.175
However, unlike the ISTSS expert guidelines, our review includes only evidence from RCTs and we
were able to also show that phasing of interventions moderated effectiveness, making our findings
more robust and trustworthy.
Current NICE guidance suggests that, when several problems need to be addressed, especially in the
presence of multiple traumatic events or when presented with comorbid problems, trauma-focused
interventions should perhaps be extended and wrapped around a broader care plan. However, we
showed that unmodified and existing trauma-focused treatments delivered individually or as part of
multicomponent packages were also shown to be effective for managing associated symptoms of
depression and anxiety in people exposed to complex trauma.
Although the underlying findings from the pooled results across all complex trauma populations show that
trauma-focused interventions are effective for PTSD and associated mental disorder comorbidities, the
effects were less pronounced in veterans and war-affected populations. A recent rapid review of service
provision for UK armed forces veterans with PTSD included a meta-review of seven systematic reviews
and concluded that there was limited and low-quality evidence in favour of EMDR, cognitive processing
therapy, trauma-focused CBT and exposure-based therapies for PTSD symptoms and depression.176 In
addition, this rapid review also found evidence in favour of a broad range of pharmacotherapies for PTSD
and depression in veterans. Previous reviews have shown that SSRIs are superior to placebo for PTSD
in a wide range of populations with PTSD, including those exposed to combat trauma.177 By contrast,
our findings showed that only antipsychotics were effective for reducing PTSD symptoms in veterans,
suggesting that pharmacotherapy might not be a candidate for first-line therapy in the presence of
complex trauma.
Although adjacent to and in some senses part of the same broader class of people affected by
humanitarian crises, we undertook separate subgroup analyses of war-affected populations and of
refugees. Among the war-affected populations, we showed that trauma-focused CBT was effective for
reducing PTSD but there was little support for other approaches. Similarly, Purgato et al.178 have shown
in a Cochrane review that psychological therapies, many with a trauma focus, are effective at reducing
PTSD among people affected by humanitarian crises. The pooled treatment effect for PTSD identified
by Purgato et al.178 was twice that identified in our review and this might be accounted for by their
exclusive focus on low- to middle-income countries and the inclusion of studies of children and
adolescents. Our findings and those of Purgato et al.178 were very similar, however, when assessing
the impact of psychological interventions on depression and anxiety in adults alone.
Dorrepaal et al.179 have previously shown that trauma-focused therapies, especially those that include
exposure, can benefit people with a history of childhood sexual abuse. Of note in our review was that
single-component and non-trauma-focused interventions were the most effective for associated depression
symptoms among childhood sexual abuse populations, suggesting that different combinations of therapies
that include non-trauma- as well as trauma-focused approaches might be warranted in this population.
Among refugees and asylum seekers resettled in high-income countries, manualised and brief narrative
exposure therapies based on CBT have been shown to be effective for PTSD symptoms.180 There is a
strong argument that treatment provision for conflict-affected and displaced populations should be
provided as part of multiagency care and extend beyond PTSD symptoms.181 In the absence of such
integrated and multiagency care, our review at least confirms that trauma-focused interventions are
superior to control for PTSD and can also be effective for depression too.
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A review based on 21 studies (11 of which measured PTSD) showed that brief psychological
interventions that are tailored to meet the additional needs of people exposed to intimate partner
domestic violence are effective for PTSD, depression, increased self-esteem and functioning.182 The
most effective classes of interventions were CBT and IPT. Our findings partially concur, but are based
on a very narrow and limited data set drawn from few studies. In the light of the thin evidence base,
there is a consensus that further well-designed and controlled studies of the effectiveness of
interventions for survivors of intimate partner violence are needed, especially with a focus on how
setting moderates effectiveness.
There was a less clear picture about the effectiveness of treatments for the CPTSD symptom cluster.
Conventional stand-alone trauma-focused interventions were not effective in treating emotional
dysregulation or interpersonal problems, but did have a positive impact on negative self-concept. In
keeping with the ISTSS expert consensus guidelines for CPTSD, we identified phase-based approaches
as a leading candidate intervention for managing emotional dysregulation, although the evidence was
based on only three trials and the result was of borderline significance. More robust evidence was
gleaned from the component network meta-analysis, which identified phasing as a key moderating
component of the effectiveness of both trauma- and non-trauma-focused interventions.
Taken together, the fact that trauma-focused interventions do less well in certain populations with
complex trauma, and only have a modest impact on disturbances of self-organisation, suggests that
our review findings endorse the current diagnostic distinction between CPTSD and PTSD. This is an
important argument that has implications for research and practice. We explicitly eschewed a diagnostic
approach to the inclusion of studies in this review, but, nonetheless, we would suggest that our findings
converge with comparable reviews that have opted to use the new ICD-11 diagnostic CPTSD category
as an organising feature of their inclusion criteria.183 Accordingly, because CPTSD exerts symptoms over
and above PTSD extending to disturbances of self-organisation, there is merit in exploring ways to
harness existing trauma- and non-trauma-focused interventions more effectively, with phase-based
interventions among the leading candidate approaches.
Strengths and limitations
Our review has a number of strengths that enhance the robustness of the findings. By taking a
non-diagnostic approach, we were able to develop and operationalise broad inclusion criteria for the
population of interest based on exposure to traumatic events that could be defined as complex using
the ICD-11 criteria for CPTSD, but which need not have been diagnosed as CPTSD. In doing so, our
search was not tied to a narrowly defined group of studies that exclusively evaluated interventions in
populations with the as yet untested diagnostic label of CPTSD, but rather captured a broader set of
studies salient to more complex trauma rather than a single event and not of an interpersonal nature.
In addition, our approach conferred a level of scientific independence from the clinical community
actively involved in research in CPTSD and, as such, we feel confident that the process of screening
and inclusion was as free from bias as possible. However, to ensure that our review linked with but
did not duplicate other ongoing evidence syntheses in the field, we convened a study advisory group
that included content and clinical experts in chronic PTSD and CPTSD. The advisory group offered
indispensable advice about how to ensure that our review retained an independent identity outside
existing evidence syntheses on CPTSD, provided scientific scrutiny about the process of the review,
and supported and enabled dissemination activities within the broader trauma studies community.
Our broad approach also extended to including both randomised and non-randomised evaluations of
psychological interventions, evaluations of pharmacological interventions and qualitative evaluations
of acceptability of interventions, making this review the largest and most comprehensive assessment
of treatment effectiveness and acceptability of interventions in complex trauma. This approach was
facilitated by conducting an extensive search across key electronic databases, as well as searching
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
specialist fee-for-service libraries and hand searching existing systematic reviews. Although we did not
double screen all titles and abstracts, we did run a pilot screening exercise whereby members of the
research team double screened a sample of abstracts and titles to familiarise themselves with the
PICO. At the title and abstract screening phase, all uncertain decisions were resolved by a consensus
meeting, thus minimising the risk of excluding relevant studies.
Additional strengths of the review include the application of robust and innovative approaches to
understanding treatment effectiveness and moderators of effectiveness. We not only completed a broad
range of meta-analyses, including subgroup analyses by population, but also explored moderators using
multivariable meta-regression. By searching extensively and adopting a broad approach to inclusion,
we were able to assemble a much larger data set than in previous reviews, enhancing our ability to
quantify and explore heterogeneity with a greater level of statistical power and reducing the chance
of spurious findings.184 Many of the meta-analyses exhibited high levels of estimated heterogeneity, but
this is a positive finding, as it appears that heterogeneity levels are being consistently underestimated
in meta-analyses.185 Because there is a link between meta-analysis size and heterogeneity levels, we
anticipated that we might detect high levels given the size of our review, but the large between-study
variability suggests that there might be other study- or patient-level variables that could explain some
of it. Individual patient data meta-analysis is likely to confer considerable advantages to accounting for
such residual heterogeneity associated with patient-level characteristics.
We were not able to fully undertake all planned PPI activities as specified in the protocol. Specifically,
we were unable to recruit service users with experience of complex trauma to join the study advisory
group. Our initial plan was to use The Retreat hospital in York to identify eligible candidates for
the advisory group, but the length of time that elapsed between applying for and securing research
governance permissions meant that opportunities to do this were prohibitively curtailed. However,
during this down time, we worked with the Involvement Lead and Iram Shah from The Retreat to offer
experts by experience from a voluntary organisation run by service users for people affected by mental
health problems to contribute to a series of telephone and face-to-face focus groups. These groups,
in lieu of lay membership of the advisory group, contributed critical thinking about the focus of our
review and generated data that informed the scope of the research prioritisation exercise. In addition,
via our network with the Tees, Esk and Wear Valleys NHS Foundation Trust, we invited service users
by experience (as well as key stakeholders from the scientific and clinical communities with an interest
in trauma and stress research) to attend and contribute to the research prioritisation day. We also
engaged a wider group of stakeholders and service users in the research prioritisation exercise via
our social media presence. In these ways, we were still able to build PPI into our review in ways
that aligned with established best practice for user involvement in systematic reviews.186
We originally committed to using the ROBINS-I40 tool for assessing the risk of bias in non-RCTs, but
ultimately we opted for a more parsimonious approach afforded by a quality appraisal checklist widely
used by NICE in public health guidelines. Although the ROBINS-I tool has emerged as the most likely
gold standard method for assessing the risk of bias in non-randomised studies of interventions, it was
decided that the tool operated at too high a level of resolution for the purposes of our review and
the resource needed to use this tool appropriately would have outstripped capacity within the team
at a time when the emphasis was on data extraction and assessing the risk of bias in over 100 RCTs.
Future studies that intend on including both non-RCTs and RCTs should ensure that there is sufficient
capacity within the review team to use the ROBINS-I tool.
Despite using an extensive search strategy and applying broad inclusion criteria, there is an under-
representation of studies in our review with a focus on complex trauma populations drawn from prison
settings and survivors of torture and forced migrant labour, otherwise known as modern slavery.
Future work should look to identify ways to ensure these populations are not overlooked. In addition,
our search did not capture a critical mass of studies that included outcomes related to comorbid
psychiatric states such as borderline personality disorder. This might have been off set had we adopted
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a more clinical and diagnostic approach to our inclusion criteria, but we have previously explained that
our review set out to explicitly avoid running searches around diagnostic labels. Finally, while we did
include populations with comorbidities, including psychiatric disorders and common mental health
problems, we excluded those with dual diagnosis of complex trauma and substance and alcohol misuse
on the grounds that these populations are likely to require care that is different from and more
specialist than that typically provided in the context of PTSD. However, recent work among ex-serving
regular personnel deployed to combat roles in Iraq or Afghanistan has highlighted that populations
with dual diagnoses (e.g. mental health problems and alcohol misuse) are an important feature following
exposure to complex trauma.187
A further limitation relates to the use of standard frequentist approaches to random-effects meta-
analyses. When there are few studies included in the meta-analyses, there is the potential for bias in
estimating the heterogeneity parameter.
Conclusions and implications for research
The funder called for a review to identify the most promising front runners that the Health Technology
Assessment programme could then consider for future primary research in complex trauma as part of a
separate call.
We have identified that trauma-focused CBT and other trauma-focused interventions, including
EMDR, delivered as single-component or multicomponent approaches are superior to control for
PTSD symptoms and associated mental comorbidities. However, the size of these positive treatment
effects was not equivalent across populations exposed to complex trauma, with treatments being least
effective among veterans. Phase-based interventions, along with non-trauma-focused intervention
components including mindfulness and relaxation, are potentially among the most effective approaches
for PTSD symptoms in people with a history of complex trauma, such as childhood sexual abuse. In
addition, there was inconclusive evidence that existing trauma-focused interventions are effective
in treating the symptom cluster associated with disturbances of self-organisation typically seen in
CPTSD. There is scope to identify if phase-based approaches are more effective than non-phase-based
approaches for PTSD and the broader symptom profile associated with complex trauma. There was
little evidence of effectiveness of pharmacological interventions for PTSD or for associated mental
comorbidities, and no trial that tested the effectiveness of pharmacological interventions for outcomes
related to disturbances of self-organisation.
Going forward, we can synthesise the findings from our meta-analyses and from the stakeholder and
service user research prioritisation event and draw up a long-list of research questions for consideration
in future funding calls. These research questions come under five main topic domains: (1) the effectiveness
of psychological and/or pharmacological interventions, (2) the process and implementation of care,
(3) understanding the lived experience of complex trauma, (4) the safety and adverse event profile of
interventions and (5) methodological considerations about trials in complex trauma.
1. studies about the effectiveness of interventions
¢ definitive and fully powered evaluations of the effectiveness of interventions in complex trauma
with long-term follow-up (i.e. at least 12 months), especially in veterans, childhood sexual abuse
populations and populations affected by humanitarian crises
¢ phase-based versus non-phase-based interventions
¢ trauma-focused versus non-trauma-focused interventions (including IPT, DBT, mindfulness
and relaxation)
¢ integrated and multiagency care packages versus control
¢ pharmacological interventions versus placebo.
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2. studies about the process and implementation of care
¢ qualitative and quantitative process evaluations that draw on best practice for understanding
the relationship between intervention and programme theory and anticipated outputs and trial
results (Medical Research Council guidance)
¢ measuring fidelity and adherence to interventions
¢ understanding if contexts (e.g. setting, timing of delivery) moderate outcomes
¢ assessing what was delivered (i.e. intervention content) and how it was delivered (e.g.
individual vs. group) with a view to drawing conclusions about drivers of effectiveness
¢ qualitative evaluations of the acceptability and feasibility of interventions among people exposed
to complex interventions to inform barriers to and facilitators of treatment uptake, especially in
refugees and asylum seekers.
3. studies about understanding the lived experience of people with a history of complex trauma
¢ qualitative evaluations that draw on a phenomenological perspective to elicit in-depth narratives
of the day-to-day lived experience of people with a history of complex trauma
¢ ethnographic research to illustrate commonalities and differences in the lived experience of
complex trauma across population subgroups.
4. studies about the safety and adverse event profile of interventions for people with a history of
complex trauma
¢ evaluations of adverse events associated with trauma- and non-trauma-focused psychological
interventions (e.g. rates of re-traumatisation)
¢ evaluations of adverse events associated with pharmacological treatments in all complex
trauma populations.
5. studies about methodological considerations in trials among people with a history of complex
traumatic events
¢ developing a core outcome set for trials in complex trauma that include outcomes related to
disturbances of self-organisation and mental comorbidities
¢ testing the validity of the new ICD-11 diagnostic category for CPTSD to identify and recruit
eligible participants to experimental studies.
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Appendix 1 Literature search strategies for
the effectiveness review
L iterature searches of the following databases were conducted: CINAHL, CENTRAL, EMBASE,International Pharmaceutical Abstracts, MEDLINE, PILOTS, PsycINFO and Science Citation Index.
The original searches carried out in April and May 2017 identified 17,177 records, which were
downloaded, imported into EndNote bibliographic software and de-duplicated to leave 10,212
unique records.
CINAHL via EBSCOhost
Search date: 20 April 2017.
Records retrieved: 1919.
Date range searched: 1937 onwards.
TABLE 15 Search strategy for CINAHL via EBSCOhost
Search terms Search options
S1 (MH “Violence”) OR (MH “Exposure to Violence”)
S2 TX violence
S3 (MH “Domestic Violence”) OR (MH “Intimate Partner Violence”) OR (MH “Dating Violence”)
S4 TX (batter$ N2 (wife* or wive* or woman or women or men or husband* or partner*)) OR TX
(physical* N2 (abus* or assault* or violen* or aggress*)) OR TX emotional N2 abus*
S5 (MH “Rape”)
S6 TX rape OR TX (sexual* N2 (assault* or abus* or violen* or aggress*))
S7 (MH “Child Abuse, Sexual”) OR (MH “Child Abuse Survivors”) OR (MH “Sexual Abuse”) OR (MH “Child
Abuse”)
S8 TX “child* sexual abuse”
S9 TX child* N2 exploit* OR TX child* N2 neglect* OR TX child* N2 trauma* OR TX (“non accidental
injur*” or “non-accidental injur*” or “nonaccidental injur*”)
S10 TX “human rights abuse*”
S11 (MH “Human Trafficking”)
S12 TX ((human or person* or people) N2 (traffick* or exploit*)) OR TX ((forced or exploit*) N2 labour*)
S13 organ N2 traffick*
S14 TX slavery or slaves or “slave trade”
S15 (MH “Torture”) OR (MH “Torture Survivors”)
S16 (MH “Prostitution”)
S17 TX (prostitut* or brothel*) OR TX (sex* N2 (exploit* or traffick*))
S18 (MH “Terrorism”)
S19 TX (terrorism or terrorist*) OR TX “political terror*”
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TABLE 15 Search strategy for CINAHL via EBSCOhost (continued )
Search terms Search options
S20 (MH “War”) OR (MH “War Crimes”)
S21 (MH “Holocaust”)
S22 TX ethnic* N2 cleans* OR TX genocide OR TX (civil N2 (unrest or conflict* or disturb* or war or wars
or warfare)) OR TX (persecution or victimisation or victimization) OR TX (captivity or imprison*) OR
TX concentration camp*
S23 (MH “Disasters”) OR (MH “Natural Disasters”) OR (MH “Mass Casualty Incidents”)
S24 catastrophe* or (“catastrophic event*”) or (“catastrophic experience*”)
S25 (MH “Survivors+”)
S26 (MH “Refugees”)
S27 TX refugee* OR TX “asylum seek*” OR TX migrant* OR TX ((forcibly or internally) N2 displaced) OR
TX (displace* N2 (people or person* or civilian*))
S28 (MH “Crime Victims”) OR (MH “Victims”)
S29 (MH “Prisoners”)
S30 (MH “Veterans”)
S31 TX ((expose* or exposure) N2 (abuse or assault* or disaster* or terror* or torture* or trauma* or rape
or violen* or war or warfare)) OR TX (survivor* N2 (abuse or assault* or disaster* or terror* or
torture* or trauma* or rape or violen* or war or warfare)) OR TX (victim* N2 (abuse or assault* or
crime or disaster* or rape or terror* or torture* or trauma* or violen* or war or warfare)) OR TX
(witness* N2 (abuse or assault* or disaster* or rape or terror* or torture* or trauma* or violen* or war
or warfare))
S32 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26
OR S27 OR S28 OR S29 OR S30 OR S31 (143,422)
S33 (MH “Stress Disorders, Post-Traumatic+”)
S34 TX (PTSD or CPTSD) OR TX posttrauma* OR TX post-trauma* OR TX “post trauma*” OR TX “post
traumatic stress” OR TX “combat stress*” OR TX “combat disorder*” OR TX DESNOS OR TX “complex
trauma*” OR TX complex N3 trauma* OR TX “traumatic stress” OR TX “traumatic memor*”
S35 TX traumatisation OR TX traumatization OR TX (trauma* N3 (expos* or event* or experienc*))
S36 S33 OR S34 OR S35 (28,298)
S37 (MH “Cognitive Therapy+”) OR TX “cognitive behaviour* therap*” OR TX “cognitive behavior* therap*”
OR TX “cognitive restructuring” OR TX “cognitive rescripting” OR TX “cognitive processing therap*”
OR TX (CPT or CBT or TFCBT) OR TX “cognitive therap*” OR TX “cognitive behavioural treat*” OR TX
“cognitive behavioral treat*” OR TX “cognitive trauma therap*” OR TX “trauma focus* CBT”
S38 (MH “Behavior Therapy”) OR TX (behavior* N2 (therap* or treat* or modif*)) OR TX (behavior* N2
(therap* or treat* or modif*)) OR TX ((dialectical behavio*) N1 (therap* or treat*)) OR TX (biofeedback
or neurofeedback or (“sensory feedback”)) OR TX psychological N2 desensiti#ation OR TX (“eye
movement desensiti#ation reprocessing”) OR TX EMDR OR TX (exposure N1 (therap* or treat*)) OR
TX “live exposure” OR TX “imaginal exposure” OR TX “prolonged exposure therapy”
S39 TX “imaginal flooding” OR TX “exposure inhibition therap*” OR TX “implosive therap*” OR TX “image
habituation” OR TX “inoculation training”




S43 (MH “Eye Movement Desensitization and Reprogramming”)
S44 (MH “Virtual Reality Exposure Therapy”)
S45 (MH “Hypnosis”)
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TABLE 15 Search strategy for CINAHL via EBSCOhost (continued )
Search terms Search options
S46 TX hypnosis or hypnotherap*
S47 (MH “Mindfulness”)
S48 TX mindfulness
S49 TX “supportive therap*” OR TX (non-directive N1 (counselling or counseling)) OR TX ((non directive)
N1 (counselling or counseling))
S50 ((MH “Psychotherapy”) OR (MH “Psychotherapy, Brief”) OR (MH “Psychotherapy, Group”) OR
(MH “Psychotherapy, Psychodynamic”)) OR TX psychodynamic N1 therap* OR TX “inter personal
psychotherap*” OR TX “interpersonal psychotherap*” OR TX IPT OR TX “compassion therap*” OR TX
“accelerated resolution*”OR TX “sensorimotor therap*”OR TX “schema therap*”OR TX stress N2 manag*
S51 (MH “Counseling”) OR TX “non-directive counsel*” OR TX “non directive counsel*” OR TX
“nondirective counsel*” OR “compassion therap*”
S52 S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR
S49 OR S50 OR S51 (99,780)
S53 ((MH “Hypnotics and Sedatives”)) OR TX (alprazolam or amobarbital or azaperone or barbital or
bromisovalum or “chloral hydrate” or chloralose or chlordiazepoxide or chlormethiazole or
dexmedetomidine or diazepam or diphenhydramine or eszopiclone or ethchlorvynol or etomidate
or etorphine or flurazepam or glutethimide or hexobarbital or lorazepam or medazepam or
medetomidine or mephobarbital or meprobamate or methapyrilene or methaqualone or midazolam or
nitrazepam or oxazepam or paraldehyde or pentobarbital or phenobarbital or propofol or secobarbital
or temazepam or thiamylal or thiopental or xylazine) OR TX “z drugs”
S54 (MH “Antianxiety Agents+”) OR (bromazepam or buspirone or chlormezanone or “clorazepate
dipotassium” or estazolam or flunitrazepam or fluvoxamine or nordazepam or ondansetron or
oxprenolol or prazepam or pregabalin or ritanserin or tranylcypromine or trazodone or triazolam or
zolazepam or benzodiazepines or benzodiazepinones or “sedative antihistamine*” or promethazine)
S55 (MH “Antidepressive Agents+”) OR TX (benactyzine or clorgyline or deanol or “desvenlafaxine
succinate” or “duloxetine hydrochloride” or iproniazid or isocarboxazid or “lithium carbonate” or
“lithium compounds” or moclobemide or nialamide or phenelzine or pizotyline or rolipram or sertraline
or tranylcypromine or “vilazodone hydrochloride” or Imipramine or mirtazapine)
S56 (MH “Antipsychotic Agents+”) OR TX (acepromazine or aripiprazole or azaperone or benperidol or
butaclamol or chlorpromazine or chlorprothixene or clopenthixol or clozapine or droperidol or etazolate
or flupenthixol or fluphenazine or fluspirilene or haloperidol or loxapine or “lurasidone hydrochloride” or
mesoridazine or methiothepin or methotrimeprazine or molindone or ondansetron or “paliperidone
palmitate” or penfluridol or perazine or perphenazine or pimozide or prochlorperazine) OR TX (promazine
or “quetiapine fumarate” or raclopride or remoxipride or reserpine or risperidone or ritanserin or
spiperone or sulpiride or thioridazine or thiothixene or “tiapride hydrochloride” or trifluoperazine or
trifluperidol or triflupromazine or olanzapine)
S57 (MH “Anticonvulsants+”) OR TX (anticonvulsants or acetazolamide or bromides or carbamazepine or
clonazepam or “clorazepate dipotassium” or diazepam or dimethadione or estazolam or ethosuximide
or flunarizine or lorazepam or “magnesium sulfate” or medazepam or mephenytoin or mephobarbital
or meprobamate or nitrazepam or paraldehyde or phenobarbital or phenytoin or pregabalin or
primidone or riluzole or thiopental or tiletamine or trimethadione or “valproic acid” or vigabatrin)
S58 (MH “Antimanic Agents+”) OR TX (“lithium chloride” or “lithium compounds” or lamotrigine or topiramate)
S59 (MH “Monoamine Oxidase Inhibitors+”) OR TX (chlorphenamidine or clorgyline or cuprizone or
furazolidone or harmaline or harmine or isocarboxazid or moclobemide or monocrotophos or
pargyline or selegiline or tranylcypromine or Prazosin or N-Methyl-3,4-methylenedioxyamphetamine
or MDMA or ecstasy)
S60 S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 (68,988)
S61 S32 AND S36 AND S52 (1786)
S62 S32 AND S36 AND S60 (229)
S63 S61 OR S62 (1936)
S64 S61 OR S62 (1919) 1992 ONWARDS
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CENTRAL via The Cochrane Library
Search date: 21 April 2017.
Records retrieved: 637.
Date range searched: from inception.
TABLE 16 Search strategy for CENTRAL via The Cochrane Library
#1 MeSH descriptor: [Violence] explode all trees
#2 violence:ti,ab,kw (Word variations have been searched)
#3 MeSH descriptor: [Domestic Violence] explode all trees
#4 MeSH descriptor: [Intimate Partner Violence] explode all trees
#5 MeSH descriptor: [Battered Women] explode all trees
#6 batter* near/2 (wife* or wive* or woman or women or men or husband* or partner*):ti,ab,kw (Word variations
have been searched)
#7 physical* near/2 (abus* or assault* or violen* or aggress*):ti,ab,kw (Word variations have been searched)
#8 emotional* near/2 abus*:ti,ab,kw (Word variations have been searched)
#9 MeSH descriptor: [Rape] explode all trees
#10 rape:ti,ab,kw or sexual* near/2 (abus* or assault* or violen* or aggress*):ti,ab,kw (Word variations have been
searched)
#11 MeSH descriptor: [Child Abuse, Sexual] explode all trees
#12 child* sexual abuse:ti,ab,kw (Word variations have been searched)
#13 child* near/2 (exploit* or neglect* or trauma*):ti,ab,kw (Word variations have been searched)
#14 non accidental injur*:ti,ab,kw or non-accidental injur*:ti,ab,kw or nonaccidental injur*:ti,ab,kw (Word variations
have been searched)
#15 MeSH descriptor: [Human Rights Abuses] explode all trees
#16 MeSH descriptor: [Human Trafficking] explode all trees
#17 (human or person or people) near/2 (traffick* or exploit*):ti,ab,kw (Word variations have been searched)
#18 (forced or exploit*) near/2 labour:ti,ab,kw (Word variations have been searched)
#19 MeSH descriptor: [Organ Trafficking] explode all trees
#20 MeSH descriptor: [Slavery] explode all trees
#21 MeSH descriptor: [Torture] explode all trees
#22 slavery or enslave* or torture*:ti,ab,kw (Word variations have been searched)
#23 MeSH descriptor: [Sex Workers] explode all trees
#24 MeSH descriptor: [Prostitution] explode all trees
#25 prostitut* or brothel*:ti,ab,kw (Word variations have been searched)
#26 sex* near/2 (exploit* or traffick*):ti,ab,kw (Word variations have been searched)
#27 MeSH descriptor: [Terrorism] explode all trees
#28 terrorism or terrorist*:ti,ab,kw (Word variations have been searched)
#29 political terror*:ti,ab,kw (Word variations have been searched)
#30 MeSH descriptor: [Torture] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#31 MeSH descriptor: [Warfare] explode all trees
#32 MeSH descriptor: [Armed Conflicts] explode all trees
#33 MeSH descriptor: [War Crimes] explode all trees
#34 MeSH descriptor: [Genocide] explode all trees
#35 MeSH descriptor: [Holocaust] explode all trees
#36 MeSH descriptor: [Ethnic Cleansing] explode all trees
#37 civil near/2 (unrest or conflict* or disturbance* or war or wars or warfare):ti,ab,kw (Word variations have been
searched)
#38 persecution or victimization or victimisation:ti,ab,kw (Word variations have been searched)
#39 captivity or imprison* or concentration camp*:ti,ab,kw (Word variations have been searched)
#40 MeSH descriptor: [Disasters] explode all trees
#41 MeSH descriptor: [Earthquakes] explode all trees
#42 MeSH descriptor: [Tsunamis] explode all trees
#43 natural disaster*:ti,ab,kw (Word variations have been searched)
#44 earthquake* or tsunami*:ti,ab,kw (Word variations have been searched)
#45 humanitarian near/1 (crisis or crises):ti,ab,kw (Word variations have been searched)
#46 catastrophe* or catastrophic event* or catastrophic experience*:ti,ab,kw (Word variations have been searched)
#47 MeSH descriptor: [Survivors] explode all trees
#48 MeSH descriptor: [Refugees] explode all trees
#49 asylum seeker* or refugee* or migrant*:ti,ab,kw (Word variations have been searched)
#50 (forcibly or internally) near/2 displace*:ti,ab,kw (Word variations have been searched)
#51 displace* near/2 (people or person* or civilian*):ti,ab,kw (Word variations have been searched)
#52 MeSH descriptor: [Crime Victims] explode all trees
#53 MeSH descriptor: [Adult Survivors of Child Abuse] explode all trees
#54 MeSH descriptor: [Disaster Victims] explode all trees
#55 MeSH descriptor: [Prisoners] explode all trees
#56 MeSH descriptor: [Prisoners of War] explode all trees
#57 MeSH descriptor: [Slaves] explode all trees
#58 MeSH descriptor: [Veterans] explode all trees
#59 MeSH descriptor: [Military Personnel] explode all trees
#60 exposure near/2 (abuse or assault* or disaster* or terror* or torture* or trauma* or rape or violen* or war or
warfare):ti,ab,kw (Word variations have been searched)
#61 exposed near/2 (abuse or assault* or disaster* or terror* or torture* or trauma* or rape or violen* or war or
warfare):ti,ab,kw (Word variations have been searched)
#62 survivor* near/2 (abuse or assault* or disaster* or terror* or torture* or trauma* or rape or violen* or war or
warfare):ti,ab,kw (Word variations have been searched)
#63 victim* near/2 (abuse or assault* or crime or disaster* or rape or terror* or torture* or trauma* or violen* or war
or warfare):ti,ab,kw (Word variations have been searched)
#64 witness* near/2 (abuse or assault* or disaster* or rape or terror* or torture* or trauma* or violen* or war or
warfare):ti,ab,kw (Word variations have been searched)
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#65 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49
or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64
#66 MeSH descriptor: [Stress Disorders, Post-Traumatic] explode all trees
#67 PTSD or CPTSD:ti,ab,kw (Word variations have been searched)
#68 posttrauma*:ti,ab,kw (Word variations have been searched)
#69 post-trauma*:ti,ab,kw (Word variations have been searched)
#70 post trauma*:ti,ab,kw (Word variations have been searched)
#71 “post traumatic stress”:ti,ab,kw (Word variations have been searched)
#72 combat stress:ti,ab,kw (Word variations have been searched)
#73 combat disorder*:ti,ab,kw (Word variations have been searched)
#74 DESNOS:ti,ab,kw (Word variations have been searched)
#75 extreme distress:ti,ab,kw (Word variations have been searched)
#76 complex near/3 trauma:ti,ab,kw (Word variations have been searched)
#77 traumatic stress:ti,ab,kw (Word variations have been searched)
#78 traumatic memories:ti,ab,kw (Word variations have been searched)
#79 traumatization:ti,ab,kw (Word variations have been searched)
#80 “traumatisation”:ti,ab,kw (Word variations have been searched)
#81 trauma near/3 (expos* or event* or experienc*):ti,ab,kw (Word variations have been searched)
#82 #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81
#83 #65 and #82
#84 MeSH descriptor: [Cognitive Therapy] explode all trees
#85 cognitive near/2 therap*:ti,ab,kw (Word variations have been searched)
#86 “cognitive restructuring”:ti,ab,kw (Word variations have been searched)
#87 cognitive rescripting:ti,ab,kw (Word variations have been searched)
#88 “cognitive processing therapy”:ti,ab,kw (Word variations have been searched)
#89 CPT:ti,ab,kw (Word variations have been searched)
#90 cognitive near/2 treat*:ti,ab,kw (Word variations have been searched)
#91 CBT or TFCBT:ti,ab,kw (Word variations have been searched)
#92 MeSH descriptor: [Behavior Therapy] explode all trees
#93 behavior* near/2 (therap* or treat* or modif*):ti,ab,kw (Word variations have been searched)
#94 behaviour* near/2 (therap* or treat* or modif*):ti,ab,kw (Word variations have been searched)
#95 MeSH descriptor: [Biofeedback, Psychology] explode all trees
#96 MeSH descriptor: [Feedback, Sensory] explode all trees
#97 MeSH descriptor: [Neurofeedback] explode all trees
#98 biofeedback:ti,ab,kw (Word variations have been searched)
#99 “neurofeedback”:ti,ab,kw (Word variations have been searched)
#100 “sensory feedback”:ti,ab,kw (Word variations have been searched)
#101 MeSH descriptor: [Eye Movement Desensitization Reprocessing] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#102 MeSH descriptor: [Implosive Therapy] explode all trees
#103 MeSH descriptor: [Virtual Reality Exposure Therapy] explode all trees
#104 psychological near/2 desensit*:ti,ab,kw (Word variations have been searched)
#105 “Eye Movement Desensitization Reprocessing”:ti,ab,kw or “Eye Movement Desensitisation Reprocessing”:ti,ab,kw
(Word variations have been searched)
#106 EMDR:ti,ab,kw (Word variations have been searched)
#107 exposure near/1 (therap* or treat*):ti,ab,kw (Word variations have been searched)
#108 “live exposure”:ti,ab,kw (Word variations have been searched)
#109 “imaginal exposure”:ti,ab,kw (Word variations have been searched)
#110 “prolonged exposure therapy”:ti,ab,kw (Word variations have been searched)
#111 “imaginal flooding”:ti,ab,kw (Word variations have been searched)
#112 “exposure inhibition therapy”:ti,ab,kw (Word variations have been searched)
#113 “implosive therapy”:ti,ab,kw (Word variations have been searched)
#114 “image habituation”:ti,ab,kw (Word variations have been searched)
#115 “inoculation training”:ti,ab,kw (Word variations have been searched)
#116 MeSH descriptor: [Acceptance and Commitment Therapy] explode all trees
#117 acceptance near/2 therap*:ti,ab,kw (Word variations have been searched)
#118 commitment near/2 therap*:ti,ab,kw (Word variations have been searched)
#119 MeSH descriptor: [Hypnosis] explode all trees
#120 hypnosis:ti,ab,kw (Word variations have been searched)
#121 hypnotherap*:ti,ab,kw (Word variations have been searched)
#122 MeSH descriptor: [Mindfulness] explode all trees
#123 mindfulness:ti,ab,kw (Word variations have been searched)
#124 supportive near/1 therap*:ti,ab,kw (Word variations have been searched)
#125 non-directive near/1 counsel*:ti,ab,kw (Word variations have been searched)
#126 nondirective near/2 counsel*:ti,ab,kw (Word variations have been searched)
#127 “non directive” near/1 counsel*:ti,ab,kw (Word variations have been searched)
#128 MeSH descriptor: [Psychotherapy] explode all trees
#129 MeSH descriptor: [Psychotherapy, Brief] explode all trees
#130 MeSH descriptor: [Cognitive Therapy] explode all trees
#131 MeSH descriptor: [Psychotherapy, Group] explode all trees
#132 MeSH descriptor: [Psychotherapy, Multiple] explode all trees
#133 MeSH descriptor: [Psychotherapy, Psychodynamic] explode all trees
#134 MeSH descriptor: [Psychotherapy, Rational-Emotive] explode all trees
#135 psychodynamic near/1 therap*:ti,ab,kw (Word variations have been searched)
#136 interpersonal near/1 psychotherap*:ti,ab,kw (Word variations have been searched)
#137 compassion near/2 therap*:ti,ab,kw (Word variations have been searched)
#138 “accelerated resolution”:ti,ab,kw (Word variations have been searched)
#139 sensorimotor near/2 therap*:ti,ab,kw (Word variations have been searched)
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#140 schema near/1 therap*:ti,ab,kw (Word variations have been searched)
#141 MeSH descriptor: [Counseling] explode all trees
#142 #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or
#99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112
or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121 or #122 or #123 or #124 or #125 or
#126 or #127 or #128 or #129 or #130 or #131 or #132 or #133 or #134 or #135 or #136 or #137 or #138 or #139
or #140 or #141
#143 MeSH descriptor: [Hypnotics and Sedatives] explode all trees
#144 MeSH descriptor: [Alprazolam] explode all trees
#145 MeSH descriptor: [Amobarbital] explode all trees
#146 MeSH descriptor: [Azaperone] explode all trees
#147 MeSH descriptor: [Barbital] explode all trees
#148 MeSH descriptor: [Bromisovalum] explode all trees
#149 MeSH descriptor: [Chloral Hydrate] explode all trees
#150 MeSH descriptor: [Chloralose] explode all trees
#151 MeSH descriptor: [Chlordiazepoxide] explode all trees
#152 MeSH descriptor: [Chlormethiazole] explode all trees
#153 MeSH descriptor: [Dexmedetomidine] explode all trees
#154 MeSH descriptor: [Diazepam] explode all trees
#155 MeSH descriptor: [Diphenhydramine] explode all trees
#156 MeSH descriptor: [Eszopiclone] explode all trees
#157 MeSH descriptor: [Ethchlorvynol] explode all trees
#158 MeSH descriptor: [Etomidate] explode all trees
#159 MeSH descriptor: [Etorphine] explode all trees
#160 MeSH descriptor: [Flurazepam] explode all trees
#161 MeSH descriptor: [Glutethimide] explode all trees
#162 MeSH descriptor: [Hexobarbital] explode all trees
#163 MeSH descriptor: [Lorazepam] explode all trees
#164 MeSH descriptor: [Medazepam] explode all trees
#165 MeSH descriptor: [Medetomidine] explode all trees
#166 MeSH descriptor: [Mephobarbital] explode all trees
#167 MeSH descriptor: [Meprobamate] explode all trees
#168 MeSH descriptor: [Methapyrilene] explode all trees
#169 MeSH descriptor: [Methaqualone] explode all trees
#170 MeSH descriptor: [Midazolam] explode all trees
#171 MeSH descriptor: [Nitrazepam] explode all trees
#172 MeSH descriptor: [Oxazepam] explode all trees
#173 MeSH descriptor: [Paraldehyde] explode all trees
#174 MeSH descriptor: [Pentobarbital] explode all trees
#175 MeSH descriptor: [Phenobarbital] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#176 MeSH descriptor: [Propofol] explode all trees
#177 MeSH descriptor: [Secobarbital] explode all trees
#178 MeSH descriptor: [Temazepam] explode all trees
#179 MeSH descriptor: [Thiamylal] explode all trees
#180 MeSH descriptor: [Thiopental] explode all trees
#181 MeSH descriptor: [Xylazine] explode all trees
#182 #143 or #144 or #145 or #146 or #147 or #148 or #149 or #150 or #151 or #152 or #153 or #154 or #155
or #156 or #157 or #158 or #159 or #160 or #161 or #162 or #163 or #164 or #165 or #166 or #167 or #168 or
#169 or #170 or #171 or #172 or #173 or #174 or #175 or #176 or #177 or #178 or #179 or #180 or #181
#183 “z drugs”:ti,ab,kw (Word variations have been searched)
#184 MeSH descriptor: [Anti-Anxiety Agents] explode all trees
#185 MeSH descriptor: [Bromazepam] explode all trees
#186 MeSH descriptor: [Buspirone] explode all trees
#187 MeSH descriptor: [Chlormezanone] explode all trees
#188 MeSH descriptor: [Estazolam] explode all trees
#189 MeSH descriptor: [Flunitrazepam] explode all trees
#190 MeSH descriptor: [Fluvoxamine] explode all trees
#191 MeSH descriptor: [Nordazepam] explode all trees
#192 MeSH descriptor: [Ondansetron] explode all trees
#193 MeSH descriptor: [Oxprenolol] explode all trees
#194 MeSH descriptor: [Prazepam] explode all trees
#195 MeSH descriptor: [Pregabalin] explode all trees
#196 MeSH descriptor: [Ritanserin] explode all trees
#197 MeSH descriptor: [Tranylcypromine] explode all trees
#198 MeSH descriptor: [Trazodone] explode all trees
#199 MeSH descriptor: [Triazolam] explode all trees
#200 MeSH descriptor: [Zolazepam] explode all trees
#201 MeSH descriptor: [Benzodiazepines] explode all trees
#202 MeSH descriptor: [Benzodiazepinones] explode all trees
#203 sedative near/1 antihistamine*:ti,ab,kw (Word variations have been searched)
#204 MeSH descriptor: [Promethazine] explode all trees
#205 #183 or #184 or #185 or #186 or #187 or #188 or #189 or #190 or #191 or #192 or #193 or #194 or #195
or #196 or #197 or #198 or #199 or #200 or #201 or #202 or #203 or #204
#206 MeSH descriptor: [Antidepressive Agents] explode all trees
#207 MeSH descriptor: [Benactyzine] explode all trees
#208 MeSH descriptor: [Clorgyline] explode all trees
#209 MeSH descriptor: [Deanol] explode all trees
#210 MeSH descriptor: [Desvenlafaxine Succinate] explode all trees
#211 MeSH descriptor: [Duloxetine Hydrochloride] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#212 MeSH descriptor: [Iproniazid] explode all trees
#213 MeSH descriptor: [Isocarboxazid] explode all trees
#214 MeSH descriptor: [Lithium Compounds] explode all trees
#215 MeSH descriptor: [Moclobemide] explode all trees
#216 MeSH descriptor: [Nialamide] explode all trees
#217 MeSH descriptor: [Phenelzine] explode all trees
#218 MeSH descriptor: [Pizotyline] explode all trees
#219 MeSH descriptor: [Rolipram] explode all trees
#220 MeSH descriptor: [Sertraline] explode all trees
#221 MeSH descriptor: [Tranylcypromine] explode all trees
#222 MeSH descriptor: [Vilazodone Hydrochloride] explode all trees
#223 MeSH descriptor: [Imipramine] explode all trees
#224 #206 or #207 or #208 or #209 or #210 or #211 or #212 or #213 or #214 or #215 or #216 or #217 or #218
or #219 or #220 or #221 or #222 or #223
#225 MeSH descriptor: [Antipsychotic Agents] explode all trees
#226 MeSH descriptor: [Acepromazine] explode all trees
#227 MeSH descriptor: [Aripiprazole] explode all trees
#228 MeSH descriptor: [Azaperone] explode all trees
#229 MeSH descriptor: [Benperidol] explode all trees
#230 MeSH descriptor: [Butaclamol] explode all trees
#231 MeSH descriptor: [Chlorpromazine] explode all trees
#232 MeSH descriptor: [Chlorprothixene] explode all trees
#233 MeSH descriptor: [Clopenthixol] explode all trees
#234 MeSH descriptor: [Clozapine] explode all trees
#235 MeSH descriptor: [Droperidol] explode all trees
#236 MeSH descriptor: [Etazolate] explode all trees
#237 MeSH descriptor: [Flupenthixol] explode all trees
#238 MeSH descriptor: [Fluphenazine] explode all trees
#239 MeSH descriptor: [Fluspirilene] explode all trees
#240 MeSH descriptor: [Haloperidol] explode all trees
#241 MeSH descriptor: [Loxapine] explode all trees
#242 MeSH descriptor: [Mesoridazine] explode all trees
#243 MeSH descriptor: [Methiothepin] explode all trees
#244 MeSH descriptor: [Methotrimeprazine] explode all trees
#245 MeSH descriptor: [Molindone] explode all trees
#246 MeSH descriptor: [Paliperidone Palmitate] explode all trees
#247 MeSH descriptor: [Penfluridol] explode all trees
#248 MeSH descriptor: [Perazine] explode all trees
#249 MeSH descriptor: [Perphenazine] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#250 MeSH descriptor: [Pimozide] explode all trees
#251 MeSH descriptor: [Prochlorperazine] explode all trees
#252 MeSH descriptor: [Promazine] explode all trees
#253 MeSH descriptor: [Quetiapine Fumarate] explode all trees
#254 MeSH descriptor: [Raclopride] explode all trees
#255 MeSH descriptor: [Remoxipride] explode all trees
#256 MeSH descriptor: [Reserpine] explode all trees
#257 MeSH descriptor: [Risperidone] explode all trees
#258 MeSH descriptor: [Ritanserin] explode all trees
#259 MeSH descriptor: [Spiperone] explode all trees
#260 MeSH descriptor: [Sulpiride] explode all trees
#261 MeSH descriptor: [Thioridazine] explode all trees
#262 MeSH descriptor: [Thiothixene] explode all trees
#263 MeSH descriptor: [Tiapride Hydrochloride] explode all trees
#264 MeSH descriptor: [Trifluoperazine] explode all trees
#265 MeSH descriptor: [Trifluperidol] explode all trees
#266 MeSH descriptor: [Triflupromazine] explode all trees
#267 “olanzapine”:ti,ab,kw (Word variations have been searched)
#268 #225 or #226 or #227 or #228 or #229 or #230 or #231 or #232 or #233 or #234 or #235 or #236 or #237
or #238 or #239 or #240 or #241 or #242 or #243 or #244 or #245 or #246 or #247 or #248 or #249 or #250 or
#251 or #252 or #253 or #254 or #255 or #256 or #257 or #258 or #259 or #260 or #261 or #262 or #263 or #264
or #265 or #266 or #267
#269 MeSH descriptor: [Anticonvulsants] explode all trees
#270 MeSH descriptor: [Acetazolamide] explode all trees
#271 MeSH descriptor: [Bromides] explode all trees
#272 MeSH descriptor: [Carbamazepine] explode all trees
#273 MeSH descriptor: [Clonazepam] explode all trees
#274 MeSH descriptor: [Clorazepate Dipotassium] explode all trees
#275 MeSH descriptor: [Diazepam] explode all trees
#276 MeSH descriptor: [Dimethadione] explode all trees
#277 MeSH descriptor: [Estazolam] explode all trees
#278 MeSH descriptor: [Ethosuximide] explode all trees
#279 MeSH descriptor: [Flunarizine] explode all trees
#280 MeSH descriptor: [Lorazepam] explode all trees
#281 MeSH descriptor: [Magnesium Sulfate] explode all trees
#282 MeSH descriptor: [Medazepam] explode all trees
#283 MeSH descriptor: [Mephenytoin] explode all trees
#284 MeSH descriptor: [Mephobarbital] explode all trees
#285 MeSH descriptor: [Meprobamate] explode all trees
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TABLE 16 Search strategy for CENTRAL via The Cochrane Library (continued )
#286 MeSH descriptor: [Nitrazepam] explode all trees
#287 MeSH descriptor: [Paraldehyde] explode all trees
#288 MeSH descriptor: [Phenobarbital] explode all trees
#289 MeSH descriptor: [Phenytoin] explode all trees
#290 MeSH descriptor: [Pregabalin] explode all trees
#291 MeSH descriptor: [Primidone] explode all trees
#292 MeSH descriptor: [Riluzole] explode all trees
#293 MeSH descriptor: [Thiopental] explode all trees
#294 MeSH descriptor: [Tiletamine] explode all trees
#295 MeSH descriptor: [Trimethadione] explode all trees
#296 MeSH descriptor: [Valproic Acid] explode all trees
#297 MeSH descriptor: [Vigabatrin] explode all trees
#298 #269 or #270 or #271 or #272 or #273 or #274 or #275 or #276 or #277 or #278 or #279 or #280 or #281
or #282 or #283 or #284 or #285 or #286 or #287 or #288 or #289 or #290 or #291 or #292 or #293 or #294 or
#295 or #296 or #297
#299 MeSH descriptor: [Antimanic Agents] explode all trees
#300 MeSH descriptor: [Lithium Chloride] explode all trees
#301 “lamotrigine”:ti,ab,kw (Word variations have been searched)
#302 “topiramate”:ti,ab,kw (Word variations have been searched)
#303 MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees
#304 MeSH descriptor: [Chlorpheniramine] explode all trees
#305 MeSH descriptor: [Clorgyline] explode all trees
#306 MeSH descriptor: [Cuprizone] explode all trees
#307 MeSH descriptor: [Furazolidone] explode all trees
#308 MeSH descriptor: [Harmaline] explode all trees
#309 MeSH descriptor: [Harmine] explode all trees
#310 MeSH descriptor: [Isocarboxazid] explode all trees
#311 MeSH descriptor: [Moclobemide] explode all trees
#312 MeSH descriptor: [Monocrotophos] explode all trees
#313 MeSH descriptor: [Pargyline] explode all trees
#314 MeSH descriptor: [Selegiline] explode all trees
#315 MeSH descriptor: [Tranylcypromine] explode all trees
#316 MeSH descriptor: [Prazosin] explode all trees
#317 MeSH descriptor: [N-Methyl-3,4-methylenedioxyamphetamine] explode all trees
#318 MDMA:ti,ab,kw or ecstasy:kw (Word variations have been searched)
#319 #299 or #300 or #301 or #302 or #303 or #304 or #305 or #306 or #307 or #308 or #309 or #310 or #311
or #312 or #313 or #314 or #315 or #316 or #317 or #318
#320 #182 or #205 or #224 or #268 or #298 or #319
#321 #83 and #142
#322 #83 and #320
#323 #321 or #322
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EMBASE via Ovid
Search date: 19 April 2017.
Records retrieved: 5473.
Date range searched: 1974 to 2017 week 16.
TABLE 17 Search strategy for EMBASE via Ovid
1 exp Violence/ (127,415)
2 violence.ti,ab. (42,364)
3 Exposure to Violence/ (299)
4 Domestic Violence/(8799)
5 Sexual Violence/ (1468)
6 Battered Woman/ (3115)
7 (batter$ adj2 (wife$ or wive$ or woman or women or men or husband$ or partner$)).ti,ab. (973)
8 (physical$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (12,350)
9 (emotional$ adj2 abus$).ti,ab. (2304)
10 Rape/(7255)
11 Sexual Assault/ (1440)
12 rape.ti,ab. (7034)
13 (sexual$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (23,249)
14 Child Sexual Abuse/ (8661)
15 child$ sexual abuse.ti,ab. (4983)
16 Child Abuse/ (27,390)
17 (child$ adj2 exploit$).ti,ab. (221)
18 child neglect.ti,ab. (490)
19 (child$ adj2 trauma).ti,ab. (6375)
20 (non accidental injur$ or non-accidental injur$ or nonaccidental injury).ti,ab. (755)
21 Human Rights Abuse/ (1442)
22 Human Trafficking/(259)
23 ((human or person or people) adj2 (traffick$ or exploit$)).ti,ab. (907)
24 ((forced or exploit$) adj2 labour).ti,ab. (62)
25 Organ Trafficking/ (190)
26 Slavery/ (115)
27 Torture/ (2635)
28 (slavery or enslave$ or torture$).ti,ab. (2768)
29 Prostitution/ (8919)
30 (prostitut$ or brothel$).ti,ab. (3430)
31 (sex$ adj2 (exploit$ or traffick$)).ti,ab. (618)
32 exp Terrorism/ (9017)
33 (terrorism or terrorist$).ti,ab. (6169)
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TABLE 17 Search strategy for EMBASE via Ovid (continued )
34 political terror$.ti,ab. (19)
35 Torture/ (2635)
36 exp warfare/ (18,460)
37 War crime/ (174)
38 Genocide/ (334)
39 Holocaust/ (369)
40 Ethnic Conflict/ (58)
41 (civil adj (unrest or conflict$ or disturbance$ or war or wars or warfare)).ti,ab. (1866)
42 (persecution or victimization or victimisation).ti,ab. (7768)
43 (captivity or imprison$ or concentration camp$).ti,ab. (6611)
44 exp Disasters/ (27,191)
45 natural disaster$.ti,ab. (3220)
46 (earthquake$ or tsunami$).ti,ab. (8306)
47 (humanitarian adj (crisis or crises)).ti,ab. (230)
48 (catastrophe$ or catastrophic event$ or catastrophic experience$).ti,ab. (7315)
49 exp Survivor/ (65,046)
50 Refugee/ (9945)
51 (asylum seeker$ or refugee$ or migrant$).ti,ab. (22,105)
52 ((forcibly or internally) adj2 displace$).ti,ab. (518)
53 (displace$ adj2 (people or person$ or civilian$)).ti,ab. (769)
54 Crime Victim/(1526)
55 exp Childhood Trauma Survivor/ (209)
56 Disaster Victim/ (296)
57 exp Prisoner/ (15,304)




62 ((expose$ or exposure) adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$
or war or warfare)).ti,ab. (8060)
63 (survivor$ adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$ or war or
warfare)).ti,ab. (2541)
64 (victim$ adj2 (abuse or assault$ or crime or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war
or warfare)).ti,ab. (9275)
65 (witness$ adj2 (abuse or assault$ or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war or
warfare)).ti,ab. (1147)
66 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 (372,799)
67 Posttraumatic Stress Disorder/ (48,288)
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TABLE 17 Search strategy for EMBASE via Ovid (continued )
71 “post trauma$”.ti,ab. (32,384)
72 post traumatic stress.ti,ab. (12,118)
73 post traumatic stress.kw. (2904)
74 combat stress$.ti,ab. (414)
75 combat disorder$.ti,ab. (19)
76 DESNOS.ti,ab. (37)
77 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
78 complex trauma$.ti,ab. (468)
79 (complex adj3 trauma$).ti,ab. (1446)
80 traumatic stress.ti,ab. (14,496)
81 traumatic memor$.ti,ab. (767)
82 traumatization.ti,ab. (1253)
83 traumatisation.ti,ab. (258)
84 (trauma$ adj3 (expos$ or event$ or experienc$)).ti,ab. (20,684)
85 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 (99,034)
86 66 and 85 (29,961)
87 exp Cognitive Therapy/ (44,498)
88 cognitive behaviour$ therapy.ti,ab. (5617)
89 cognitive behavior$ therapy.ti,ab. (10,869)
90 cognitive restructuring.ti,ab. (1117)
91 cognitive rescripting.ti,ab. (0)
92 cognitive processing therapy.ti,ab. (197)
93 CPT.ti,ab. (15,303)
94 cognitive therapy.ti,ab. (3567)
95 cognitive behavioural treatment$.ti,ab. (569)
96 cognitive behavioral treatment$.ti,ab. (1915)
97 (CBT or TFCBT).ti,ab. (11,649)
98 cognitive trauma therapy.ti,ab. (7)
99 trauma focus$ CBT.ti,ab. (48)
100 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 (65,898)
101 exp Behavior Therapy/ (42,878)
102 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (35,788)
103 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (13,871)
104 (dialectical behavio$ adj (therap$ or treat$)).ti,ab. (829)
105 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (21,789)
106 (biofeedback or neurofeedback or sensory feedback).ti,ab. (11,442)
107 eye movement desensitization reprocessing/or implosive therapy/or virtual reality exposure therapy/ (414)
108 (psychological adj2 desensiti$).ti,ab. (9)
109 eye movement desensiti?ation reprocessing.ti,ab. (39)
110 EMDR.ti,ab. (560)
111 (exposure adj (therap$ or treat$)).ti,ab. (2851)
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TABLE 17 Search strategy for EMBASE via Ovid (continued )
112 live exposure.ti,ab. (16)
113 imaginal exposure.ti,ab. (183)
114 prolonged exposure therapy.ti,ab. (120)
115 imaginal flooding.ti,ab. (27)
116 exposure inhibition therap$.ti,ab. (0)
117 implosive therap$.ti,ab. (58)
118 image habituation.ti,ab. (4)
119 inoculation training.ti,ab. (114)
120 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or
116 or 117 or 118 or 119 (107,793)
121 “Acceptance and Commitment Therapy”/ (780)
122 (acceptance adj2 therap$).ti,ab. (384)
123 (commitment adj2 therap$).ti,ab. (858)
124 Hypnosis/ (14,590)
125 (hypnosis or hypnotherap$).ti,ab. (9008)
126 Mindfulness/ (3696)
127 mindfulness.ti,ab. (5250)
128 supportive therap$.ti,ab. (5535)
129 (non-directive adj (counselling or counseling)).ti,ab. (118)
130 (nondirective adj (counselling or counseling)).ti,ab. (51)
131 (non directive adj (counselling or counseling)).ti,ab. (118)
132 Psychotherapy/or Group Therapy/or Psychodynamic Psychotherapy/ (104,777)
133 psychodynamic therap$.ti,ab. (636)
134 inter personal psychotherap$.ti,ab. (1)
135 interpersonal psychotherap$.ti,ab. (940)
136 IPT.ti,ab. (2383)
137 (compassion adj2 therap$).ti,ab. (58)
138 accelerated resolution.ti,ab. (120)
139 sensorimotor therap$.ti,ab. (24)
140 schema therapy.ti,ab. (180)
141 (stress adj2 manag$).ti,ab. (6629)
142 supportive therap$.ti,ab. (5535)
143 Counseling/ (75,492)
144 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (170)
145 compassion therap$.ti,ab. (2)
146 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or
136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 (209,736)
147 100 or 120 or 146 (330,152)
148 hypnotic sedative agent/or alprazolam/or amobarbital/or azaperone/or barbital/or bromisovalum/or chloral
hydrate/or chloralose/or chlordiazepoxide/or chlomethiazole/or dexmedetomidine/or diazepam/or diphenhydramine/or
eszopiclone/or ethchlorvynol/or etomidate/or etorphine/or flurazepam/or glutethimide/or hexobarbital/or lorazepam/
or medazepam/or medetomidine/or methylphenobarbital/or meprobamate/or methapyrilene/or methaqualone/or
midazolam/or nitrazepam/or oxazepam/or paraldehyde/or pentobarbital/or phenobarbital/or propofol/or secobarbital/
or temazepam/or thiamylal/or thiopental/or xylazine/ (321,753)
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International Pharmaceutical Abstracts via ProQuest
Search date: 30 August 2017.
The initial search identified 625 records.
Date range searched: 1970 onwards.
TABLE 17 Search strategy for EMBASE via Ovid (continued )
149 z drugs.ti,ab. (207)
150 anxiolytic agent/or bromazepam/or buspirone/or chlormezanone/or clorazepate dipotassium/or estazolam/or
flunitrazepam/or fluvoxamine/or nordazepam/or ondansetron/or oxprenolol/or prazepam/or pregabalin/or ritanserin/or
tranylcypromine/or trazodone/or triazolam/or zolazepam/ (100,358)
151 benzodiazepine derivative/ (40,227)
152 sedative antihistamine$.ti,ab. (114)
153 promethazine/ (13,661)
154 antidepressive agent/or benactyzine/or clorgyline/or deanol/or desvenlafaxine/or duloxetine/or iproniazid/or
isocarboxazid/or lithium carbonate/or lithium derivative/or moclobemide/or nialamide/or phenelzine/or pizotifen/or
rolipram/or sertraline/or tranylcypromine/or vilazodone/ (147,901)
155 Imipramine/ (34,101)
156 mirtazapine/ (10,903)
157 neuroleptic agent/or acepromazine/or aripiprazole/or azaperone/or benperidol/or butaclamol/or chlorpromazine/
or chlorprothixene/or clopenthixol/or clozapine/or droperidol/or etazolate/or flupentixol/or fluphenazine/or fluspirilene/
or haloperidol/or loxapine/or lurasidone/or mesoridazine/or metitepine/or methotrimeprazine/or molindone/or
ondansetron/or paliperidone/or penfluridol/or perazine/or perphenazine/or pimozide/or prochlorperazine/or promazine/
or quetiapine/or raclopride/or remoxipride/or reserpine/or risperidone/or ritanserin/or spiperone/or sulpiride/or
thioridazine/or tiothixene/or tiapride/or trifluoperazine/or trifluperidol/or triflupromazine/ (250,352)
158 olanzapine/ (30,419)
159 anticonvulsive agent/or acetazolamide/or bromides/or carbamazepine/or clonazepam/or clorazepate dipotassium/
or diazepam/or dimethadione/or estazolam/or ethosuximide/or flunarizine/or lorazepam/or magnesium sulfate/or
medazepam/or mephenytoin/or methylphenobarbital/or meprobamate/or nitrazepam/or paraldehyde/or phenobarbital/
or phenytoin/or pregabalin/or primidone/or riluzole/or thiopental/or tiletamine/or trimethadione/or valproic acid/or
vigabatrin/ (370,923)
160 tranquilizer/or lithium chloride/or lithium derivative/ (25,358)
161 lamotrigine/ (21,972)
162 topiramate/ (18,900)
163 monoamine oxidase inhibitor/or chlorphenamidine/or clorgyline/or cuprizone/or furazolidone/or harmaline/or
harmine/or isocarboxazid/or moclobemide/or monocrotophos/or pargyline/or selegiline/or tranylcypromine/ (44,538)
164 Prazosin/ (22,822)
165 3,4 methylenedioxyamphetamine/ (2221)
166 (MDMA or ecstasy).ti,ab. (6467)
167 148 or 149 or 150 or 151 or 152 or 153 or 154 or 155 or 156 or 157 or 158 or 159 or 160 or 161 or 162 or
163 or 164 or 165 or 166 (904,230)
168 86 and 147 (4620)
169 86 and 167 (1616)
170 168 or 169 (5607)
171 limit 170 to yr=“1992 -Current” (5473)
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MEDLINE via Ovid
Search date: 18 April 2017.
Records retrieved: 2818.
Database: Ovid MEDLINE Epub Ahead of Print and In-Process & Other Non-Indexed Citations, Ovid
MEDLINE Daily and Ovid MEDLINE.
Date range searched: 1946 to present.
TABLE 18 Search strategy for International Pharmaceutical Abstracts via ProQuest
(SU.EXACT(“Stress disorders”)) OR (PTSD or CPTSD) OR (posttrauma* or post-trauma*) OR (“post traumatic stress”) OR
(“combat disorder*”) OR (“combat stress”) OR DESNOS OR (traumatisation OR traumatization) OR (complex NEAR/3
trauma*) OR (trauma* NEAR/3 (expos* or event* or experienc*))
TABLE 19 Search strategy for MEDLINE via Ovid
1 exp Violence/ (84,653)
2 violence.ti,ab. (38,287)
3 Domestic Violence/ (5769)
4 Intimate Partner Violence/ (716)
5 Battered Women/ (2579)
6 (batter$ adj2 (wife$ or wive$ or woman or women or men or husband$ or partner$)).ti,ab. (870)
7 (physical$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (10,464)
8 (emotional$ adj2 abus$).ti,ab. (1749)
9 Rape/ (6157)
10 rape.ti,ab. (6600)
11 (sexual$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (19,466)
12 Child Sexual Abuse/ (9551)
13 child$ sexual abuse.ti,ab. (4339)
14 (child$ adj2 exploit$).ti,ab. (200)
15 child neglect.ti,ab. (468)
16 (child$ adj2 trauma).ti,ab. (4689)
17 (non accidental injur$ or non-accidental injur$ or nonaccidental injury).ti,ab. (533)
18 Human Rights Abuses/ (734)
19 Human Trafficking/ (177)
20 ((human or person or people) adj2 (traffick$ or exploit$)).ti,ab. (818)
21 ((forced or exploit$) adj2 labour).ti,ab. (56)
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TABLE 19 Search strategy for MEDLINE via Ovid (continued )
25 (slavery or enslave$ or torture$).ti,ab. (2480)
26 Sex Work/ (5675)
27 (prostitut$ or brothel$).ti,ab. (3946)
28 (sex$ adj2 (exploit$ or traffick$)).ti,ab. (561)
29 Terrorism/ (4718)
30 (terrorism or terrorist$).ti,ab. (5408)
31 political terror$.ti,ab. (16)
32 Torture/ (1996)
33 exp warfare/ (35,511)
34 exp Armed Conflicts/ (8467)
35 War crimes/ (1197)
36 Genocide/ (84)
37 Holocaust/ (782)
38 Ethnic Cleansing/ (0)
39 (civil adj (unrest or conflict$ or disturbance$ or war or wars or warfare)).ti,ab. (1859)
40 (persecution or victimization or victimisation).ti,ab. (7276)
41 (captivity or imprison$ or concentration camp$).ti,ab. (6151)
42 exp Disasters/ (67,463)
43 Earthquakes/ (3095)
44 Tsunamis/ (708)
45 natural disaster$.ti,ab. (2928)
46 (earthquake$ or tsunami$).ti,ab. (7947)
47 (humanitarian adj (crisis or crises)).ti,ab. (221)
48 (catastrophe$ or catastrophic event$ or catastrophic experience$).ti,ab. (5922)
49 exp Survivors/ (22,782)
50 Refugees/ (8204)
51 (asylum seeker$ or refugee$ or migrant$).ti,ab. (21,535)
52 ((forcibly or internally) adj2 displace$).ti,ab. (476)
53 (displace$ adj2 (people or person$ or civilian$)).ti,ab. (763)
54 Crime Victims/ (7200)
55 Adult Survivors of Child Abuse/ (1437)
56 Disaster Victims/ (96)
57 Prisoners/ (15,110)
58 Prisoners of War/ (469)
59 Slaves/ (31)
60 Veterans/ (13,136)
61 Military Personnel/ (35,416)
62 ((expose$ or exposure) adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$
or war or warfare)).ti,ab. (7019)
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TABLE 19 Search strategy for MEDLINE via Ovid (continued )
63 (survivor$ adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$ or war or
warfare)).ti,ab. (2319)
64 (victim$ adj2 (abuse or assault$ or crime or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war
or warfare)).ti,ab. (8160)
65 (witness$ adj2 (abuse or assault$ or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war or
warfare)).ti,ab. (1041)
66 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 (331,505)
67 Stress Disorders, Post Traumatic/ (26,733)
68 (PTSD or CPTSD).ti,ab. (18,107)
69 posttrauma$.ti,ab. (30,066)
70 post-trauma$.ti,ab. (25,637)
71 “post trauma$”.ti,ab. (25,637)
72 post traumatic stress.ti,ab. (9289)
73 post traumatic stress.kw. (88)
74 combat stress$.ti,ab. (343)
75 combat disorder$.ti,ab. (15)
76 DESNOS.ti,ab. (31)
77 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
78 complex trauma$.ti,ab. (403)
79 (complex adj3 trauma$).ti,ab. (1217)
80 traumatic stress.ti,ab. (10,740)
81 traumatic memor$.ti,ab. (579)
82 traumatization.ti,ab. (990)
83 traumatisation.ti,ab. (192)
84 (trauma$ adj3 (expos$ or event$ or experienc$)).ti,ab. (16,288)
85 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 (75,076)
86 66 and 85 (24,059)
87 exp Cognitive Therapy/ (22,441)
88 cognitive behaviour$ therapy.ti,ab. (3982)
89 cognitive behavior$ therapy.ti,ab. (8052)
90 cognitive restructuring.ti,ab. (723)
91 cognitive rescripting.ti,ab. (0)
92 cognitive processing therapy.ti,ab. (178)
93 CPT.ti,ab. (10,770)
94 cognitive therapy.ti,ab. (2397)
95 cognitive behavioural treatment$.ti,ab. (403)
96 cognitive behavioral treatment$.ti,ab. (1378)
97 (CBT or TFCBT).ti,ab. (7996)
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TABLE 19 Search strategy for MEDLINE via Ovid (continued )
98 cognitive trauma therapy.ti,ab. (6)
99 trauma focus$ CBT.ti,ab. (31)
100 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 (40,659)
101 exp Behavior Therapy/ (64,582)
102 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (26,789)
103 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (9862)
104 (dialectical behavio$ adj (therap$ or treat$)).ti,ab. (581)
105 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (9330)
106 (biofeedback or neurofeedback or sensory feedback).ti,ab. (8461)
107 eye movement desensitization reprocessing/or implosive therapy/or virtual reality exposure therapy/ (1347)
108 (psychological adj2 desensiti$).ti,ab. (4)
109 eye movement desensiti?ation reprocessing.ti,ab. (25)
110 EMDR.ti,ab. (372)
111 (exposure adj (therap$ or treat$)).ti,ab. (2282)
112 live exposure.ti,ab. (11)
113 imaginal exposure.ti,ab. (147)
114 prolonged exposure therapy.ti,ab. (99)
115 imaginal flooding.ti,ab. (13)
116 exposure inhibition therap$.ti,ab. (0)
117 implosive therap$.ti,ab. (43)
118 image habituation.ti,ab. (3)
119 inoculation training.ti,ab. (78)
120 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or
116 or 117 or 118 or 119 (90,057)
121 “Acceptance and Commitment Therapy”/ (184)
122 (acceptance adj2 therap$).ti,ab. (257)
123 (commitment adj2 therap$).ti,ab. (603)
124 Hypnosis/ (8730)
125 (hypnosis or hypnotherap$).ti,ab. (7561)
126 Mindfulness/ (1325)
127 mindfulness.ti,ab. (4005)
128 supportive therap$.ti,ab. (3906)
129 (non-directive adj (counselling or counseling)).ti,ab. (100)
130 (nondirective adj (counselling or counseling)).ti,ab. (54)
131 (non directive adj (counselling or counseling)).ti,ab. (100)
132 Psychotherapy/or Psychotherapy, Brief/or Psychotherapy, Group/or Psychotherapy, Multiple/or Psychotherapy,
Psychodynamic/or Psychotherapy, Rational-emotive/ (65,822)
133 psychodynamic therap$.ti,ab. (431)
134 inter personal psychotherap$.ti,ab. (1)
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TABLE 19 Search strategy for MEDLINE via Ovid (continued )
135 interpersonal psychotherap$.ti,ab. (778)
136 IPT.ti,ab. (1907)
137 (compassion adj2 therap$).ti,ab. (39)
138 accelerated resolution.ti,ab. (86)
139 sensorimotor therap$.ti,ab. (21)
140 schema therapy.ti,ab. (106)
141 (stress adj2 manag$).ti,ab. (5168)
142 supportive therap$.ti,ab. (3906)
143 Counseling/(32,854)
144 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (155)
145 compassion therap$.ti,ab. (1)
146 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or
136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 or 145 (122,017)
147 100 or 120 or 146 (211,031)
148 “hypnotics and sedatives”/or alprazolam/or amobarbital/or azaperone/or barbital/or bromisovalum/or chloral
hydrate/or chloralose/or chlordiazepoxide/or chlormethiazole/or dexmedetomidine/or diazepam/or diphenhydramine/
or eszopiclone/or ethchlorvynol/or etomidate/or etorphine/or flurazepam/or glutethimide/or hexobarbital/or
lorazepam/or medazepam/or medetomidine/or mephobarbital/or meprobamate/or methapyrilene/or methaqualone/or
midazolam/or nitrazepam/or oxazepam/or paraldehyde/or pentobarbital/or phenobarbital/or propofol/or secobarbital/
or temazepam/or thiamylal/or thiopental/or xylazine/ (114,648)
149 z drugs.ti,ab. (120)
150 anti-anxiety agents/or bromazepam/or buspirone/or chlormezanone/or clorazepate dipotassium/or estazolam/or
flunitrazepam/or fluvoxamine/or nordazepam/or ondansetron/or oxprenolol/or prazepam/or pregabalin/or ritanserin/or
tranylcypromine/or trazodone/or triazolam/or zolazepam/ (33,101)
151 benzodiazepines/or benzodiazepinones/ (23,660)
152 sedative antihistamine$.ti,ab. (61)
153 promethazine.ti,ab. (2061)
154 antidepressive agents/or benactyzine/or clorgyline/or deanol/or desvenlafaxine succinate/or duloxetine
hydrochloride/or iproniazid/or isocarboxazid/or lithium carbonate/or lithium compounds/or moclobemide/or nialamide/
or phenelzine/or pizotyline/or rolipram/or sertraline/or tranylcypromine/or vilazodone hydrochloride/ (55,533)
155 Imipramine/ (9832)
156 mirtazapine.ti,ab. (1765)
157 antipsychotic agents/or acepromazine/or aripiprazole/or azaperone/or benperidol/or butaclamol/or chlorpromazine/
or chlorprothixene/or clopenthixol/or clozapine/or droperidol/or etazolate/or flupenthixol/or fluphenazine/or fluspirilene/or
haloperidol/or loxapine/or lurasidone hydrochloride/or mesoridazine/or methiothepin/or methotrimeprazine/or molindone/
or ondansetron/or paliperidone palmitate/or penfluridol/or perazine/or perphenazine/or pimozide/or prochlorperazine/or
promazine/or quetiapine fumarate/or raclopride/or remoxipride/or reserpine/or risperidone/or ritanserin/or spiperone/or
sulpiride/or thioridazine/or thiothixene/or tiapride hydrochloride/or trifluoperazine/or trifluperidol/or triflupromazine/
(114,997)
158 olanzapine.ti,ab. (7555)
159 anticonvulsants/or acetazolamide/or bromides/or carbamazepine/or clonazepam/or clorazepate dipotassium/or
diazepam/or dimethadione/or estazolam/or ethosuximide/or flunarizine/or lorazepam/or magnesium sulfate/or
medazepam/or mephenytoin/or mephobarbital/or meprobamate/or nitrazepam/or paraldehyde/or phenobarbital/or
phenytoin/or pregabalin/or primidone/or riluzole/or thiopental/or tiletamine/or trimethadione/or valproic acid/or
vigabatrin/ (129,932)
160 antimanic agents/or lithium chloride/or lithium compounds/ (9229)
161 lamotrigine.ti,ab. (4632)
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PILOTS via ProQuest
Search date: 2 May 2017.
Two separate searches were conducted: one for psychological interventions and a second for
pharmacological interventions.
Total records retrieved: 1981.
Date range searched: 1987 onwards.
TABLE 19 Search strategy for MEDLINE via Ovid (continued )
162 topiramate.ti,ab. (4045)
163 monoamine oxidase inhibitors/or chlorphenamidine/or clorgyline/or cuprizone/or furazolidone/or harmaline/or
harmine/or isocarboxazid/or moclobemide/or monocrotophos/or pargyline/or selegiline/or tranylcypromine/ (17,953)
164 Prazosin/ (7567)
165 N-Methyl-3,4-methylenedioxyamphetamine/ (3644)
166 (MDMA or ecstasy).ti,ab. (5232)
167 148 or 149 or 150 or 151 or 152 or 153 or 154 or 155 or 156 or 157 or 158 or 159 or 160 or 161 or 162 or
163 or 164 or 165 or 166 (407,459)
168 86 and 147 (2717)
169 86 and 167 (405)
170 168 or 169 (3004)
171 limit 170 to yr=“1992 -Current” (2818)
TABLE 20 Search strategy for PILOTS via ProQuest
Set Search Results
Psychological interventions search strategy
S1 (SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband* OR
partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional* NEAR/
1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner Rape”
OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
43,537°
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TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR
“Railroad Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen* OR
war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR
trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR crime
OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare)) OR
(witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))
S2 (cognitive N2 therap*) OR (cognitive N2 treat*) OR (cognitive N1 rescript*) OR (cognitive N1
restructur*) OR CPT OR CBT OR TFCBT OR (trauma N2 CBT)
812°
S4 (behav* N2 therap*) OR (behav* N2 treat*) OR (behav* N2 modif*) OR biofeedback OR
neurofeedback OR “sensory feedback” OR “eye movement desensitization reprocessing” OR “eye
movement desensitisation reprocessing” OR EMDR
1077°
S6 (exposure N2 therap*) OR (exposure N2 treat*) OR “live exposure” OR “imaginal exposure” OR
“imaginal flooding” OR “exposure inhibition therapy” OR (implosive N2 therap*) OR “image
habituation” OR “inoculation training”
223°
S8 (acceptance N2 therap*) OR (commitment N2 therap*) OR hypnosis OR hypnotherap* OR
mindfulness OR (supportive N2 therap*) OR (non-directive N2 counsel*) OR (nondirective N2
counsel*) OR psychotherapy OR “group therapy”
6900°
S9 (psychodynamic N1 therap*) OR (interpersonal psychotherap*) OR IPT OR (compassion N2 therap*)
OR “accelerated resolution” OR (sensorimotor N1 therap*) OR (schema N1 therap*)
756°
S10 ((cognitive N2 therap*) OR (cognitive N2 treat*) OR (cognitive N1 rescript*) OR (cognitive N1
restructur*) OR CPT OR CBT OR TFCBT OR (trauma N2 CBT)) OR ((behav* N2 therap*) OR (behav*
N2 treat*) OR (behav* N2 modif*) OR biofeedback OR neurofeedback OR “sensory feedback” OR
“eye movement desensitization reprocessing” OR “eye movement desensitisation reprocessing” OR
EMDR) OR ((exposure N2 therap*) OR (exposure N2 treat*) OR “live exposure” OR “imaginal
exposure” OR “imaginal flooding” OR “exposure inhibition therapy” OR (implosive N2 therap*) OR
“image habituation” OR “inoculation training”) OR ((acceptance N2 therap*) OR (commitment N2
therap*) OR hypnosis OR hypnotherap* OR mindfulness OR (supportive N2 therap*) OR (non-
directive N2 counsel*) OR (nondirective N2 counsel*) OR psychotherapy OR “group therapy”) OR
((psychodynamic N1 therap*) OR (interpersonal psychotherap*) OR IPT OR (compassion N2 therap*)
OR “accelerated resolution” OR (sensorimotor N1 therap*) OR (schema N1 therap*))
8207°
S11 ((SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband* OR
partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional* NEAR/
1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner Rape”
OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen*
OR aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
5986°
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TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR
“Railroad Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen*
OR war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture*
OR trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR
crime OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare))
OR (witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))) AND (((cognitive N2 therap*) OR (cognitive N2 treat*) OR
(cognitive N1 rescript*) OR (cognitive N1 restructur*) OR CPT OR CBT OR TFCBT OR (trauma N2
CBT)) OR ((behav* N2 therap*) OR (behav* N2 treat*) OR (behav* N2 modif*) OR biofeedback OR
neurofeedback OR “sensory feedback” OR “eye movement desensitization reprocessing” OR “eye
movement desensitisation reprocessing” OR EMDR) OR ((exposure N2 therap*) OR (exposure N2
treat*) OR “live exposure” OR “imaginal exposure” OR “imaginal flooding” OR “exposure inhibition
therapy” OR (implosive N2 therap*) OR “image habituation” OR “inoculation training”) OR
((acceptance N2 therap*) OR (commitment N2 therap*) OR hypnosis OR hypnotherap* OR
mindfulness OR (supportive N2 therap*) OR (non-directive N2 counsel*) OR (nondirective N2
counsel*) OR psychotherapy OR “group therapy”) OR ((psychodynamic N1 therap*) OR (interpersonal
psychotherap*) OR IPT OR (compassion N2 therap*) OR “accelerated resolution” OR (sensorimotor
N1 therap*) OR (schema N1 therap*)))
S12 SU.EXACT(“Complex PTSD”) OR SU.EXACT(“PTSD”) 18,871°
S13 (((SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband*
OR partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional*
NEAR/1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner
Rape” OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen*
OR aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR “Railroad
Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen* OR
war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR
trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR crime
OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare)) OR
1955°
continued
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
145
TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
(witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))) AND (((cognitive N2 therap*) OR (cognitive N2 treat*) OR
(cognitive N1 rescript*) OR (cognitive N1 restructur*) OR CPT OR CBT OR TFCBT OR (trauma N2
CBT)) OR ((behav* N2 therap*) OR (behav* N2 treat*) OR (behav* N2 modif*) OR biofeedback OR
neurofeedback OR “sensory feedback” OR “eye movement desensitization reprocessing” OR “eye
movement desensitisation reprocessing” OR EMDR) OR ((exposure N2 therap*) OR (exposure N2
treat*) OR “live exposure” OR “imaginal exposure” OR “imaginal flooding” OR “exposure inhibition
therapy” OR (implosive N2 therap*) OR “image habituation” OR “inoculation training”) OR
((acceptance N2 therap*) OR (commitment N2 therap*) OR hypnosis OR hypnotherap* OR
mindfulness OR (supportive N2 therap*) OR (non-directive N2 counsel*) OR (nondirective N2
counsel*) OR psychotherapy OR “group therapy”) OR ((psychodynamic N1 therap*) OR (interpersonal
psychotherap*) OR IPT OR (compassion N2 therap*) OR “accelerated resolution” OR (sensorimotor
N1 therap*) OR (schema N1 therap*)))) AND (SU.EXACT(“Complex PTSD”) OR SU.EXACT(“PTSD”))
S14 (((SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband*
OR partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional*
NEAR/1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner
Rape” OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen*
OR aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR “Railroad
Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen*
OR war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture*
OR trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR
crime OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare)) OR
(witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))) AND (((cognitive N2 therap*) OR (cognitive N2 treat*) OR
(cognitive N1 rescript*) OR (cognitive N1 restructur*) OR CPT OR CBT OR TFCBT OR (trauma N2
CBT)) OR ((behav* N2 therap*) OR (behav* N2 treat*) OR (behav* N2 modif*) OR biofeedback OR
neurofeedback OR “sensory feedback” OR “eye movement desensitization reprocessing” OR “eye
movement desensitisation reprocessing” OR EMDR) OR ((exposure N2 therap*) OR (exposure N2
treat*) OR “live exposure” OR “imaginal exposure” OR “imaginal flooding” OR “exposure inhibition
therapy” OR (implosive N2 therap*) OR “image habituation” OR “inoculation training”) OR
((acceptance N2 therap*) OR (commitment N2 therap*) OR hypnosis OR hypnotherap* OR
mindfulness OR (supportive N2 therap*) OR (non-directive N2 counsel*) OR (nondirective N2
counsel*) OR psychotherapy OR “group therapy”) OR ((psychodynamic N1 therap*) OR (interpersonal
psychotherap*) OR IPT OR (compassion N2 therap*) OR “accelerated resolution” OR (sensorimotor
N1 therap*) OR (schema N1 therap*)))) AND (SU.EXACT(“Complex PTSD”) OR SU.EXACT(“PTSD”))
Limits applied
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TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
Pharmacological interventions search strategy
S1 (SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband*
OR partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional*
NEAR/1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner
Rape” OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen*
OR aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR
“Railroad Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen* OR
war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR
trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR crime
OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare)) OR
(witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))
43,537°
S12 SU.EXACT(“Complex PTSD”) OR SU.EXACT(“PTSD”) 18,871°
S13 ((SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family
Violence”)) OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband*
OR partner*)) OR (physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional*
NEAR/1 abus*) OR (SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape” OR “Partner
Rape” OR “Rape”) OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen*
OR aggress*)) OR SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR
aggress*)) OR (child* NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*” OR
“non-accidental injur*” OR “nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human
OR person OR people) NEAR/2 (traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR
SU.EXACT(“Slavery”) OR SU.EXACT(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT
(“Prostitution”) OR (prostitution* OR brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR
SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical Warfare” OR “Civil Warfare” OR “Humanitarian
Intervention” OR “Military Intervention” OR “War”) OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War
Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR SU.EXACT(“Persecution”) OR (civil NEAR/1
(unrest OR conflict* OR disturbance* OR war OR wars OR warfare)) OR (persecution OR
victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT(“Concentration Camps”)
OR (SU.EXACT(“Avalanches” OR “Blizzards” OR “Drought” OR “Earthquakes” OR “Epidemics” OR
“Epizootics” OR “Famine” OR “Floods” OR “Hurricanes” OR “Landslides” OR “Lightning” OR “Natural
Disasters” OR “Tornadoes” OR “Tsunamis” OR “Volcanoes”) OR SU.EXACT(“Accidents” OR “Agent
Orange” OR “Air Traffic Accidents” OR “Avalanches” OR “Blizzards” OR “Building Collapse” OR
“Disasters” OR “Drought” OR “Earthquakes” OR “Epidemics” OR “Epizootics” OR “Explosions” OR
“Famine” OR “Fires” OR “Floods” OR “Home Accidents” OR “Hurricanes” OR “Industrial Accidents”
OR “Landmines” OR “Landslides” OR “Lightning” OR “Motor Traffic Accidents” OR “Natural Disasters”
13,010°
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Set Search Results
OR “Nuclear Accidents” OR “Nuclear Testing” OR “Oil Spills” OR “Pedestrian Accidents” OR
“Railroad Accidents” OR “Ship Accidents” OR “Technological Disasters” OR “Tornadoes” OR “Toxic
Contamination” OR “Tsunamis” OR “Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR
(catastrophe OR catastrophic) OR SU.EXACT(“Survivors”) OR SU.EXACT(“Asylum Seekers” OR
“Refugees”) OR ((forcibly OR internally) NEAR/1 displace*) OR (displace* NEAR/1 (people OR person*
OR civilian*)) OR (victim* NEAR/2 (crime* OR disaster*)) OR (SU.EXACT(“Political Prisoners”) OR
SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military Personnel”) OR ((expose* OR exposure)
NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture* OR trauma* OR rape OR violen*
OR war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture*
OR trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/2 (abuse OR assault* OR
crime OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR war OR warfare))
OR (witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR
trauma* OR violen* OR war OR warfare))) AND (SU.EXACT(“Complex PTSD”) OR SU.EXACT(“PTSD”))
S14 alprazolam or amobarbital or azaperone or barbital or bromisovalum or chloral hydrate or chloralose
or chlordiazepoxide or chlormethiazole or dexmedetomidine or diazepam or diphenhydramine or
eszopiclone or ethchlorvynol or etomidate or etorphine or flurazepam or glutethimide or hexobarbital
or lorazepam or medazepam or medetomidine or mephobarbital or meprobamate or methapyrilene
or methaqualone or midazolam or nitrazepam or oxazepam or paraldehyde or pentobarbital or
phenobarbital or propofol or secobarbital or temazepam or thiamylal or thiopental or xylazine
77°
S15 bromazepam or buspirone or chlormezanone or clorazepate dipotassium or estazolam or
flunitrazepam or fluvoxamine or nordazepam or ondansetron or oxprenolol or prazepam or
pregabalin or ritanserin or tranylcypromine or trazodone or triazolam or zolazepam
84°
S16 benzodiazepines or benzodiazepinones or promethazine or benactyzine or clorgyline or deanol or
desvenlafaxine succinate or duloxetine hydrochloride or iproniazid or isocarboxazid or lithium
carbonate or lithium compounds or moclobemide or nialamide or phenelzine or pizotyline or rolipram
or sertraline or tranylcypromine or vilazodone hydrochloride or Imipramine or mirtazapine
547°
S17 acepromazine or aripiprazole or azaperone or benperidol or butaclamol or chlorpromazine or
chlorprothixene or clopenthixol or clozapine or droperidol or etazolate or flupenthixol or
fluphenazine or fluspirilene or haloperidol or loxapine or lurasidone hydrochloride or mesoridazine
or methiothepin or methotrimeprazine or molindone or ondansetron or paliperidone palmitate or
penfluridol or perazine or perphenazine or pimozide or prochlorperazine or promazine or quetiapine
fumarate or raclopride or remoxipride or reserpine or risperidone or ritanserin or spiperone or
sulpiride or thioridazine or thiothixene or tiapride hydrochloride or trifluoperazine or trifluperidol or
triflupromazine or olanzapine
107°
S18 acetazolamide or bromides or carbamazepine or clonazepam or clorazepate dipotassium or diazepam
or dimethadione or estazolam or ethosuximide or flunarizine or lorazepam or magnesium sulfate
or medazepam or mephenytoin or mephobarbital or meprobamate or nitrazepam or paraldehyde or
phenobarbital or phenytoin or pregabalin or primidone or riluzole or thiopental or tiletamine or
trimethadione or valproic acid or vigabatrin or lithium chloride or lithium compounds or lamotrigine
or topiramate
145°
S19 monoamine oxidase inhibitors or chlorphenamidine or clorgyline or cuprizone or furazolidone or
harmaline or harmine or isocarboxazid or moclobemide or monocrotophos or pargyline or selegiline
or tranylcypromine or Prazosin or N-Methyl-3,4-methylenedioxyamphetamine or MDMA or ecstasy
197°
S20 hypnotics OR (hypnotic drugs) OR sedatives OR (sedative drugs) OR “anti-anxiety drug*” OR “anti-
anxiety agent*” OR “antidepressive agent*” OR “antidepressive drug*” OR “antipsychotic agent*” OR
“antipsychotic drug*”
413°
S21 “antimanic agent*” OR “antimanic drug*” OR anticonvulsants OR “anticonvulsant drug*” OR “z drug*” 176°
S22 (alprazolam or amobarbital or azaperone or barbital or bromisovalum or chloral hydrate or chloralose
or chlordiazepoxide or chlormethiazole or dexmedetomidine or diazepam or diphenhydramine or
eszopiclone or ethchlorvynol or etomidate or etorphine or flurazepam or glutethimide or hexobarbital
or lorazepam or medazepam or medetomidine or mephobarbital or meprobamate or methapyrilene
or methaqualone or midazolam or nitrazepam or oxazepam or paraldehyde or pentobarbital or
phenobarbital or propofol or secobarbital or temazepam or thiamylal or thiopental or xylazine)
OR (bromazepam or buspirone or chlormezanone or clorazepate dipotassium or estazolam or
flunitrazepam or fluvoxamine or nordazepam or ondansetron or oxprenolol or prazepam or
pregabalin or ritanserin or tranylcypromine or trazodone or triazolam or zolazepam) OR
(benzodiazepines or benzodiazepinones or promethazine or benactyzine or clorgyline or deanol or
desvenlafaxine succinate or duloxetine hydrochloride or iproniazid or isocarboxazid or lithium
1302°
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TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
carbonate or lithium compounds or moclobemide or nialamide or phenelzine or pizotyline or
rolipram or sertraline or tranylcypromine or vilazodone hydrochloride or Imipramine or mirtazapine)
OR (acepromazine or aripiprazole or azaperone or benperidol or butaclamol or chlorpromazine
or chlorprothixene or clopenthixol or clozapine or droperidol or etazolate or flupenthixol or
fluphenazine or fluspirilene or haloperidol or loxapine or lurasidone hydrochloride or mesoridazine
or methiothepin or methotrimeprazine or molindone or ondansetron or paliperidone palmitate or
penfluridol or perazine or perphenazine or pimozide or prochlorperazine or promazine or quetiapine
fumarate or raclopride or remoxipride or reserpine or risperidone or ritanserin or spiperone or
sulpiride or thioridazine or thiothixene or tiapride hydrochloride or trifluoperazine or trifluperidol
or triflupromazine or olanzapine) OR (acetazolamide or bromides or carbamazepine or clonazepam or
clorazepate dipotassium or diazepam or dimethadione or estazolam or ethosuximide or flunarizine or
lorazepam or magnesium sulfate or medazepam or mephenytoin or mephobarbital or meprobamate
or nitrazepam or paraldehyde or phenobarbital or phenytoin or pregabalin or primidone or riluzole or
thiopental or tiletamine or trimethadione or valproic acid or vigabatrin or lithium chloride or lithium
compounds or lamotrigine or topiramate) OR (monoamine oxidase inhibitors or chlorphenamidine or
clorgyline or cuprizone or furazolidone or harmaline or harmine or isocarboxazid or moclobemide
or monocrotophos or pargyline or selegiline or tranylcypromine or Prazosin or N-Methyl-3,4-
methylenedioxyamphetamine or MDMA or ecstasy) OR (hypnotics OR (hypnotic drugs) OR sedatives
OR (sedative drugs) OR “anti-anxiety drug*” OR “anti-anxiety agent*” OR “antidepressive agent*” OR
“antidepressive drug*” OR “antipsychotic agent*” OR “antipsychotic drug*”) OR (“antimanic agent*” OR
“antimanic drug*” OR anticonvulsants OR “anticonvulsant drug*” OR “z drug*”)
S23 (((SU.EXACT(“Dating Violence”) OR SU.EXACT(“Interpersonal Violence”) OR SU.EXACT(“Family Violence”))
OR (batter* NEAR/2 (wife* OR wive* OR woman OR women OR men OR husband* OR partner*)) OR
(physical* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (emotional* NEAR/1 abus*) OR
(SU.EXACT(“Acquaintance Rape”) OR SU.EXACT(“Acquaintance Rape”OR “Partner Rape”OR “Rape”)
OR SU.EXACT(“Partner Rape”)) OR (sexual* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR
SU.EXACT(“Child Abuse”) OR (child* NEAR/2 (abus* OR assault* OR violen* OR aggress*)) OR (child*
NEAR/2 (exploit* OR neglect* OR trauma*)) OR (“non accidental injur*”OR “non-accidental injur*”OR
“nonaccidental injur*”) OR SU.EXACT(“Human Trafficking”) OR ((human OR person OR people) NEAR/2
(traffick* OR exploit*)) OR ((forced OR exploit*) NEAR/2 labour) OR SU.EXACT(“Slavery”) OR SU.EXACT
(“Torture”) OR (slavery OR enslave* OR torture*) OR SU.EXACT(“Prostitution”) OR (prostitution* OR
brothel*) OR (sex* NEAR/2 (exploit* OR traffick*)) OR SU.EXACT(“Terrorism”) OR SU.EXACT(“Chemical
Warfare”OR “Civil Warfare”OR “Humanitarian Intervention”OR “Military Intervention”OR “War”)
OR SU.EXACT(“Genocide”) OR (SU.EXACT(“War Neuroses”) OR SU.EXACT(“War Imprisonment”)) OR
SU.EXACT(“Persecution”) OR (civil NEAR/1 (unrest OR conflict* OR disturbance* OR war OR wars OR
warfare)) OR (persecution OR victimization OR victimisation) OR (captivity OR imprison*) OR SU.EXACT
(“Concentration Camps”) OR (SU.EXACT(“Avalanches”OR “Blizzards”OR “Drought”OR “Earthquakes”OR
“Epidemics”OR “Epizootics”OR “Famine”OR “Floods”OR “Hurricanes”OR “Landslides”OR “Lightning”OR
“Natural Disasters”OR “Tornadoes”OR “Tsunamis”OR “Volcanoes”) OR SU.EXACT(“Accidents”OR “Agent
Orange”OR “Air Traffic Accidents”OR “Avalanches”OR “Blizzards”OR “Building Collapse”OR “Disasters”
OR “Drought”OR “Earthquakes”OR “Epidemics”OR “Epizootics”OR “Explosions”OR “Famine”OR “Fires”
OR “Floods”OR “Home Accidents”OR “Hurricanes”OR “Industrial Accidents”OR “Landmines”OR
“Landslides”OR “Lightning”OR “Motor Traffic Accidents”OR “Natural Disasters”OR “Nuclear Accidents”
OR “Nuclear Testing”OR “Oil Spills”OR “Pedestrian Accidents”OR “Railroad Accidents”OR “Ship
Accidents”OR “Technological Disasters”OR “Tornadoes”OR “Toxic Contamination”OR “Tsunamis”OR
“Volcanoes”)) OR (humanitarian NEAR/1 (crisis OR crises)) OR (catastrophe OR catastrophic) OR SU.EXACT
(“Survivors”) OR SU.EXACT(“Asylum Seekers”OR “Refugees”) OR ((forcibly OR internally) NEAR/1
displace*) OR (displace* NEAR/1 (people OR person* OR civilian*)) OR (victim* NEAR/2 (crime* OR
disaster*)) OR (SU.EXACT(“Political Prisoners”) OR SU.EXACT(“Prisoners of War”)) OR SU.EXACT(“Military
Personnel”) OR ((expose* OR exposure) NEAR/2 (abuse OR assault* OR disaster* OR terror* OR torture*
OR trauma* OR rape OR violen* OR war OR warfare)) OR (survivor* NEAR/2 (abuse OR assault* OR
disaster* OR terror* OR torture* OR trauma* OR rape OR violen* OR war OR warfare)) OR (victim* NEAR/
2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR torture* OR trauma* OR violen* OR
war OR warfare)) OR (witness* NEAR/2 (abuse OR assault* OR crime OR disaster* OR rape OR terror* OR
torture* OR trauma* OR violen* OR war OR warfare))) AND (SU.EXACT(“Complex PTSD”) OR SU.EXACT
(“PTSD”))) AND ((alprazolam or amobarbital or azaperone or barbital or bromisovalum or chloral hydrate or
chloralose or chlordiazepoxide or chlormethiazole or dexmedetomidine or diazepam or diphenhydramine
or eszopiclone or ethchlorvynol or etomidate or etorphine or flurazepam or glutethimide or hexobarbital
or lorazepam or medazepam or medetomidine or mephobarbital or meprobamate or methapyrilene or
methaqualone or midazolam or nitrazepam or oxazepam or paraldehyde or pentobarbital or phenobarbital
or propofol or secobarbital or temazepam or thiamylal or thiopental or xylazine) OR (bromazepam or
buspirone or chlormezanone or clorazepate dipotassium or estazolam or flunitrazepam or fluvoxamine or
199°
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PsycINFO via Ovid
Search date: 18 April 2017.
Records retrieved: 2658.
Date range searched: 1806 to April week 2 2017.
TABLE 20 Search strategy for PILOTS via ProQuest (continued )
Set Search Results
nordazepam or ondansetron or oxprenolol or prazepam or pregabalin or ritanserin or tranylcypromine or
trazodone or triazolam or zolazepam) OR (benzodiazepines or benzodiazepinones or promethazine or
benactyzine or clorgyline or deanol or desvenlafaxine succinate or duloxetine hydrochloride or iproniazid
or isocarboxazid or lithium carbonate or lithium compounds or moclobemide or nialamide or phenelzine
or pizotyline or rolipram or sertraline or tranylcypromine or vilazodone hydrochloride or Imipramine or
mirtazapine) OR (acepromazine or aripiprazole or azaperone or benperidol or butaclamol or chlorpromazine
or chlorprothixene or clopenthixol or clozapine or droperidol or etazolate or flupenthixol or fluphenazine
or fluspirilene or haloperidol or loxapine or lurasidone hydrochloride or mesoridazine or methiothepin or
methotrimeprazine or molindone or ondansetron or paliperidone palmitate or penfluridol or perazine
or perphenazine or pimozide or prochlorperazine or promazine or quetiapine fumarate or raclopride
or remoxipride or reserpine or risperidone or ritanserin or spiperone or sulpiride or thioridazine or
thiothixene or tiapride hydrochloride or trifluoperazine or trifluperidol or triflupromazine or olanzapine)
OR (acetazolamide or bromides or carbamazepine or clonazepam or clorazepate dipotassium or diazepam
or dimethadione or estazolam or ethosuximide or flunarizine or lorazepam or magnesium sulfate
or medazepam or mephenytoin or mephobarbital or meprobamate or nitrazepam or paraldehyde or
phenobarbital or phenytoin or pregabalin or primidone or riluzole or thiopental or tiletamine or
trimethadione or valproic acid or vigabatrin or lithium chloride or lithium compounds or lamotrigine
or topiramate) OR (monoamine oxidase inhibitors or chlorphenamidine or clorgyline or cuprizone or
furazolidone or harmaline or harmine or isocarboxazid or moclobemide or monocrotophos or pargyline
or selegiline or tranylcypromine or Prazosin or N-Methyl-3,4-methylenedioxyamphetamine or MDMA or
ecstasy) OR (hypnotics OR (hypnotic drugs) OR sedatives OR (sedative drugs) OR “anti-anxiety drug*”
OR “anti-anxiety agent*”OR “antidepressive agent*”OR “antidepressive drug*”OR “antipsychotic agent*”
OR “antipsychotic drug*”) OR (“antimanic agent*”OR “antimanic drug*”OR anticonvulsants OR
“anticonvulsant drug*”OR “z drug*”))
TABLE 21 Search strategy for PsycINFO via Ovid
1 exp Violence/ (66,551)
2 Exposure to Violence/ (509)
3 violence.ti,ab. (60,703)
4 Domestic Violence/ (10,282)
5 Intimate Partner Violence/ (5917)
6 Battered Females/ (3011)
7 Partner Abuse/ (4576)
8 (batter$ adj2 (wife$ or wive$ or woman or women or men or husband$ or partner$)).ti,ab. (2311)
9 Physical Abuse/ (5465)
10 (physical$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (14,559)
11 Emotional Abuse/ (2267)
12 (emotional$ adj2 abus$).ti,ab. (2704)
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TABLE 21 Search strategy for PsycINFO via Ovid (continued )
13 Rape/ (5043)
14 rape.ti,ab. (7403)
15 (sexual$ adj2 (abus$ or assault$ or violen$ or aggress$)).ti,ab. (30,943)
16 Child Abuse/ (26,161)
17 Sexual Abuse/ (18,589)
18 child$ sexual abuse.ti,ab. (8393)
19 Incest/ (2526)
20 (child$ adj2 exploit$).ti,ab. (354)
21 Child Neglect/ (3628)
22 child neglect.ti,ab. (642)
23 (child$ adj2 trauma).ti,ab. (4693)
24 (non accidental injur$ or non-accidental injur$ or nonaccidental injur$).ti,ab. (48)
25 Human Trafficking/ (595)
26 ((human or person or people) adj2 (traffick$ or exploit$)).ti,ab. (543)
27 ((forced or exploit$) adj2 labour).ti,ab. (40)
28 Slavery/ (215)
29 Torture/ (1151)
30 (slavery or torture$ or enslave$).ti,ab. (3946)
31 Prostitution/ (2998)
32 (prostitut$ or brothel$).ti,ab. (2805)
33 (sex$ adj2 (exploit$ or traffick$)).ti,ab. (1080)
34 Terrorism/ (6711)
35 (terrorism or terrorist$).ti,ab. (7151)
36 political terror$.ti,ab. (71)
37 Torture/ (1151)
38 War/ (12,259)
39 Combat Experience/ (2479)
40 Genocide/ (899)
41 Holocaust/ (1199)
42 Mass Murder/ (84)
43 (civil adj (unrest or conflict$ or disturbance$ or war or wars or warfare)).ti,ab. (1682)
44 (persecution or victimization or victimisation).ti,ab. (15,549)
45 (captivity or imprison$ or concentration camp$).ti,ab. (5516)
46 exp Disasters/ (7760)
47 Natural Disasters/ (4227)
48 natural disaster$.ti,ab. (2344)
49 (earthquake$ or tsunami$).ti,ab. (2820)
50 (humanitarian adj (crisis or crises)).ti,ab. (106)
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TABLE 21 Search strategy for PsycINFO via Ovid (continued )
51 (catastrophe$ or catastrophic event$ or catastrophic experience$).ti,ab. (1943)
52 exp Survivors/ (11,959)
53 Holocaust Survivors/ (1105)
54 Refugees/ (4568)
55 (asylum seeker$ or refugee$ or migrant$).ti,ab. (13,548)
56 ((forcibly or internally) adj displace$).ti,ab. (237)
57 (displace$ adj (people or person$ or civilian$)).ti,ab. (408)
58 Crime Victims/ (4167)
59 Victimization/ (18,276)
60 Prisoners/ (9692)
61 “Prisoners of War”/ (472)
62 Slavery/ (215)
63 Military Veterans/ (10,341)
64 ((expose$ or exposure) adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$
or war or warfare)).ti,ab. (9024)
65 (survivor$ adj2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or violen$ or war or
warfare)).ti,ab. (4321)
66 (victim$ adj2 (abuse or assault$ or crime or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war
or warfare)).ti,ab. (9727)
67 (witness$ adj2 (abuse or assault$ or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war or
warfare)).ti,ab. (1747)
68 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 or 66 or 67 (213,458)
69 exp Posttraumatic Stress Disorder/ (27,018)
70 Complex PTSD/ (123)
71 DESNOS/ (15)
72 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
73 (PTSD or CPTSD).ti,ab. (25,381)
74 posttrauma$.ti,ab. (26,998)
75 post-trauma$.ti,ab. (11,564)
76 “post trauma$”.ti,ab. (11,564)
77 post traumatic stress.ti,ab. (8923)
78 post traumatic stress.id. (2783)
79 combat stress$.ti,ab. (497)
80 combat disorder$.ti,ab. (12)
81 DESNOS.ti,ab. (54)
82 complex trauma$.ti,ab. (515)
83 (complex adj2 trauma$).ti,ab. (689)
84 traumatic stress.ti,ab. (11,630)
85 traumatic memor$.ti,ab. (1290)
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TABLE 21 Search strategy for PsycINFO via Ovid (continued )
86 traumatization.ti,ab. (1511)
87 traumatisation.ti,ab. (154)
88 (trauma adj2 (expos$ or event$ or experienc$)).ti,ab. (6634)
89 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87
or 88 (47,567)
90 68 and 89 (25,142)
91 exp Cognitive Therapy/ (12,639)
92 cognitive behaviour$ therapy.ti,ab. (3854)
93 cognitive behavior$ therapy.ti,ab. (13,015)
94 cognitive restructuring.ti,ab. (2074)
95 cognitive rescripting.ti,ab. (0)
96 cognitive processing therapy.ti,ab. (272)
97 CPT.ti,ab. (1922)
98 cognitive therapy.ti,ab. (5335)
99 cognitive behavioural treatment$.ti,ab. (520)
100 cognitive behavioral treatment$.ti,ab. (2997)
101 (CBT or TFCBT).ti,ab. (10,616)
102 cognitive trauma therapy.ti,ab. (8)
103 trauma focus$ CBT.ti,ab. (57)
104 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 (33,767)
105 exp Behavior Therapy/ (18,509)
106 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (41,822)
107 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (7365)
108 (dialectical behavio$ therap$ or dialectical behavio$ treat$).ti,ab. (1461)
109 DBT.ti,ab. (1135)
110 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (1205)
111 (biofeedback or neurofeedback or sensory feedback).ti,ab. (6695)
112 desensitization, psychologic/or eye movement desensitization reprocessing/or implosive therapy/or virtual reality
exposure therapy/ (421)
113 (psychological adj2 desensiti$).ti,ab. (5)
114 Eye Movement Desensitization Therapy/ (1230)
115 eye movement desensiti?ation reprocessing.ti,ab. (61)
116 EMDR.ti,ab. (1346)
117 Exposure Therapy/ (1979)
118 (exposure adj (therap$ or treat$)).ti,ab. (2200)
119 prolonged exposure therap$.ti,ab. (151)
120 live exposure.ti,ab. (22)
121 imaginal exposure.ti,ab. (280)
122 imaginal flooding.ti,ab. (35)
continued
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
153
TABLE 21 Search strategy for PsycINFO via Ovid (continued )
123 exposure inhibition therap$.ti,ab. (1)
124 implosive therap$.ti,ab. (143)
125 image habituation.ti,ab. (5)
126 inoculation training.ti,ab. (292)
127 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or
120 or 121 or 122 or 123 or 124 or 125 or 126 (65,864)
128 (acceptance adj2 therap$).ti,ab. (376)
129 (commitment adj2 therap$).ti,ab. (1501)
130 Hypnosis/ (7091)
131 (hypnosis or hypnotherap$).ti,ab. (11,623)
132 Mindfulness/ (6583)
133 mindfulness.ti,ab. (8091)
134 (supportive adj (therap$ or psychotherap$)).ti,ab. (1490)
135 (non-directive adj (counselling or counseling)).ti,ab. (81)
136 (nondirective adj (counselling or counseling)).ti,ab. (113)
137 (non directive adj (counselling or counseling)).ti,ab. (81)
138 psychodynamic therap$.ti,ab. (1317)
139 inter personal psychotherap$.ti,ab. (1)
140 interpersonal psychotherap$.ti,ab. (1197)
141 interpersonal therapy.ti,ab. (512)
142 IPT.ti,ab. (974)
143 (compassion adj2 therap$).ti,ab. (105)
144 accelerated resolution.ti,ab. (8)
145 sensorimotor therap$.ti,ab. (11)
146 schema therapy.ti,ab. (312)
147 Stress Management/ (4566)
148 Supportive Psychotherapy/ (480)
149 Group Psychotherapy/ (18,367)
150 Counseling/ (21,293)
151 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (197)
152 compassion therap$.ti,ab. (4)
153 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or
143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 151 or 152 (71,049)
154 104 or 127 or 153 (140,028)
155 hypnotic drugs/or amobarbital/or apomorphine/or barbital/or chloral hydrate/or codeine/or flurazepam/or
glutethimide/or hexobarbital/or meprobamate/or methaqualone/or nitrazepam/or pentobarbital/or phenobarbital/or
secobarbital/or thalidomide/or thiopental/or triazolam/ (5588)
156 hypnotics.ti,ab. (1574)
157 hypnotic drug$.ti,ab. (399)
158 z drug$.ti,ab. (43)
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Science Citation Index via Web of Science
Search date: 20 April 2017.
Records retrieved: 1066.
Date range searched: 1900 onwards.
TABLE 21 Search strategy for PsycINFO via Ovid (continued )
159 tranquilizing drugs/or amitriptyline/or benactyzine/or doxepin/or haloperidol/or meprobamate/or minor
tranquilizers/or neuroleptic drugs/or phenothiazine derivatives/or pimozide/or thiothixene/ (27,445)
160 exp benzodiazepines/ (9874)
161 sedative antihistamine$.ti,ab. (13)
162 promethazine.ti,ab. (184)
163 antidepressant drugs/or bupropion/or citalopram/or fluoxetine/or fluvoxamine/or iproniazid/or isocarboxazid/or
lithium carbonate/or methylphenidate/or mianserin/or moclobemide/or molindone/or nefazodone/or nialamide/or
nomifensine/or paroxetine/or phenelzine/or pheniprazine/or pipradrol/or serotonin norepinephrine reuptake inhibitors/




166 neuroleptic drugs/or aripiprazole/or clozapine/or molindone/or nialamide/or olanzapine/or quetiapine/or
reserpine/or risperidone/or spiroperidol/or sulpiride/or tetrabenazine/ (28,386)
167 mood stabilizers/or anticonvulsive drugs/or carbamazepine/or lithium/or valproic acid/ (13,520)





173 monoamine oxidase inhibitors/or iproniazid/or isocarboxazid/or moclobemide/or nialamide/or pargyline/or
phenelzine/or pheniprazine/or tranylcypromine/ (2188)
174 antihypertensive drugs/or alpha methylparatyrosine/or captopril/or chlorpromazine/or clonidine/or guanethidine/
or hexamethonium/or hydralazine/or mecamylamine/or methyldopa/or phenoxybenzamine/or quinpirole/ (4387)
175 alpha blocker anti-hypertensive$.ti,ab. (0)
176 alpha blocker antihypertensive$.ti,ab. (0)
177 prazosin.ti,ab. (618)
178 Methylenedioxymethamphetamine/ (1923)
179 (mdma or ecstasy).ti,ab. (3061)
180 155 or 156 or 157 or 158 or 159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or
170 or 171 or 172 or 173 or 174 or 175 or 176 or 177 or 178 or 179 (99,763)
181 90 and 154 (2588)
182 90 and 180 (306)
183 181 or 182 (2861)
184 limit 183 to human (2798)
185 limit 184 to yr=“1992 -Current” (2658)
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TABLE 22 Search strategy for Science Citation Index via Web of Science
#16 1066 #15 OR #11
Indexes=SCI-EXPANDED Timespan=1992-2017
#15 204 #14 AND #7
Indexes=SCI-EXPANDED Timespan=1992-2017
#14 352,711 #13 OR #12
Indexes=SCI-EXPANDED Timespan=1992-2017
#13 188,961 TS=((hypnotic or sedative) NEAR/1 (drug$ or agent$)) OR TS=(hypnotics or sedatives) OR
TS=(alprazolam or amobarbital or azaperone or barbital or bromisovalum or “chloral hydrate”
or chloralose or chlordiazepoxide or chlormethiazole or dexmedetomidine or diazepam or
diphenhydramine or eszopiclone or ethchlorvynol or etomidate or etorphine or flurazepam or
glutethimide or hexobarbital or lorazepam or medazepam or medetomidine or mephobarbital
or meprobamate or methapyrilene or methaqualone or midazolam or nitrazepam or oxazepam or
paraldehyde or pentobarbital or phenobarbital or propofol or secobarbital or temazepam or
thiamylal or thiopental or xylazine) OR TS=(“z drug$”) OR TS=(“anti-anxiety agent$” or “anti-anxiety
drug$”) OR TS=(“antianxiety agent$” or “antianxiety drug$”) OR TS=(“anti anxiety agent$” or “anti
anxiety drug$”) OR TS=(“anxiolytic agent$” or “anxiolytic drug$” or anxiolytics) OR TS=(bromazepam
or buspirone or chlormezanone or “clorazepate dipotassium” or estazolam or flunitrazepam or
fluvoxamine or nordazepam or ondansetron or oxprenolol or prazepam or pregabalin or ritanserin or
tranylcypromine or trazodone or triazolam or zolazepam or benzodiazepines or benzodiazepinones
or “sedative antihistamine$” or promethazine) OR TS=(“antidepressive agent$” or “antidepressive
drug$” or antidepressives) OR TS=(“anti-depressive agent$” or “anti-depressive drug$” or
antidepressives) OR TS=(“anti depressive agent$” or “anti depressive drug$” or antidepressives) OR
TS=(benactyzine or clorgyline or deanol or “desvenlafaxine succinate” or “duloxetine hydrochloride”
or iproniazid or isocarboxazid or “lithium carbonate” or “lithium compounds” or moclobemide or
nialamide or phenelzine or pizotyline or rolipram or sertraline or tranylcypromine or “vilazodone
hydrochloride” or imipramine or mirtazapine) OR TS=(“antipsychotic agent$” or “antipsychotic drug$”
or antipsychotics) OR TS=(“anti-psychotic agent$” or “anti-psychotic drug$” or anti-psychotics) OR
TS=(“anti psychotic agent$” or “anti psychotic drug$” or anti psychotics) OR TS=(acepromazine
or aripiprazole or azaperone or benperidol or butaclamol or chlorpromazine or chlorprothixene or
clopenthixol or clozapine or droperidol or etazolate or flupenthixol or fluphenazine or fluspirilene
or haloperidol or loxapine or lurasidone hydrochloride or mesoridazine or methiothepin or
methotrimeprazine or molindone or ondansetron or “paliperidone palmitate” or penfluridol or
perazine or perphenazine or pimozide or prochlorperazine or promazine or quetiapine fumarate
or raclopride or remoxipride or reserpine or risperidone or ritanserin or spiperone or sulpiride or
thioridazine or thiothixene or “tiapride hydrochloride” or trifluoperazine or trifluperidol or
triflupromazine or olanzapine)
Indexes=SCI-EXPANDED Timespan=1992-2017
#12 202,663 TS=(“anticonvulsants agent$” or “anticonvulsant drug$” or anticonvulsants) OR TS=(“anti-convulsants
agent$” or “anti-convulsant drug$” or anti-convulsants) OR TS=(“anti convulsants agent$” or “anti
convulsant drug$” or anti convulsants) OR TS=(acetazolamide or bromides or carbamazepine or
clonazepam or “clorazepate dipotassium” or diazepam or dimethadione or estazolam or ethosuximide
or flunarizine or lorazepam or magnesium sulfate or medazepam or mephenytoin or mephobarbital
or meprobamate or nitrazepam or paraldehyde or phenobarbital or phenytoin or pregabalin or
primidone or riluzole or thiopental or tiletamine or trimethadione or “valproic acid” or vigabatrin)
OR TS=(“antimanic agent$” or “antimanic drug$”) OR TS=(“anti-manic agent$” or “anti-manic drug$”)
OR TS=(“anti manic agent$” or “anti manic drug$”) OR TS=(“lithium chloride” or “lithium compounds”
or lamotrigine or topiramate) OR TS=(“monoamine oxidase inhibitors” or chlorphenamidine or
clorgyline or cuprizone or furazolidone or harmaline or harmine or isocarboxazid or moclobemide
or monocrotophos or pargyline or selegiline or tranylcypromine or Prazosin or “N-Methyl-3
4-methylenedioxyamphetamine” or MDMA or ecstasy)
Indexes=SCI-EXPANDED Timespan=1992-2017
#11 915 #10 AND #7
Indexes=SCI-EXPANDED Timespan=1992-2017
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TABLE 22 Search strategy for Science Citation Index via Web of Science (continued )
#10 130,643 #9 OR #8
Indexes=SCI-EXPANDED Timespan=1992-2017
#9 75,396 TS=(acceptance NEAR/2 therap$) OR TS=(commitment NEAR/2 therap$) OR TS=(hypnosis or
hypnotherap$) OR TS=(mindfulness) OR TS=(“supportive therapy”) OR TS=(non-directive NEAR/1
(counselling or counseling)) OR TS=(nondirective NEAR/1 (counselling or counseling)) OR TS=
(“non directive” NEAR/1 (counselling or counseling)) OR TS=(psychotherapy or “brief psychotherapy”
or “group psychotherapy” or “psychodynamic psychotherapy”) OR TS=(“rational emotive
psychotherapy”) OR TS=(“rational-emotive psychotherapy”) OR TS=(“psychodynamic therap$”)
OR TS=(“inter personal psychotherap$” or “interpersonal psychotherap$” or “inter-personal
psychotherap$”) OR TS=((compassion or schema or sensorimotor) NEAR/2 therap$) OR TS=
(counseling or counselling) OR TS=(“accelerated resolution”)
Indexes=SCI-EXPANDED Timespan=1992-2017
#8 60,687 TS=(cognitive NEAR/3 (therap$ or treat$ or restructur$ or rescript$)) OR TS=(CBT or CPT or
TFCBT) OR TS=(“trauma focus$ CBT”) OR TS=(behavior$ NEAR/2 (therap$ or treat$ or modif$))
OR TS=(behaviour$ NEAR/2 (therap$ or treat$ or modif$)) OR TS=(biofeedback or neurofeedback
or “sensory feedback”) OR TS=(“implosive therapy”) OR TS=(“virtual reality therapy”) OR TS=
(psychological NEAR/2 desensiti$) OR TS=(“eye movement desensitisation reprocessing” or “eye
movement desensitization reprocessing”) OR TS=(EMDR) OR TS=(exposure NEAR/2 (imaginal or live
or prolonged or therap$ or treat$)) OR TS=(“imaginal flooding”) OR TS=(“image habituation”) OR
TS=(“inoculation training”)
Indexes=SCI-EXPANDED Timespan=1992-2017
#7 9164 #6 AND #5
Indexes=SCI-EXPANDED Timespan=1992-2017
#6 29,452 TOPIC: (“posttraumatic stress disorder*”) OR TOPIC: (“post-traumatic stress disorder*”) OR TOPIC:
(“post traumatic stress disorder*”) OR TOPIC: (“posttraumatic stress*”) OR TOPIC: (“post-traumatic
stress*”) OR TOPIC: (“post traumatic stress*”) OR TOPIC: (“traumatic stress*”) OR TOPIC:
(posttrauma$ or post-trauma$ or “post trauma$”) OR TOPIC: (“combat stress” or “combat disorder”)
OR TOPIC: (DESNOS) OR TOPIC: (“extreme distress”) OR TOPIC: (“complex trauma”) OR TOPIC:
(complex NEAR/3 trauma) OR TOPIC: (traumatic NEAR/2 (stress or memor$)) OR TOPIC:
(traumatization or traumatisation) OR TOPIC: (trauma$ NEAR/3 (expos$ or event$ or experienc$))
Indexes=SCI-EXPANDED Timespan=1992-2017
#5 288,605 #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED Timespan=1992-2017
#4 29,766 TOPIC: (victim$) OR TOPIC: (prisoner$) OR TOPIC: (soldier$ or veteran$) AND TOPIC: ((expose$
or exposure) NEAR/2 (abuse or assault$ or disaster$ or terror$ or torture$ or trauma$ or rape or
violen$ or war or warfare)) AND TOPIC: (survivor$ NEAR/2 (abuse or assault$ or disaster$ or terror$
or torture$ or trauma$ or rape or violen$ or war or warfare)) AND TOPIC: (victim$ NEAR/2 (abuse or
assault$ or crime or disaster$ or rape or terror$ or torture$ or trauma$ or violen$ or war or warfare))
AND TOPIC: (witness$ NEAR/2 (abuse or assault$ or disaster$ or rape or terror$ or torture$ or
trauma$ or violen$ or war or warfare))
Indexes=SCI-EXPANDED Timespan=1992-2017
#3 202,637 TOPIC: (disaster$ or earthquake$ or tsunami$) OR TOPIC: (“natural disaster$”) OR TOPIC:
(humanitarian NEAR/2 (crisis or crises)) OR TOPIC: (catastrophe$ or “catastrophic event$” or
“catastrophic experience$”) OR TOPIC: (survivor*) OR TOPIC: (refugee$ or “asylum seeker$” or
migrant$) OR TOPIC: ((forcibly or internally) NEAR/2 displace$) OR TOPIC: (displace$ NEAR/2
(people or person$ or civilian$))
Indexes=SCI-EXPANDED Timespan=1992-2017
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TABLE 22 Search strategy for Science Citation Index via Web of Science (continued )
#2 25,515 TOPIC: (“human rights abuse*”) OR TOPIC: ((human or person or people) NEAR/2 (traffick$ or
exploit$)) OR TOPIC: ((forced or exploit$) NEAR/2 labour) OR TOPIC: (“organ traffick$”) OR TOPIC:
(slavery or “slave trade$” or enslave$) OR TOPIC: (torture$) OR TOPIC: (prostitution or “sex work$”
or brothel$) OR TOPIC: (sex NEAR/2 (exploit$ or traffick$)) OR TOPIC: (terrorism or terrorist$ or
“political terror$”) OR TOPIC: (warfare or “war crime$” or “armed conflict$” or “civil conflict” or “civil
war$” or “civil unrest”) OR TOPIC: (“ethnic conflict$” or “ethnic unrest” or “ethnic cleans*” or
genocide or holocaust) OR TOPIC: (persecution or victimization or victimisation) OR TOPIC:
(imprison$ or “concentration camp”)
Indexes=SCI-EXPANDED Timespan=1992-2017
#1 47,352 TS=(violence) OR TS=(batter* NEAR/2 (wife$ or wive$ or woman or women or men or husband$ or
partner$)) OR TS=(physical$ NEAR/2 (abus$ or assault$ or violen$ or aggress$)) OR TS=(emotional
near/2 abus*) OR TS=(rape) OR TS=(sexual$ NEAR/2 (abus$ or assault$ or violen$ or aggress$)) OR
TS=(child$ NEAR/2 (abus$ or exploit or maltreat$ or neglect$ or trauma$)) OR TS=(“non accidental
injur$” or “non-accidental injur$” or “nonaccidental injur$”)
Indexes=SCI-EXPANDED Timespan=1992-2017
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Appendix 2 Literature search strategies for
the qualitative acceptability review
The original searches were carried out in June 2017 using the following databases: CINAHL,EMBASE, MEDLINE and PsycINFO. Results were restricted to 1992 onwards.





The total number of records identified before de-duplication was 4289; after de-duplication,
3162 records were left.
This set was subsequently de-duplicated against the results of the effectiveness searches to leave a
total of 1574 records.
CINAHL via EBSCOhost
Search date: 1 June 2017.
TABLE 23 Search strategy for CINAHL via EBSCOhost
Search terms Search options
S1 (MH “Stress Disorders, Post-Traumatic+”)
S2 TX (PTSD or CPTSD) OR TX posttrauma* OR TX post-trauma* OR TX “post trauma*” OR
TX “post traumatic stress” OR TX “combat stress*” OR TX “combat disorder*” OR TX
DESNOS OR TX “complex trauma*” OR TX “complex N3 trauma*” OR TX “traumatic
stress” OR TX “traumatic memor*”
S3 TX traumatisation OR TX traumatization OR TX (trauma* N3 (expos* or event* or
experienc*))
S4 S1 OR S2 OR S3
S5 (MH “Cognitive Therapy+”) OR TX “cognitive behaviour* therap*” OR TX “cognitive
behavior* therap*” OR TX “cognitive restructuring” OR TX “cognitive rescripting” OR TX
“cognitive processing therap*” OR TX (CPT or CBT or TFCBT) OR TX “cognitive therap*”
OR TX “cognitive behavioural treat*” OR TX “cognitive behavioral treat*” OR TX
“cognitive trauma therap*” OR TX “trauma focus* CBT”
S6 (MH “Behavior Therapy”) OR TX (behavior* N2 (therap* or treat* or modif*)) OR TX
(behavior* N2 (therap* or treat* or modif*)) OR TX ((“dialectical behavio*”) N1 (therap*
or treat*)) OR TX (biofeedback or neurofeedback or “sensory feedback”) OR TX
psychological N2 desensiti#ation OR TX “eye movement desensiti#ation reprocessing”
OR TX EMDR OR TX (exposure N1 (therap* or treat*)) OR TX “live exposure” OR TX
“imaginal exposure” OR TX “prolonged exposure therapy”
S7 TX “imaginal flooding” OR TX “exposure inhibition therap*” OR TX “implosive therap*” OR
TX “image habituation” OR TX “inoculation training”
S8 ((MH “Acceptance and Commitment Therapy”)) OR TX acceptance N2 therap* OR TX
commitment N2 therap*
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TABLE 23 Search strategy for CINAHL via EBSCOhost (continued )
Search terms Search options
S9 (MH “Biofeedback”)
S10 (MH “Feedback”)
S11 (MH “Eye Movement Desensitization and Reprogramming”)
S12 (MH “Virtual Reality Exposure Therapy”)
S13 (MH “Hypnosis”)
S14 TX hypnosis or hypnotherap*
S15 (MH “Mindfulness”)
S16 TX mindfulness
S17 TX “supportive therap*” OR TX (non-directive N1 (counselling or counseling)) OR TX (“non
directive” N1 (counselling or counseling))
S18 ((MH “Psychotherapy”) OR (MH “Psychotherapy, Brief”) OR (MH “Psychotherapy, Group”)
OR (MH “Psychotherapy, Psychodynamic”)) OR TX psychodynamic N1 therap* OR TX
“inter personal psychotherap*” OR TX “interpersonal psychotherap*” OR TX IPT OR TX
“compassion therap*” OR TX “accelerated resolution*” OR TX “sensorimotor therap*” OR
TX “schema therap*” OR TX stress N2 manag*
S19 (MH “Counseling”) OR TX “non-directive counsel*” OR TX “non directive counsel*” OR TX
“nondirective counsel*” OR “compassion therap*”
S20 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
OR S17 OR S18 OR S19
S21 ((MH “Hypnotics and Sedatives”)) OR TX (alprazolam or amobarbital or azaperone or
barbital or bromisovalum or “chloral hydrate” or chloralose or chlordiazepoxide or
chlormethiazole or dexmedetomidine or diazepam or diphenhydramine or eszopiclone
or ethchlorvynol or etomidate or etorphine or flurazepam or glutethimide or hexobarbital
or lorazepam or medazepam or medetomidine or mephobarbital or meprobamate or
methapyrilene or methaqualone or midazolam or nitrazepam or oxazepam or paraldehyde o...
S22 (MH “Antianxiety Agents+”) OR (bromazepam or buspirone or chlormezanone or
“clorazepate dipotassium” or estazolam or flunitrazepam or fluvoxamine or nordazepam
or ondansetron or oxprenolol or prazepam or pregabalin or ritanserin or tranylcypromine
or trazodone or triazolam or zolazepam or benzodiazepines or benzodiazepinones or
“sedative antihistamine*” or promethazine)
S23 (MH “Antidepressive Agents+”) OR TX (benactyzine or clorgyline or deanol or
“desvenlafaxine succinate” or “duloxetine hydrochloride” or iproniazid or isocarboxazid or
“lithium carbonate” or “lithium compounds” or moclobemide or nialamide or phenelzine
or pizotyline or rolipram or sertraline or tranylcypromine or “vilazodone hydrochloride”
or Imipramine or mirtazapine)
S24 (MH “Antipsychotic Agents+”) OR TX (acepromazine or aripiprazole or azaperone
or benperidol or butaclamol or chlorpromazine or chlorprothixene or clopenthixol or
clozapine or droperidol or etazolate or flupenthixol or fluphenazine or fluspirilene or
haloperidol or loxapine or “lurasidone hydrochloride” or mesoridazine or methiothepin
or methotrimeprazine or molindone or ondansetron or “paliperidone palmitate” or
penfluridol or perazine or perphenazine or pimozide or prochlorperazine) OR TX (p...
S25 (MH “Anticonvulsants+”) OR TX (anticonvulsants or acetazolamide or bromides or
carbamazepine or clonazepam or “clorazepate dipotassium” or diazepam or dimethadione
or estazolam or ethosuximide or flunarizine or lorazepam or “magnesium sulfate”
or medazepam or mephenytoin or mephobarbital or meprobamate or nitrazepam or
paraldehyde or phenobarbital or phenytoin or pregabalin or primidone or riluzole or
thiopental or tiletamine or trimethadione or “valproic acid” or vigabatrin)
S26 (MH “Antimanic Agents+”) OR TX (“lithium chloride” or “lithium compounds” or
lamotrigine or topiramate)
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TABLE 23 Search strategy for CINAHL via EBSCOhost (continued )
Search terms Search options
S27 (MH “Monoamine Oxidase Inhibitors+”) OR TX (chlorphenamidine or clorgyline or
cuprizone or furazolidone or harmaline or harmine or isocarboxazid or moclobemide or
monocrotophos or pargyline or selegiline or tranylcypromine or Prazosin or N-Methyl-3,
4-methylenedioxyamphetamine or MDMA or ecstasy)
S28 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S29 S4 AND S20 (3665)
S30 S4 AND S28 (820)
S31 S29 OR S30 (4259)
S32 (MH “Qualitative Studies”) (74,214)
S33 (MH “Interviews”) OR (MH “Unstructured Interview”) OR (MH “Semi-Structured
Interview”)
(156,659)
S34 (MH “Ethnographic Research”) (6044)
S35 (MH “Grounded Theory”) (11,936)
S36 (MH “Thematic Analysis”) (41,678)
S37 (MH “Observational Methods”) OR (MH “Participant Observation”) (16,594)
S38 (MH “Field Notes”) (6623)
S39 (MH “Narratives”) (11,936)
S40 (MH “Field Studies”) (2485)
S41 (MH “Audiorecording”) (36,402)
S42 (MH “Focus Groups”) (31,284)
S43 (MH “Descriptive Research”) (60,598)
S44 (MH “Case Studies”) (16,717)
S45 (MH “Discourse Analysis”) (3490)
S46 (MH “Exploratory Research”) (29,405)
S47 (MH “Phenomenology”) (2577)
S48 (MH “Naturalistic Inquiry”) (929)
S49 (MH “Open-Ended Questionnaires”) (3206)
S50 (MH “Videorecording”) (22,181)
S51 (MH “Anthropology, Cultural”) (1713)
S52 “conversation* analysis” OR “comparative method*” OR hermeneutic* OR participatory OR
in-depth OR key informant* OR narration*
(45,445)
S53 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42
OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52
(325,689)
S54 S31 AND S53 (470)
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
161
EMBASE via Ovid
Search date: 1 June 2017.
Date range searched: 1980 to 2017 week 22.
TABLE 24 Search strategy for EMBASE via Ovid
1 Posttraumatic Stress Disorder/ (45,884)
2 (PTSD or CPTSD).ti,ab. (22,707)
3 posttrauma$.ti,ab. (34,058)
4 post-trauma$.ti,ab. (30,965)
5 “post trauma$”.ti,ab. (30,965)
6 post traumatic stress.ti,ab. (12,036)
7 post traumatic stress.kw. (2854)
8 combat stress$.ti,ab. (405)
9 combat disorder$.ti,ab. (18)
10 DESNOS.ti,ab. (39)
11 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
12 complex trauma$.ti,ab. (454)
13 (complex adj3 trauma$).ti,ab. (1408)
14 traumatic stress.ti,ab. (14,416)
15 traumatic memor$.ti,ab. (768)
16 traumatization.ti,ab. (1152)
17 traumatisation.ti,ab. (242)
18 (trauma$ adj3 (expos$ or event$ or experienc$)).ti,ab. (20,405)
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (95,383)
20 exp Cognitive Therapy/ (42,280)
21 cognitive behaviour$ therapy.ti,ab. (5626)
22 cognitive behavior$ therapy.ti,ab. (10,664)
23 cognitive restructuring.ti,ab. (1093)
24 cognitive rescripting.ti,ab. (0)
25 cognitive processing therapy.ti,ab. (197)
26 CPT.ti,ab. (15,122)
27 cognitive therapy.ti,ab. (3508)
28 cognitive behavioural treatment$.ti,ab. (571)
29 cognitive behavioral treatment$.ti,ab. (1879)
30 (CBT or TFCBT).ti,ab. (11,500)
31 cognitive trauma therapy.ti,ab. (7)
32 trauma focus$ CBT.ti,ab. (46)
33 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (64,373)
34 exp Behavior Therapy/ (40,674)
35 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (33,760)
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TABLE 24 Search strategy for EMBASE via Ovid (continued )
36 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (13,506)
37 (dialectical behavio$ adj (therap$ or treat$)).ti,ab. (811)
38 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (20,411)
39 (biofeedback or neurofeedback or sensory feedback).ti,ab. (10,762)
40 eye movement desensitization reprocessing/or implosive therapy/or virtual reality exposure therapy/ (438)
41 (psychological adj2 desensiti$).ti,ab. (6)
42 eye movement desensiti?ation reprocessing.ti,ab. (38)
43 EMDR.ti,ab. (559)
44 (exposure adj (therap$ or treat$)).ti,ab. (2781)
45 live exposure.ti,ab. (16)
46 imaginal exposure.ti,ab. (180)
47 prolonged exposure therapy.ti,ab. (111)
48 imaginal flooding.ti,ab. (20)
49 exposure inhibition therap$.ti,ab. (0)
50 implosive therap$.ti,ab. (36)
51 image habituation.ti,ab. (4)
52 inoculation training.ti,ab. (115)
53 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52
(102,846)
54 “Acceptance and Commitment Therapy”/ (709)
55 (acceptance adj2 therap$).ti,ab. (363)
56 (commitment adj2 therap$).ti,ab. (838)
57 Hypnosis/ (12,985)
58 (hypnosis or hypnotherap$).ti,ab. (8081)
59 Mindfulness/ (3457)
60 mindfulness.ti,ab. (5257)
61 supportive therap$.ti,ab. (5309)
62 (non-directive adj (counselling or counseling)).ti,ab. (114)
63 (nondirective adj (counselling or counseling)).ti,ab. (50)
64 (non directive adj (counselling or counseling)).ti,ab. (114)
65 Psychotherapy/or Group Therapy/or Psychodynamic Psychotherapy/ (93,420)
66 psychodynamic therap$.ti,ab. (627)
67 inter personal psychotherap$.ti,ab. (1)
68 interpersonal psychotherap$.ti,ab. (930)
69 IPT.ti,ab. (2387)
70 (compassion adj2 therap$).ti,ab. (62)
71 accelerated resolution.ti,ab. (112)
72 sensorimotor therap$.ti,ab. (22)
73 schema therapy.ti,ab. (174)
74 (stress adj2 manag$).ti,ab. (6583)
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TABLE 24 Search strategy for EMBASE via Ovid (continued )
75 supportive therap$.ti,ab. (5309)
76 Counseling/ (52,136)
77 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (165)
78 compassion therap$.ti,ab. (2)
79 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72
or 73 or 74 or 75 or 76 or 77 or 78 (174,613)
80 33 or 53 or 79 (291,814)
81 19 and 80 (10,397)
82 hypnotic sedative agent/or alprazolam/or amobarbital/or azaperone/or barbital/or bromisovalum/or chloral
hydrate/or chloralose/or chlordiazepoxide/or chlomethiazole/or dexmedetomidine/or diazepam/or diphenhydramine/or
eszopiclone/or ethchlorvynol/or etomidate/or etorphine/or flurazepam/or glutethimide/or hexobarbital/or lorazepam/
or medazepam/or medetomidine/or methylphenobarbital/or meprobamate/or methapyrilene/or methaqualone/or
midazolam/or nitrazepam/or oxazepam/or paraldehyde/or pentobarbital/or phenobarbital/or propofol/or secobarbital/
or temazepam/or thiamylal/or thiopental/or xylazine/ (276,213)
83 z drugs.ti,ab. (207)
84 anxiolytic agent/or bromazepam/or buspirone/or chlormezanone/or clorazepate dipotassium/or estazolam/or
flunitrazepam/or fluvoxamine/or nordazepam/or ondansetron/or oxprenolol/or prazepam/or pregabalin/or ritanserin/or
tranylcypromine/or trazodone/or triazolam/or zolazepam/ (91,974)
85 benzodiazepine derivative/ (36,147)
86 sedative antihistamine$.ti,ab. (115)
87 promethazine/ (11,286)
88 antidepressive agent/or benactyzine/or clorgyline/or deanol/or desvenlafaxine/or duloxetine/or iproniazid/or
isocarboxazid/or lithium carbonate/or lithium derivative/or moclobemide/or nialamide/or phenelzine/or pizotifen/or
rolipram/or sertraline/or tranylcypromine/or vilazodone/ (131,288)
89 Imipramine/ (29,724)
90 mirtazapine/ (10,727)
91 neuroleptic agent/or acepromazine/or aripiprazole/or azaperone/or benperidol/or butaclamol/or chlorpromazine/or
chlorprothixene/or clopenthixol/or clozapine/or droperidol/or etazolate/or flupentixol/or fluphenazine/or fluspirilene/or
haloperidol/or loxapine/or lurasidone/or mesoridazine/or metitepine/or methotrimeprazine/or molindone/or ondansetron/
or paliperidone/or penfluridol/or perazine/or perphenazine/or pimozide/or prochlorperazine/or promazine/or quetiapine/
or raclopride/or remoxipride/or reserpine/or risperidone/or ritanserin/or spiperone/or sulpiride/or thioridazine/or
tiothixene/or tiapride/or trifluoperazine/or trifluperidol/or triflupromazine/ (221,511)
92 olanzapine/ (29,757)
93 anticonvulsive agent/or acetazolamide/or bromides/or carbamazepine/or clonazepam/or clorazepate dipotassium/
or diazepam/or dimethadione/or estazolam/or ethosuximide/or flunarizine/or lorazepam/or magnesium sulfate/or
medazepam/or mephenytoin/or methylphenobarbital/or meprobamate/or nitrazepam/or paraldehyde/or phenobarbital/
or phenytoin/or pregabalin/or primidone/or riluzole/or thiopental/or tiletamine/or trimethadione/or valproic acid/or
vigabatrin/ (323,161)
94 tranquilizer/or lithium chloride/or lithium derivative/ (21,662)
95 lamotrigine/ (21,528)
96 topiramate/ (18,511)
97 monoamine oxidase inhibitor/or chlorphenamidine/or clorgyline/or cuprizone/or furazolidone/or harmaline/or
harmine/or isocarboxazid/or moclobemide/or monocrotophos/or pargyline/or selegiline/or tranylcypromine/(38,999)
98 Prazosin/ (21,809)
99 3,4 methylenedioxyamphetamine/ (1999)
100 (MDMA or ecstasy).ti,ab. (6408)
101 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or
100 (796,293)
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TABLE 24 Search strategy for EMBASE via Ovid (continued )
102 19 and 101 (6845)
103 81 or 102 (15,327)
104 qualitative research/ (44,728)
105 unstructured interview/or semi structured interview/or interview/ (180,660)
106 ethnography/ (1859)
107 grounded theory/ (4097)
108 thematic analysis/ (6983)
109 observational method/ (1260)
110 participant observation/ (4400)
111 narrative/ (5915)
112 field study/ (2893)
113 audio recording/ (1997)
114 descriptive research/ (14,116)
115 discourse analysis/ (760)
116 hermeneutics/ (167)
117 naturalistic inquiry/ (459)
118 phenomenology/ (8633)
119 participatory research/ (3550)
120 recording/ (41,930)
121 cultural anthropology/ (48,605)
122 case stud$.ti,ab. (92,088)
123 comparative method$.ti,ab. (2818)
124 field notes.ti,ab. (1743)
125 focus group$.ti,ab. (39,224)
126 conversation$ analysis.ti,ab. (506)
127 exploratory stud$.ti,ab. (13,200)
128 open-ended.ti,ab. (12,795)
129 in-depth.ti,ab. (55,739)
130 key informant$.ti,ab. (5832)
131 narration.ti,ab. (644)
132 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or
119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 (505,231)
133 103 and 132 (1259)
134 (accept$ or adherence or attitude$ or belief$ or believ$ or choice$ or choos$ or drop out$ or experienc$ or
feasib$ or opinion$ or perceiv$ or percept$ or prefer$ or uptake or view$ or withdraw$).ti. (761,456)
135 103 and 134 (637)
136 133 or 135 (1799)
137 limit 136 to yr=“1992 -Current” (1749)
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MEDLINE via Ovid
Search date: 1 June 2017.
Database: Ovid MEDLINE Epub Ahead of Print and In-Process & Other Non-Indexed Citations, Ovid
MEDLINE Daily and Ovid MEDLINE.
Date range searched: 1946 to present.
TABLE 25 Search strategy for MEDLINE via Ovid
1 Stress Disorders, Post Traumatic/ (27,020)
2 (PTSD or CPTSD).ti,ab. (18,404)
3 posttrauma$.ti,ab. (30,457)
4 post-trauma$.ti,ab. (25,925)
5 “post trauma$”.ti,ab. (25,925)
6 post traumatic stress.ti,ab. (9454)
7 post traumatic stress.kw. (96)
8 combat stress$.ti,ab. (348)
9 combat disorder$.ti,ab. (15)
10 DESNOS.ti,ab. (30)
11 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
12 complex trauma$.ti,ab. (409)
13 (complex adj3 trauma$).ti,ab. (1224)
14 traumatic stress.ti,ab. (10,931)
15 traumatic memor$.ti,ab. (594)
16 traumatization.ti,ab. (1004)
17 traumatisation.ti,ab. (192)
18 (trauma$ adj3 (expos$ or event$ or experienc$)).ti,ab. (16,547)
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (75,969)
20 exp Cognitive Therapy/ (22,774)
21 cognitive behaviour$ therapy.ti,ab. (4058)
22 cognitive behavior$ therapy.ti,ab. (8246)
23 cognitive restructuring.ti,ab. (728)
24 cognitive rescripting.ti,ab. (0)
25 cognitive processing therapy.ti,ab. (181)
26 CPT.ti,ab. (10,875)
27 cognitive therapy.ti,ab. (2427)
28 cognitive behavioural treatment$.ti,ab. (408)
29 cognitive behavioral treatment$.ti,ab. (1406)
30 (CBT or TFCBT).ti,ab. (8178)
31 cognitive trauma therapy.ti,ab. (6)
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TABLE 25 Search strategy for MEDLINE via Ovid (continued )
32 trauma focus$ CBT.ti,ab. (31)
33 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (41,296)
34 exp Behavior Therapy/ (65,175)
35 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (27,210)
36 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (9995)
37 (dialectical behavio$ adj (therap$ or treat$)).ti,ab. (587)
38 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (9410)
39 (biofeedback or neurofeedback or sensory feedback).ti,ab. (8547)
40 eye movement desensitization reprocessing/or implosive therapy/or virtual reality exposure therapy/ (1375)
41 (psychological adj2 desensiti$).ti,ab. (4)
42 eye movement desensiti?ation reprocessing.ti,ab. (25)
43 EMDR.ti,ab. (376)
44 (exposure adj (therap$ or treat$)).ti,ab. (2318)
45 live exposure.ti,ab. (11)
46 imaginal exposure.ti,ab. (149)
47 prolonged exposure therapy.ti,ab. (101)
48 imaginal flooding.ti,ab. (13)
49 exposure inhibition therap$.ti,ab. (0)
50 implosive therap$.ti,ab. (43)
51 image habituation.ti,ab. (3)
52 inoculation training.ti,ab. (79)
53 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 (91,074)
54 “Acceptance and Commitment Therapy”/ (187)
55 (acceptance adj2 therap$).ti,ab. (262)
56 (commitment adj2 therap$).ti,ab. (615)
57 Hypnosis/ (8767)
58 (hypnosis or hypnotherap$).ti,ab. (7616)
59 Mindfulness/ (1406)
60 mindfulness.ti,ab. (4162)
61 supportive therap$.ti,ab. (3938)
62 (non-directive adj (counselling or counseling)).ti,ab. (100)
63 (nondirective adj (counselling or counseling)).ti,ab. (54)
64 (non directive adj (counselling or counseling)).ti,ab. (100)
65 Psychotherapy/or Psychotherapy, Brief/or Psychotherapy, Group/or Psychotherapy, Multiple/or Psychotherapy,
Psychodynamic/or Psychotherapy, Rational-emotive/ (66,081)
66 psychodynamic therap$.ti,ab. (435)
67 inter personal psychotherap$.ti,ab. (1)
68 interpersonal psychotherap$.ti,ab. (788)
69 IPT.ti,ab. (1934)
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TABLE 25 Search strategy for MEDLINE via Ovid (continued )
70 (compassion adj2 therap$).ti,ab. (41)
71 accelerated resolution.ti,ab. (86)
72 sensorimotor therap$.ti,ab. (22)
73 schema therapy.ti,ab. (113)
74 (stress adj2 manag$).ti,ab. (5239)
75 supportive therap$.ti,ab. (3938)
76 Counseling/ (33,064)
77 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (155)
78 compassion therap$.ti,ab. (1)
79 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72
or 73 or 74 or 75 or 76 or 77 or 78 (122,833)
80 33 or 53 or 79 (212,817)
81 “hypnotics and sedatives”/or alprazolam/or amobarbital/or azaperone/or barbital/or bromisovalum/or chloral
hydrate/or chloralose/or chlordiazepoxide/or chlormethiazole/or dexmedetomidine/or diazepam/or diphenhydramine/
or eszopiclone/or ethchlorvynol/or etomidate/or etorphine/or flurazepam/or glutethimide/or hexobarbital/or
lorazepam/or medazepam/or medetomidine/or mephobarbital/or meprobamate/or methapyrilene/or methaqualone/or
midazolam/or nitrazepam/or oxazepam/or paraldehyde/or pentobarbital/or phenobarbital/or propofol/or secobarbital/
or temazepam/or thiamylal/or thiopental/or xylazine/ (115,279)
82 z drugs.ti,ab. (129)
83 anti-anxiety agents/or bromazepam/or buspirone/or chlormezanone/or clorazepate dipotassium/or estazolam/or
flunitrazepam/or fluvoxamine/or nordazepam/or ondansetron/or oxprenolol/or prazepam/or pregabalin/or ritanserin/or
tranylcypromine/or trazodone/or triazolam/or zolazepam/ (33,247)
84 benzodiazepines/or benzodiazepinones/ (23,792)
85 sedative antihistamine$.ti,ab. (61)
86 promethazine.ti,ab. (2067)
87 antidepressive agents/or benactyzine/or clorgyline/or deanol/or desvenlafaxine succinate/or duloxetine
hydrochloride/or iproniazid/or isocarboxazid/or lithium carbonate/or lithium compounds/or moclobemide/or nialamide/
or phenelzine/or pizotyline/or rolipram/or sertraline/or tranylcypromine/or vilazodone hydrochloride/ (55,863)
88 Imipramine/ (9836)
89 mirtazapine.ti,ab. (1789)
90 antipsychotic agents/or acepromazine/or aripiprazole/or azaperone/or benperidol/or butaclamol/or chlorpromazine/
or chlorprothixene/or clopenthixol/or clozapine/or droperidol/or etazolate/or flupenthixol/or fluphenazine/or fluspirilene/
or haloperidol/or loxapine/or lurasidone hydrochloride/or mesoridazine/or methiothepin/or methotrimeprazine/or
molindone/or ondansetron/or paliperidone palmitate/or penfluridol/or perazine/or perphenazine/or pimozide/or
prochlorperazine/or promazine/or quetiapine fumarate/or raclopride/or remoxipride/or reserpine/or risperidone/or
ritanserin/or spiperone/or sulpiride/or thioridazine/or thiothixene/or tiapride hydrochloride/or trifluoperazine/or
trifluperidol/or triflupromazine/ (115,485)
91 olanzapine.ti,ab. (7626)
92 anticonvulsants/or acetazolamide/or bromides/or carbamazepine/or clonazepam/or clorazepate dipotassium/
or diazepam/or dimethadione/or estazolam/or ethosuximide/or flunarizine/or lorazepam/or magnesium sulfate/or
medazepam/or mephenytoin/or mephobarbital/or meprobamate/or nitrazepam/or paraldehyde/or phenobarbital/or
phenytoin/or pregabalin/or primidone/or riluzole/or thiopental/or tiletamine/or trimethadione/or valproic acid/or
vigabatrin/ (130,525)
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TABLE 25 Search strategy for MEDLINE via Ovid (continued )
96 monoamine oxidase inhibitors/or chlorphenamidine/or clorgyline/or cuprizone/or furazolidone/or harmaline/or
harmine/or isocarboxazid/or moclobemide/or monocrotophos/or pargyline/or selegiline/or tranylcypromine/ (18,012)
97 Prazosin/ (7586)
98 N-Methyl-3,4-methylenedioxyamphetamine/ (3654)
99 (MDMA or ecstasy).ti,ab. (5261)
100 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 (409,556)
101 19 and 80 (5684)
102 19 and 100 (1860)
103 101 or 102 (7197)
104 Qualitative Research/ (34,279)
105 interview/ (27,920)
106 Grounded Theory/ (570)
107 Personal Narratives/ (2920)
108 Focus Groups/ (23,242)
109 Hermeneutics/ (122)
110 Anthropology, Cultural/ (5645)
111 interview$.ti,ab. (295,531)
112 ethnog$.ti,ab. (8787)
113 case stud$.ti,ab. (75,187)
114 grounded theory.ti,ab. (9150)
115 thematic analysis.ti,ab. (9942)
116 observational method$.ti,ab. (584)
117 comparative method$.ti,ab. (2606)
118 field notes.ti,ab. (1605)
119 participant observation.ti,ab. (2952)
120 narrative$.ti,ab. (26,469)
121 field stud$.ti,ab. (12,896)
122 audio recording.ti,ab. (240)
123 focus group$.ti,ab. (34,349)
124 conversation$ analysis.ti,ab. (454)
125 descriptive stud$.ti,ab. (22,097)
126 discourse analysis.ti,ab. (1338)
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PsycINFO via Ovid
Search date: 1 June 2017.
Date range searched: 1987 to May Week 4 2017.
TABLE 25 Search strategy for MEDLINE via Ovid (continued )
134 semi-structured.ti,ab. (29,761)
135 key informant$.ti,ab. (5436)
136 tape record$.ti,ab. (3069)
137 narration.ti,ab. (467)
138 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or
119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or
135 or 136 or 137 (546,383)
139 103 and 138 (951)
140 (accept$ or adherence or attitude$ or belief$ or believ$ or choice$ or choos$ or drop out$ or experienc$ or
feasib$ or opinion$ or perceiv$ or percept$ or prefer$ or uptake or view$ or withdraw$).ti. (680,726)
141 103 and 140 (344)
142 139 or 141 (1212)
143 limit 142 to yr=“1992 -Current” (1151)
TABLE 26 Search strategy for PsycINFO via Ovid
1 exp Posttraumatic Stress Disorder/ (26,903)
2 Complex PTSD/ (130)
3 DESNOS/ (15)
4 “Disorders of Extreme Distress Not Otherwise Specified”.ti,ab. (0)
5 (PTSD or CPTSD).ti,ab. (25,512)
6 posttrauma$.ti,ab. (26,670)
7 post-trauma$.ti,ab. (11,375)
8 “post trauma$”.ti,ab. (11,375)
9 post traumatic stress.ti,ab. (8922)
10 post traumatic stress.id. (2822)
11 combat stress$.ti,ab. (450)
12 combat disorder$.ti,ab. (12)
13 DESNOS.ti,ab. (54)
14 complex trauma$.ti,ab. (527)
15 (complex adj2 trauma$).ti,ab. (699)
16 traumatic stress.ti,ab. (11,652)
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TABLE 26 Search strategy for PsycINFO via Ovid (continued )
20 (trauma adj2 (expos$ or event$ or experienc$)).ti,ab. (6690)
21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (46,932)
22 exp Cognitive Therapy/ (11,610)
23 cognitive behaviour$ therapy.ti,ab. (3892)
24 cognitive behavior$ therapy.ti,ab. (12,974)
25 cognitive restructuring.ti,ab. (1765)
26 cognitive rescripting.ti,ab. (0)
27 cognitive processing therapy.ti,ab. (277)
28 CPT.ti,ab. (1871)
29 cognitive therapy.ti,ab. (5079)
30 cognitive behavioural treatment$.ti,ab. (521)
31 cognitive behavioral treatment$.ti,ab. (2909)
32 (CBT or TFCBT).ti,ab. (10,696)
33 cognitive trauma therapy.ti,ab. (8)
34 trauma focus$ CBT.ti,ab. (57)
35 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (32,467)
36 exp Behavior Therapy/ (11,576)
37 (behavior$ adj2 (therap$ or treat$ or modif$)).ti,ab. (33,755)
38 (behaviour$ adj2 (therap$ or treat$ or modif$)).ti,ab. (6941)
39 (dialectical behavio$ therap$ or dialectical behavio$ treat$).ti,ab. (1477)
40 DBT.ti,ab. (1136)
41 biofeedback, psychology/or feedback, sensory/or neurofeedback/ (1224)
42 (biofeedback or neurofeedback or sensory feedback).ti,ab. (4469)
43 desensitization, psychologic/or eye movement desensitization reprocessing/or implosive therapy/or virtual reality
exposure therapy/ (152)
44 (psychological adj2 desensiti$).ti,ab. (3)
45 Eye Movement Desensitization Therapy/ (1241)
46 eye movement desensiti?ation reprocessing.ti,ab. (61)
47 EMDR.ti,ab. (1367)
48 Exposure Therapy/ (1988)
49 (exposure adj (therap$ or treat$)).ti,ab. (2129)
50 prolonged exposure therap$.ti,ab. (153)
51 live exposure.ti,ab. (21)
52 imaginal exposure.ti,ab. (267)
53 imaginal flooding.ti,ab. (21)
54 exposure inhibition therap$.ti,ab. (1)
55 implosive therap$.ti,ab. (29)
56 image habituation.ti,ab. (5)
57 inoculation training.ti,ab. (226)
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TABLE 26 Search strategy for PsycINFO via Ovid (continued )
58 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
or 55 or 56 or 57 (51,566)
59 (acceptance adj2 therap$).ti,ab. (347)
60 (commitment adj2 therap$).ti,ab. (1499)
61 Hypnosis/(3983)
62 (hypnosis or hypnotherap$).ti,ab. (6655)
63 Mindfulness/ (6716)
64 mindfulness.ti,ab. (8233)
65 (supportive adj (therap$ or psychotherap$)).ti,ab. (1186)
66 (non-directive adj (counselling or counseling)).ti,ab. (40)
67 (nondirective adj (counselling or counseling)).ti,ab. (52)
68 (non directive adj (counselling or counseling)).ti,ab. (40)
69 psychodynamic therap$.ti,ab. (1267)
70 inter personal psychotherap$.ti,ab. (1)
71 interpersonal psychotherap$.ti,ab. (1175)
72 interpersonal therapy.ti,ab. (502)
73 IPT.ti,ab. (963)
74 (compassion adj2 therap$).ti,ab. (107)
75 accelerated resolution.ti,ab. (9)
76 sensorimotor therap$.ti,ab. (9)
77 schema therapy.ti,ab. (321)
78 Stress Management/ (4239)
79 Supportive Psychotherapy/ (461)
80 Group Psychotherapy/ (12,925)
81 Counseling/ (15,966)
82 (non-directive counsel$ or non directive counsel$ or nondirective counsel$).ti,ab. (92)
83 compassion therap$.ti,ab. (4)
84 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77
or 78 or 79 or 80 or 81 or 82 or 83 (53,717)
85 35 or 58 or 84 (108,582)
86 21 and 85 (5589)
87 hypnotic drugs/or amobarbital/or apomorphine/or barbital/or chloral hydrate/or codeine/or flurazepam/or
glutethimide/or hexobarbital/or meprobamate/or methaqualone/or nitrazepam/or pentobarbital/or phenobarbital/or
secobarbital/or thalidomide/or thiopental/or triazolam/ (3430)
88 hypnotics.ti,ab. (1260)
89 hypnotic drug$.ti,ab. (286)
90 z drug$.ti,ab. (44)
91 tranquilizing drugs/or amitriptyline/or benactyzine/or doxepin/or haloperidol/or meprobamate/or minor
tranquilizers/or neuroleptic drugs/or phenothiazine derivatives/or pimozide/or thiothixene/ (21,857)
92 exp benzodiazepines/ (7742)
93 sedative antihistamine$.ti,ab. (13)
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TABLE 26 Search strategy for PsycINFO via Ovid (continued )
94 promethazine.ti,ab. (125)
95 antidepressant drugs/or bupropion/or citalopram/or fluoxetine/or fluvoxamine/or iproniazid/or isocarboxazid/or
lithium carbonate/or methylphenidate/or mianserin/or moclobemide/or molindone/or nefazodone/or nialamide/or
nomifensine/or paroxetine/or phenelzine/or pheniprazine/or pipradrol/or serotonin norepinephrine reuptake inhibitors/




98 neuroleptic drugs/or aripiprazole/or clozapine/or molindone/or nialamide/or olanzapine/or quetiapine/or
reserpine/or risperidone/or spiroperidol/or sulpiride/or tetrabenazine/ (25,765)
99 mood stabilizers/or anticonvulsive drugs/or carbamazepine/or lithium/or valproic acid/ (11,793)





105 monoamine oxidase inhibitors/or iproniazid/or isocarboxazid/or moclobemide/or nialamide/or pargyline/or
phenelzine/or pheniprazine/or tranylcypromine/ (1627)
106 antihypertensive drugs/or alpha methylparatyrosine/or captopril/or chlorpromazine/or clonidine/or guanethidine/
or hexamethonium/or hydralazine/or mecamylamine/or methyldopa/or phenoxybenzamine/or quinpirole/ (2481)
107 alpha blocker anti-hypertensive$.ti,ab. (0)
108 alpha blocker antihypertensive$.ti,ab. (0)
109 prazosin.ti,ab. (579)
110 Methylenedioxymethamphetamine/ (1926)
111 (mdma or ecstasy).ti,ab. (2879)
112 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104
or 105 or 106 or 107 or 108 or 109 or 110 or 111 (83,790)
113 21 and 112 (1054)
114 86 or 113 (6545)
115 Qualitative Research/ (7366)
116 exp INTERVIEWS/ (9209)
117 exp ETHNOGRAPHY/ (7251)
118 exp Grounded Theory/ (3212)
119 exp Observation Methods/ (3079)
120 exp NARRATIVES/ (16,768)
121 exp Audiotapes/ (250)
122 exp Discourse Analysis/ (7393)
123 conversation/ (7816)
124 exp HERMENEUTICS/ (1857)
125 exp PHENOMENOLOGY/ (10,792)
126 exp Participation/ (11,842)
127 exp Informants/ (734)
continued
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
173
TABLE 26 Search strategy for PsycINFO via Ovid (continued )
128 anthropology/ (4659)
129 case stud$.ti,ab. (74,204)
130 thematic analysis.ti,ab. (7137)
131 comparative method$.ti,ab. (1958)
132 field notes.ti,ab. (3029)
133 audio recording.ti,ab. (214)
134 focus group$.ti,ab. (27,182)
135 conversation$ analysis.ti,ab. (1659)
136 descriptive study.ti,ab. (5331)
137 exploratory stud$.ti,ab. (12,989)
138 naturalistic.ti,ab. (11,518)
139 (open-ended or in-depth).ti,ab. (52,099)
140 semi-structured.ti,ab. (26,340)
141 key informant$.ti,ab. (2662)
142 tape record$.ti,ab. (1949)
143 narration.ti,ab. (1417)
144 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or
130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 (271,473)
145 114 and 144 (652)
146 (accept$ or adherence or attitude$ or belief$ or believ$ or choice$ or choos$ or drop out$ or experienc$ or
feasib$ or opinion$ or perceiv$ or percept$ or prefer$ or uptake or view$ or withdraw$).ti. (288,349)
147 114 and 146 (346)
148 145 or 147 (947)
149 limit 148 to yr=“1992 -Current” (919)
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Appendix 3 List of studies excluded,
with reasons
TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion
Authors (year) Reason for exclusion
Abramowitz et al. (2008)188 Intervention did not meet criteria
Acierno et al. (2016)189 Intervention did not meet criteria
Aderka et al. (2013)190 Population did not meet criteria
Adler et al. (2009)191 Intervention did not meet criteria
Alderman et al. (2009)192 Study design did not meet criteria
Alderman et al. (2009)193 Study design did not meet criteria
Allan et al. (2015)194 Study design did not meet criteria
Allon (2015)195 Population did not meet criteria
Alvarez et al. (2011)196 Study design did not meet criteria
Amin et al. (2013)197 Article is a conference abstract
Angelo et al. (2008)198 Study design did not meet criteria
Arntz et al. (2007)199 Population did not meet criteria
Ayoughi et al. (2012)200 Study design did not meet criteria
Baños et al. (2011)201 Population did not meet criteria
Basharpoor et al. (2011)202 Population did not meet criteria
Bass et al. (2013)203 Population did not meet criteria
Batka et al. (2016)204 Intervention did not meet criteria
Benedek (2011)205 Study design did not meet criteria
Bensimon et al. (2012)206 Intervention did not meet criteria
Betancourt et al. (2014)207 Population did not meet criteria
Bisson (2003)208 Study design did not meet criteria
Bisson (2007)209 Population did not meet criteria
Blevins et al. (2011)210 Intervention did not meet criteria
Bohus et al. (2013)211 Population did not meet criteria
Bolton et al. (2014)212 Population did not meet criteria
Bomyea et al. (2015)213 Population did not meet criteria
Bormann et al. (2008)214 Intervention did not meet criteria
Bormann et al. (2013)215 Intervention did not meet criteria
Bormann et al. (2014)216 Article is a conference abstract
Bradley and Follingstad (2003)217 Population did not meet criteria
Brady et al. (2000)218 Population did not meet criteria
Bremner et al. (2004)219 Study design did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Bremner et al. (2011)220 Article is a conference abstract
Brown et al. (2014)221 Intervention did not meet criteria
Bryan et al. (2016)222 Study design did not meet criteria
Bui et al. (2016)223 Article is a conference abstract
Byers et al. (2010)224 Study design did not meet criteria
Byers (2010)225 Study design did not meet criteria
Campbell et al. (2016)226 Intervention did not meet criteria
Carlson et al. (1998)157 Duplicate article
Carr et al. (2012)227 Intervention did not meet criteria
Castillo et al. (2016)228 Population did not meet criteria
Cates et al. (2004)229 Study design did not meet criteria
Celik et al. (2011)65 Duplicate article
Chemtob et al. (1997)230 Population did not meet criteria
Chen et al. (2013)231 Outcomes did not meet criteria
Chesney et al. (2014)232 Article is a conference abstract
Church et al. (2013)233 Intervention did not meet criteria
Church (2014)234 Study design did not meet criteria
Clark et al. (1999)235 Study design did not meet criteria
Classen et al. (2011)236 Population did not meet criteria
Cloitre and Koenen (2001)237 Study design did not meet criteria
Cole et al. (2007)238 Population did not meet criteria
Connolly and Sakai (2011)239 Intervention did not meet criteria
Cort et al. (2014)240 Study design did not meet criteria
Coulter (2010)241 Intervention did not meet criteria
Crespo and Arinero (2010)242 Population did not meet criteria
David et al. (2006)243 Study design did not meet criteria
Davidson et al. (1993)244 Study design did not meet criteria
Davidson et al. (2001)245 Population did not meet criteria
Davidson et al. (2001)246 Population did not meet criteria
Davis et al. (2000)247 Study design did not meet criteria
Davis et al. (2004)73 Duplicate article
Davis et al. (2008)72 Duplicate article
Davis et al. (2011)248 Population did not meet criteria
Dawson et al. (2016)249 Population did not meet criteria
Dempsey et al. (2014)233 Article is a conference abstract
Dieperink et al. (2008)250 Intervention did not meet criteria
Difede et al. (2014)251 Population did not meet criteria
Dorrepaal et al. (2012)252 Population did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Dorrepaal et al. (2013)253 Outcomes did not meet criteria
Doruk et al. (1999)254 Non-English language article
Dougherty (2002)255 Population did not meet criteria
Drozdek (1997)256 Study design did not meet criteria
Droždek and Bolwerk (2010)257 Intervention did not meet criteria
Drožđek et al. (2012)258 Intervention did not meet criteria
Duffy and Malloy (1994)259 Study design did not meet criteria
Duffy et al. (2007)260 Population did not meet criteria
Dunn et al. (2007)261 Population did not meet criteria
Durham et al. (2005)262 Study design did not meet criteria
Echeburúa et al. (1997)263 Population did not meet criteria
Echeburúa et al. (2014)264 Comparator did not meet criteria
Edmond et al. (2004)265 Outcomes did not meet criteria
Ekstrom et al. (2016)266 Article is a conference abstract
Ekstrom et al. (2016)267 Article is a conference abstract
Elkjaer et al. (2012)268 Article is a conference abstract
Ertl et al. (2011)269 Population did not meet criteria
Esala et al. (2017)270 Intervention did not meet criteria
Falsetti et al. (2003)271 Population did not meet criteria
Farchi and Gidron (2010)272 Intervention did not meet criteria
Fiorillo et al. (2017)273 Study design did not meet criteria
Foa et al. (1991)274 Population did not meet criteria
Foa et al. (1999)275 Population did not meet criteria
Foa et al. (2005)276 Population did not meet criteria
Forbes et al. (2001)277 Study design did not meet criteria
Forbes et al. (2008)278 Population did not meet criteria
Forbes et al. (2012)279 Population did not meet criteria
Ford et al. (2011)280 Population did not meet criteria
Fortney et al. (2015)281 Intervention did not meet criteria
Fortney et al. (2015)282 Intervention did not meet criteria
Frommberger et al. (2004)283 Population did not meet criteria
Galovski et al. (2009)284 Study design did not meet criteria
Galovski et al. (2012)285 Population did not meet criteria
Gamito et al. (2009)286 Study design did not meet criteria
Garfield et al. (2001)287 Study design did not meet criteria
Gatz et al. (2007)288 Population did not meet criteria
Gebler and Maercker (2007)289 Non-English language article
continued
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
177
TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Gelpin et al. (1996)290 Population did not meet criteria
Gillin et al. (2001)291 Study design did not meet criteria
Ginsberg (2003)292 Study design did not meet criteria
Ginzburg et al. (2009)293 Outcomes did not meet criteria
Glover (1993)294 Study design did not meet criteria
Glynn et al. (1999)295 Intervention did not meet criteria
Goldberg et al. (2003)296 Study design did not meet criteria
Gosselin et al. (2016)297 Article is a conference abstract
Graham-Bermann and Miller (2013)298 Intervention did not meet criteria
Gray et al. (2012)299 Study design did not meet criteria
Gros et al. (2011)300 Comparator did not meet criteria
Gros et al. (2011)301 Comparator did not meet criteria
Gutner et al. (2013)302 Population did not meet criteria
Hall et al. (2014)303 Outcomes did not meet criteria
Hamner (1996)304 Article is a letter to the editor
Hamner et al. (2003)305 Study design did not meet criteria
Harris et al. (2011)306 Intervention did not meet criteria
Haynes et al. (2012)307 Article is a conference abstract
Hébert and Bergeron (2007)308 Population did not meet criteria
Held and Owens (2015)309 Population did not meet criteria
Hensel-Dittmann et al. (2011)310 Population did not meet criteria
Hertzberg et al. (2000)311 Population did not meet criteria
Hertzberg et al. (2002)312 Study design did not meet criteria
Hijazi et al. (2013)313 Article is a conference abstract
Hobfoll et al. (2016)314 Population did not meet criteria
Holliday et al. (2015)315 Population did not meet criteria
Hopton and Huta (2013)316 Population did not meet criteria
Hughes and Rasmussen (2010)162 Study design did not meet criteria
Igreja et al. (2004)317 Intervention did not meet criteria
Ironson et al. (2002)318 Population did not meet criteria
Ivarsson et al. (2014)319 Population did not meet criteria
Iverson et al. (2011)320 Outcomes did not meet criteria
Jaberghaderi et al. (2002)321 Population did not meet criteria
Jain et al. (2012)322 Intervention did not meet criteria
Jenkins et al. (2014)323 Article is a conference abstract
Jerud et al. (2014)324 Population did not meet criteria
Jetly et al. (2015)325 Study design did not meet criteria
Johnson et al. (2011)326 Population did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Kaiser et al. (2010)327 Outcomes did not meet criteria
Karatzias et al. (2016)328 Study design did not meet criteria
Kaslow et al. (2010)329 Population did not meet criteria
Kelly et al. (2016)330 Article is a conference abstract
Kelly and Garland (2016)331 Population did not meet criteria
Khazaie et al. (2016)332 Population did not meet criteria
King et al. (2011)333 Article is a conference abstract
King et al. (2016)334 Population did not meet criteria
King et al. (2016)335 Population did not meet criteria
Kip et al. (2013)336 Population did not meet criteria
Kip et al. (2014)337 Outcomes did not meet criteria
Kluepfel et al. (2013)338 Population did not meet criteria
Koehn (2007)339 Study design did not meet criteria
Kozarić-Kovacić et al. (2005)340 Study design did not meet criteria
Kozaric-Kovacic and Pivac (2007)341 Study design did not meet criteria
Kozel et al. (2016)342 Article is a conference abstract
Krakow et al. (2000)343 Population did not meet criteria
Krakow et al. (2001)344 Population did not meet criteria
Kreidler (2005)345 Population did not meet criteria
Krüger et al. (2014)346 Population did not meet criteria
Krystal et al. (2011)99 Population did not meet criteria
Kuckertz et al. (2014)347 Population did not meet criteria
Labrador et al. (2006)348 Non-English language article
Lampe et al. (2008)349 Non-English language article
Lang et al. (2012)350 Article is a study protocol
Lange et al. (2001)351 Population did not meet criteria
Lange et al. (2003)352 Population did not meet criteria
Lange et al. (2003)353 Population did not meet criteria
Largo-Marsh (1996)354 Article is a dissertation
Liebling et al. (2016)355 Intervention did not meet criteria
Liedl et al. (2011)356 Retracted study
Lim et al. (2014)357 Article is a conference abstract
Littleton et al. (2016)358 Population did not meet criteria
Litz et al. (2007)359 Population did not meet criteria
Litz et al. (2012)360 Population did not meet criteria
Long et al. (2011)361 Study design did not meet criteria
Macdonald et al. (2011)362 Population did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Macklin et al. (2000)363 Study design did not meet criteria
Manteghi et al. (2014)364 Study design did not meet criteria
Margolies et al. (2013)159 Duplicate article
Martenyi et al. (2002)365 Population did not meet criteria
Martenyi et al. (2006)366 Study design did not meet criteria
Matud et al. (2016)367 Non-English language article
Mauritz et al. (2016)368 Article is a study protocol
McFall et al. (2005)369 Intervention did not meet criteria
McGlinchey et al. (2014)370 Intervention did not meet criteria
McWhirter (2011)371 Population did not meet criteria
Mehling et al. (2016)372 Article is a conference abstract
Mehta et al. (2012)373 Article is a conference abstract
Mello et al. (2009)374 Article is a study protocol
Mithoefer et al. (2011)375 Population did not meet criteria
Monson et al. (2006)376 Population did not meet criteria
Monson et al. (2012)377 Intervention did not meet criteria
Morland et al. (2010)378 Comparator did not meet criteria
Morland et al. (2011)379 Comparator did not meet criteria
Morland et al. (2014)380 Comparator did not meet criteria
Morland et al. (2015)381 Comparator did not meet criteria
Moser et al. (2010)382 Comparator did not meet criteria
Mughal et al. (2015)383 Intervention did not meet criteria
Murray et al. (2016)384 Outcomes did not meet criteria
Muzik et al. (2015)385 Intervention did not meet criteria
Nacasch et al. (2011)386 Population did not meet criteria
Nagy et al. (1993)387 Study design did not meet criteria
Nakamura et al. (2011)388 Intervention did not meet criteria
Neuner et al. (2010)389 Population did not meet criteria
Neylan et al. (2001)390 Study design did not meet criteria
Neylan et al. (2003)391 Study design did not meet criteria
Nijdam et al. (2012)392 Population did not meet criteria
Niles et al. (2012)160 Article is a conference abstract
Niles et al. (2013)393 Outcomes did not meet criteria
Nishith et al. (1999)394 Population did not meet criteria
Nishith et al. (2015)395 Study design did not meet criteria
Ochsner Margolies et al. (2012)396 Article is a conference abstract
Oman and Bormann (2015)397 Intervention did not meet criteria
Padala (2006)398 Study design did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Padala et al. (2006)399 Population did not meet criteria
Paivio et al. (2010)400 Comparator did not meet criteria
Paunovic (2011)401 Population did not meet criteria
Peskind et al. (2003)402 Study design did not meet criteria
Petty et al. (2001)403 Study design did not meet criteria
Pigeon et al. (2009)404 Study design did not meet criteria
Pigeon et al. (2015)405 Article is a conference abstract
Pivac and Kozarić-Kovacić (2006)406 Study design did not meet criteria
Pokhariyal et al. (2012)407 Population did not meet criteria
Pollack et al. (2011)408 Population did not meet criteria
Possemato et al. (2011)409 Intervention did not meet criteria
Possemato et al. (2016)410 Comparator did not meet criteria
Price (2005)411 Intervention did not meet criteria
Price (2006)412 Intervention did not meet criteria
Pruiksma et al. (2012)413 Article is a conference abstract
Pruiksma et al. (2013)414 Article is a conference abstract
Ragsdale et al. (1996)415 Population did not meet criteria
Rahman et al. (2016)416 Population did not meet criteria
Randall et al. (1995)417 Study design did not meet criteria
Raskind et al. (2003)418 Study design did not meet criteria
Raskind et al. (2012)419 Article is a conference abstract
Raskind et al. (2013)123 Duplicate article
Raskind (2014)420 Article is a conference abstract
Rauch et al. (2014)421 Article is a conference abstract
Rauch et al. (2015)422 Population did not meet criteria
Ready et al. (2006)423 Study design did not meet criteria
Reed (2004)424 Article is a dissertation
Renner et al. (2011)425 Intervention did not meet criteria
Resick and Schnicke (1992)426 Population did not meet criteria
Resick et al. (2002)427 Population did not meet criteria
Resick et al. (2003)428 Study design did not meet criteria
Resick et al. (2008)429 Comparator did not meet criteria
Resick et al. (2017)430 Comparator did not meet criteria
Rimane and Rosner (2013)431 Article is a study protocol
Robert et al. (2009)432 Study design did not meet criteria
Rodgman et al. (2016)433 Study design did not meet criteria
Rosenbaum et al. (2015)434 Intervention did not meet criteria
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Rothbaum (1997)435 Population did not meet criteria
Rothbaum et al. (2001)436 Study design did not meet criteria
Rothbaum et al. (2005)437 Population did not meet criteria
Rothbaum et al. (2008)438 Study design did not meet criteria
Rothbaum et al. (2014)129 Study design did not meet criteria
Ryan et al. (2005)439 Intervention did not meet criteria
Sachsse et al. (2006)440 Study design did not meet criteria
Sack et al. (2017)441 Outcomes did not meet criteria
Salloum et al. (2015)442 Intervention did not meet criteria
Sautter et al. (2015)443 Intervention did not meet criteria
Schaal et al. (2009)444 Comparator did not meet criteria
Schnurr et al. (2003)445 Population did not meet criteria
Schnurr et al. (2007)446 Population did not meet criteria
Schnurr et al. (2009)447 Outcomes did not meet criteria
Schnurr and Lunney (2015)448 Study design did not meet criteria
Schnurr and Lunney (2016)449 Study design did not meet criteria
Seppälä et al. (2014)450 Intervention did not meet criteria
Sezgin and Punamäki (2008)451 Study design did not meet criteria
Shearing et al. (2011)452 Population did not meet criteria
Short (2005)453 Study design did not meet criteria
Silver et al. (1995)454 Study design did not meet criteria
Skinhoj et al. (2001)455 Study design did not meet criteria
Smith et al. (2012)456 Study design did not meet criteria
Spence et al. (2014)457 Population did not meet criteria
Spiegel et al. (2004)458 Study design did not meet criteria
Stade et al. (2015)459 Intervention did not meet criteria
Stalker and Fry (1999)460 Study design did not meet criteria
Steil et al. (2011)461 Article is a conference abstract
Stein et al. (2006)462 Study design did not meet criteria
Steinert et al. (2017)463 Population did not meet criteria
Steuwe et al. (2016)464 Study design did not meet criteria
Stovall-McClough and Cloitre (2003)465 Study design did not meet criteria
Su et al. (2007)466 Non-English language article
Sulejmanpasic-Arslanagic and Bise Srebrenka (2015)467 Article is a conference abstract
Surís et al. (2010)468 Intervention did not meet criteria
Surís et al. (2013)469 Population did not meet criteria
Swanson et al. (2009)470 Study design did not meet criteria
Taing et al. (2011)471 Article is a conference abstract
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TABLE 27 Studies excluded at full-text screening stage, with reasons for exclusion (continued )
Authors (year) Reason for exclusion
Talbot et al. (2011)472 Population did not meet criteria
Talbot et al. (2014)473 Population did not meet criteria
Tan et al. (2011)474 Comparator did not meet criteria
Tarquinio et al. (2012)475 Population did not meet criteria
Tarrier and Sommerfield (2004)476 Population did not meet criteria
Thomaes et al. (2015)477 Non-English language article
Thorp et al. (2012)478 Study design did not meet criteria
Tourigny et al. (2005)479 Non-English language article
Truijens and Van Emmerik (2014)480 Population did not meet criteria
van den Berg and van der Gaag (2012)481 Population did not meet criteria
van der Kolk et al. (2007)482 Population did not meet criteria
van Emmerik et al. (2008)483 Population did not meet criteria
Vera et al. (2011)484 Population did not meet criteria
Villarreal et al. (2007)485 Study design did not meet criteria
Villarreal et al. (2010)486 Study design did not meet criteria
Vitriol et al. (2009)487 Intervention did not meet criteria
Weine et al. (2008)488 Intervention did not meet criteria
Wells and Colbear (2012)489 Population did not meet criteria
Westbury and Tutty (1999)490 Intervention did not meet criteria
Wood et al. (2011)491 Study design did not meet criteria
Yeh et al. (2011)492 Population did not meet criteria
Yehua (2003)493 Study design did not meet criteria
Yehuda et al. (2015)494 Population did not meet criteria
Yuen et al. (2015)495 Comparator did not meet criteria
Ziemba (et al. 2014)496 Comparator did not meet criteria
Zimmermann et al. (2005)497 Non-English language article
Zimmermann et al. (2007)498 Study design did not meet criteria
Zisook et al. (2000)499 Study design did not meet criteria
Zlotnick et al. (2011)500 Population did not meet criteria
Zoellner et al. (1999)501 Population did not meet criteria
Zohar et al. (2002)147 Duplicate article
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Appendix 4 Characteristics of randomised
controlled trials included
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Intensity (duration, frequency and
length of sessions)




EMDR EMDR; SCTF Waitlist Duration: NR
Frequency: NR
Length of sessions: seven sessions,
90 minutes each
Face to face; community/refugee camp;
Turkish psychologists trained at level 1




EMDR EMDR; SCTF Waitlist Duration: 5 weeks
Frequency: NR
Length of sessions: NR
Face to face/online; community/




NET TFCBT; SCTF Waitlist Duration: NR
Frequency: weekly or biweekly
Length of sessions: 12 sessions, average
length 108 minutes (SD 17 minutes)





MBSR Mindfulness; SCNTF Waitlist/continued
treatment
Duration: 4 weeks
Frequency: twice a week
Length of sessions: eight sessions,
90 minutes each
Face to face; hospital; psychologist
Bichescu et al.
(2007)61
NET TFCBT; MCTF Psychoeducation Duration: 5 weeks
Frequency: weekly or biweekly
Length of sessions: 120 minutes
Face to face, individual; setting NR;








































Intensity (duration, frequency and
length of sessions)
Delivery (method, setting and type of
professional)
Beidel et al. (2011)60 Trauma management
therapy with exposure
TFCBT; MCTF Duration: 17 weeks
Frequency: exposure three times per
week; social and emotional rehabilitation
twice a week (2 weeks), weekly for
10 weeks
Length of sessions: 14 sessions of
exposure, length NR. Social and emotional
rehabilitation 90 minutes
Face to face, individual and group;
setting NR; doctoral-level therapists
Exposure-only therapy Exposure only Duration: 17 weeks
Frequency: three times per week
Length of sessions:14 sessions of





NTFCBT; SCNTF Waitlist Duration: NR
Frequency: NR
Length of sessions: 12 sessions, length NR
Face to face, individual; primary health
clinics and one outpatient clinic;
community mental health workers
(nurses, pharmacist assistants or
physician assistants) with a mental
health background
CPT TFCBT; SCTF Duration: NR
Frequency: NR
Length of sessions: 12 sessions, length NR
Buhmann et al.
(2016)63
CBT TFCBT; NA Waitlist Duration: 6 months
Frequency: weekly
Length of sessions: 16 sessions, length NR
Face to face; mental health clinic;



















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)






EMDR; SCTF Waitlist Duration: 6 weeks
Frequency: twice a week
Length of sessions: 12 sessions,
60–75 minutes each
Face to face, individual; clinic based;
experienced therapists, EMDR trained
therapists with research and clinical
backgrounds
Biofeedback relaxation NTFCBT; SCNTF Duration: 6 weeks
Frequency: twice a week
Length of sessions: 12 sessions,
40 minutes each




Chard (2005)66 CPT for sexual abuse
survivors
TFCBT; MCTF Waitlist Duration: 17 weeks
Frequency: weekly individual and group
sessions
Length of sessions: group sessions
90 minutes, individual sessions 60 minutes
Face to face, individual and group;
Centre for Traumatic Stress Studies;
graduate psychology students with
background in behavioural
interventions and mental health
Classen et al.
(2001)68
Trauma-focused therapy NA; NA (data were
presented together)
Waitlist Duration: 24 weeks
Frequency: weekly
Length of sessions: 90 minutes
Face to face, group; setting NR;
experienced group leaders supervised
by an expert in trauma (therapists
included psychologists and one
licensed MFCC)
Present-centred therapy Duration: 24 weeks
Frequency: weekly








































Intensity (duration, frequency and
length of sessions)
Delivery (method, setting and type of
professional)




Frequency: weekly STAIR/twice weekly
modified PE
Length of sessions: 16 sessions, STAIR
60 minutes, modified PE 90 minutes
Face to face, individual; setting NR;
clinical psychologist
STAIR/exposure DBT; MCTF Duration: 16 weeks
Frequency: weekly
Length of sessions: NR
Face to face, individual; setting NR;
master’s/doctorate psychologist/social
work staff/expert clinicians with
mental health backgrounds
STAIR/support DBT; MCNTF Duration: 16 weeks
Frequency: weekly
Length of sessions: NR
Face to face, individual; setting NR;
master’s/doctorate psychologist/social
work staff/expert clinicians with
mental health backgrounds
Cook et al. (2010)71 Imagery rehearsal
therapy
TFCBT; MCTF Duration: 6 weeks
Frequency: weekly
Length of sessions: 90 minutes
Face to face, group; setting NR;























































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)








Length of sessions: two sessions,
90 minutes
Face to face, individual; setting NR;




EMDR; SCTF Duration: NR
Frequency: NR




EMDR EMDR; SCTF Delayed treatment Duration: 6 weeks
Frequency: weekly
Length of sessions: 90 minutes





Frequency: weekly Length of sessions:
90 minutes




NTFCBT; SCNTF Optimised usual
care
Duration: 6 weeks
Frequency: three times per week
Length of sessions: 18 sessions, log in
15–30 minutes, homework 30 minutes
Computer/telephone; remote setting;
online/nurse support
Feske (2008)79 PE TFCBT; SCTF Treatment as usual Duration: 12 weeks
Frequency: weekly
Length of sessions: 9–12 total sessions,
PE 90 minutes, treatment as usual
60 minutes
Face to face, individual (individual and
group for controls); community clinic
setting; trained master’s-level social









































Intensity (duration, frequency and
length of sessions)




PE by iPhone (Apple Inc.,
Cupertino, CA, USA)
TFCBT; SCTF Treatment as usual Duration: 10 weeks
Frequency: 10 sessions within 12 weeks
Length of sessions: NR
iPhone-based video chat;




TFCBT; SCTF Treatment as usual Duration: 10 weeks
Frequency: 10 sessions within 12 weeks
Length of sessions: NR
Computer-based teleconference;






TFCBT; SCTF Waitlist Duration: NR
Frequency: NR
Length of sessions: 12 sessions, length NR
Face to face, individual; setting NR;
professional NR
Exposure in imagination TFCBT; SCTF Duration: NR
Frequency: NR
Length of sessions: 12 sessions, length NR
Computer-based teleconference;






TFCBT; MCTF Placebo Duration: 8 weeks
Frequency: weekly
Length of sessions: eight sessions,
45 minutes each
Face to face; setting NR; master’s-level







TFCBT; SCTF No intervention Duration: 2 weeks
Frequency: approximately every other day
Length of sessions: 1–2 hours
Face to face (individual and group);
non-governmental organisation
reintegration centre for war-affected



















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)
Delivery (method, setting and type of
professional)
Hijazi et al. (2014)87 Brief NET TFCBT; SCTF Waitlist Duration: 3 weeks
Frequency: weekly
Length of sessions: 60–90 minutes
Face to face; private room setting
according to participant preference
(e.g. own home, church, community
centre); therapists trained by a licensed








Length of sessions: inpatient
Face to face; hospital; professionals
NR, but with mental health background
Hinton et al.
(2004)90
CBT TFCBT; SCTF Delayed treatment Duration: 11 weeks
Frequency: weekly
Length of sessions: NR
Face to face, individual; setting NR;




CBT TFCBT; SCTF Delayed treatment Duration: 12 weeks
Frequency: weekly
Length of sessions: NR
Face to face, individual; setting NR;
psychiatrist





Length of sessions: NR
Face to face; setting NR; trained






TFCBT; MCTF Waitlist Duration: NR
Frequency: NR
Length of sessions: two sessions,
treatment 90 minutes, booster 50 minutes
Face to face/use of internet; specialist
PTSD outpatient centres; one at
university and two at large psychiatric
hospitals; therapist supervised by








































Intensity (duration, frequency and
length of sessions)
Delivery (method, setting and type of
professional)








Length of sessions: NR
Face to face, individual; setting NR;
psychologist, clinical social workers,
psychology post-docs, marriage and
family therapist trainees and psychiatry
residents, with mental health
backgrounds
PE TFCBT; SCTF Waitlist Face to face/use of internet; specialist
PTSD outpatient centres; one at
university and two at large psychiatric
hospitals; therapist supervised by
senior therapist (both authors)
Keane et al. (1989)94 Implosive (flooding)
therapy
TFCBT; SCTF Waitlist Duration: NR
Frequency: NR
Length of sessions: 14 sessions (plus an
additional two sessions if deemed
appropriate by therapist), 90 minutes
Face to face (individual); VA medical




MBSR and treatment as
usual
Mindfulness; SCNTF Treatment as usual Duration: 8 weeks
Frequency: weekly
Length of sessions: 2.5 hours (plus 7-hour
retreat)
Face to face (group); VA medical
centre; professional instructors with
mental health backgrounds










Length of sessions: 8 hours
Face to face (group); PTSD outpatient
clinic (for veterans); therapists with a




Internet-based CBT TFCBT; SCTF Waitlist Duration: 5 weeks
Frequency: twice a week
Length of sessions: not fixed



















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)




IPT IPT; SCNTF Waitlist Duration: 16 weeks
Frequency: weekly
Length of sessions: 2 hours







TFCBT; MCTF Waitlist Duration: 4 weeks
Frequency: NR
Length of sessions: 1.5 hours, 8.5 mean
total sessions







TFCBT; MCTF Delayed treatment Duration: 4–6 weeks
Frequency: twice a week
Length of sessions: 60 minutes, 8–11 total
sessions
Face to face, individual; setting NR;
professionals included clinical
psychologist, advanced degree nurses,
master’s in counselling psychology,
victim witness advocate, baccalaureate
degree and several years of experience





Biofeedback; NA Treatment as usual Duration: 3 weeks
Frequency: twice a week
Length of sessions: 20 minutes
Face to face (individual) via computer;








Treatment as usual Duration: 52 weeks
Frequency: weekly
Length of sessions: 2.25 hours
Face to face (group); outpatient mental








CBT for insomnia with
imagery rehearsal
therapy




Length of sessions: 60 minutes; four
individual sessions, with break between
second and third sessions









































Intensity (duration, frequency and
length of sessions)








Length of sessions: 2 hours for first seven
sessions, 1.5 hours for final seven sessions
Face to face, individual; setting NR;
psychologists and master’s-level clinical
social workers




Length of sessions: 2 hours for first seven





TFCBT; SCTF Waitlist Duration: 10 weeks
Frequency: up to twice a week, closer to
weekly
Length of sessions: NR




IPT IPT; SCNTF Waitlist Duration: 3 weeks
Frequency: twice a week
Length of sessions: NR
Face to face; private rooms of
community-based support organisation;
members of Sudanese community





TFCBT; SCTF Minimal attention Duration: 5 weeks
Frequency: twice a week
Length of sessions: NR
Face to face; setting NR; therapist with
training on manualised CBT treatment





NTFCBT; SCNTF Treatment as usual Duration: 4 consecutive weeks
Frequency: weekly
Length of sessions: four sessions, one hour
Face to face/group/individual; specialist


















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)




NET TFCBT; SCTF Monitoring Duration: 3 weeks
Frequency: twice a week
Length of sessions: 2 hours
Face to face; setting NR; lay
counsellors without mental health
background
Trauma counselling TFCBT; SCTF Duration: 3 weeks
Frequency: twice a week
Length of sessions: 2 hours
Neuner et al.
(2004)114
NET TFCBT; SCTF Psychoeducation Duration: 3 weeks
Frequency: four sessions in 3 weeks
Length of sessions: 90 minutes (up to
120 minutes in exceptional circumstances)
Face to face (individual); setting NR;
doctoral-level psychologists or
graduate students with experience in
other therapies (e.g. counselling)
Supportive counselling TFCBT; SCTF Duration: 3 weeks
Frequency: four sessions in 3 weeks
Length of sessions: 90 minutes (up to
120 minutes in exceptional circumstances)
Niles et al. (2012)115 Mindfulness Mindfulness; SCNTF Psychoeducation Duration: 8 weeks
Frequency: weekly
Length of sessions: 45 minutes in-person
sessions, 20 minutes telephone sessions
Remotely (individual); mostly
home-based; two female clinicians




CPT for sexual abuse TFCBT; SCTF Minimal attention Duration: 17 weeks
Frequency: NR
Length of sessions: NR
Face to face, individual and group;








































Intensity (duration, frequency and
length of sessions)




CBT TFCBT; SCTF Minimal attention Duration: 4–5 months
Frequency: weekly
Length of sessions: NR
Face to face, individual; setting NR;
clinical psychology doctoral student
Exposure-only therapy Exposure only; SCTF Duration: 4–5 months
Frequency: weekly
Length of sessions: 20 minutes
Polusny et al.
(2015)120
MBSR Mindfulness; SCNTF Duration: 9 weeks
Frequency: weekly
Length of sessions: 2.5 hours
Face to face, group; VA medical centre;
instructors and doctoral-level clinicians













Length of sessions: 1.5 hours
Face to face individual/group; VA
medical centre; physicians expert in



















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)




Virtual reality exposure TFCBT; SCTF Duration: NR
Frequency: NR
Length of sessions: 90 minutes,
10 sessions
Face to face, individual; setting NR;
professional NR








Forgiveness therapy Other psychotherapy;
SCNTF
Alternative therapy Duration: 5–12 months
Frequency: weekly
Length of sessions: 1 hour, average
duration 7.95 months
Face to face, individual; setting NR;
trained psychiatric nurse
Reger et al. (2016)126 Virtual reality exposure TFCBT; SCTF Waitlist Duration: 5 weeks
Frequency: weekly or twice weekly
Length of sessions: 1.5–2 hours,
10 sessions in total
Face to face (individual); army military
installation; doctoral-level clinicians
PE TCBT; SCTF Duration: 5 weeks
Frequency: weekly or twice weekly
Length of sessions: 1.5–2 hours,








































Intensity (duration, frequency and
length of sessions)






TFCBT; SCTF Duration: NR
Frequency: twice a week
Length of sessions: 90 minutes,
12 sessions in total
Face to face, group; setting NR; civilian
therapists with mental health
background
Present-centred therapy Other psychotherapy;
SCNTF
Duration: NR
Frequency: twice a week
Length of sessions: 90 minutes,
12 sessions in total
Rogers et al.
(1999)130
EMDR EMDR; SCTF Duration: one session
Frequency: once
Length of sessions: 60–90 minutes
Face to face, individual; setting NR;




Exposure only; SCTF Duration: one session
Frequency: once
Length of sessions: 60–90 minutes
Sikkema et al.
(2007)131
HIV and trauma coping
group
NTFCBT; SCNTF Waitlist Duration: 15 weeks
Frequency: weekly
Length of sessions: 90 minutes
Face to face; community clinics; clinical
psychologists/clinical social workers
Support group NTFCBT; SCNTF Duration: 15 weeks
Frequency: weekly


















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)




Coping skills programme NTFCBT; SCNTF HIV support group Duration: 15 weeks
Frequency: weekly
Length of sessions: 90 minutes
Face to face (group); community health




NET TFCBT; SCTF Treatment as usual Duration: 10 weeks
Frequency: weekly
Length of sessions: 90 minutes




therapists, clinical social workers





Length of sessions: 1 hour
Face to face (individual); VA hospital;
master’s-level clinicians
Ter Heide et al.
(2011)138
EMDR EMDR; SCTF Duration: 11 weeks
Frequency: weekly
Length of sessions: 90 minutes
(60 minutes dedicated to EMDR)
Face to face, individual; centre for
psychotrauma; psychotherapists,
psychiatrist, health-care psychologists
Stabilisation EMDR; SCNTF Duration: 11 weeks
Frequency: weekly
Length of sessions: 60 minutes




Ter Heide et al.
(2016)139
EMDR EMDR; SCTF Duration: 9 weeks
Frequency: NR
Length of sessions: 12 hours overall
Face to face (individual); treatment
centre for CPTSD; clinical
psychologists and psychotherapists
Stabilisation as usual Stabilisation; SCNTF Duration: 9 weeks
Frequency: NR








































Intensity (duration, frequency and
length of sessions)






TFCBT; MCTF Usual care Duration: 12 weeks
Frequency: fortnightly
Length of sessions: 1 hour




Mindfulness meditation Mindfulness; SCNTF Sitting quietly Duration: 6 weeks
Frequency: weekly
Length of sessions: 20 minutes
Face to face and remote, individual;





Biofeedback; SCNTF Duration: 6 weeks
Frequency: weekly
Length of sessions: 20 minutes








CBT and group therapy
(physiotherapy and
exercises)
TFCBT; MCTF Waitlist Duration: 10 weeks
Frequency: twice a week
Length of sessions: group sessions 60–90
minutes, individual sessions 90 minutes
(60 minutes for CBT intervention, 15- to
20-minute period of breathing training
using a biofeedback device, 10–15
minutes for reviewing and note taking)
Face to face (individual and group);
rehabilitation centre (for torture
victims); therapists and



















































































































































































































































































































































































































































Intensity (duration, frequency and
length of sessions)
Delivery (method, setting and type of
professional)
Weiss et al. (2015),
trial 1: CETA144
CETA TFCBT; MCTF Waitlist Duration: 8–12 weeks
Frequency: weekly
Length of sessions: 50–60 minutes,
8–12 sessions in total
Face to face, individual; community;
community mental health workers
Weiss et al. (2015),
trial 2: CPT144
CPT TFCBT; SCTF Waitlist Duration: 12 weeks
Frequency: weekly
Length of sessions: NR
Face to face, individual; community;







Waitlist Duration: 4 days
Frequency: 3 consecutive days and
1-month follow-up
Length of sessions: day long
Face to face, group; community; local







Frequency: 3 consecutive days and
1-month follow-up
Length of sessions: day long
Zlotnick et al.
(1997)146
Affect management Waitlist Duration: 15 weeks
Frequency: weekly
Length of sessions: 2 hours
Face to face (group); setting NR;
therapist with mental health
background
CETA, common elements treatment approach; CPT, cognitive processing therapy; MCTF, multicomponent trauma-focused; MCNTF, multicomponent non-trauma-focused; MFCC, Marriage,
Family and Child Counsellor; NTFCBT, non-trauma-focused CBT; PE, prolonged exposure; SCNTF, single-component non-trauma-focused; SCTF, single-component trauma-focused;



















































Rivastigmine augmented therapy of
citalopram and sodium valproate
Duration: 12 weeks
Frequency: twice a day
Dose: Weeks 1–4 1.5 mg twice a day,
Week 5 3mg twice a day in addition to





Risperidone Antipsychotic Placebo First 4 weeks delivered in conjunction
with an inpatient psychosocial
programme. The remainder of the




Dose: initiated at 1 mg, increased to 3 mg




Bupropion SR Antidepressant Placebo Duration: 8 weeks
Frequency: once or twice a day
Dose: 100 mg/day for 2 weeks. Dose
increased to 100mg twice a day as
indicated. No significant improvement at
4 weeks resulted in a maximum dose of
150 mg twice a day
Celik et al.
(2011)65
Paroxetine SSRI/antidepressant Duration: 8 weeks
Frequency: once a day
Dose: initiated at 10 mg/day for Week 1,
then increased to 20mg for Weeks 2 and
3, 30 mg for Weeks 4 and 5, 40 mg for
Weeks 6 and 7 and 60mg for Weeks
8–12 (if tolerated/clinically indicated)
Amitriptyline Antidepressant Duration: 8 weeks
Frequency: once a day
Dose: initiated at 75mg/day for Weeks 1–3
(initial dose of 25mg for Days 1–3, 50mg
for Days 4–7 and 75mg for Days 8–21),
then increased to 100mg from Week 4
(as necessary) and up to 200mg or down
to 75mg from Week 5 (as necessary)
continued
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category Control(s) Intensity (duration, frequency and dose)
Chung et al.
(2004)67
Mirtazapine Antidepressant Duration: 6 weeks
Frequency: daily
Dose: initiated at mean dose of
19.1 ± 8.53 mg/day, Weeks 1–2
31.5 ± 9.13 mg/day, Weeks 2–6
38.5 ± 12.10 mg/day
Sertraline SSRI/antidepressant Duration: 6 weeks
Frequency: daily
Dose: initiated at 58.2 ± 24.15 mg/day,
Weeks 1–2 89.8± 23.89 mg/day and
Weeks 2–6 115.3 ± 36.02 mg/day




Nefazodone Antidepressant Placebo Duration: 12 weeks
Frequency: twice a day
Dose: initiated at 100 mg, increased
by 100mg every 4 days as tolerated,




Divalproex Anticonvulsant Placebo Duration: 8 weeks
Frequency: twice a day
Dose: initiated at 500 mg twice a day,
increased by 500mg as tolerated to a
maximum of 3000 mg/day
Friedman et al.
(2007)82
Sertraline SSRI/antidepressant Placebo Duration: 12 weeks
Frequency: daily
Dose: initiated at 25 mg/day, Week 2
increased dose to 50 mg/day where
dose-limiting adverse events did not
present. Subjects who failed to respond
received titrated weekly increment of
50 mg up to a maximum of 200 mg/day
Germain et al.
(2012)84
Prazosin Prazosin Placebo Duration: 8 weeks
Frequency: daily
Dose/length of sessions: initiated at 1 mg,
increasing over the following weeks to
2 mg, 4 mg, 6 mg, 10 mg and 15mg. Final
mean dose 8.9 mg
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Dose: initiated at 1 mg/day, increased to a









Dose: initiated at 1 mg at night. Increased
by 1mg/week to 3mg. After 4 weeks, a
further 1 mg increase could be made if
tolerated and clinically indicated
Lindley et al.
(2007)104
Topiramate Anticonvulsant Placebo Duration: 7 weeks
Frequency: daily
Dose: initiated at 25 mg, increased by




Risperidone Antipsychotic Placebo Duration: 6 weeks
Frequency: daily
Dose: initiated at 0.5 mg, increased
fortnightly to maximum 2mg/day
Naylor et al.
(2013)112
Paroxetine SSRI/antidepressant Placebo Duration: 12 weeks
Frequency: daily
Dose: flexible dosing 10–40mg/day










Dose/length of sessions: sertraline
initiated at 25 mg, titrated 50mg each




Sertraline SSRI/antidepressant Placebo Duration: 10 weeks
Frequency: daily
Dose: initiated at 50 mg/day, flexible
adjustment fortnightly to a maximum of
200mg/day
continued
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category Control(s) Intensity (duration, frequency and dose)
Raskind et al.
(2007)122
Prazosin Prazosin Placebo Duration: 8 weeks
Frequency: daily
Dose: initiated at 1 mg/nightly for 3 days.
Days 3–7 increased to 2 mg/day based
on response. Persistence of traumatic
nightmares increased dose to 2 mg per
week up to 10mg/day at Day 28.
Persistent lack of response allowed
additional 5mg to a maximum of 15mg/day.
Mean daily dose of prazosin was 13 (3)mg
and of placebo capsules was 14 (2)mg
Raskind et al.
(2013)123
Prazosin Prazosin Placebo Duration: 15 weeks
Frequency: once or twice daily
Dose: titrated 1–2mg/day, depending
on gender. Week 2: males (AM 1mg, PM
4mg), females (AM 1mg, PM 2mg);
Week 3: males (AM 2mg, PM 6mg),
females (AM 1mg, PM 2mg); Week 4:
males (AM 2mg, PM 10mg), females
(AM 2mg, PM 6mg); Week 5: males
(AM 5mg, PM 15mg), females (AM 2mg,
PM 10mg); Week 6: males (AM 5mg,
PM 20mg), females (AM 2 mg, PM 10 mg)
Reich et al.
(2004)127
Risperidone Antipsychotic Placebo Duration: 8 weeks
Frequency: daily (can be divided into two
or three doses)
Dose: initiated at 0.5 mg/day, increased to
1 mg/day at 3 days, then increased by
1mg/day for 1 week up to target dose of
4 mg/day until symptom relief reported.
Dosage increased to maximum of 8mg/day
if lack of response by Week 5
Smajkic et al.
(2001)133
Paroxetine SSRI/antidepressant Duration: 6 weeks
Frequency: daily
Dose: 20 mg once daily for 14 days then,
if tolerated at 2 weeks, the dosage was
continued
Sertraline SSRI/antidepressant Duration: 6 weeks
Frequency: daily
Dose: 50 mg once daily for 14 days then,
if tolerated at 2 weeks, 100 mg once daily
Venlafaxine Antidepressant Duration: 6 weeks
Frequency: twice a day
Dose: 37.5 mg twice daily for 14 days
then, if tolerated at 2 weeks, 75 mg
twice daily
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Antipsychotic Placebo Adjunctive olanzapine for subjects




Dose: initiated at 10 mg, increased to




Fluoxetine SSRI/antidepressant Placebo Duration: 5 weeks
Frequency: daily
Dose: initiated at 20 mg/day, increased
weekly to a maximum of 60mg
Zohar et al.
(2002)147
Sertraline SSRI/antidepressant Placebo Duration: 10 weeks
Frequency: daily
Dose: initiated at 50 mg/day, flexible
titration in 50 mg increments fortnightly
up to a maximum of 200mg
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TABLE 30 Intervention characteristics for randomised controlled studies included comparing combined psychological and pharmacological interventions
Authors (year) Intervention(s) Intervention categories Control(s)
Intensity (duration, frequency and
strength of dose/length of sessions)









Waitlist Duration: 6 months
Frequency: psychoeducation and CBT
weekly, sertraline daily
Dose/length of sessions: 10 consultations
and 16 sessions of CBT
Sertraline increased by 25–50mg to a
maximum dose of 200 mg. Mianserin
given at 10–30mg, titrated weekly by
10mg
Face to face; mental health clinic;


















Frequency: group therapy twice weekly,
tianeptine daily
Dose/length of sessions: 37.5 mg/day,
NR for group therapy
Face to face; setting NR; psychiatrist
and psychologist with mental health
backgrounds






Frequency: group therapy twice weekly,
fluoxetine daily
Dose/length of sessions: 40 mg/day,





































Authors (year) Intervention(s) Intervention categories Control(s)
Intensity (duration, frequency and
strength of dose/length of sessions)













Dose/length of sessions: dose of drug and
length of sessions NR. Mean maximal dose
68± 20mg
Face to face; setting NR; master’s-level
psychologist with mental health








Dose/length of sessions: dose of drug and
length of sessions NR. Mean maximal dose
225 ± 55mg







Frequency: CBT NR, sertraline daily
Dose/length of sessions: CBT 10 sessions,
length NR
Sertraline initiated at 25 mg, titrated by
50mg each week to a maximum of
200mg. Mean final dose 100mg/day















































































































































































































































































































































































































































TABLE 30 Intervention characteristics for randomised controlled studies included comparing combined psychological and pharmacological interventions (continued )
Authors (year) Intervention(s) Intervention categories Control(s)
Intensity (duration, frequency and
strength of dose/length of sessions)












Dose/length of sessions: introductory
session, five therapeutic sessions,
90 minutes each
D-cycloserine delivered at 50 mg
30 minutes before exposure
Face to face; setting NR; doctoral-level
clinicians with a mental health








Dose/length of sessions: introductory
session, five therapeutic sessions,
90 minutes each
Alprazolam delivered at 0.25 mg





































Authors (year) Intervention(s) Intervention categories Control(s)
Intensity (duration, frequency and
strength of dose/length of sessions)




Venlafaxine and CBT Antidepressant and
TFCBT
Duration: 20–24 weeks
Frequency: venlafaxine daily, CBT weekly
Dose/length of sessions: 10 sessions
with a psychiatrist, 16 sessions with a
psychologist
Venlafaxine initiated at 37.5–75 mg/day,
increased weekly by 37.5–75mg for
6 weeks. Rest of trial, monthly increases
up to a maximum of 375 mg
Face to face; psychiatry centre;
psychiatrist
Sertraline and CBT SSRI/antidepressant and
TFCBT
Duration: 20–24 weeks
Frequency: venlafaxine daily, CBT weekly
Dose/length of sessions: 10 sessions
with a psychiatrist, 16 sessions with a
psychologist
Sertraline initiated at 25–50mg/day,
increased weekly by 25–50mg for
6 weeks. Rest of trial, monthly















































































































































































































































































































































































































































Appendix 5 Population characteristics of
included randomised controlled trials
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
213













Refugee Turkey/Syria I= 35.27 (13.21), C= 37.92 (9.06) 24.14 NR NR NR No
Acarturk et al.
(2016)54
Refugee Turkey/Syria I= 33.32, C= 34.04 26 NR Syrian refugees (100%) NR Yes
Adenauer et al.
(2011)55














Veterans Iran I= 50.08 (4.5), Placebo= 51.5 (6.4),
No intervention= 49.08 (6.13)






War affected Iran Range: I= 35–45 (57.1%),
46–55 (35.8%), 56–60 (7.1%);
C= 35–45 (35.7%), 46–55 (64.3%)





Veteran USA 51.6 (4.2) 100 White (n= 44),





Veteran USA 50.39 (7.46) 79 African American (64%),
white (29%), other (7%)
War trauma (50%), domestic
violence (7%), rape (3.5%),
motor vehicle accident (7%),
homicide (7%), medical illness
(11%), death/suicide of a
loved one (7%), childhood




Veteran USA I= 58.93, C= 59.76 100 White (100%) Veterans (100%) NR Yes (100%)
Bichescu et al.
(2007)61





















































BADT= 36.9 (12.4), CPT= 41.5
(13.7), C= 42.3 (12.5)
BADT= 43,
CPT= 42, C= 41











Refugee Denmark Medication+ psychoeducation+
CBT= 45 (10), medication+
psychoeducation= 43 (9),
CBT= 46 (8), waitlist= 47 (8)
59 NR Refugees (including those
who had experienced torture,
a refugee camp/asylum centre





















Veterans (100%) NR Yes (100%)
Celik et al.
(2011)65
Veteran Turkey I= 32.5 (4.7), C= 29.1 (7.4) NR NR Veterans (100%) On average, both







USA 32.77 (8.87) 0 African American (14%),
white (81.4%), Hispanic,


































































































































































































































































































































































































































































































abuse (100%): sexual and
physical abuse (48%), sexual




























The large majority also
experienced interpersonal
abuse as adults (including
domestic violence, sexual






















































































I= combat (96%), sexual
trauma (4%)













Veteran USA 55.2 (6.8) 98 NR Combat-related trauma (95%) NR Yes (100%)
Devilly et al.
(1998)74































Index traumas: adult sexual
assault (47.6%), domestic
violence (23.8%), child sexual










































































































































































































































































































































































































































































Mixed Croatia Median= 48 (range 37–60) 100 NR Veterans with combat
experience from the
















Veteran USA I= 45, C= 46 I= 79, C= 81 White: I= 67%, C= 75% Primary exposure: being in
war or combat (I=men
85.3%, women 11.1%;
C=men 88.1%, women 6.3%),
physical or sexual assault
(I=men 2.9%, women 66.7%;



















Veteran USA BSI= 40 (14.1), prazosin= 39.4

















































































I= 3.7 (SD 1.6),






















of family or friends (65.1%),
witnessed rotten corpses










physical injury from combat/






























































































































































































































































































































































































































































Veteran Germany I= 29 (7.62), C= 28.8 (3.4) 100 NR Soldiers (100%) NR NR
Hinton et al.
(2004)90
Refugee USA NR I= 50, C= 50 Vietnamese (100%) Refugees (100%). All men
were ex-political detainees
(former Southern Vietnamese






Refugee USA I= 50.9 (6.11), C= 52.7 (7.43) I= 40, C= 40 Cambodian refugees Cambodian refugees living in
the USA (100%)
NR Yes (100%)
































































































(HR= 82%, PE= 82%,
PC= 94%)
Domestic violence (HR= 76%,
PE= 71%, C= 65%)
Child abuse (HR= 100%,
PE= 59%, C= 82%)
Adult abuse (HR= 71%,






















28.1 (7.43) 28 Iraqi War related (including bomb












































































































































































































































































































































































































































































I=mean of 6.8 (SD= 4.2),
different types of
interpersonal traumas
C=mean of 5.7 (SD= 3.5),
different types of
interpersonal traumas
Sexual trauma (97.1%, of
which 97.9% were before
12 years of age), physical





Veteran USA I= 54.2 (10.8), C= 54.5 (10.6) 96.6 Means (SD)
White (not Hispanic):
I= 84 (63.2), C= 93 (69.4)
Black (not Hispanic):
I= 25 (18.8), C= 25 (18.7)
Hispanic: I= 16 (12.0),
C= 11 (8.2)
Other: I= 8 (6), C= 5 (3.7)





USA 36.4 (9.1) 0 White (n= 18), Asian
(n= 10), Pacific Islander














(1.6%), other or mixed
ethnicity (13.6%)
All physically, sexually and/or
psychologically abused by
intimate romantic partner.
Physically hurt more than five
times (68%), physically hurt



















































Veteran USA Range: 18–25 (35.9%), 26–35
(33.3%), ≥ 36 (30.7%)




























Veteran USA I= 52.9 (0.7), C= 53.9 (0.4) 100 White (62.5%), African
American (17.5%),
Hispanic (16%), other (5%)

























































































































































































































































































































































































































































































CBT= life threat (34.5%),
injured (41.4%), penetrated
(72.4%), mean age at
onset= 6.1(2)
PCT= life threat (5%), injured
(31.8%), penetrated (59.1%),
mean age at onset= 7.6(2.8)
Waitlist= life threat (26.1%),
injured (27.3%), penetrated
(56.5%), mean age at
onset= 6.1(2.9)
CBT= childhood physical
abuse (82.8%), adult physical
abuse (58.6%), adult sexual
trauma (44.8%), mean number
of trauma types= 3.3 (1)
PCT= childhood physical
abuse (81.8%), adult physical
abuse (68.2%), adult sexual
trauma (63.6%), mean number
of trauma types= 3.1 (1.3)
Waitlist= childhood physical
abuse (73.9%), adult physical
abuse (60.9%), adult sexual
trauma (43.5%), mean number


















































Veteran USA I= 28 (range: 22–43), C= 28.8
(range: 21–45)
I= 90, C= 100 NR Active duty service members
with PTSD (100%)
I= shot (10%), ambush (20%),
improvised explosive device
blast (20%), mortar attack




device blast (30%), close
combat (10%), firefight (20%),






Refugee Egypt I= 31.3, C= 30.4 19 Sudanese Refugees (no further detail) NR Yes
Miyahira et al.
(2012)109





Veteran USA I= 48.9 (8.3), C= 53.5 (3.0) 100 White (80%), black
(13.3%), Hispanic (6.7%)









































































































































































































































































































































































































































































Veteran USA I= 39.21 (4.7), C= 35.86 (9.69) NR NR Combat-related (41.6%),
non-combat related with a
history of combat (41.6%) and














Refugee Uganda NET= 31.9 (6.7), supportive
counselling= 33.8 (7.9),
psychoeducation= 34.2 (6.9)
37 Sudanese Refugees (including those










13.1–14.5 types of traumatic
events in groups. Majority of





Veteran USA 52.0 (13.0) 100 White, not Hispanic
(76%, n= 25), black, not
Hispanic (15%, n= 5),
white, Hispanic (6%, n= 2)

















(100%). Sexual abuse events
reported: vaginal and/or anal
penetration, kissing, fondling























































Refugee Sweden 37.9 (7.6) 85 NR Refugees (100%). Experienced
more than one traumatic
event (70%). Primary
traumatic events (assumed to
be based on 16 completers):
torture= 6, combat= 6,
physical assault in civilian
life= 5, witnessing murder
of significant others= 4,
witnessing massacre= 3,
assault with weapon in
civilian life= 2, transportation
accident= 2, witnessing
physical assault in civilian
life= 2, witnessing assault
with weapon in civilian
life= 2, witnessing sudden
violent death= 2, witnessing
murder of strangers= 2,
death threats against
family= 2, threat of
torture= 1, sexual assault= 1,
exposure to toxic
substance= 1, death threats





Veteran USA I= 57.6 (10.4), C= 59.4 (9.2) MBSR= 79,
PCT= 90
MBSR=white (81%),
black (5%), other (4%),
mixed (10%)
PCT=white (86%),




I= combat exposure (68%),
sexual trauma (37%), physical
assault (68%), disaster




C= combat exposure (80%),
sexual trauma (19%), physical
assault (63%), disaster















































































































































































































































































































































































































































































Veteran USA I= 46.3 (16.4), C= 47.4 (16.2) 87.1 White (82.3%) Veterans NR Yes (48.4%)
Raskind et al.
(2007)122
Veteran USA 56 (9) 95 White (n= 26), African
American (n= 11),
Asian American (n= 1),
Hispanic (n= 1) and














Active duty soldiers returned
from Afghanistan and Iraq
(100%)
I=mean number of
deployments 2.6 (SD 4.0),
combat experiences scale
score 10.9 (SD 3.8)
C=mean number of
deployments 1.9 (SD 1.2),
combat experiences scale







Veteran USA Virtual reality exposure= 57 (range:
53–61), PCT= 58 (range: 55–62)
100 White (54.5%), African
American (45.5%)













ignoring (100%), threats of
abandonment (25%), threats
of personal harm (30%),
threats of harm to property
or pets (20%), sexual abuse
(30%: n= 5 ridicule followed
by demands for sexual
favours, n= 1 threats of
physical harm combined with


















































Veteran USA Virtual reality exposure= 29.52
(6.47), PE= 30.89 (7.09),
C= 30.39 (6.45)







USA I= 30.6, C= 24.2 0 White: I= 75%, C= 100%
African American:
I= 16.7%, C= 0%
Asian American: I= 8.3%,
C= 0%
Trauma related to childhood:
emotional (I= 66.7%,
C= 54.5%), verbal (I= 50%,
C= 77.8%), physical (I= 50%,
C= 44.4%), sexual abuse







(I= 25%, C= 11.1%)
Agoraphobia with
panic disorder
(I= 16.6%, C= 0%)
Agoraphobia without
panic disorder





(I= 25%, C= 0%)




(I= 8.3%, C= 0%)
Obsessive–
compulsive disorder







































































































































































































































































































































































































































































Active duty military with





Veteran USA Range: 47–53 100 NR Vietnam veterans (100%) NR Yes (100%)
Rothbaum et al.
(2014)129
Veteran USA D-cycloserine+ PE= 34.9,
alprazolam+ PE= 36.2, C= 34.3
95 Black (50.6%), white
(41.6%), Hispanic (5%)








USA Female= 43.18 (6.99), male= 41.75
(6.99)





abuse. 62% of women and












USA 42.3 (6.8) 47 Overall: African American
(68%), Hispanic (17%),
white (10%)
Childhood sexual abuse NR Yes (40%)
Smajkic et al.
(2001)133
Refugee USA 51.34 (10.11) Venlafaxine= 100,
sertraline= 40,
paroxetine= 25



































































































Refugee Germany I= 34.5 (11.1), C= 36.6 (11.0) I= 67, C= 73 Region of origin:
I=Afghanistan (14%),





Iraq (23%), Middle East
(remaining countries)
(17%), Africa (26%), other
countries (17%)
Refugees and asylum seekers
with PTSD (100%). Mean
number of traumatic events:



















































































































































































































































































































































































































































































I= 43.1 (10.7), C= 39.8 (11.9) 69 The vast majority of
refugees came from Iraq,
Afghanistan or countries















I= 40 (9.31), C= 43 (7.93) I= 50, C= 70 Origin: Afghanistan (20%),
Algeria (5%), Bosnia
(20%), Iran (10%), Iraq
(30%), Lebanon (5%),
Turkey (5%)
Asylum seekers and refugees.
Experienced 10 separate
events, on average, including:
murder/unnatural death of






































































Veteran USA MM= 53.3 (12.6), SB= 52.2 (12.5),
MM+ SB= 50 (12.8), SQ= 53 (11.8)







Combat veterans with PTSD
(100%)
Combat exposure: MM= 24.1
(9.4), SB= 22.5 (8.5),
MM+ SB= 26.6 (10.3),
SQ= 25.8 (9.8)
Lifetime trauma (Life Events
Checklist): MM= 32.2 (7.8),
SB= 33.7 (5.7),














War affected Iraq I= 41.6 (11.3), C= 45.16 (11.1) Male: I= (67.7),
C= (32.3)
NR Survivors of systemic







War affected Iraq I= 40 (12.3), C= 41 (9.5) I= 67.4, C= 62.5 NR Survivors of systemic






























































































































































































































































































































































































































































War affected Burundi 38.6 (12.8) 65.6 Hutu (52.4%), Tutsi
(47.6%)
Witnessed: mixed (e.g. rape,
serious injury owing to
combat)
Experienced: combat (98.8%),
forced to hide (97.1%),
unnatural death of family
member (96.7%), lack of
food/water (95%), narrowly
escaping death (91.7%), lack
of shelter (90.4%), ill health
without medical care (86.2%),
loss of personal property
(81.9%), confined indoors
owing to danger (79.5%),
betrayed and placed at risk
of death (41.7%), serious
physical injury from combat
(35%), forced to hide among







USA 39 (9.59) 0 99% white (n= 1: Native
American)





Veteran Israel I= 41 (6), C= 38 (9) I= 83, C= 95 NR Veterans (100%) NR Yes (100%)
BATD, Behavioural Activation Treatment for Depression; BSI, Brief Symptom Inventory; CETA, common elements treatment approach; C, control; CPT, cognitive processing therapy; HR, holographic





































Appendix 6 Characteristics of included
non-randomised controlled studies
TABLE 32 Characteristics of the interventions in the non-randomised controlled studies of intervention effectiveness
included
Authors (year) Intervention(s) Control(s)
Intensity (duration,
frequency and strength of
dose/length of sessions)












Unclear for treatment as
usual group
Face to face (group); outpatient
veterans’ affairs clinic; doctoral-
and master’s-level clinicians












50 minutes, 25 hours total




CBT Duration: 24 weeks
Frequency: weekly
Dose/length of sessions: NR
Face to face (individual); army
PTSD treatment centre;
psychiatrists, clinical





Dose/length of sessions: NR
Lundqvist et al.
(2006)151
Group therapy Waitlist Duration: 2 years (phase 1,
5 months; phase 2, 4
months; phase 3, 1 year)
Frequency: twice a week
(phase 1), weekly (phase 2),
monthly (phase 3)
Dose/length of sessions: NR
Face to face (group); hospital
psychiatric outpatient unit;




Duration: 2 years (phase 1,
5 months; phase 2, 4
months; phase 3, 1 year)
Frequency: twice a week
(phase 1), weekly (phase 2),
monthly (phase 3)
Dose/length of sessions: NR
continued
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TABLE 32 Characteristics of the interventions in the non-randomised controlled studies of intervention effectiveness
included (continued )
Authors (year) Intervention(s) Control(s)
Intensity (duration,
frequency and strength of
dose/length of sessions)







No intervention Duration: 20 weeks
Frequency: weekly
Dose/length of sessions: NR








Face to face (individual); setting
NR; trained therapists






Olanzapine Duration: 6 weeks




Drug intervention; delivered by
hospital for PTSD; psychiatrists
Fluphenazine Duration: 6 weeks






Individual therapy No intervention Duration: 1 year
Frequency: weekly
Dose/length of sessions: NR
Face to face (individual); setting
NR; master’s-level social
workers and psychologists
Group therapy Duration: 1 year
Frequency: weekly
Dose/length of sessions: NR
Face to face (group); setting NR;
therapists with a baccalaureate
degree in psychology and social







Waitlist Duration: 20 weeks
Frequency: weekly
Dose/length of sessions: NR
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Appendix 7 Population characteristics of
included non-randomised controlled studies
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Veteran USA I = 60.1 (9.7),
C= 58.3 (8.3)
NR NR Veterans 65% of participants from the
treatment group and 76% from











Bosnian refugees (100%). Highly
stressful war-related events:
I = close to death (97%), forced
separation (82.3%), murder of family/
friends (70.6%), murder of strangers
(67.7%), physical torture (70.6%),
combat situation (50%), rape/sexual
abuse (41.2%), brainwashed (85.3%),
lack of food/water (67.7%), unnatural
death of friends (58.8%), lost/
kidnapped (64.7%), lack of medical
care (70.6%), no shelter (79.4%),
imprisoned (55.9%), serious injury
(70.6%), isolation (41.2%); number
of events 10.7 (SD 4.4)
C= close to death (100%), forced
separation (93.3%), murder of family/
friends (83.3%), murder of strangers
(83.3%), physical torture (93.4%),
combat situation (63.4%), rape/sexual
abuse (50%), brainwashed (96.7%),
lack of food/water (86.6%), unnatural
death of friends (80%), lost/kidnapped
(86.6%), lack of medical care (70%),
no shelter (96.7%), imprisoned (80%),
serious injury (90%), isolation (66.7%);



















































Veteran Israel I = 30.8 (11.4),
C= 33.4 (11.45)










C= 41 (range: 28–55)
0%
(100% female)










NR Childhood sexual abuse NR NR
Narimani et al.
(2008)153
War affected Iran Overall: 47.95 (5.07) NR Iranian
(100%)






Veteran Croatia I = 37.2 (4.5),
C= 38.1 (4.8)
100% NR Veterans All participants had comorbid
psychotic symptoms: 37 (68%)
had psychotic depression with
auditory hallucinations or auditory
and visual hallucinations; 18 (37%)












Former political prisoners (100%).
Most common experiences of
torture/ill treatment: different types
of beatings such as by gun or baton
(87.8%), psychological abuse such
as sham execution (75.5%); classic
torture methods less common:
burning with cigarettes (13.8%),









NR Childhood sexual abuse (incest) NR NR














































































































































































































































































































































































































































Appendix 8 Risk-of-bias gradings of included
randomised controlled trials
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FIGURE 26 Risk-of-bias ratings across the domains of the Cochrane tool for all included RCTs.
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Appendix 9 Summary tables of clinical
effectiveness analyses
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Effectiveness of psychological interventions across all populations
Post-traumatic stress disorder outcomes





Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
All SMD –0.90 (95% CI –1.14 to –0.66),
I2 = 85.3%, number of trials = 39, n= 2506
SMD –0.45 (95% CI –0.82 to –0.08),
I2= 79.4%, number of trials= 10, n = 738
SMD –0.35 (95% CI –0.72, 0.03),




SMD –1.09 (95% CI –1.44 to –0.75),
I2 = 86%, number of trials = 21, n= 1283
SMD –0.64 (95% CI –1.10 to –0.18),
I2= 44.9%, number of trials= 4, n= 206
– –
EMDR SMD –1.07 (95% CI –1.65 to –0.50),
I2 = 75.4%, number of trials = 7, n = 244
– SMD –0.15 (95% CI –0.62, 0.32),
I2 = 0%, number of trials = 2, n = 71
–
IPT SMD –1.41 (95% CI –1.97 to –0.85),
I2 = 0%, number of trials = 2, n= 66
– – –
Mindfulness SMD –0.26 (95% CI –0.55, 0.04),
I2 = 0%, number of trials = 3, n= 183
SMD –0.08 (95% CI –0.68, 0.52),




SMD –0.05 (95% CI –0.23, 0.13),
I2 = 0%, number of trials = 3, n= 548
SMD –0.02 (95% CI –0.25, 0.20),





SMD –1.16 (95% CI –1.52 to –0.81),
I2 = 86.2%, number of trials = 23, n= 1264
SMD –0.94 (95% CI –1.56 to –0.32),





SMD –0.73 (95% CI –1.11 to –0.35),





SMD –0.39 (95% CI –0.66 to –0.12),
I2 = 69.6%, number of trials = 11, n= 936
SMD –0.05, (95% CI –0.23, 0.14),
I2= 0%, number of trials= 5, n= 462
SMD –0.64 (95% CI –1.82, 0.53),




Effect size –1.13 (95% CI –1.54 to –0.73),






































Complex post-traumatic stress disorder outcomes






End of treatment Follow-up after < 6 months End of treatment Follow-up after < 6 months
Emotional
dysregulation
All SMD –0.38 (95% CI –0.88 to 0.12),
I2= 74.5%, number of trials = 7, n= 289
SMD –0.42 (95% CI –1.53 to 0.69),
I2= 72.3%, number of trials= 2, n= 51
– –
Trauma-focused CBT SMD –0.17 (95% CI –0.82 to 0.49),
I2= 60.6%, number of trials = 3, n= 103
SMD –0.42 (95% CI –1.53 to 0.69),




– – – –
Multicomponent and trauma-
focused interventions




SMD –0.04 (95% CI –0.41 to 0.33),
I2= 23.9%, number of trials = 4, n= 163
– – –
Phase-based interventions SMD –0.76 (95% CI –1.79 to 0.27),




All SMD –0.59 (95% CI –1.28 to 0.11),
I2= 61.9%, number of trials = 2, n= 94
– – –
Trauma-focused CBT – – – –
Single-component and
trauma-focused interventions
– – – –
Multicomponent and trauma-
focused interventions




– – – –
Phase-based interventions SMD –0.59 (95% CI –1.28 to 0.11),





















































































































































































































































































































































































































































End of treatment Follow-up after < 6 months End of treatment Follow-up after < 6 months
Negative
self-concept
All SMD 1.81 (95% CI 0.73 to 2.89),
I2= 90%, number of trials= 5, n= 215
– – –
Trauma-focused CBT SMD 2.22 (95% CI 0.75 to 3.70),





– – – –
Multicomponent and trauma-
focused interventions
SMD 2.93 (95% CI 2.40 to 3.45),





SMD 1.14 (95% CI 0.01 to 2.27),
I2= 72.6%, number of trials = 2, n= 70
– – –










































Post treatment Follow-up after < 6 months Post treatment
Follow-up after
< 6 months
All SMD –0.89 (95% CI –1.15 to –0.64),
I2= 81.3%, number of trials= 30, n= 1793
SMD –0.51 (95% CI –0.80 to –0.22),
I2 = 48%, number of trials = 9, n= 410
SMD –0.32 (95% CI –1.23 to 0.59),
I2= 47.8%, number of trials = 2, n= 72
–
Trauma-focused CBT SMD –0.91 (95% CI –1.31 to –0.51),
I2= 87.3%, number of trials= 14, n= 1042
SMD –0.72 (95% CI –1.43 to –0.01),
I2 = 56.6%, number of trials = 3, n = 104
– –
EMDR SMD –1.12 (95% CI –1.68 to –0.55),
I2 = 65.2%, number of trials= 5, n = 182
– SMD –0.32 (95% CI –1.23 to 0.59),
I2= 47.8%, number of trials = 2, n= 72
–
IPT SMD –1.17 (95% CI –1.71 to –0.62),
I2 = 0%, number of trials= 2, n = 66
– – –
Mindfulness SMD –0.43 (95% CI –0.73 to –0.13),
I2 = 0%, number of trials= 3, n = 186
SMD –0.41 (95% CI –0.79 to –0.02),
I2 = 0%, number of trials = 2, n = 109
– –
Non-trauma-focused CBT SMD –0.05 (95% CI –0.48 to 0.39),




SMD –1.14 (95% CI –1.54 to –0.74),
I2= 86.6%, number of trials= 17, n= 1034
SMD –0.85 (95% CI –1.42 to –0.29),




SMD –0.75 (95% CI –1.22 to –0.29),




SMD –0.48 (95% CI –0.72 to –0.25),
I2 = 42.0%, number of trials= 10, n = 594
SMD –0.30, (95% CI –0.56 to –0.04),
I2= 0%, number of trials= 5, n= 236
– –
Phase-based interventions Effect size –1.03 (95% CI –1.43 to –0.63),















































































































































































































































































































































































































































TABLE 37 Effectiveness of psychological interventions on anxiety outcomes for all trauma populations
Psychological interventions vs. control
Control Active control
Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
All SMD –0.81 (95% CI –1.18 to –0.46),
I2= 83.4%, number of trials= 13, n = 1136
– – –
Trauma-focused CBT SMD –0.60 (95% CI –1.01 to –0.19),
I2= 85.5%, number of trials= 8, n= 832
– – –
EMDR SMD –1.05 (95% CI –1.50 to –0.61),
I2= 9.2%, number of trials = 4, n= 102
– – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and trauma-focused
interventions
SMD –0.76 (95% CI –1.15 to –0.37),




SMD –0.85 (95% CI –1.60 to –0.10),




SMD –0.18 (95% CI –0.53 to 0.17),
I2= 26.9%, number of trials= 2, n= 225
– – –
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Sleep quality
TABLE 39 Effectiveness of psychological interventions on sleep quality outcomes for all trauma populations
Psychological interventions vs. control
Control Active control
Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
All SMD –1.00 (95% CI –1.49 to –0.51),
I2 = 28.8%, number of trials = 3, n= 111
– – –
Trauma-focused CBT SMD –1.30 (95% CI –1.87 to –0.73),
I2 = 0%, number of trials = 2, n= 59
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and trauma-focused interventions – – – –
Multicomponent and trauma-focused interventions – – – –
Single-component non-trauma-focused interventions – – – –





































Effectiveness of psychological interventions by trauma exposure
Veterans






Post treatment Follow-up after < 6 months Post treatment
Follow-up after
< 6 months
PTSD symptoms All SMD –0.48 (95% CI –0.72 to –0.24),
I2= 41.7%, number of trials = 14, n = 502
SMD –0.20 (95% CI –0.72 to 0.33),
I2= 63.1%, number of trials= 4, n= 180
SMD –0.44 (95% CI –0.98 to 0.10),
I2= 64%, number of trials = 4, n = 188
–
Trauma-focused CBT SMD –0.77 (95% CI –1.20 to –0.33),
I2= 44.6%, number of trials = 5, n= 199
– SMD –0.26 (95% CI –0.88 to 0.35),
I2= 51.1%, number of trials= 2, n= 126
–
EMDR SMD –0.58 (95% CI –1.00 to –0.16),
I2= 11.1%, number of trials = 4, n= 106
– – –
IPT – – – –
Mindfulness SMD –0.26 (95% CI –0.55 to 0.04),
I2= 0%, number of trials= 3, n = 186
SMD –0.08 (95% CI –0.68 to 0.52),








SMD –0.51 (95% CI –0.79 to –0.23),





SMD –1.05 (95% CI –1.80 to –0.30),





SMD –0.16 (95% CI –0.42 to 0.10),
I2= 0%, number of trials= 4, n = 244
SMD 0.01 (95% CI –0.36 to 0.36),





























































































































































































































































































































































































































































All SMD –0.56 (95% CI –0.84 to –0.28),
I2= 46.8%, number of trials= 11, n= 445
SMD –0.38 (95% CI –0.78 to 0.01),




SMD –1.02 (95% CI –1.72 to –0.32),
I2= 51%, number of trials= 3, n= 112
– – –
EMDR SMD –0.91 (95% CI –2.28 to 0.47),
I2= 77.7%, number of trials= 2, n = 44
– – –
IPT – – – –
Mindfulness SMD –0.43 (95% CI –0.73 to –0.13),
I2= 0%, number of trials= 3, n= 186
SMD –0.41 (95% CI –0.79 to –0.02),








SMD –0.87 (95% CI –1.50 to –0.24),





SMD –0.86 (95% CI –1.89 to 0.17),





SMD –0.33 (95% CI –0.61 to –0.05),
I2= 20.7%, number of trials= 5, n= 268
SMD –0.27 (95% CI –0.56 to 0.02),
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War-affected populations





Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
PTSD symptoms All SMD –0.46 (95% CI –0.68 to –0.25),
I2= 50.4%, number of trials= 8, n = 933
– – –
Trauma-focused CBT SMD –0.48 (95% CI –0.82 to –0.15),
I2= 74.8%, number of trials= 6, n = 713
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and
trauma-focused interventions
SMD –0.51 (95% CI –0.80 to –0.23),




SMD –0.41 (95% CI –0.80 to –0.02),




– – – –









































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
Depression symptoms All – – – –
Trauma-focused CBT SMD –0.48 (95% CI –0.82 to –0.15),
I2= 74.8%, number of trials= 6, n = 827
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and
trauma-focused interventions
SMD –0.47 (95% CI –0.89 to –0.05),




SMD –0.44 (95% CI –1.34 to 0.45),




– – – –
Phase-based interventions – – – –
Anxiety symptoms All – – – –
Trauma-focused CBT SMD –0.64 (95% CI –1.18 to –0.10),
I2= 90.4%, number of trials= 5, n = 691
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and
trauma-focused interventions
SMD –0.70 (95% CI –1.48 to 0.08),




SMD –0.52 (95% CI –1.53 to 0.50),




– – – –



















































































































































































































































































































































































































































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
PTSD
symptoms
All SMD –0.90 (95% CI –1.43 to –0.37),
I2= 89.6%, number of trials = 9, n= 687
SMD –0.27 (95% CI –0.71, 0.17),
I2= 53.6%, number of trials= 3, n= 323
– –
Trauma-focused CBT SMD –1.22 (95% CI –2.40 to –0.05),
I2= 90.3%, number of trials = 3, n= 153
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT SMD 0.01 (95% CI –0.20 to 0.21),




SMD –1.19 (95% CI –2.04 to –0.35),




– – – –
Single-component non-trauma-
focused interventions
SMD –0.54 (95% CI –1.05 to –0.03),
I2= 83.4%, number of trials = 5, n= 494
SMD –0.08 (95% CI –0.31 to 0.15),
I2= 0%, number of trials= 2, n= 295
– –









































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
Depression
symptoms
All SMD –0.82 (95% CI –1.10 to –0.55),
I2= 0%, number of trials = 5, n= 234
SMD –0.52 (95% CI –0.99 to –0.04),
I2= 0%, number of trials= 2, n= 76
– –
Trauma-focused CBT SMD –0.50 (95% CI –0.95 to –0.05),
I2= 0%, number of trials = 2, n= 79
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and trauma-
focused interventions
SMD –0.58 (95% CI –0.95 to –0.21),




– – – –
Single-component non-trauma-
focused interventions
SMD –0.92 (95% CI –1.36 to –0.48),
I2= 0%, number of trials = 2, n= 93
– – –
Phase-based interventions – – – –
Anxiety
symptoms
All – – – –
Trauma-focused CBT – – – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and trauma-
focused interventions
SMD –0.87 (95% CI –1.76 to 0.03),




– – – –
Single-component non-trauma-
focused interventions
– – – –




















































































































































































































































































































































































































































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
PTSD
symptoms
All SMD –1.84 (95% CI –2.18 to –1.49),
I2= 0%, number of trials= 6, n= 188
SMD –0.66 (95% CI –1.22 to –0.09),




SMD –2.12 (95% CI –2.71 to –1.53),
I2= 0%, number of trials= 3, n= 71
SMD –0.40 (95% CI –0.87 to 0.06),
I2= 40.1%, number of trials= 2, n= 165
– –
EMDR SMD –1.72 (95% CI –2.19 to –1.26),
I2= 0%, number of trials= 2, n= 99
– SMD –0.15 (95% CI –0.62 to 0.32),
I2= 0%, number of trials= 2, n= 71
SMD –0.15 (95% CI –0.80 to 0.49),
I2= 22.4%, number of trials= 2,
n= 71
IPT – – – –
Mindfulness – – – –
Non-trauma-focused
CBT




SMD –1.87 (95% CI –2.24 to –1.51),
I2= 0%, number of trials= 5, n= 170
SMD –0.67 (95% CI –1.65 to 0.32),









– – – –
Phase-based
interventions










































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
Depression
symptoms
All SMD –1.56 (95% CI –1.93 to –1.16),
I2= 0%, number of trials= 5, n= 148
SMD –0.73 (95% CI –1.57 to 0.10),




SMD –2.03 (95% CI –2.92 to –1.13),
I2= 0%, number of trials= 2, n= 31
SMD –0.73 (95% CI –1.57 to 0.10),
I2= 81.3%, number of trials= 2, n= 133
– –
EMDR SMD –1.46 (95% CI –1.90 to –1.01),
I2= 0%, number of trials= 2, n= 99
– SMD –0.32 (95% CI –1.23 to 0.59),
I2= 47.8%, number of trials= 2,
n= 72
SMD –0.01 (95% CI –0.47 to 0.45),
I2= 0%, number of trials= 2, n= 73
IPT – – – –
Mindfulness – – – –
Non-trauma-focused
CBT




SMD –1.57 (95% CI –1.97 to –1.17),
I2= 0%, number of trials= 4, n= 130
SMD –0.73 (95% CI –1.57 to 0.10),









– – – –
Phase-based
interventions




















































































































































































































































































































































































































































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
Anxiety
symptoms
All – – – –
Trauma-focused
CBT
– – – –
EMDR – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused
CBT












– – – –
Phase-based
interventions











































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
PTSD symptoms All – – – –
Trauma-focused CBT SMD –2.92 (95% CI –3.45 to –2.39),
I2 = 0%, number of trials = 2, n = 117
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and
trauma-focused interventions
– – – –
Multicomponent and
trauma-focused interventions
– – – –
Single-component non-trauma-
focused interventions
– – – –
Phase-based interventions – – – –
Depression
symptoms
All – – – –
Trauma-focused CBT SMD –3.24 (95% CI –4.40 to –2.09),
I2 = 66.6%, number of trials = 2, n = 117
– – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –



















































































































































































































































































































































































































































Post treatment Follow-up after < 6 months Post treatment Follow-up after < 6 months
Single-component and trauma-
focused interventions
– – – –
Multicomponent and trauma-
focused interventions
– – – –
Single-component non-trauma-
focused interventions
– – – –
Phase-based interventions – – – –
Anxiety symptoms All – – – –
Trauma-focused CBT – – – –
EMDR – – – –
IPT – – – –
Mindfulness – – – –
Non-trauma-focused CBT – – – –
Single-component and trauma-
focused interventions
– – – –
Multicomponent and trauma-
focused interventions
– – – –
Single-component non-trauma-
focused interventions
– – – –






































All studies included in analyses were conducted in veteran populations.
Post-traumatic stress disorder
Depression





Post treatment Follow-up after < 6 months
All – –
Antidepressants SMD –0.50 (95% CI –1.22 to 0.22), I2= 87%,
number of trials= 6, n= 338
–
SSRIs SMD –0.61 (95% CI –1.64 to 0.41), I2= 92.2%,
number of trials= 4, n= 293
–
Antipsychotics SMD –0.45 (95% CI –0.85 to –0.05), I2= 51.2%,
number of trials= 5, n= 365
–
Anticonvulsants SMD –0.16 (95% CI –0.77 to 0.45), I2= 45.5%,
number of trials= 2, n= 106
–
Prazosin SMD –0.52 (95% CI –1.03 to –0.02), I2= 41.4%,
number of trials= 3, n= 110
–





Post treatment Follow-up after < 6 months
All – –
Antidepressants SMD 0.07 (95% CI –0.20 to 0.34), I2 = 0%,
number of trials = 3, n = 220
–
SSRIs – –
Antipsychotics SMD –0.71 (95% CI –1.44 to 0.03), I2 = 58.3%,
number of trials = 2, n = 266
–
Anticonvulsants SMD 0.02 (95% CI –0.37 to 0.40), I2 = 0%,
number of trials = 2, n = 106
–
Prazosin SMD –0.37 (95% CI –1.21 to 0.47), I2 = 68.5%,
number of trials = 2, n = 76
–
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Psychosis






Post treatment Follow-up after < 6 months
PANSS-positive All – –
Antidepressants – –
SSRIs – –
Antipsychoticsa Mean difference –1.75 (95% CI –4.04 to 0.54),




PANSS-negative All – –
Antidepressants – –
SSRIs – –
Antipsychoticsa Mean difference 0.54 (95% CI –0.14 to 1.22),




PANSS: total All – –
Antidepressants – –
SSRIs – –
Antipsychoticsa Mean difference 0.04 (95% CI –2.08 to 2.16),









Antipsychoticsa Mean difference –0.18 (95% CI –1.39 to 1.03),




a All antipsychotics were risperidone.
APPENDIX 9
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Sleep quality











Prazosin SMD –0.73 (95% CI –1.12 to –0.34), I2 = 0%,
number of trials = 3, n = 109
–
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Appendix 10 Forest plots of results of
effectiveness meta-analyses
Psychological interventions versus control in all trauma populations
Post-traumatic stress disorder symptoms




Intervention (n) Control (n) ES (95% CI) Weight (%)
Favours control
Meffert (2014)108
Overall (I2 = 0.0%; p = 0.826)





– 1.37 (– 2.03 to – 0.71)
– 1.51 (– 2.58 to – 0.44)




FIGURE 27 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all IPT interventions
with control.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
11 8 –1.88 (–2.99 to –0.77) 3.78
Bolton (2014)62 101 66 –0.43 (–0.74 to –0.11) 5.86
Chard (2005)66 36 37 –2.33 (–2.93 to –1.73) 5.20
Franklin (2017)81 6 7 –1.05 (–2.22 to 0.13) 3.61
Hermenau (2013)86 15 15 –0.41 (–1.13 to 0.31) 4.85
Hinton (2005)89 20 20 –2.17 (–2.96 to –1.38) 4.67
Hinton (2004)90 6 6 –2.40 (–3.94 to –0.85) 2.77
Jung (2013)92 14 14 –0.83 (–1.61 to –0.06) 4.71
Keane (1989)94 11 31 –0.24 (–0.93 to 0.45) 4.95
Knaevelsrud (2015)96 79 80 –0.92 (–1.25 to –0.59) 5.83
Kubany (2003)100 18 14 –2.99 (–4.02 to –1.96) 3.99
Kubany (2004)101 45 40 –2.89 (–3.51 to –2.28) 5.16
Margolies (2011)105 15 12 –1.12 (–1.94 to –0.30) 4.58
McDonagh (2005)106 29 23 –0.50 (–1.06 to 0.06) 5.31
McLay (2011)107 10 9 –0.68 (–1.61 to 0.25) 4.27
Miyahira (2012)109 10 12 –0.50 (–1.35 to 0.35) 4.48
Reger (2016)126 30 47 –0.40 (–0.86 to 0.07) 5.54
Ulmer (2011)140 12 9 –1.81 (–2.85 to –0.77) 3.97
Wang (2016)143 13 15 0.01 (–0.74 to 0.75) 4.80
Weiss (2015) trial 1: CETA144 99 50 –0.70 (–1.05 to –0.35) 5.79
Overall (I2 = 86.0%; p = 0.000)
NOTE: weights are from random-effects analysis
124Weiss (2015) trial 2: CPT144 64 –0.26 (–0.56 to 0.05)
–1.09 (–1.44 to –0.75)
5.87
100.00
–3 –2 –1 0 1 32
Favours intervention Favours control
FIGURE 28 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all trauma-focused CBT
interventions with control. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
15 14 –1.70 (–2.56 to –0.84) 13.41
Acarturk (2016)54 37 33 –2.17 (–2.77 to –1.58) 15.91
Carlson (1997)64 10 10 –0.94 (–1.85 to –0.04) 12.94
Devilly (1998)74 12 10 –0.03 (–0.87 to 0.81) 13.58
Edmond (1999)76 20 19 –1.09 (–1.77 to –0.42) 15.15
Himmerich (2016)88
Overall (I2 = 75.4%; p = 0.000)





–0.47 (–1.12 to 0.18)
–1.00 (–1.84 to –0.17)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control




Intervention (n) Control (n) ES (95% CI) Weight (%)
25 22 –0.50 (–1.08 to 0.08) 26.26
Possemato (2016)121
Overall (I2 = 0.0%; p = 0.517)





–0.05 (–0.55 to 0.45)
–0.27 (–0.75 to 0.20)




– 2 – 1 0 1 2
Favours intervention Favours control
FIGURE 30 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all mindfulness
interventions with control.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
114 66 –0.25 (–0.64 to 0.14) 19.49
Engel (2015)78 29 29 0.13 (–0.38 to 0.65) 11.08
Sikkema (2007)131
Overall (I2 = 0.0%; p = 0.566)





0.09 (–0.27 to 0.45)
–0.03 (–0.28 to 0.22)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
FIGURE 31 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all non-trauma-focused
CBT interventions with control.
First author (year)
Acarturk (2015)53
Intervention (n) Control (n) ES (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 5.82
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 6.61
Adenauer (2011)55 11 8 –2.05 (–3.19 to –0.91) 4.67
Bolton (2014)62 101 66 –0.38 (–0.69 to –0.06) 7.24
Carlson (1998)64 10 11 –1.64 (–2.64 to –0.64) 5.12
Devilly (1998)74 13 10 –0.23 (–1.06 to 0.59) 5.71
Edmond (1999)76 20 19 –0.74 (–1.39 to –0.09) 6.31
Franklin (2017)81 6 7 –1.60 (–2.88 to –0.32) 4.25
Hinton (2004)89 6 6 –1.99 (–3.42 to –0.56) 3.83
Jung (2013)92 14 14 –0.49 (–1.25 to 0.26) 5.96
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 7.20
Kubany (2003)100 18 14 –3.97 (–5.19 to –2.75) 4.42
Kubany (2004)101 45 40 –2.77 (–3.37 to –2.17) 6.47
McDonagh (2005)106 29 22 –0.51 (–1.07 to 0.05) 6.58
Miyahira (2012)109 10 12 0.09 (–0.75 to 0.93) 5.67
Reger (2016)126
Overall (I2 = 86.6%; p = 0.000)
NOTE: weights are from random-effects analysis
30
124Weiss (2015) trial 2: CPT144
46
64
–0.56 (–1.03 to –0.09)
–0.28 (–0.59 to 0.02)




–3 –2 –1 0 1 32
Favours intervention Favours control
FIGURE 32 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all single-component
trauma-focused interventions with control. CPT, cognitive processing therapy.
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ES (95% CI) Weight (%)
36 37 –2.33 (–2.93 to –1.73) 13.02
Cloitre (2002)69 22 24 –1.30 (–1.93 to –0.66) 12.71
Himmerich (2016)88 21 17 –0.47 (–1.12 to 0.18) 12.64
Margolies (2011)105 15 12 –1.12 (–1.94 to –0.30) 11.32
Ulmer (2011)140 12 9 –1.81 (–2.85 to –0.77) 9.69
Wang (2016)143 13 15 0.01 (–0.74 to 0.75) 11.92
Weiss (2015) trial 1 CETA144
Overall (I2 = 83.5%; p = 0.000)





–0.70 (–1.05 to –0.35)
–0.28 (–0.73 to 0.17)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 33 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all multicomponent
trauma-focused interventions with control. CETA, common elements treatment approach.
First author (year)
Bolton (2014)62
Intervention (n) Control (n) ES (95% CI) Weight (%)
114 66 –0.25 (–0.64 to 0.14) 11.03
Engel (2015)78 29 29 0.13 (–0.38 to 0.65) 9.40
Kearney (2013)95 25 22 –0.50 (–1.08 to 0.08) 8.59
Krupnick (2008)98 32 16 –1.37 (–2.03 to –0.71) 7.69
McDonagh (2005)106 22 23 –0.89 (–1.50 to –0.28) 8.22
Meffert (2014)108 10 8 –1.51 (–2.58 to –0.44) 4.43
Possemato (2016)121 36 26 –0.05 (–0.55 to 0.45) 9.54
Sikkema (2007)131 73 48 0.09 (–0.27 to 0.45) 11.34
Sikkema (2013)132 124 123 –0.03 (–0.28 to 0.22) 12.74
Wahbeh (2016)142
Overall (I2 = 69.6%; p = 0.000)





–0.27 (–0.75 to 0.20)
–0.85 (–1.57 to –0.14)




–1.0 –0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 34 Meta-analysis of post-treatment effect size (ES) for PTSD total symptoms, comparing all single-component
non-trauma-focused interventions with control.
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SMD (95% CI) Weight (%)
9 12 –1.02 (–1.95 to –0.10) 26.51
Hermenau (2013)86
Overall (I2 = 60.6%; p = 0.079)





0.11 (–0.61 to 0.83)
0.17 (–0.38 to 0.72)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control








SMD (95% CI) Weight (%)
32 16 0.09 (–0.51 to 0.69) 27.52
McDonagh (2005)106 22 23 0.08 (–0.51 to 0.66) 28.61
Meffert (2014)108
Overall (I2 = 23.9%; p = 0.268)





–0.97 (–1.96 to 0.02)
0.09 (–0.46 to 0.63)




– 2 – 1 0 21
Favours intervention Favours control
FIGURE 36 Meta-analysis of post-treatment SMD for emotional dysregulation, comparing single-component and
non-trauma-focused interventions with control.
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Intervention (n) Control (n) SMD (95% CI) Weight (%)
14 14 0.76 (–0.01 to 1.53) 33.75
Kubany (2003)100
Overall (I2 = 90.4%; p = 0.000)





3.07 (2.03 to 4.12)
2.88 (2.27 to 3.49)




– 3 – 2 – 1 0 1 32
Favours interventionFavours control
FIGURE 37 Meta-analysis of post-treatment SMD for negative self-concept, comparing all trauma-focused CBT
interventions with control (positive SMD equals improvement in symptoms).
First author (year)
Kubany (2003)100
Intervention (n) Control (n) SMD (95% CI) Weight (%)
Kubany (2004)101
Overall (I2 = 0.0%; p = 0.753)





3.07 (2.03 to 4.12)
2.88 (2.27 to 3.49)




– 3 – 2 – 1 0 1 2 3
Favours interventionFavours control
FIGURE 38 Meta-analysis of post-treatment SMD for negative self-concept, comparing all multicomponent and
trauma-focused interventions with control (positive SMD equals improvement in symptoms).
First author (year)
Reed (2006)125
Intervention (n) Control (n) SMD (95% CI) Weight (%)
Wahbeh (2016)142
Overall (I2 = 72.6%; p = 0.056)





1.81 (0.75 to 2.87)
0.64 (0.07 to 1.21)




– 3 – 2 – 1 0 1 2 3
Favours interventionFavours control
FIGURE 39 Meta-analysis of post-treatment SMD for negative self-concept, comparing all single-component and
non-trauma-focused interventions with control (positive SMD equals improvement in symptoms).
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Intervention (n) Control (n) SMD (95% CI) Weight (%)
Krupnick (2008)98
Overall (I2 = 61.9%; p = 0.105)





–0.94 (–1.55 to –0.33)
–0.23 (–0.84 to 0.37)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control








ES (95% CI) Weight (%)
101 66 –0.38 (–0.69 to –0.06) 7.87
Chard (2005)66 36 37 –2.00 (–2.57 to –1.44) 7.12
Franklin (2017)81 6 7 –1.60 (–2.88 to –0.32) 4.54
Jung (2013)92 14 14 –0.49 (–1.25 to 0.26) 6.43
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 7.82
Kubany (2003)100 18 14 –3.97 (–5.19 to –2.75) 4.72
Kubany (2004)101 45 40 –2.77 (–3.37 to –2.17) 7.00
Margolies (2011)105 14 9 –1.40 (–2.33 to –0.46) 5.73
McDonagh (2005)106 29 22 –0.51 (–1.07 to 0.05) 7.12
Miyahira (2012)109 10 12 0.09 (–0.75 to 0.93) 6.10
Reger (2016)126 30 46 –0.56 (–1.03 to –0.09) 7.43
Ulmer (2011)140 12 9 –0.34 (–1.22 to 0.53) 5.98
Wang (2016)143 13 15 0.08 (–0.67 to 0.82) 6.47
Weiss (2015) trial 1: CETA144
Overall (I2 = 88.5%; p = 0.000)
NOTE: weights are from random-effects analysis
99
124Weiss (2015) trial 2: CPT144
50
64
–0.84 (–1.20 to –0.49)
–0.28 (–0.59 to 0.02)




–3 –2 –1 0 1 32
Favours intervention Favours control
FIGURE 41 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all trauma-focused CBT
interventions with control. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 19.29
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 24.11
Carlson (1997)64 10 11 –1.64 (–2.64 to –0.64) 15.74
Devilly (1998)74
Overall (I2 = 65.2%; p = 0.022)





–0.23 (–1.06 to –0.59)
–0.74 (–1.39 to –0.09)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control




Intervention (n) Control (n) ES (95% CI) Weight (%)
Meffert (2014)108
Overall (I2 = 0.0%; p = 0.524)





–1.06 (–1.70 to –0.42)
–1.46 (–2.52 to –0.40)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 43 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all IPT interventions
with control.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
25 22 –0.62 (–1.21 to –0.03) 26.14
Possemato (2016)121
Overall (I2 = 0.0%; p = 0.685)





–0.28 (–0.78 to 0.23)
–0.43 (–0.92 to 0.05)




– 1– 2 0 1 2
Favours intervention Favours control








ES (95% CI) Weight 
(%)
Teng (2008)137
Overall (I2 = 10.0%; p = 0.292)





0.13 (–0.39 to 0.64)
–0.33 (–0.99 to 0.34)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 45 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all non-trauma-focused
CBT interventions with control.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 5.82
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 6.61
Adenauer (2011)55 11 8 –2.05 (–3.19 to –0.91) 4.67
Bolton (2014)62 101 66 –0.38 (–0.69 to –0.06) 7.24
Carlson (1997)64 10 11 –1.64 (–2.64 to –0.64) 5.12
Devilly (1998)74 13 10 –0.23 (–1.06 to 0.59) 5.71
Edmond (1999)76 20 19 –0.74 (–1.39 to –0.09) 6.31
Franklin (2017)81 6 7 –1.60 (–2.88 to –0.32) 4.25
Hinton (2004)89 6 6 –1.99 (–3.42 to –0.56) 3.83
Jung (2013)92 14 14 –0.49 (–1.25 to 0.26) 5.96
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 7.20
Kubany (2003)100 18 14 –3.97 (–5.19 to –2.75) 4.42
Kubany (2004)101 45 40 –2.77 (–3.37 to –2.17) 6.47
McDonagh (2005)106 29 22 –0.51 (–1.07 to 0.05) 6.58
Miyahira (2012)109 10 12 0.09 (–0.75 to 0.93) 5.67
Reger (2016)126
Overall (I2 = 86.6%; p = 0.000)
NOTE: weights are from random-effects analysis
30
124Weiss (2015) trial 2: CPT144
46
64
–0.56 (–1.03 to –0.09)
–0.28 (–0.59 to 0.02)




–3 –2 –1 0 1 32
Favours intervention Favours control
FIGURE 46 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all single-component
and trauma-focused CBT interventions with control. CPT, cognitive processing therapy.
First author (year)
Chard (2005)66
Intervention (n) Control (n) ES (95% CI) Weight (%)
36 37 –2.00 (–2.57 to –1.44) 18.09
Cloitre (2002)69 22 24 –1.22 (–1.85 to –0.59) 17.31
Margolies (2011)105 14 9 –1.40 (–2.33 to –0.46) 13.78
Ulmer (2011)140 12 9 –0.34 (–1.22 to 0.53) 14.52
Wang (2016)143
Overall (I2 = 79.4%; p = 0.000)
NOTE: weights are from random-effects analysis
13
99Weiss (2015) trial 1: CETA144
15
50
0.08 (–0.67 to 0.82)
–0.84 (–1.20 to –0.49)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 47 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all multicomponent and
trauma-focused interventions with control. CETA, common elements treatment approach.
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Intervention (n) Control (n) ES (95% CI) Weight (%)
114 66 –0.28 (–0.58 to 0.03) 17.83
Engel (2015)78 29 29 0.13 (–0.39 to 0.64) 11.46
Kearney (2013)95 25 22 –0.62 (–1.21 to –0.03) 9.84
Krupnick (2008)98 32 16 –1.06 (–1.70 to –0.42) 8.86
McDonagh (2005)106 22 23 –0.78 (–1.39 to –0.18) 9.43
Meffert (2014)108 10 8 –1.46 (–2.52 to –0.40) 4.13
Moradi (2014)111 12 12 –0.72 (–1.55 to 0.11) 6.13
Possemato (2016)121 36 26 –0.28 (–0.78 to 0.23) 11.66
Teng (2008)137
Overall (I2 = 42.0%; p = 0.078)





–0.33 (–0.99 to 0.34)
–0.43 (–0.92 to 0.05)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
FIGURE 48 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing all single-component
and non-trauma-focused interventions with control.
First author (year)
Carlson (1997)64
Intervention (n) Control (n) ES (95% CI) Weight (%)
10 11 –1.39 (–2.36 to –0.43) 19.71
Devilly (1998)74 13 10 –0.43 (–1.27 to 0.40) 25.66
Edmond (1999)76
Overall (I2 = 9.2%; p = 0.347)





–1.35 (–2.05 to –0.65)
–0.99 (–1.96 to –0.02)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
FIGURE 49 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing EMDR interventions
with control.
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ES (95% CI) Weight (%)
101 66 –0.25 (–0.56 to 0.06) 12.81
Carlson (1997)64 10 11 –1.39 (–2.36 to –0.43) 7.58
Devilly (1998)74 13 10 –0.43 (–1.27 to 0.40) 8.56
Edmond (1999)76 20 19 –1.35 (–2.05 to –0.65) 9.67
Franklin (2017)81 6 7 –1.39 (–2.63 to –0.16) 5.87
Jensen (1994)91 11 8 –0.99 (–1.96 to –0.02) 7.55
Knaevelsrud (2015)96 79 80 –1.55 (–1.90 to –1.19) 12.51
McDonagh (2005)106 29 22 –0.43 (–0.99 to 0.13) 10.86
Reger (2016)126
Overall (I2 = 81.5%; p = 0.000)
NOTE: weights are from random-effects analysis
30
124Weiss (2015) trial 2: CPT144
47
64
–0.14 (–0.59 to 0.32)
–0.33 (–0.63 to –0.03)




–3 –2 –1 0 1 2 3
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 50 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing single-component and
trauma-focused interventions with control. CPT, cognitive processing therapy.
First author (year)
Cloitre (2002)69
ES (95% CI) Weight 
(%)
22 24 –1.54 (–2.21 to –0.88) 31.74
Wang (2016)143
Overall (I2 = 80.4%; p = 0.006)
NOTE: weights are from random-effects analysis
13
99Weiss (2015) trial 1: CETA144
15
50
0.06 (–0.68 to 0.80)
–0.98 (–1.34 to –0.62)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 51 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing multicomponent and
trauma-focused interventions with control. CETA, common elements treatment approach.
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ES (95% CI) Weight (%)
McDonagh (2005)106
Overall (I2 = 26.9%; p = 0.242)





–0.07 (–0.37 to 0.24)
–0.46 (–1.06 to 0.13)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 52 Meta-analysis of post-treatment effect size (ES) for anxiety symptoms, comparing single-component and
non-trauma-focused interventions with control.
First author (year)
Knaevelsrud (2015)96
ES (95% CI) Weight (%)
79 80 0.84 (0.51 to 1.16) 31.60
McDonagh (2005)106 29 23 0.14 (–0.40 to 0.69) 26.42
Miyahira (2012)109
Overall (I2 = 73.9%; p = 0.009)





–0.23 (–1.08 to 0.61)
–0.12 (–0.84 to 0.60)




– 1.0 – 0.5 0 1.00.5
Favours control Favours intervention
Intervention (n) Control (n)
FIGURE 53 Meta-analysis of post-treatment effect size (ES) for quality of life, comparing trauma-focused CBT
interventions with control (positive ES favours intervention).
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ES (95% CI) Weight (%)
20 17 –1.23 (–1.94 to –0.52) 33.39
Ulmer (2011)140
Overall (I2 = 28.8%; p = 0.245)





–1.43 (–2.39 to –0.47)
–0.63 (–1.19 to –0.07)




– 3 – 2 – 1 0 21 3
Favours intervention Favours control
Intervention (n) Control (n)




ES (95% CI) Weight (%)
Ulmer (2011)140
Overall (I2 = 0.0%; p = 0.747)





–1.23 (–1.94 to –0.52)
–1.43 (–2.39 to –0.47)




– 3 – 2 – 1 0 1 2 3
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 55 Meta-analysis of post-treatment effect size (ES) for sleep quality, comparing trauma-focused CBT
interventions with control.
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Psychological interventions versus control in trauma subgroups
Veterans
Post-traumatic stress disorder symptoms
First author (year)
Franklin (2017)81
SMD (95% CI) Weight (%)
6 7 –1.05 (–2.22 to 0.13) 10.21
Keane (1989)94 11 31 –0.24 (–0.93 to 0.45) 19.81
Margolies (2011)105 15 12 –1.12 (–1.94 to –0.30) 16.44
McLay (2011)107 10 9 –0.68 (–1.61 to 0.25) 14.13
Reger (2016)126
Overall (I2 = 44.6%; p = 0.108)





–0.40 (–0.86 to 0.07)
–1.81 (–2.85 to –0.77)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 56 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing trauma-focused CBT
interventions with control in veteran populations.
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –0.94 (–1.85 to –0.04) 19.54
Devilly (1998)74 12 10 –0.03 (–0.87 to 0.81) 22.52
Himmerich (2016)88
Overall (I2 = 11.1%; p = 0.337)





–0.47 (–1.12 to 0.18)
–1.00 (–1.84 to –0.17)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 57 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing EMDR interventions with control
in veteran populations.
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SMD (95% CI) Weight (%)
25 22 –0.50 (–1.08 to 0.08) 26.26
Possemato (2016)121
Overall (I2 = 0.0%; p = 0.517)





–0.05 (–0.55 to 0.45)
–0.27 (–0.75 to 0.20)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 58 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing mindfulness interventions with
control in veteran populations.
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –0.94 (–1.85 to –0.04) 9.54
Devilly (1998)74 12 10 –0.03 (–0.87 to 0.81) 11.16
Franklin (2017)81 6 7 –1.05 (–2.22 to 0.13) 5.69
Jensen (1994)91 13 12 –1.00 (–1.84 to –0.17) 11.23
Keane (1989)94 11 31 –0.24 (–0.93 to 0.45) 16.51
McLay (2011)107
Overall (I2 = 0.0%; p = 0.515)





–0.68 (–1.61 to 0.25)
–0.40 (–0.86 to 0.07)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 59 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing single-component and trauma-
focused interventions with control in veteran populations.
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SMD (95% CI) Weight 
(%)
21 17 –0.47 (–1.12 to 0.18) 39.54
Margolies (2011)105
Overall (I2 = 59.4%; p = 0.085)





–1.12 (–1.94 to –0.30)
–1.81 (–2.85 to –0.77)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 60 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing multicomponent and
trauma-focused interventions with control in veteran populations.
First author (year)
Engel (2015)78
SMD (95% CI) Weight 
(%)
29 29 0.13 (–0.38 to 0.65) 25.10
Kearney (2013)95 25 22 –0.50 (–1.08 to 0.08) 19.67
Possemato (2016)121
Overall (I2 = 0.0%; p = 0.399)





–0.05 (–0.55 to 0.45)
–0.27 (–0.75 to 0.20)




– 1.0 – 0.5 0 1.00.5





FIGURE 61 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing single-component and
non-trauma-focused interventions with control in veteran populations.
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SMD (95% CI) Weight (%)
6 7 –1.60 (–2.88 to –0.32) 13.47
Margolies (2011)105 14 9 –1.40 (–2.33 to –0.46) 21.15
Reger (2016)126
Overall (I2 = 39.8%; p = 0.173)





–0.56 (–1.03 to –0.09)
–0.34 (–1.22 to –0.53)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 62 Meta-analysis of post-treatment SMD for total depression symptoms, comparing trauma-focused CBT
interventions with control in veteran populations.
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
Devilly (1998)74
Overall (I2 = 77.7%; p = 0.034)





–1.64 (–2.64 to –0.64)
–0.23 (–1.06 to 0.59)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 63 Meta-analysis of post-treatment SMD for total depression symptoms, comparing EMDR interventions with
control in veteran populations.
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SMD (95% CI) Weight (%)
25 22 –0.62 (–1.21 to –0.03) 26.14
Possemato (2016)121
Overall (I2 = 0.0%; p = 0.685)





–0.28 (–0.78 to 0.23)
–0.43 (–0.92 to 0.05)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 64 Meta-analysis of post-treatment SMD for total depression symptoms, comparing mindfulness interventions
with control in veteran populations.
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –1.64 (–2.64 to –0.64) 21.36
Devilly (1998)74 13 10 –0.23 (–1.06 to 0.59) 25.79
Franklin (2017)81
Overall (I2 = 56.0%; p = 0.078)





–1.60 (–2.88 to –0.32)
–0.56 (–1.03 to –0.09)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 65 Meta-analysis of post-treatment SMD for total depression symptoms, comparing single-component and
trauma-focused interventions with control in veteran populations.
APPENDIX 10




SMD (95% CI) Weight (%)
Ulmer (2011)140
Overall (I2 = 61.4%; p = 0.107)





–1.40 (–2.33 to –0.46)
–0.34 (–1.22 to 0.53)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 66 Meta-analysis of post-treatment SMD for total depression symptoms, comparing multicomponent and
trauma-focused interventions with control in veteran populations.
First author (year)
Engel (2015)78
SMD (95% CI) Weight (%)
29 29 0.13 (–0.39 to 0.64) 22.74
Kearney (2013)95 25 22 –0.62 (–1.21 to –0.03) 18.52
Moradi (2014)111 12 12 –0.72 (–1.55 to 0.11) 10.30
Possemato (2016)121
Overall (I2 = 20.7%; p = 0.283)





–0.28 (–0.78 to 0.23)
–0.43 (–0.92 to 0.05)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 67 Meta-analysis of post-treatment SMD for total depression symptoms, comparing single-component and
non-trauma-focused interventions with control in veteran populations.
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SMD (95% CI) Weight (%)
Reger (2016)126
Overall (I2 = 71.3%; p = 0.062)





–1.39 (–2.63 to –0.16)
–0.14 (–0.59 to 0.32)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 68 Meta-analysis of post-treatment SMD for total anxiety symptoms, comparing trauma-focused CBT
interventions with control in veteran populations.
First author (year)
Carlson (1997)64
SMD (95% CI) Weight (%)
10 11 –1.39 (–2.36 to –0.43) 30.47
Devilly (1998)74
Overall (I2 = 10.6%; p = 0.327)





–0.43 (–1.27 to 0.40)
–0.99 (–1.96 to –0.02)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 69 Meta-analysis of post-treatment SMD for total anxiety symptoms, comparing EMDR interventions with
control in veteran populations.
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War-affected populations
Post-traumatic stress disorder symptoms
First author (year)
Bolton (2014)62
ES (95% CI) Weight (%)
101 66 –0.43 (–0.74 to –0.11) 20.10
Hermenau (2013)86 15 15 –0.41 (–1.13 to 0.31) 7.81
Knaevelsrud (2015)96 79 80 –0.92 (–1.25 to –0.59) 19.47
Miyahira (2012)109 10 12 –0.50 (–1.35 to 0.35) 6.03
Wang (2016)143 13 15 0.01 (–0.74 to 0.75) 7.51
Weiss (2015) trial 1:
CETA144
Overall (I2 = 50.0%; p = 0.062)
NOTE: weights are from random-effects analysis
99




–0.70 (–1.05 to –0.35)
–0.26 (–0.56 to 0.05)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 70 Meta-analysis of post-treatment effect size (ES) for total PTSD symptoms, comparing trauma-focused CBT




ES (95% CI) Weight (%)
13 15 0.01 (–0.74 to 0.75) 19.66
Weiss (2015) trial 1:
CETA144
Overall (I2 = 48.3%; p = 0.145)





–0.70 (–1.05 to –0.35)
–0.28 (–0.73 to 0.17)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 71 Meta-analysis of post-treatment effect size (ES) for total PTSD symptoms, comparing multicomponent
trauma-focused interventions with control in war-affected populations. CETA, common elements treatment approach.
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SMD (95% CI) Weight (%)
101 66 –0.38 (–0.69 to –0.06) 28.61
Knaevelsrud (2015)96 79 80 –1.03 (–1.36 to –0.70) 28.08
Miyahira (2012)109
Overall (I2 = 79.1%; p = 0.002)
NOTE: weights are from random-effects analysis
10




–0.09 (–0.75 to 0.93)
–0.28 (–0.59 to 0.02)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 72 Meta-analysis of post-treatment SMD for depression symptoms, comparing single-component and trauma-
focused interventions with control in war-affected populations. CPT, cognitive processing therapy.
First author (year)
Wang (2016)143
ES (95% CI) Weight (%)
Overall (I2 = 79.1%; p = 0.029)
NOTE: weights are from random-effects analysis
13




0.08 (–0.67 to 0.82)
–0.84 (–1.20 to –0.49)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 73 Meta-analysis of post-treatment effect size (ES) for depression symptoms, comparing multicomponent and
trauma-focused interventions with control in war-affected populations. CETA, common elements treatment approach.
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SMD (95% CI) Weight (%)
101 66 –0.25 (–0.56 to 0.06) 33.48
Knaevelsrud (2015)96
Overall (I2 = 94.3%; p = 0.000)
NOTE: weights are from random-effects analysis
79
124Weiss (2015) trial 2: CPT144
80
64
–1.55 (–1.90 to –1.19)
–0.33 (–0.63 to –0.03)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 74 Meta-analysis of post-treatment SMD for total anxiety symptoms, comparing single-component and
trauma-focused interventions with control in war-affected populations. CPT, cognitive processing therapy.
First author (year)
Wang (2016)143
ES (95% CI) Weight (%)
Overall (I2 = 83.7%; p = 0.013)
NOTE: weights are from random-effects analysis
13




0.06 (–0.68 to 0.80)
–0.98 (–1.34 to –0.62)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 75 Meta-analysis of post-treatment effect size (ES) for total anxiety symptoms, comparing multicomponent and
trauma-focused interventions with control in war-affected populations. CETA, common elements treatment approach.
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
291
Childhood sexual abuse populations
Post-traumatic stress disorder symptoms
First author (year)
Chard (2005)66
SMD (95% CI) Weight (%)
36 37 –2.33 (–2.93 to –1.73) 33.83
Jung (2013)92
Overall (I2 = 90.3%; p = 0.000)





–0.83 (–1.61 to –0.06)
–0.50 (–1.06 to –0.06)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 76 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing trauma-focused CBT
interventions with control in childhood sexual abuse populations.
First author (year)
Sikkema (2007)131
SMD (95% CI) Weight (%)
Sikkema (2013)132
Overall (I2 = 0.0%; p = 0.587)





0.09 (–0.27 to 0.45)
–0.03 (–0.28 to 0.22)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 77 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing non-trauma-focused CBT
interventions with control in childhood sexual abuse populations.
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SMD (95% CI) Weight (%)
20 19 –1.09 (–1.77 to –0.42) 30.88
Jung (2013)92
Overall (I2 = 0.0%; p = 0.403)





–0.83 (–1.61 to –0.06)
–0.50 (–1.06 to –0.06)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 78 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing single-component and
trauma-focused interventions with control in childhood sexual abuse populations.
First author (year)
Krupnick (2008)98
SMD (95% CI) Weight (%)
32 16 –1.37 (–2.03 to –0.71) 17.83
McDonagh (2005)106 22 23 –0.89 (–1.50 to –0.28) 18.62
Sikkema (2007)131 73 48 0.09 (–0.27 to 0.45) 22.55
Sikkema (2013)132
Overall (I2 = 83.4%; p = 0.000)





–0.03 (–0.28 to 0.22)
–0.85 (–1.57 to –0.14)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 79 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing single-component and
non-trauma-focused interventions with control in childhood sexual abuse populations.
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SMD (95% CI) Weight (%)
36 37 –2.00 (–2.57 to –1.44) 34.16
Jung (2013)92
Overall (I2 = 87.9%; p = 0.000)





–0.49 (–1.25 to 0.26)
–0.51 (–1.07 to 0.05)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 80 Meta-analysis of post-treatment SMD for depression symptoms, comparing trauma-focused CBT
interventions with control in childhood sexual abuse populations.
First author (year)
Edmond (1999)76
SMD (95% CI) Weight (%)
20 19 –0.74 (–1.39 to –0.09) 32.49
Jung (2013)92
Overall (I2 = 0.0%; p = 0.844)





–0.49 (–1.25 to 0.26)
–0.51 (–1.07 to 0.05)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 81 Meta-analysis of post-treatment SMD for depression symptoms, comparing single-component and
trauma-focused interventions with control in childhood sexual abuse populations.
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SMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.538)





–1.06 (–1.70 to –0.42)
–0.78 (–1.39 to –0.18)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 82 Meta-analysis of post-treatment SMD for depression symptoms, comparing single-component and
non-trauma-focused interventions with control in childhood sexual abuse populations.
First author (year)
McDonagh (2005)106
SMD (95% CI) Weight (%)
Overall (I2 = 75.2%; p = 0.045)





–0.43 (–0.99 to 0.13)
–1.35 (–2.05 to –0.65)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 83 Meta-analysis of post-treatment SMD for anxiety symptoms, comparing single-component and trauma-focused
interventions with control in childhood sexual abuse populations.
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Refugee populations
Post-traumatic stress disorder symptoms
First author (year)
Adenauer (2011)55
SMD (95% CI) Weight (%)
11 8 –1.88 (–2.99 to –0.77) 28.65
Hinton (2005)89
Overall (I2 = 0.0%; p = 0.852)





–2.17 (–2.96 to –1.38)
–2.40 (–3.94 to –0.85)




– 1.0– 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 84 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing trauma-focused CBT
interventions with control in refugee populations.
First author (year)
Acarturk (2015)53
SMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.944)





–1.70 (–2.56 to –0.84)
–1.74 (–2.29 to –1.18)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 85 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing EMDR interventions with control
in refugee populations.
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SMD (95% CI) Weight (%)
15 14 –1.70 (–2.56 to –0.84) 18.18
Acarturk (2016)54 37 33 –1.74 (–2.29 to –1.18) 43.82
Adenauer (2011)55 11 8 –1.88 (–2.99 to –0.77) 10.89
Hinton (2005)89
Overall (I2 = 0.0%; p = 0.847)





–2.17 (–2.96 to –1.38)
–2.40 (–3.94 to –0.85)




– 1.0– 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 86 Meta-analysis of post-treatment SMD for total PTSD symptoms, comparing single-component and
trauma-focused interventions with control in refugee populations.
First author (year)
Adenauer (2011)55
SMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.953)





–2.05 (–3.19 to –0.91)
–1.99 (–3.42 to –0.56)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 87 Meta-analysis of post-treatment SMD for depression symptoms, comparing trauma-focused CBT
interventions with control in refugee populations.
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SMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.455)





–1.20 (–2.00 to –0.41)
–1.57 (–2.11 to –1.03)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)




SMD (95% CI) Weight (%)
15 14 –1.20 (–2.00 to –0.41) 25.11
Acarturk (2016)54 37 33 –1.57 (–2.11 to –1.03) 54.89
Adenauer (2011)55
Overall (I2 = 0.0%; p = 0.612)





–2.05 (–3.19 to –0.91)
–1.99 (–3.42 to –0.56)




– 1.0 – 0.5 0 1.00.5
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 89 Meta-analysis of post-treatment SMD for depression symptoms, comparing single-component and
trauma-focused interventions with control in refugee populations.
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Pharmacological interventions versus placebo
Post-traumatic stress disorder symptoms
First author (year)
Becker (2007)59
SMD (95% CI) Weight 
(%)
15 7 –0.22 (–1.12 to 0.68) 15.44
Davis (2004)73 14 9 –0.23 (–1.07 to 0.61) 15.93
Friedman (2007)82 86 83 0.08 (–0.22 to 0.38) 19.61
Naylor (2013)112 5 7 0.23 (–0.92 to 1.38) 13.39
Panahi (2011)118
Overall (I2 = 87.0%; p = 0.000)





–1.86 (–2.43 to –1.30)
–0.78 (–1.41 to –0.15)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 90 Meta-analysis of post-treatment SMD for PTSD symptoms, comparing antidepressants with placebo.
First author (year)
Friedman (2007)82
SMD (95% CI) Weight 
(%)
86 83 0.08 (–0.22 to 0.38) 27.60
Naylor (2013)112 5 7 0.23 (–0.92 to 1.38) 20.82
Panahi (2011)118
Overall (I2 = 92.2%; p = 0.000)





–1.86 (–2.43 to –1.30)
–0.78 (–1.41 to –0.15)




– 1.0 – 0.5 0 1.00.5





FIGURE 91 Meta-analysis of post-treatment SMD for PTSD symptoms, comparing SSRIs with placebo.
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SMD (95% CI) Weight (%)
22 25 –0.65 (–1.24 to –0.06) 21.95
Hamner (2003)85 19 18 0.07 (–0.58 to 0.71) 20.00
Krystal (2011)99 123 124 –0.21 (–0.46 to 0.04) 36.44
Monnelly (2003)110
Overall (I2 = 51.2%; p = 0.085)





–1.35 (–2.49 to –0.21)
–0.96 (–1.92 to –0.01)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 92 Meta-analysis of post-treatment SMD for PTSD symptoms, comparing antipsychotics with placebo.
First author (year)
Davis (2008)72
SMD (95% CI) Weight (%)
Overall (I2 = 45.5%; p = 0.176)





0.07 (–0.36 to 0.50)
–0.59 (–1.43 to 0.26)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 93 Meta-analysis of post-treatment SMD for PTSD symptoms, comparing anticonvulsants with placebo.
First author (year)
Germain (2012)84
SMD (95% CI) Weight (%)
15 13 –0.12 (–0.86 to 0.63) 29.39
Raskind (2007)122
Overall (I2 = 41.4%; p = 0.182)





–0.38 (–1.06 to 0.30)
–0.97 (–1.57 to –0.37)




– 1.0 – 0.5 0 0.5 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 94 Meta-analysis of post-treatment SMD for PTSD symptoms, comparing prazosin with placebo.
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SMD (95% CI) Weight 
(%)
18 10 –0.05 (–0.83 to 0.72) 11.90
Davis (2004)73
Overall (I2 = 0.0%; p = 0.632)





–0.27 (–1.12 to 0.57)
0.14 (–0.17 to 0.44)




– 1.0 – 0.5 0 0.5 1.0





FIGURE 95 Meta-analysis of post-treatment SMD for depression symptoms, comparing antidepressants with placebo.
First author (year)
Krystal (2011)99
SMD (95% CI) Weight 
(%)
Overall (I2 = 58.3%; p = 0.122)





–0.45 (–0.70 to –0.20)
–1.26 (–2.25 to –0.26)




– 1.0 – 0.5 0.50 1.0





FIGURE 96 Meta-analysis of post-treatment SMD for depression symptoms, comparing antipsychotics with placebo.
First author (year)
Davis (2008)72
SMD (95% CI) Weight 
(%)
Overall (I2 = 0.0%; p = 0.397)





–0.07 (–0.50 to 0.36)
0.33 (–0.50 to 1.17)




– 1.0 – 0.5 0.50 1.0





FIGURE 97 Meta-analysis of post-treatment SMD for depression symptoms, comparing anticonvulsants with placebo.
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WMD (95% CI) Weight (%)
22 23 –3.63 (–6.12 to –1.14) 29.12
Hamner (2003)85
Overall (I2 = 76.9%; p = 0.013)





–2.20 (–4.88 to 0.48)
–0.20 (–0.76 to 0.36)




– 4 – 2 0 2 4
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 98 Meta-analysis of post-treatment weighted mean difference (WMD) for positive psychotic symptoms,
comparing risperidone with placebo.
First author (year)
Hamner (2003)85
WMD (95% CI) Weight 
(%)
Overall (I2 = 0.0%; p = 0.657)





–0.20 (–3.52 to 3.12)
0.57 (–0.12 to 1.26)




– 1.0 – 0.5 0.50 1.0
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 99 Meta-analysis of post-treatment weighted mean difference (WMD) for negative psychotic symptoms,
comparing risperidone with placebo.
First author (year)
Hamner (2003)85
WMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.434)





–4.20 (–15.03 to 6.63)
0.21 (–1.95 to 2.37)




– 10 – 5 50 10
Favours intervention Favours control
Intervention (n) Control (n)
FIGURE 100 Meta-analysis of post-treatment weighted mean difference (WMD) for total psychotic symptoms,
comparing risperidone with placebo.
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Intervention (n) Control (n) WMD (95% CI) Weight (%)
Overall (I2 = 0.0%; p = 0.589)





–1.80 (–7.80 to 4.20)
–0.11 (–1.35 to 1.13)




– 10 – 5 50 10
Favours intervention Favours control
FIGURE 101 Meta-analysis of post-treatment weighted mean difference (WMD) for general psychopathology symptoms,
comparing risperidone with placebo.
First author (year)
Carlson (1998)64
Intervention (n) Control (n) OR (95% CI) Weight (%)
23 12 6.13 (0.23 to 162.50) 3.27
Chard (2005)66 36 35 1.04 (0.34 to 3.16) 13.34
Engel (2015)78 43 37 0.59 (0.18 to 1.95) 12.57
Franklin (2017)81 19 8 0.04 (0.00 to 0.70) 3.81
Gamito (2010)83 7 3 0.62 (0.02 to 19.58) 2.98
Kearney (2013)95 25 22 0.55 (0.05 to 6.49) 5.17
Margolies (2013)105 20 20 1.71 (0.40 to 7.34) 10.39
McDonagh (2005)106 51 23 0.40 (0.10 to 1.55) 11.13
McLay (2011)107 10 10 3.32 (0.12 to 91.60) 3.20
Miyahira (2012)109 29 13 0.21 (0.05 to 0.94) 10.14
Possemato (2016)121
Overall (I2 = 41.8%; p = 0.063)





0.07 (0.01 to 0.33)
0.43 (0.16 to 1.15)




1.00.50.30.20.1 2.0 3.0 5.0 10.0
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FIGURE 102 Meta-analysis of OR of attrition from all psychological interventions compared with control, among a
veteran population.
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OR (95% CI) Weight 
(%)
61 63 0.23 (0.09 to 0.63) 49.21
Germain (2012)84 17 16 0.80 (0.17 to 3.73) 20.80
Niles (2012)115
Overall (I2 = 0.0%; p = 0.589)





0.46 (0.07 to 2.98)
0.27 (0.05 to 1.57)





Favours intervention Favours control









OR (95% CI) Weight 
(%)
27 15 0.72 (0.20 to 2.58) 20.44
Friedman (2007)82 86 83 0.47 (0.22 to 0.98) 43.29
Panahi (2011)118
Overall (I2 = 24.9%; p = 0.262)
NOTE: weights are from random-effects analysis
35
33van der Kolk (1994)141
35
31
1.78 (0.39 to 8.09)
0.26 (0.07 to 0.92)











FIGURE 104 Meta-analysis of OR of attrition from antidepressants compared with placebo, among a veteran population.
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OR (95% CI) Weight (%)
33 32 0.03 (0.00 to 0.54) 9.04
Hamner (2003)85 19 18 0.56 (0.15 to 2.10) 25.82
Krystal (2011)99 147 149 1.03 (0.56 to 1.91) 42.78
Monnelly (2003)110 8 8 0.29 (0.01 to 8.37) 7.02
Reich (2004)127
Overall (I2 = 41.8%; p = 0.143)





0.86 (0.11 to 6.62)
(Excluded)






Favours intervention Favours control
Control (n)
FIGURE 105 Meta-analysis of OR of attrition from antidepsychotics compared with placebo, among a veteran population.
First author (year)
Davis (2008)72
OR (95% CI) Weight (%)
Overall (I2 = 13.3%; p = 0.283)





0.70 (0.24 to 2.05)
0.27 (0.07 to 1.04)
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FIGURE 106 Meta-analysis of OR of attrition from anticonvulsants compared with placebo, among a veteran population.
DOI: 10.3310/hta24430 Health Technology Assessment 2020 Vol. 24 No. 43
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Melton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
305




OR (95% CI) Weight 
(%)
31 27 0.31 (0.07  to 1.28) 34.73
Jung (2013)92 17 17 1.00 (0.17 to 5.83) 27.07
Krupnick (2008)98 32 16 0.03 (0.00 to 0.62) 12.96
Sikkema (2007)131
Overall (I2 = 26.5%; p = 0.245)





0.10 (0.01 to 1.65)
0.10 (0.00 to 2.13)




 0.1  0.2  0.3  0.5 1.0 2.0 3.0 5.0 10.0
Intervention 
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Control 
(n)
FIGURE 107 Meta-analysis of OR of attrition from all psychological interventions compared with control, among a
childhood sexual abuse population.
First author (year)
Acarturk (2015)53
OR (95% CI) Weight 
(%)
49 49 1.49 (0.62  to 3.62) 40.26
Adenauer (2011)55 16 18 2.75 (0.67 to 11.24) 15.85
Hijazi (2014)87 41 22 0.93 (0.08 to 10.85) 5.20
Meffert (2014)108
Overall (I2 = 0.0%; p = 0.547)





0.42 (0.04 to 4.81)
0.79 (0.30 to 2.07)
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Control 
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FIGURE 108 Meta-analysis of OR of attrition from all psychological interventions compared with control, among a
refugee population.
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OR (95% CI) Weight (%)
Overall (I2 = 76.7%; p = 0.038)





0.40 (0.19 to 0.84)
5.14 (0.52 to 51.29)
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Control (n)
FIGURE 109 Meta-analysis of OR of attrition from all psychological interventions compared with control, among a
domestic violence population.
Azad Marzabadi (2014)57
OR (95% CI) Weight (%)
16 16 1.00 (0.12 to 8.13) 13.21
Hermenau (2013)86 19 19 0.18 (0.01 to 4.00) 7.03
Knaevelsrud (2015)96 79 80 1.03 (0.55 to 1.94) 39.90
Weiss (2015) trial 1: CETA144 99 50 0.39 (0.02 to 8.20) 7.23
Weiss (2015) trial 2: CPT144
Overall (I2 = 36.7%; p = 0.162)





0.04 (0.00 to 0.62)
1.13 (0.31 to 4.09)
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Control (n)
FIGURE 110 Meta-analysis of OR of attrition from all psychological interventions compared with control, among a
war-affected population. CETA, common elements treatment approach; CPT, cognitive treatment therapy.
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Appendix 11 Characteristics of qualitative
studies included
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and data collection CERQual outcome
Bermudez et al.
(2013),163 USA

































































Pilot study to inform
future research. Offers
insight into dropout rates
and reasons for attrition,
as well as effects of




Study to examine the
use of motivational
interviewing with women
receiving services at a
domestic violence shelter
Women in domestic
shelters who have been
exposed to domestic
violence. Experimental
group (n= 10) and
control group (n = 10)
were included in the
mixed-methods study but
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veterans (n = 48)
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for asylum seekers with
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